0001628280-23-038618.txt : 20231113 0001628280-23-038618.hdr.sgml : 20231113 20231113161614 ACCESSION NUMBER: 0001628280-23-038618 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 88 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DELCATH SYSTEMS, INC. CENTRAL INDEX KEY: 0000872912 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 061245881 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-16133 FILM NUMBER: 231398989 BUSINESS ADDRESS: STREET 1: 1633 BROADWAY STREET 2: SUITE 22C CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: (212) 489-2100 MAIL ADDRESS: STREET 1: 1633 BROADWAY STREET 2: SUITE 22C CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: DELCATH SYSTEMS INC DATE OF NAME CHANGE: 19990607 10-Q 1 dcth-20230930.htm 9.30.2023 10-Q dcth-20230930
000087291212-312023Q3falsehttp://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember00008729122023-01-012023-09-3000008729122023-11-08xbrli:shares00008729122023-09-30iso4217:USD00008729122022-12-31iso4217:USDxbrli:shares0000872912us-gaap:ProductMember2023-07-012023-09-300000872912us-gaap:ProductMember2022-07-012022-09-300000872912us-gaap:ProductMember2023-01-012023-09-300000872912us-gaap:ProductMember2022-01-012022-09-300000872912us-gaap:ProductAndServiceOtherMember2023-07-012023-09-300000872912us-gaap:ProductAndServiceOtherMember2022-07-012022-09-300000872912us-gaap:ProductAndServiceOtherMember2023-01-012023-09-300000872912us-gaap:ProductAndServiceOtherMember2022-01-012022-09-3000008729122023-07-012023-09-3000008729122022-07-012022-09-3000008729122022-01-012022-09-3000008729122023-03-3100008729122023-06-300000872912us-gaap:PreferredStockMember2022-12-310000872912us-gaap:CommonStockMember2022-12-310000872912us-gaap:AdditionalPaidInCapitalMember2022-12-310000872912us-gaap:RetainedEarningsMember2022-12-310000872912us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000872912us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100008729122023-01-012023-03-310000872912us-gaap:CommonStockMember2023-01-012023-03-310000872912us-gaap:RetainedEarningsMember2023-01-012023-03-310000872912us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000872912us-gaap:PreferredStockMember2023-03-310000872912us-gaap:CommonStockMember2023-03-310000872912us-gaap:AdditionalPaidInCapitalMember2023-03-310000872912us-gaap:RetainedEarningsMember2023-03-310000872912us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000872912us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000008729122023-04-012023-06-300000872912dcth:PreferredF1StockMemberus-gaap:CommonStockMember2023-04-012023-06-300000872912dcth:PreferredF1StockMemberus-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000872912dcth:PreferredF1StockMember2023-04-012023-06-300000872912dcth:SeriesF2PreferredStockMemberus-gaap:PreferredStockMember2023-04-012023-06-300000872912us-gaap:AdditionalPaidInCapitalMemberdcth:SeriesF2PreferredStockMember2023-04-012023-06-300000872912dcth:SeriesF2PreferredStockMember2023-04-012023-06-300000872912us-gaap:CommonStockMember2023-04-012023-06-300000872912us-gaap:RetainedEarningsMember2023-04-012023-06-300000872912us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000872912us-gaap:PreferredStockMember2023-06-300000872912us-gaap:CommonStockMember2023-06-300000872912us-gaap:AdditionalPaidInCapitalMember2023-06-300000872912us-gaap:RetainedEarningsMember2023-06-300000872912us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000872912us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000872912dcth:SeriesF2PreferredStockMemberus-gaap:PreferredStockMember2023-07-012023-09-300000872912dcth:SeriesF2PreferredStockMemberus-gaap:CommonStockMember2023-07-012023-09-300000872912us-gaap:AdditionalPaidInCapitalMemberdcth:SeriesF2PreferredStockMember2023-07-012023-09-300000872912dcth:SeriesF2PreferredStockMember2023-07-012023-09-300000872912dcth:SeriesF3PreferredStockMemberus-gaap:PreferredStockMember2023-07-012023-09-300000872912dcth:SeriesF3PreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000872912dcth:SeriesF3PreferredStockMember2023-07-012023-09-300000872912dcth:SeriesF3PreferredStockMemberus-gaap:CommonStockMember2023-07-012023-09-300000872912us-gaap:SeriesEPreferredStockMemberus-gaap:PreferredStockMember2023-07-012023-09-300000872912us-gaap:SeriesEPreferredStockMemberus-gaap:CommonStockMember2023-07-012023-09-300000872912us-gaap:CommonStockMember2023-07-012023-09-300000872912us-gaap:RetainedEarningsMember2023-07-012023-09-300000872912us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000872912us-gaap:PreferredStockMember2023-09-300000872912us-gaap:CommonStockMember2023-09-300000872912us-gaap:AdditionalPaidInCapitalMember2023-09-300000872912us-gaap:RetainedEarningsMember2023-09-300000872912us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-3000008729122022-06-3000008729122022-03-3100008729122022-09-3000008729122021-12-310000872912us-gaap:PreferredStockMember2021-12-310000872912us-gaap:CommonStockMember2021-12-310000872912us-gaap:AdditionalPaidInCapitalMember2021-12-310000872912us-gaap:RetainedEarningsMember2021-12-310000872912us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000872912us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100008729122022-01-012022-03-310000872912us-gaap:RetainedEarningsMember2022-01-012022-03-310000872912us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000872912us-gaap:PreferredStockMember2022-03-310000872912us-gaap:CommonStockMember2022-03-310000872912us-gaap:AdditionalPaidInCapitalMember2022-03-310000872912us-gaap:RetainedEarningsMember2022-03-310000872912us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000872912us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-3000008729122022-04-012022-06-300000872912us-gaap:RetainedEarningsMember2022-04-012022-06-300000872912us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000872912us-gaap:PreferredStockMember2022-06-300000872912us-gaap:CommonStockMember2022-06-300000872912us-gaap:AdditionalPaidInCapitalMember2022-06-300000872912us-gaap:RetainedEarningsMember2022-06-300000872912us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000872912us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000872912us-gaap:CommonStockMember2022-07-012022-09-300000872912us-gaap:RetainedEarningsMember2022-07-012022-09-300000872912us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000872912us-gaap:PreferredStockMember2022-09-300000872912us-gaap:CommonStockMember2022-09-300000872912us-gaap:AdditionalPaidInCapitalMember2022-09-300000872912us-gaap:RetainedEarningsMember2022-09-300000872912us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000872912dcth:AccountsPayableAccruedExpensesAndLeaseLiabilitiesMember2023-09-300000872912dcth:LoanPrincipalPaymentsMember2023-09-300000872912dcth:LeaseLiabilitiesMember2023-09-300000872912dcth:ThirdPartySettlementMember2023-09-300000872912dcth:ConvertibeNotePrincipalPaymentsMember2023-09-300000872912srt:ScenarioPreviouslyReportedMember2022-09-300000872912srt:RestatementAdjustmentMember2022-09-300000872912dcth:AsRevisedMember2022-09-300000872912srt:ScenarioPreviouslyReportedMember2022-07-012022-09-300000872912srt:RestatementAdjustmentMember2022-07-012022-09-300000872912dcth:AsRevisedMember2022-07-012022-09-300000872912srt:ScenarioPreviouslyReportedMember2022-01-012022-09-300000872912srt:RestatementAdjustmentMember2022-01-012022-09-300000872912dcth:AsRevisedMember2022-01-012022-09-300000872912dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember2023-03-150000872912us-gaap:LandBuildingsAndImprovementsMember2023-09-300000872912us-gaap:LandBuildingsAndImprovementsMember2022-12-310000872912us-gaap:BuildingMember2023-09-300000872912us-gaap:ComputerEquipmentMember2023-09-300000872912us-gaap:ComputerEquipmentMember2022-12-310000872912us-gaap:LeaseholdsAndLeaseholdImprovementsMember2023-09-300000872912us-gaap:LeaseholdsAndLeaseholdImprovementsMember2022-12-310000872912us-gaap:EquipmentMember2023-09-300000872912us-gaap:EquipmentMember2022-12-310000872912us-gaap:FurnitureAndFixturesMember2023-09-300000872912us-gaap:FurnitureAndFixturesMember2022-12-310000872912country:US2023-07-012023-09-300000872912country:US2023-01-012023-09-300000872912country:US2022-07-012022-09-300000872912country:US2022-01-012022-09-300000872912country:IE2023-07-012023-09-300000872912country:IE2022-07-012022-09-300000872912country:IE2022-01-012022-09-300000872912country:IE2023-01-012023-09-300000872912country:US2023-09-300000872912country:IE2023-09-30xbrli:pure0000872912us-gaap:LoansPayableMember2023-09-300000872912us-gaap:LoansPayableMember2022-12-310000872912us-gaap:ConvertibleNotesPayableMember2023-09-300000872912us-gaap:ConvertibleNotesPayableMember2022-12-3100008729122022-01-012022-12-310000872912dcth:DecemberThirtyFirstTwoThousandTwentyThreeMember2023-09-300000872912dcth:DecemberThirtyFirstTwoThousandTwentyFourMember2023-09-300000872912dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMembersrt:MaximumMember2021-08-060000872912dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember2021-08-060000872912dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember2021-08-062021-08-060000872912dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember2023-09-302023-09-300000872912dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember2023-03-152023-03-150000872912dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMemberdcth:ConditionForTheExtensionOfPeriodOfInterestOnlyPaymentsMember2023-03-312023-03-310000872912dcth:PreferredTrancheAWarrantMember2023-08-142023-08-140000872912dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMemberus-gaap:WarrantMember2021-08-062021-08-060000872912dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMemberus-gaap:WarrantMember2021-08-060000872912dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMemberdcth:ConditionForTheExtensionOfPeriodOfInterestOnlyPaymentsMember2023-03-310000872912dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember2022-07-012022-09-300000872912dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember2023-07-012023-09-300000872912dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember2022-01-012022-09-300000872912dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember2023-01-012023-09-300000872912dcth:SecuredConvertibleNotesPayableMember2023-09-300000872912us-gaap:ConvertibleNotesPayableMemberdcth:EightPointZeroPercentageJulyTwoThousandAndNineteenNotesMember2023-09-300000872912us-gaap:SeriesEPreferredStockMember2023-09-300000872912dcth:EightPointZeroPercentageJulyTwoThousandAndNineteenNotesMemberus-gaap:ConvertibleDebtMember2022-01-012022-09-300000872912dcth:EightPointZeroPercentageJulyTwoThousandAndNineteenNotesMemberus-gaap:ConvertibleDebtMember2023-01-012023-09-300000872912us-gaap:SeriesEPreferredStockMemberdcth:SecuredConvertibleNotesPayableMember2021-08-060000872912dcth:PreferredPurchaseAgreementMemberdcth:SeriesF1PreferredStockMember2023-03-292023-03-290000872912dcth:PreferredPurchaseAgreementMemberdcth:SeriesF1PreferredStockMember2023-03-290000872912dcth:SeriesF3PreferredStockMemberdcth:PreferredTrancheAWarrantMember2023-03-292023-03-290000872912dcth:PreferredPurchaseAgreementMemberdcth:SeriesF3PreferredStockMember2023-03-290000872912dcth:PreferredPurchaseAgreementMemberdcth:PreferredTrancheBWarrantMember2023-03-292023-03-290000872912dcth:PreferredPurchaseAgreementMemberdcth:SeriesF4PreferredStockMember2023-03-290000872912dcth:PreferredWarrantLiabilitiesMember2023-03-292023-03-290000872912dcth:PreferredWarrantLiabilitiesMember2023-03-290000872912dcth:SeriesF1PreferredStockMemberdcth:PreferredWarrantLiabilitiesMember2023-03-292023-03-290000872912dcth:PreferredPurchaseAgreementMemberdcth:PreferredTrancheAWarrantMember2023-07-012023-09-300000872912dcth:PreferredPurchaseAgreementMemberus-gaap:CommonStockMemberdcth:PreferredTrancheAWarrantMember2023-07-012023-09-300000872912dcth:PreferredPurchaseAgreementMemberus-gaap:CommonStockMember2023-09-300000872912dcth:PreferredPurchaseAgreementMemberdcth:SeriesF4PreferredStockMember2023-07-012023-09-300000872912dcth:PreferredPurchaseAgreementMemberdcth:PreferredTrancheBWarrantMember2023-07-012023-09-300000872912dcth:PreferredPurchaseAgreementMemberdcth:SeriesF2PreferredStockMember2023-09-300000872912dcth:SeriesF2PreferredStockMember2023-09-300000872912dcth:SeriesF3PreferredStockMember2023-09-300000872912dcth:SeriesF4PreferredStockMember2023-09-300000872912dcth:SeriesF1SeriesF2AndF3PreferredStockMember2023-01-012023-09-300000872912us-gaap:CommonStockMember2023-09-300000872912dcth:CommonPurchaseAgreementMemberdcth:TrancheAWarrantsMember2023-03-272023-03-270000872912dcth:CommonPurchaseAgreementMemberdcth:TrancheBWarrantsMember2023-03-272023-03-270000872912dcth:CommonPurchaseAgreementMemberdcth:TrancheAWarrantsMember2023-03-292023-03-290000872912dcth:CommonPurchaseAgreementMemberdcth:TrancheAWarrantsMember2023-08-142023-08-140000872912dcth:CommonPurchaseAgreementMemberdcth:TrancheBWarrantsMember2023-03-292023-03-290000872912dcth:CommonPurchaseAgreementMemberdcth:TrancheBWarrantsMember2023-09-3000008729122023-03-290000872912dcth:ControlledEquityOfferingSalesAgreementMemberdcth:CantorFitzgeraldAndCoMember2023-09-3000008729122023-05-310000872912us-gaap:SeriesAPreferredStockMember2023-09-300000872912us-gaap:SeriesBPreferredStockMember2023-09-300000872912us-gaap:SeriesCPreferredStockMember2023-09-300000872912us-gaap:SeriesDPreferredStockMember2023-09-300000872912dcth:SeriesE1PreferredStockMember2023-09-300000872912dcth:SeriesF1PreferredStockMember2023-09-3000008729122023-06-122023-06-120000872912dcth:ExercisePriceRangeFromTwoPointEightThreeToFiftyOnePointFiveZeroMembersrt:MinimumMember2023-09-300000872912dcth:ExercisePriceRangeFromTwoPointEightThreeToFiftyOnePointFiveZeroMembersrt:MaximumMember2023-09-300000872912dcth:ExercisePriceRangeFromTwoPointEightThreeToFiftyOnePointFiveZeroMember2023-09-300000872912dcth:ExercisePriceRangeFromTwoPointEightThreeToFiftyOnePointFiveZeroMember2023-01-012023-09-300000872912dcth:ExercisePriceRangeAboveFiftyOnePointFiveZeroMember2023-09-300000872912dcth:ExercisePriceRangeAboveFiftyOnePointFiveZeroMember2023-01-012023-09-300000872912us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300000872912us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300000872912us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300000872912us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300000872912us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000872912us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300000872912us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000872912us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300000872912us-gaap:CostOfSalesMember2023-07-012023-09-300000872912us-gaap:CostOfSalesMember2022-07-012022-09-300000872912us-gaap:CostOfSalesMember2023-01-012023-09-300000872912us-gaap:CostOfSalesMember2022-01-012022-09-300000872912dcth:CommonWarrantsMember2022-12-310000872912dcth:CommonWarrantsMember2023-01-012023-09-300000872912dcth:CommonWarrantsMember2023-09-300000872912dcth:RangeOfExercisePricesPointZeroOneRangeMember2023-09-300000872912dcth:RangeOfExercisePricesPointZeroOneRangeMemberdcth:CommonWarrantsMember2023-09-300000872912dcth:RangeOfExercisePricesPointZeroOneRangeMemberdcth:CommonWarrantsMember2023-01-012023-09-300000872912dcth:RangeOfExercisePricesSixPointZeroRangeMember2023-09-300000872912dcth:RangeOfExercisePricesSixPointZeroRangeMemberdcth:CommonWarrantsMember2023-09-300000872912dcth:RangeOfExercisePricesSixPointZeroRangeMemberdcth:CommonWarrantsMember2023-01-012023-09-300000872912dcth:RangeOfExercisePricesTenPointZeroRangeMember2023-09-300000872912dcth:RangeOfExercisePricesTenPointZeroRangeMemberdcth:CommonWarrantsMember2023-09-300000872912dcth:RangeOfExercisePricesTenPointZeroRangeMemberdcth:CommonWarrantsMember2023-01-012023-09-300000872912dcth:RangeOfExercisePricesFourPointFiveZeroRangeMember2023-09-300000872912dcth:PreferredWarrantsMember2022-12-310000872912dcth:PreferredWarrantsMember2023-01-012023-09-300000872912dcth:PreferredWarrantsMember2023-09-300000872912dcth:MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember2021-08-310000872912dcth:MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember2021-08-012021-08-310000872912dcth:MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember2023-01-310000872912dcth:MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember2023-07-310000872912dcth:CommonStockWarrantsMember2023-01-012023-09-300000872912dcth:CommonStockWarrantsMember2022-01-012022-09-300000872912dcth:AssumedConversationOfPreferredStockWarrantsMember2023-01-012023-09-300000872912dcth:AssumedConversationOfPreferredStockWarrantsMember2022-01-012022-09-300000872912dcth:AssumedConversionOfPreferredStockMember2023-01-012023-09-300000872912dcth:AssumedConversionOfPreferredStockMember2022-01-012022-09-300000872912dcth:AssumedConversionOfConvertibleNotesMember2023-01-012023-09-300000872912dcth:AssumedConversionOfConvertibleNotesMember2022-01-012022-09-300000872912us-gaap:EmployeeStockOptionMember2023-01-012023-09-300000872912us-gaap:EmployeeStockOptionMember2022-01-012022-09-300000872912dcth:MedacMember2021-04-30iso4217:EUR00008729122021-10-120000872912dcth:MedacMember2022-12-302022-12-300000872912dcth:MedacMember2022-12-300000872912us-gaap:OtherLiabilitiesMemberdcth:MedacMember2023-09-300000872912us-gaap:OtherNoncurrentLiabilitiesMemberdcth:MedacMember2023-09-300000872912dcth:MedacMemberdcth:AccruedExpensesMember2023-09-300000872912dcth:LachmanMember2023-01-240000872912dcth:LachmanMember2023-07-052023-07-050000872912dcth:ContingentLiabilitiesMember2022-12-310000872912us-gaap:WarrantMember2022-12-310000872912dcth:ContingentLiabilitiesMember2023-01-012023-09-300000872912us-gaap:WarrantMember2023-01-012023-09-300000872912dcth:ContingentLiabilitiesMember2023-09-300000872912us-gaap:WarrantMember2023-09-300000872912srt:MinimumMemberdcth:PreferredAndCommonWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-03-290000872912srt:MaximumMemberdcth:PreferredAndCommonWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-03-290000872912srt:MaximumMemberdcth:PreferredAndCommonWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-09-300000872912srt:MinimumMemberdcth:PreferredAndCommonWarrantsMemberus-gaap:MeasurementInputExpectedTermMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-03-290000872912srt:MaximumMemberdcth:PreferredAndCommonWarrantsMemberus-gaap:MeasurementInputExpectedTermMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-03-290000872912srt:MaximumMemberdcth:PreferredAndCommonWarrantsMemberus-gaap:MeasurementInputExpectedTermMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-09-300000872912us-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMemberdcth:PreferredAndCommonWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-03-290000872912us-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMemberdcth:PreferredAndCommonWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-03-290000872912us-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMemberdcth:PreferredAndCommonWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-09-300000872912us-gaap:MeasurementInputExpectedDividendRateMemberdcth:PreferredAndCommonWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-03-290000872912us-gaap:MeasurementInputExpectedDividendRateMemberdcth:PreferredAndCommonWarrantsMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-09-300000872912us-gaap:FairValueInputsLevel1Member2023-09-300000872912us-gaap:FairValueInputsLevel2Member2023-09-300000872912us-gaap:FairValueInputsLevel3Member2023-09-300000872912us-gaap:FairValueInputsLevel1Member2022-12-310000872912us-gaap:FairValueInputsLevel2Member2022-12-310000872912us-gaap:FairValueInputsLevel3Member2022-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________________
FORM 10-Q
______________________
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
Or
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________
Commission File Number: 001-16133
______________________
DELCATH SYSTEMS, INC.
(Exact name of registrant as specified in its charter)
______________________
Delaware06-1245881
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
1633 Broadway, Suite 22C
New York, NY 10019
(Address of principal executive offices)
(212) 489-2100
(Registrant’s telephone number, including area code)
______________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.01 par value per shareDCTH
The NASDAQ Capital Market
______________________
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated fileroAccelerated filero
Non-accelerated filerxSmaller reporting companyx
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
As of November 8, 2023, 22,046,101 shares of the Company’s common stock, $0.01 par value, were outstanding.


DELCATH SYSTEMS, INC.
Table of Contents
Page
2



DELCATH SYSTEMS, INC.
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands, except share and per share data)
September 30,
2023
December 31,
2022
Assets
Current assets
Cash and cash equivalents$40,462 $7,671 
Restricted cash50 4,151 
Accounts receivable, net205 366 
Inventory2,667 1,998 
Prepaid expenses and other current assets2,712 1,969 
Total current assets46,096 16,155 
Property, plant and equipment, net1,374 1,422 
Right-of-use assets107 285 
Total assets$47,577 $17,862 
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable$753 $2,018 
Accrued expenses5,230 4,685 
Lease liabilities, current35 186 
Loan payable, current5,080 7,846 
Convertible notes payable, current2,876  
Total current liabilities13,974 14,735 
Warrant liability5,773 
Other liabilities, non-current1,111 1,144 
Loan payable, non-current 3,070 
Convertible notes payable, non-current2,000 4,772 
Total liabilities22,858 23,721 
Commitments and contingencies (see note 13)
Stockholders’ equity (deficit)
Preferred stock, $0.01 par value; 10,000,000 shares authorized; 37,787 and 11,357 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
  
Common stock, $0.01 par value; 80,000,000 shares authorized; 19,688,991 shares and 10,046,571 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
197 100 
Additional paid-in capital518,607 451,608 
Accumulated deficit(494,026)(457,484)
Accumulated other comprehensive loss(59)(83)
Total stockholders’ equity (deficit)24,719 (5,859)
Total liabilities and stockholders’ equity$47,577 $17,862 
See accompanying Notes to Condensed Consolidated Financial Statements.
3

DELCATH SYSTEMS, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(in thousands, except share and per share data)
Three months ended September 30,Nine months ended September 30,
2023202220232022
Product revenue$434 $906 $1,526 $1,909 
Other revenue   171 
Total revenues434 906 1,526 2,080 
Cost of goods sold(133)(235)(464)(449)
Gross profit301 671 1,062 1,631 
Operating expenses:
Research and development expenses4,662 4,065 12,793 14,152 
Selling, general and administrative expenses6,195 4,779 15,147 13,477 
Total operating expenses10,857 8,844 27,940 27,629 
Operating loss(10,556)(8,173)(26,878)(25,998)
Change in fair value of warrant liability(9,384) (8,224) 
Interest expense, net(395)(730)(1,454)(2,040)
Other income (expense)(5)26 14 2 
Net loss(20,340)(8,877)(36,542)(28,036)
Other comprehensive income:  
Foreign currency translation adjustments5 (46)24 (82)
Total other comprehensive loss$(20,335)$(8,923)$(36,518)$(28,118)
Common share data:  
Basic and diluted loss per common share$(1.14)$(0.96)$(2.61)$(3.29)
Weighted average number of basic and diluted shares outstanding17,863,0789,215,78613,985,2488,536,006
See accompanying Notes to Condensed Consolidated Financial Statements.
4

DELCATH SYSTEMS, INC.
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(Unaudited)
(in thousands, except share data)
Preferred Stock
$0.01 Par Value
Common Stock
$0.01 Par Value
Additional
Paid
in Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Income (Loss)
Total
No. of
Shares
AmountNo. of
Shares
Amount
Balance at January 1, 202311,357$ 10,046,571$100 $451,608 $(457,484)$(83)$(5,859)
Compensation expense for issuance of stock options— — 1,661 — — 1,661 
Private placement -issuance of common shares, net of expenses— 19,6461 55 — — 56 
Issuance of common stock with the employee stock purchase plan— 15,417— 47 — — 47 
Net loss— — — (9,000)— (9,000)
Total comprehensive income— — — — 19 19 
Balance at March 31, 202311,357$ 10,081,634$101 $453,371 $(466,484)$(64)$(13,076)
Compensation expense for issuance of stock options— — 1,661 — — 1,661 
Conversion of Series F-1 Preferred shares to common shares— 4,629,53947 11,222 — — 11,269 
Series Preferred F-2 Shares Issuance9,624— — 7,099 — — 7,099 
Prefunded warrant exercise538,82855
Issuance of common stock related to stock option exercises46822
Net loss— — — (7,202)— (7,202)
Total comprehensive income— — — —   
Balance at June 30,202320,981$ 15,250,469$153 $473,355 $(473,686)$(64)$(242)
Compensation expense for issuance of stock options2,7832,783
Conversion of Series F-2 Preferred shares to common shares(4,721)1,430,60314-14
Series F-3 Preferred Shares Issuance34,85942,38842,388
Conversion of Series F-3 Preferred shares to common shares(13,232)2,940,44030-291
Conversion of Series E Preferred shares to common shares(100)10,000
Common Stock warrant exercise31,110
Issuance of common stock with the employee stock purchase plan26,01876— 76
Issuance of common stock related to stock option exercises35111
Compensation expense for issuance of employee stock purchase plan47— 47
Net loss(20,340)(20,340)
Total comprehensive income55
Balance at September 30, 202337,787$ 19,688,991$197 $518,607 $(494,026)$(59)$24,719 

5

Preferred Stock
$0.01 Par Value
Common Stock
$0.01 Par Value
Additional
Paid
in Capital
Accumulated
Deficit
Accumulated
Other
Comprehensive
Income (Loss)
Total
No. of
Shares
AmountNo. of
Shares
Amount
Balance at January 1, 202211,357$ 7,906,728$79 $432,831 $(420,976)$18 $11,952 
Compensation expense for issuance of stock options— — 2,271  — 2,271 
Net loss— — — (9,000)— (9,000)
Total comprehensive income— — — — 2 2 
Balance at March 31, 202211,357$ 7,906,728$79 $435,102 $(429,976)$20 $5,225 
Compensation expense for issuance of stock options— — 2,119 — — 2,119 
Net loss— — — (10,159)— (10,159)
Total comprehensive income— — — — (31)(31)
Balance at June 30, 202211,3577,906,728$79 $437,221 $(440,135)$(11)$(2,846)
Compensation expense for issuance of stock options1,6271,627
Private placement - issuance of common stock and prefunded warrants, net of expense690,95474,8894,896
Net loss(8,877)(8,877)
Total comprehensive income(46)(46)
Balance at September 30, 202211,357$ 8,597,682$86 $443,737 $(449,012)$(57)$(5,246)
See accompanying Notes to Condensed Consolidated Financial Statements.
6

DELCATH SYSTEMS, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
Nine months ended September 30,
20232022
Cash flows from operating activities:  
Net loss$(36,542)$(28,036)
Adjustments to reconcile net loss to net cash used in operating activities:  
Stock option compensation expense6,152 6,016 
Depreciation expense87 98 
Warrant liability fair value adjustment8,224  
Non-cash lease expense262 339 
Amortization of debt discount582 574 
Interest expense accrued related to convertible notes120 120 
Changes in operating assets and liabilities:  
Prepaid expenses and other assets(743)708 
Accounts receivable161 (493)
Inventory(669)(515)
Accounts payable and accrued expenses(437)2,907 
Other liabilities, non-current(270)861 
Deferred revenue (170)
Net cash used in operating activities(23,073)(17,591)
Cash flows from investing activities:  
Purchase of property, plant and equipment(39)(209)
Net cash used in investing activities(39)(209)
Cash flows from financing activities:  
Net proceeds from private placement22,960 4,896 
Proceeds from the issuance of common stock relating to the employee stock purchase plan123  
Repayment of debt(6,313) 
Proceeds from exercise of warrants35,004  
Proceeds from exercise of stock options3  
Net cash provided by financing activities51,777 4,896 
Foreign currency effects on cash25 (67)
Net increase (decrease) in total cash28,690 (12,971)
Total Cash, Cash Equivalents and Restricted Cash:  
Beginning of period11,822 26,953 
End of period$40,512 $13,982 
Cash, Cash Equivalents and Restricted Cash consisted of the following:  
Cash$40,462 $9,831 
Restricted Cash50 4,151 
Total$40,512 $13,982 
Nine months ended September 30,
20232022
Supplemental Disclosure of Cash Flow Information:
Cash paid during the periods for:
Interest expense$1,122 $1,337 
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Right of use assets obtained in exchange for lease obligations$84 $ 
Conversion of mezzanine equity to common shares$11,269 $ 
Conversion of mezzanine equity to preferred shares$7,099 $ 
See accompanying Notes to Condensed Consolidated Financial Statements.
7

DELCATH SYSTEMS, INC.
Notes to the Condensed Consolidated Financial Statements
(amounts in thousands, except share and per share amounts)
(1)    General
The unaudited interim condensed consolidated financial statements of Delcath Systems, Inc. (“Delcath” or the “Company”) as of and for the three and nine months ended September 30, 2023 and 2022 should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Annual Report”), which was filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2023 and may also be found on the Company’s website (www.delcath.com). In these notes to the interim condensed consolidated financial statements the terms “us”, “we” or “our” refer to Delcath and its consolidated subsidiaries.
Description of Business
The Company is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company’s lead product, the HEPZATO KITTM (“HEPZATO” melphalan for Injection/Hepatic Delivery System), a drug/device combination product, was approved by the U.S. Food and Drug Administration (the “FDA”) on August 14, 2023 indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver with no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.
In the United States, HEPZATO is considered a combination drug and device product and is regulated as a drug by the FDA. Primary jurisdiction for regulation of HEPZATO has been assigned to the FDA’s Center for Drug Evaluation and Research. The FDA has granted Delcath six orphan drug designations (five for melphalan in the treatment of patients with ocular (uveal) melanoma, cutaneous melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and neuroendocrine tumor indications and one for doxorubicin in the treatment of patients with hepatocellular carcinoma).
The Company’s clinical development program for HEPZATO was comprised of the FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (the “FOCUS Trial”), a global registration clinical trial that investigated objective response rate in metastatic ocular melanoma (“mOM”). The Company is currently reviewing the incidence, unmet need, available efficacy data and development requirements for a broad set of liver cancers in order to select a portfolio of follow-on indications that will maximize the value of the HEPZATO platform. In addition to HEPZATO’s approved use to treat mOM, the Company believes that HEPZATO has the potential to treat other liver dominant cancers, such as Metastatic Colorectal Cancer and Cholangiocarcinoma, and plans to begin the study of HEPZATO to treat such conditions in the near future. The Company believes that the disease states it is investigating and intends to investigate are unmet medical needs that represent significant market opportunities.
As the Company prepares for commercial launch of HEPZATO, the Company continues its expanded access program (“EAP”) in the United States to make HEPZATO readily available to mOM patients. The Company is focused on continuing to treat these patients enrolled in the EAP sites.
On February 28, 2022, CHEMOSAT received Medical Device Regulation (“MDR”) certification under the European Medical Devices Regulation (2017/745/EU), which may be considered by jurisdictions when evaluating reimbursement. As of March 1, 2022, the Company has assumed direct responsibility for sales, marketing and distribution of CHEMOSAT in Europe.
Risks and Uncertainties
The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully launching and commercializing its drug/device combination products, the Company's ability to obtain regulatory approval of its such products in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians and consumers, and significant competition.
In addition, high rates of inflation have resulted in the U.S. Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks and financial institutions enter receivership or
8

become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our or our partners’ ability to access existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on our business and financial condition, including our ability to access additional capital on favorable terms, or at all, which could in the future negatively affect our ability to pursue our business strategy.
Liquidity and Going Concern
On September 30, 2023, the Company had cash, cash equivalents and restricted cash totaling $40.5 million, as compared to cash, cash equivalents and restricted cash totaling $11.8 million at December 31, 2022. During the nine months ended September 30, 2023, the Company used $23.1 million of cash in its operating activities and $6.3 million for principal payments.
The Company’s future results are subject to substantial risks and uncertainties. The Company has operated at a loss for its entire history and there can be no assurance that it will ever achieve or maintain profitability. The Company has historically funded its operations primarily with proceeds from sales of common stock, warrants and prefunded warrants for the purchase of common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements.
The Company believes that current cash and cash equivalents will enable the Company to have sufficient cash through the launch of HEPZATO. If there is a substantial delay in the launch of HEPZATO, the Company expects to need to raise additional capital under structures available to the Company, including debt and/or equity offerings, which may not be on favorable terms. If commercialization were significantly delayed, the Company would not have sufficient funds to meet its obligations within twelve months from the issuance date of these condensed consolidated financial statements. As such, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt about our ability to continue as a going concern.
The Company’s capital commitments over the next twelve months include (a) $6.0 million to satisfy accounts payable, accrued expenses and lease liabilities and (b) $8.6 million of loan principal payments. Additional capital commitments beyond the next twelve months include (a) $0.1 million of lease liabilities; (b) $1.0 million for settlement of litigation with medac; and (c) $2.0 million of convertible note principal payments, if the holders do not elect to convert the notes into equity.
Basis of Presentation
These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all wholly owned subsidiaries and all significant inter-company accounts and transactions have been eliminated in consolidation.
The preparation of interim condensed consolidated financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended September 30, 2023 and 2022; however, certain information and footnote disclosures normally included in our audited consolidated financial statements included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.
Significant Accounting Policies
Other than the policies listed below, there have been no material changes to our significant accounting policies as set forth in Note 3 Summary of Significant Accounting Policies to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
Warrant Liabilities
The Company determined the warrant liability was not in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, which classifies and measures certain financial instruments with characteristics of both liability and equity. Entities must consider whether to classify contracts that may be settled in its own stock, such as warrants, as equity of the entity or as an asset or liability. If an event that is not within the entity’s control could require net cash settlement,
9

then the contract should be classified as an asset or a liability at their fair value at issuance with subsequent changes in fair value recorded in earnings.
The Company has accounted for the Preferred Warrants as derivative instruments in accordance with ASC 815, Derivatives and Hedging. The Company classified the Preferred Warrants issued in conjunction with the Preferred Purchase Agreement (defined below) and the Common Warrants issued in conjunction with the Common Purchase Agreement (as defined below) as a liability due to the existence of a pre-specified volatility input to the Black-Scholes calculation which would be used to calculate the repurchase price of the Preferred Warrants and Common Warrants in the event of a Fundamental Transaction, as defined.
The valuations of the warrant liability and Series F-1 Preferred Stock (defined below) were determined using option pricing models. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. In addition, the Company used probabilities of the FDA approval of the HEPZATO KIT (“FDA Approval”) and of recording at least $10 million in quarterly U.S. revenue from the commercialization of HEPZATO as inputs to determine the fair value of warrants liability and Series F-1 Preferred Stock. The Company intends to adjust the fair value of the warranty liability at the end of each reporting period.
Recently Adopted and Issued Accounting Pronouncements
We have not been required to adopt any accounting standards that had a significant impact on our consolidated financial statements in the two years ended December 31, 2022. We do not expect any recently issued accounting standards to have a significant impact on our consolidated financial statements.
Revision of Previously Issued Quarterly Financial Statements
In preparation of the Company's audited financial statements as of and for year ended December 31, 2022, the Company determined it needed to correct previously reported share-based compensation expense for each quarter during 2022. The correction for share-based compensation increased the net loss in amount of $0.8 million for the first quarter of 2022, $0.5 million for the second quarter of 2022 and $0.4 million for the third quarter of fiscal 2022. The share-based compensation adjustment is a non-cash adjustment and did not have any impact on the cash balances for the Company.
10

The following tables contain the financial information for the periods previously reported and have been updated to reflect the revisions of the Company’s financial statements. The revisions do not have an impact on the Company’s cash position. The Company has not amended its previously filed Quarterly Reports on Form 10-Q for the three quarterly periods ended September 30, 2022. The impact of the revision on the Company’s financial statements for the three and nine months ended September 30, 2022 is reflected in the following table:
(In thousands)As previously reported
Adjustment
As revised
Balance Sheet for September 30, 2022 (unaudited)
Additional paid-in capital$442,066 $1,671 $443,737 
Accumulated deficit$(447,341)$(1,671)$(449,012)
Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)
Research and development expenses$3,953 $112 $4,065 
Selling, general and administrative expenses4,519 260 4,779 
Total operating expenses8,472 372 8,844 
Operating loss(7,801)(372)(8,173)
Net loss(8,505)(372)(8,877)
Total other comprehensive loss(8,551)(372)(8,923)
Basic and diluted loss per common share$(0.92)$(0.04)$(0.96)
Consolidated Statement of Operations and Comprehensive Loss for the nine months September 30, 2022 (unaudited)
Research and development expenses$13,649 $503 $14,152 
Selling, general and administrative expenses12,309 1,168 13,477 
Total operating expenses25,958 1,671 27,629 
Operating loss(24,327)(1,671)(25,998)
Net loss(26,365)(1,671)(28,036)
Total other comprehensive loss(26,447)(1,671)(28,118)
Basic and diluted loss per common share$(3.09)$(0.20)$(3.29)
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)
Compensation expense for issuance of stock options$1,255 $372 $1,627 
Net loss$(8,505)$(372)$(8,877)
Consolidated statement of Stockholders’ Equity (Deficit) for the nine months ended September 30, 2022 (unaudited)
Compensation expense for issuance of stock options$4,345 $1,671 $6,016 
Net loss$(26,365)$(1,671)$(28,036)
Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)
Net loss$(26,365)$(1,671)$(28,036)
Stock option compensation expense$4,345 $1,671 $6,016 
11

(2)    Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded in Restricted Cash on the balance sheets.
Cash, cash equivalents, and restricted cash balances were as follows:
(In thousands)September 30,
2023
December 31,
2022
Cash and cash equivalents$40,462 $7,671 
Restricted balance for loan agreement 4,000 
Letters of credit 101 
Security for credit cards50 50 
Total cash, cash equivalents and restricted cash shown in the statements of cash flows$40,512 $11,822 
On March 15, 2023, the Company returned to Avenue (as defined below) the $4.0 million held in restricted cash to pay down a portion of the outstanding Avenue Loan (defined below) balance. On March 31, 2023, the letter of credit for the sub-lease agreement for office space at 1633 Broadway, New York, NY expired.
(3)    Inventory
Inventory consists of the following:
(In thousands)September 30,
2023
December 31,
2022
Raw materials$924 $763 
Work-in-process1,582 1,102 
Finished goods161 133 
Total inventory$2,667 $1,998 
(4)    Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consist of the following:
(In thousands)September 30,
2023
December 31,
2022
Clinical trial expenses$1,630 $1,630 
Insurance premiums71 123 
Professional services655 121 
Other356 95 
Total prepaid expenses and other current assets$2,712 $1,969 
12

(5)    Property, Plant, and Equipment
Property, plant, and equipment consist of the following:
(In thousands)September 30, 2023December 31, 2022Estimated Useful Life
Buildings and land$1,301 $1,301 
30 years - Buildings
Enterprise hardware and software1,855 1,855 3 years
Leaseholds1,772 1,774 Lesser of lease term or estimated useful life
Equipment1,262 1,222 7 years
Furniture201 201 5 years
Property, plant and equipment, gross6,391 6,353 
Accumulated depreciation(5,017)(4,931)
Property, plant and equipment, net$1,374 $1,422 
Depreciation expense for the three and nine months ended September 30, 2023 and 2022 was less than $0.1 million for each period.
(6)    Accrued Expenses
Accrued expenses consist of the following:
(In thousands)September 30,
2023
December 31,
2022
Clinical expenses$2,105 $1,470 
Compensation, excluding taxes1,535 1,040 
Professional fees61 1,087 
Interest on convertible note673 553 
Other856 535 
Total accrued expenses$5,230 $4,685 
(7)    Leases
The Company recognizes right-of-use (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company leases its facilities under non-cancellable operating and financing leases. The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the ROU asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.
For the three and nine months ended September 30, 2023 and 2022, the Company recognized $0.1 million and $0.3 million, respectively, of operating lease expense in the U.S. and less than $0.1 million of operating lease expense in Ireland for the same periods.
As of September 30, 2023:
(In thousands)U.S.IrelandTotal
Operating cash flows for operating leases$238 $24 $262 
Weighted average remaining lease term0.02.8
Weighted average discount rate - operating leases8 %8 %
13

As of August 31, 2023, the lease of office space at 1633 Broadway, New York, NY was converted to a month-to-month lease. No ROU assets or lease liabilities are recognized on the balance sheet for this arrangement.
Remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows:
U.S.IrelandTotal
Year ended December 31, 2023$ $11 $11 
Year ended December 31, 2024 42 42 
Year ended December 31, 2025 42 42 
Year ended December 31, 2026 25 25 
Total 120 120 
Less present value discount (13)(13)
Operating lease liabilities included in the condensed consolidated balance sheets at September 30, 2023$ $107 $107 
(8)    Loans and Convertible Notes Payable
September 30, 2023December 31, 2022
Gross
Discount
Net
Gross
Discount
Net
Loans Payable, Current5,610 (530)5,080 8,570 (724)7,846 
Loans Payable, Non-Current   3,353 (284)3,070 
Total - Loans Payable1
$5,610 $(530)$5,080 $11,923 $(1,008)$10,916 
Convertible Notes Payable - Current$3,000 $(124)$2,876 $ $ $ 
Convertible Notes Payable - Non-Current$2,000 $ $2,000 $5,000 $(228)$4,772 
Total - Convertible Notes Payable$5,000 $(124)$4,876 $5,000 $(228)$4,772 
Total - Loans and Notes Payable10,610 16,923 
1 The gross amount includes the 4.25% final payment of $0.5 million.
Remaining maturities of the Company’s loan and convertible note payables are as follows:
(In thousands)LoansConvertible
Notes
Total
Year ended December 31, 2023$ $ $ 
Year ended December 31, 20245,610 5,000 10,610 
Total$5,610 $5,000 $10,610 
Term Loan from Avenue Venture Opportunities Fund, L.P.
On August 6, 2021, the Company entered into a Loan and Security Agreement (the “Avenue Loan Agreement”) with Avenue Venture Opportunities Fund, L.P. (the “Lender,” or “Avenue”) for a term loan in an aggregate principal amount of up to $20.0 million (the “Avenue Loan”). The Avenue Loan bears interest at an annual rate equal to the greater of (a) the sum of 7.70% plus the prime rate as reported in The Wall Street Journal and (b) 10.95%. The interest rate at September 30, 2023 was 16.20%. The Avenue Loan is secured by all of the Company’s assets globally, including intellectual property. The Avenue Loan matures on August 1, 2024.

The initial tranche of the Avenue Loan was $15.0 million, including $4.0 million that was funded into a restricted account. On March 15, 2023, the Company returned to Avenue $4.0 million held in the restricted cash to pay down a portion of the
14

outstanding loan balance, principal payments of $2.1 million and an incremental 4.25% of the final payment of $0.2 million. On March 31, 2023, the Avenue Loan Agreement was amended (the “Avenue Amendment”) to defer the interest only period to September 30, 2023, with an additional extension option upon FDA Approval for the HEPZATO KIT and subsequent receipt of at least $10 million from the sale and issuance of equity securities. On August 14, 2023, the Company received FDA approval and has subsequently received over $10 million from the exercise of Tranche A Preferred Warrants. At the Company’s option, it has elected to extend the interest only period to December 31, 2023 and principal payments are deferred until January 2024.
Up to $3.0 million of the principal amount of the Avenue Loan outstanding may be converted, at Avenue's option, into shares of the Company’s common stock at a conversion price of $11.98 per share.
The Avenue Loan Agreement requires the Company to make and maintain representations and warranties and other agreements that are customary in loan agreements of this type. The Avenue Loan Agreement also contains customary events of default, including non-payment of principal or interest, violations of covenants, bankruptcy and material judgements.
In connection with the initial entry into the Avenue Loan Agreement, the Company issued warrants to Avenue (the “Initial Avenue Warrant”) to purchase 127,755 shares of common stock at an exercise price per share equal to $0.01. The Initial Avenue Warrant is exercisable until August 31, 2026. Additionally, in connection with the Avenue Amendment, the Company issued to Avenue a warrant to purchase 34,072 shares of common stock at an exercise price per share equal to $0.01.
The Company determined that the embedded conversion option associated with the Avenue Loan did not require bifurcation and met the criteria for equity classification. In addition, the amendment was recorded under debt modification guidance. Aggregate debt discount amortization of $0.2 million and $0.6 million was recorded during the three and nine months ended September 30, 2023 and 2022, respectively. Interest expense incurred was $0.3 million and $0.4 million for the three months ended September 30, 2023 and 2022, respectively and $1.1 million and $1.3 million for the nine months ended September 30, 2023 and 2022, respectively.
Convertible Notes Payable
The Company has $2.0 million of principal outstanding related to Senior Secured Promissory Notes (the “Rosalind Notes”) which bear interest at 8% per annum. Pursuant to the original terms, the Rosalind Notes were convertible into Series E Preferred Stock at a price of $1,500 per share and were to mature on July 16, 2021. Interest expense was $0.1 million for the nine months ended September 30, 2023 and 2022, respectively.
On August 6, 2021, the Company executed an agreement to amend the Rosalind Notes to (i) reduce the conversion price to $1,198 per share of the Company’s Series E Preferred Stock; and (ii) extend the maturity date to October 30, 2024. In addition, the holders of the Rosalind Notes agreed to subordinate all of the Company’s indebtedness and obligations to Avenue and all of the holders’ security interest, to the Avenue Loan and Avenue’s security interest in the Company’s property.

(9)    Preferred Purchase Agreement
On March 27, 2023, we entered into a securities purchase agreement with certain accredited investors (the “Preferred Purchase Agreement”), pursuant to which on March 29, 2023, the Company issued and sold, in a private placement (the “Series F Preferred Offering”), (i) 24,900 shares of Series F-1 Convertible Preferred Stock, par value $0.01 per share (the “Series F-1 Preferred Stock”), (ii) tranche A warrants (the “Preferred Tranche A Warrants”) to acquire 34,859 shares of Series F-3 Convertible Preferred Stock, par value $0.01 per share (the “Series F-3 Preferred Stock”) and (iii) tranche B warrants (the “Preferred Tranche B Warrants,” together with the Preferred Tranche A Warrant, the “Preferred Warrants”) to acquire 24,900 shares of Series F-4 Convertible Preferred Stock, par value $0.01 per share (the “Series F-4 Preferred Stock”) for an aggregate offering price of $24.9 million before deducting the fees paid to the placement agent and the financial advisors and other financing expenses payable by the Company.
The gross proceeds of $24.9 million from the Series F Preferred Offering have been allocated first to the Preferred Warrant liabilities at their fair value of $4.9 million, with the residual of $20.0 million being allocated to the Series F-1 Preferred Stock.
During the three months ended September 30, 2023, all of the Preferred Tranche A Warrants were exercised for an aggregate exercise price of $34.9 million into 34,859 shares of Series F-3 Preferred Stock and 13,232 shares of Series F-3
15

Preferred Stock were concurrently converted into 2,940,440 shares of common stock (in accordance with the beneficial ownership limitations then in effect). The Preferred Tranche B Warrants are exercisable for 24,900 shares of Series F-4 Preferred Stock, with an aggregate exercise price of $24.9 million until the earlier of (i) 21 days following the Company's announcement of receipt of at least $10 million in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026.
Following stockholder approval, pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series F Convertible Voting Preferred Stock (the “Certificate of Designation”), each share of Series F-1 Preferred Stock automatically converted into shares of common stock and/or, if applicable (in accordance with the beneficial ownership limitations then in effect), shares of Series F-2 Preferred Stock, par value $0.01 per share (the “Series F-2 Preferred Stock” and, together with the Series F-1 Preferred Stock, the Series F-3 Preferred Stock and the Series F-4 Preferred Stock, the “Series F Preferred Stock”) in lieu of common stock. Subject to limitations set forth in the Certificate of Designation, the shares of Series F-2, F-3 and F-4 Preferred Stock are convertible into common stock at the option of the holder at the conversion price of $3.30 per share, $4.50 per share and $6.00 per share, respectively, rounded down to the nearest whole share, and in each case subject to the terms and limitations contained in the Certificate of Designation. As of September 30, 2023, 33,229 shares of the Company's Series F-1, F-2 and F-3 Preferred Stock were converted into 9,000,582 shares of common stock. As of September 30, 2023, there were 4,903 shares of Series F-2 Preferred Stock, 21,627 shares of Series F-3 Preferred Stock and no shares of Series F-4 Preferred Stock outstanding.
The Series F-2, F-3 and F-4 Preferred Stock are not mandatorily redeemable, redeemable at the holder’s election or contingently redeemable at the holder’s election (at this point, a Deemed Liquidation Event would potentially trigger pro rata liquidation payments to the preferred and common stockholders on a pro rata “as converted” basis). Accordingly, the Series F-2, F-3 and F-4 Preferred are now classified as permanent equity.
The Company determined that the outstanding Preferred Warrants should be liability-classified. See “Note 1 – Warrant Liabilities” for a discussion of the accounting treatment of the Common Warrants and Preferred Warrants.

(10)    Stockholders’ Equity
Public and Private Placements
Common Purchase Agreement
On March 27, 2023, the Company entered into a securities purchase agreement (the “Common Purchase Agreement”) with the Company’s Chief Executive Officer, Gerard Michel, pursuant to which the Company agreed to issue and sell, in a private placement (the “Common Offering”) shares of common stock, tranche A warrants (“Common Tranche A Warrants”) to acquire 31,110 shares of common stock, tranche B warrants (“Common Tranche B Warrants”, together with the Common Tranche A Warrants, the “Common Warrants”) to acquire 16,666 shares of common stock. On March 29, 2023, the Company closed the Common Offering.
The aggregate exercise price of the Common Tranche A Warrants issued pursuant to the Common Offering is approximately $0.1 million.
On August 14, 2023, the Company announced the receipt of the FDA Approval and all Common Tranche A Warrants were exercised and converted into 31,110 shares of common stock.
The aggregate exercise price of the Common Tranche B Warrants issued in the Common Offering is approximately $0.1 million. The Common Tranche B Warrants are exercisable for an aggregate of 16,666 shares of common stock until the earlier of 21 days following the Company’s announcement of receipt of recording at least $10 million in quarterly U.S. revenue from the commercialization of HEPZATO and March 31, 2026.
The Company determined that the outstanding Common Warrants should be liability-classified. See “Note 1 – Warrant Liabilities” for a discussion of the accounting treatment of the Common Warrants and Preferred Warrants.
Registration Rights for Preferred and Common Offerings
Pursuant to the Preferred Purchase Agreement and the Common Purchase Agreement (collectively, the “Purchase Agreements”), the Company filed a registration statement on Form S-3 (the “Resale Registration Statement”) providing for
16

the resale by the investors party thereto of the common stock issuable upon conversion of the Registrable Shares (as defined in the Purchase Agreements). The Resale Registration Statement became effective on June 28, 2023.
There is no established public trading market for the Series F Preferred Stock, the Preferred Warrants, or the Common Warrants and the Company does not intend to list such securities on any national securities exchange or nationally recognized trading system.
At-the-Market Offering
The Company has entered into a Controlled Equity OfferingSM Sales Agreement (“ATM Sales Agreement”), with Cantor Fitzgerald & Co. (the “Sales Agent”), pursuant to which the Company may offer and sell, at its sole discretion through the Sales Agent, shares of common stock having an aggregate offering price of up to $17.0 million. To date, the Company has sold approximately $4.0 million of its common stock, prior to issuance costs, under the ATM Sales Agreement. No sales were made during the three and nine months ended September 30, 2023.
Authorized Shares
In June 2023, stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of its common stock authorized for issuance from 40 million shares to 80 million shares. The Company is authorized to issue 80 million shares of common stock, $0.01 par value, and 10 million shares of preferred stock, $0.01 par value. As of September 30, 2023, the Company has designated the following preferred stock:

Designated Preferred SharesSeptember 30, 2023
Series A4,200 
Series B2,360 
Series C590 
Series D10,000 
Series E 40,000 
Series E-112,960 
Series F-1 24,900 
Series F-224,900 
Series F-334,860 
Series F-424,900 
Total179,670 
Preferred Stock
As of September 30, 2023, there were an aggregate of 11,257 shares of Series E and Series E-1, 4,903 Series F-2 and 21,627 Series F-3 Convertible Preferred Stock outstanding, respectively.
Omnibus Equity Incentive Plan
On September 30, 2020, the Company’s 2020 Omnibus Equity Incentive Plan (the “2020 Plan”) was adopted by the Company’s Board of Directors. On November 23, 2020, the Company’s stockholders approved the 2020 Plan. The 2020 Plan will continue in effect until the tenth anniversary of the date of its adoption by the Board or until earlier terminated by the Board. The 2020 Plan is administered by the Board of Directors or a committee designated by the Board of Directors. On June 12, 2023, the stockholders approved the amendment to the Company’s 2020 Plan to increase the number of shares of common stock available under the plan by 2.65 million shares. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, as well as other stock-based awards or cash awards that are deemed to be consistent with the purposes of the plan to Company employees, directors and consultants. As of September 30, 2023, there are 5,125,000 shares of common stock reserved under the 2020 Plan, of which 1,802,841 remained available to be issued.
In addition to options granted from the 2020 Plan, the Company also grants employment inducement grants pursuant to Listing Rule 5635(c) of the corporate governance rules of the NASDAQ Stock Market. These inducement grants are intended to provide incentive to certain individuals to enter into employment with the Company. Inducement grants are
17

granted outside of the 2020 Plan, however they are governed in all respects as if they were issued under the 2020 Plan. These grants do not reduce the number of options available for issuance under the 2020 Plan.
Stock Options
The following tables include information for all options granted including inducement grants that are granted outside of the 2020 Plan.
The Company values stock options using the Black-Scholes option pricing model and used the following assumptions, on a weighted-average basis, during the reporting periods:
 Nine Months Ended September 30,
 20232022
Expected terms (years)5.75.4
Expected volatility160.4%164.3%
Risk-free interest rate3.99%1.86%
Expected dividends0.00%0.00%
The following is a summary of stock option activity for the nine months ended September 30, 2023:
Number of Options Weighted Average
Exercise Price Per Share
Weighted Average
Remaining
Contractual Term
(in years)
Aggregate Intrinsic
Value
Outstanding at January 1, 20232,235,052$10.30 7.8$35,875 
Granted2,122,7576.08 9.1
Exercised(819)4.67 
Expired(115,772)8.80 
Cancelled/Forfeited(104,390)7.22 
Outstanding at September 30, 20234,136,828$8.26 8.5$72,850 
Exercisable at September 30, 20232,020,026$10.29 7.7$ 
The following table summarizes information for stock option shares outstanding and exercisable at September 30, 2023:
Options Outstanding
Range of Exercise PricesOutstanding Number of
Options
Weighted Average
Remaining Option Term
(in years)
Number of Options
$2.83 - $51.50
4,136,3298.54,136,329
$51.50+
4995.3499
4,136,8288.54,136,828
The following is a summary of share-based compensation expense in the statement of operations for the three and nine months ended September 30, 2023:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
Selling, general and administrative$1,674 $1,117 $3,774 $3,984 
Research and development1,027 458 2,095 1,872 
Cost of goods sold129 52 283 160 
Total$2,830 $1,627 $6,152 $6,016 
At September 30, 2023, there was $7.7 million of aggregate unrecognized compensation expense related employee and board stock option grants. The cost is expected to be recognized over a weighted average period of 2.4 years.
18

Common Stock Warrants
The following is a summary of common stock warrant activity for the nine months ended September 30, 2023:
 Warrants
Weighted Average Exercise Price
Weighted Average
Remaining Life
(in years)
Outstanding at January 1, 20235,153,291$7.01 
Warrants issued81,8482.94 
Warrants exercised(569,938)0.26 
Outstanding at September 30, 20234,665,201$7.76 1.9
Exercisable at September 30, 20234,665,201$7.76 1.9
The following table presents information related to common stock warrants outstanding at September 30, 2023:
Warrants Exercisable
Range of Exercise PricesOutstanding
Number of
Warrants
Weighted Average
Remaining Warrant Term
(in years)
Number of Warrants
$0.011,037,7923.41,037,792
$6.00
16,6662.516,666
$10.003,610,7431.43,610,743
4,665,2011.94,665,201
As of September 30, 2023, there were 538,828 warrants priced at $0.01 and 31,110 warrants priced at $4.50 exercised for 569,938 common shares.
Preferred Stock Warrants
The following is a summary of preferred stock warrant activity for the nine months ended September 30, 2023:
WarrantsWeighted Average Exercise PriceWeighted Average
Remaining Life
(in years)
Outstanding at January 1, 2023 $ 
Warrants issued59,7591,000 
Warrants exercised(34,859)1,000 
Outstanding at September 30, 202324,900$1,000 2.5
Exercisable at September 30, 202324,900$1,000 2.5
Employee Stock Purchase Plan
In August 2021, the Company’s Board of Directors, with shareholder approval in May 2022, adopted the Employee Stock Purchase Plan (the “ESPP”). The ESPP provides for a maximum of 260,295 shares of common stock to be purchased by participating employees. Employees who elect to participate in the ESPP will be able to purchase common stock at the lower of 85% of the fair market value of common stock on the first or last day of the applicable six-month offering period. In January 2023, an aggregate of 15,417 shares were purchased by participating employees for the offering period of July 1, 2022 to December 31, 2022. In July 2023, an aggregate of 26,018 shares were purchased by participating employees for the offering period of January 1, 2023 to June 30, 2023.

19

(11)    Net Loss per Share
Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period, without consideration of potentially dilutive securities, except for those shares that are issuable for little or no cash consideration. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options, convertible preferred shares, and preferred and common warrants are generally deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal.
The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2023 and 2022 because their effects would be anti-dilutive:
September 30,
20232022
Common stock warrants3,627,4094,461,249
Assumed conversion of preferred stock warrants4,149,994
Assumed conversion of preferred stock7,417,4731,135,721
Assumed conversion of convertible notes488,031488,031
Stock options4,136,8282,249,955
Total19,819,7358,334,956

At September 30, 2023, the Company had 1,037,792 pre-funded warrants outstanding. The following table provides a reconciliation of the weighted average shares outstanding calculation for the three and nine months ended September 30, 2023 and 2022:
Three months ended September 30,Nine months ended September 30,
2023202220232022
Weighted average shares issued16,825,2868,470,00612,745,0358,096,551
Weighted average pre-funded warrants1,037,792745,7801,240,213439,455
Weighted average shares outstanding17,863,0789,215,78613,985,2488,536,006

(12)    Income Taxes
As discussed in “Note 14—Income Taxes” to the notes to the consolidated financial statements contained in the Annual Report, the Company has a valuation allowance against the full amount of its net deferred tax assets. The Company currently provides a valuation allowance against deferred tax assets when it is more likely than not that some portion or all of its deferred tax assets will not be realized. The Company has not recognized any unrecognized tax benefits in its balance sheet.
The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. Additional information regarding the statutes of limitations can be found in Note 14 Income Taxes of the Company’s Annual Report.
The Inflation Reduction Act of 2022 included tax legislation that became effective in the first quarter of 2023. Significant legislation for corporate taxpayers includes a corporate alternative minimum tax of 15% for companies with $1 billion or more in average net financial statement profits over the three previous years, as well as a 1% indirect excise tax on the repurchase of shares by a publicly traded company. The Company does not expect this legislation to have an effect on the tax provision as of September 30, 2023, however the Company will continue to evaluate the effect on the tax provision each reporting period.

20

(13)    Commitments and Contingencies
medac Matter
In April 2021, the Company’s wholly owned subsidiary, Delcath Systems Ltd, issued to medac GmbH, a privately held, multi-national pharmaceutical company based in Germany (“medac”), an invoice for a €1 million milestone payment under a License, Supply and Marketing Agreement dated December 10, 2018 (the “medac Agreement”) between medac and the Company. The medac Agreement provided to medac the exclusive right to market and sell CHEMOSAT in certain designated countries for which the Company was entitled to a combination of upfront and success-based milestone payments as well as a fixed transfer price per unit of CHEMOSAT and specified royalties.
In response to medac’s subsequent dispute and non-payment of the invoice, on October 12, 2021, the Company notified medac in writing that it was terminating the medac Agreement due to medac’s nonpayment of the €1 million milestone payment, with the effective date of termination of the medac Agreement being April 12, 2022. On December 16, 2021, the Company initiated an arbitration proceeding pursuant to the dispute resolution procedures of the medac Agreement for the non-payment of the invoice.
On December 30, 2022, the parties reached a final settlement of the matter and the Company agreed to pay medac either (a) a royalty on sales of CHEMOSAT units over a defined minimum for a period of five years or until a maximum payment has been reached, or (b) a minimum annual payment of $0.2 million in the event the annual royalty payment does not reach the agreed minimum payment amount. The Company has estimated the fair value of the settlement to be $1.3 million as of September 30, 2023 and recorded $1.1 million as other liabilities, non-current and $0.2 million as accrued expenses on the Company’s condensed consolidated balance sheet as of September 30, 2023.
Lachman Consulting Services, Inc.
On January 24, 2023, Lachman Consultant Services, Inc (“Lachman”) served the Company with a complaint alleging that Delcath owed Lachman approximately $0.9 million in unpaid consulting fees plus interest, costs and attorneys’ fees. The dispute arose from a July 22, 2021 agreement between Lachman and Delcath under which Lachman provided assistance to the Company in regard to preparing for a FDA inspection and good manufacturing practices, training and support. A settlement was reached on July 5, 2023, under which the Company paid Lachman $0.9 million.
(14)    Fair Value Measurements
The table below presents activity within Level 3 of the fair value hierarchy, our liabilities carried at fair value for the nine months ended September 30, 2023:
Level 3
(In thousands)Contingent
liabilities
WarrantsTotal
Balance at January 1, 2023$1,280 $ $1,280 
Total change in foreign exchange(9) (9)
Fair value of the warrant liability issued 4,940 4,940 
Warrant liability fair value adjustment 8,224 8,224 
Change due to warrant exercise$ $(7,391)$(7,391)
Balance at September 30, 2023$1,271 $5,773 $7,044 
Contingent liabilities are re-measured to fair value each reporting period using projected financial targets, discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected financial targets are based on our most recent internal operational budgets and may take into consideration alternate scenarios that could result in more or less profitability for the respective service line. Increases or decreases in projected financial targets and probabilities of payment may result in significant changes in the fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs in isolation may result in a significantly lower or higher fair value measurement.
As disclosed in Note 9 and Note 10 of the Company’s consolidated financial statements, the Company allocated part of the proceeds of the Series F Preferred Offering to warrant liability issued in connection with the transaction. The valuations of the warrants were determined using option pricing models. The Company concluded that the Preferred Warrants were not in the scope of Accounting Standards Codification (ASC 480), Distinguishing Liabilities from Equity (ASC 480,) since the
21

Preferred Warrants are not mandatorily redeemable; and do not have obligations to issue a variable number of shares of preferred stock. The Company determined the Preferred Warrants met the definition of a derivative in accordance with ASC 815 but were not considered indexed to the Company’s common stock since the warrants require early settlement by repurchasing the preferred warrants for cash in an amount equal to the Black-Scholes value in the event of a Fundamental Transaction at pre-specified volatility of 100% as an input to the Black-Scholes calculation. The Company determined to record the Preferred Warrants at fair value with subsequent changes in fair value recorded in earnings at the end of each reporting period. For the three and nine months ended September 30, 2023, the Company recorded other expense of $9.4 million and $8.2 million, respectively, related to the change in fair value of the warrant liability and Tranche A Warrant exercises. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. The Company has classified the warrants as a long-term liability due to certain provisions relating to the holders’ ability to exercise the warrants beyond twelve months of the reporting date.
The fair value of the preferred and common warrants at September 30, 2023 and March 29, 2023 was determined by using option pricing models assuming the following:
March 29, 2023September 30, 2023
Risk free interest rate
3.80% - 4.80%
 4.80%
Expected term (years)
0.5 - 3.0
 2.5
Expected volatility
70% - 75%
 70%
Expected dividends0.00%0.00%
Additionally, the Company has determined that the warrant liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing models against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of the Company’s stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of the Company’s stock over that term; annual rate of dividends; and the risk-free rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of the Company’s stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The risk-free rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, the Company determined the warrant liability is most appropriately classified within Level 3 of the fair value hierarchy.
The following tables present information about the Company’s financial assets and liabilities that have been measured at fair value as of September 30, 2023 and December 31, 2022 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. In general, the fair values were determined using Level 3:
(In thousands)
Quoted Prices in
Active Markets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
September 30,
2023
Liabilities:    
Contingent liability$ $ $1,271 $1,271 
Warrant liability  5,773 5,773 
Total liabilities$ $ $7,044 $7,044 
(In thousands)Quoted Prices in
Active Markets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
December 31,
2022
Liabilities:    
Contingent liability$ $ $1,280 $1,280 
Total liabilities$ $ $1,280 $1,280 
22

Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of the financial condition and results of operations of Delcath Systems, Inc. (“Delcath” or the “Company”) should be read in conjunction with the unaudited interim condensed consolidated financial statements and notes thereto contained in Item 1 of Part I of this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Annual Report”), which was filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2023, to provide an understanding of its results of operations, financial condition and cash flows.
All references in this Quarterly Report on Form 10-Q to “we,” “our,” “us” and the “Company” refer to Delcath Systems, Inc., and its subsidiaries unless the context indicates otherwise.
This Quarterly Report on Form 10-Q and may include trademarks, service marks and trade names owned or licensed by us, including CHEMOFUSE, CHEMOSAT, CHEMOSATURATION, DELCATH, HEPZATO, HEPZATO KIT, PHP and THE DELCATH PHP SYSTEM. Solely for convenience and readability, trademarks, service marks and trade names, including logos, artwork and other visual displays, may appear in a non-traditional trademark usage manner, including without the ® or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks and trade names. All trademarks, service marks and trade names included in this Quarterly Report on Form 10-Q are the property of the Company or the Company’s licensor, as applicable.
Disclosure Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 with respect to our business, financial condition, liquidity, and results of operations. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,” “may,” “can,” “continue,” “potential,” “should,” and the negative of these terms or other comparable terminology often identify forward-looking statements. Statements in this Quarterly Report on Form 10-Q that are not historical facts are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements, including the risks discussed in Item 3 “Quantitative and Qualitative Disclosures About Market Risk,” and the risks discussed in Part II, Item 1A under “Risk Factors” and the risks detailed from time to time in our future reports filed with the SEC. These forward-looking statements include, but are not limited to, statements about:
our estimates regarding sufficiency of our cash resources, anticipated capital requirements and our need for additional financing;
the commencement of future clinical trials and the results and timing of those clinical trials;
our ability to successfully commercialize CHEMOSAT and HEPZATO, generate revenue and successfully obtain reimbursement for the procedure and system;
the initiation and success of our research and development programs;
submission and timing of applications for regulatory approval and approval thereof;
our ability to successfully source components of CHEMOSAT and HEPZATO and enter into supplier contracts;
our ability to source melphalan for use in HEPZATO;
our ability to successfully manufacture CHEMOSAT and HEPZATO;
our ability to successfully negotiate and enter into agreements with distribution, strategic and corporate partners; and
our estimates of potential market opportunities and our ability to successfully realize these opportunities.
Many of the important factors that will determine these results are beyond our ability to control or predict. You are cautioned not to put undue reliance on any forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. Except as otherwise required by law, we do not assume any obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.
23

Company Overview
We are an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our lead product, the HEPZATO KITTM (“HEPZATO” melphalan for Injection/Hepatic Delivery System), a drug/device combination product, was approved by the US Food and Drug Administration (the “FDA”) on August 14, 2023 indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver with no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.
In the United States, HEPZATO is considered a combination drug and device product and is regulated as a drug by the FDA. Primary jurisdiction for regulation of HEPZATO has been assigned to the FDA’s Center for Drug Evaluation and Research. The FDA has granted us six orphan drug designations (five for melphalan in the treatment of patients with ocular (uveal) melanoma, cutaneous melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and neuroendocrine tumor indications and one for doxorubicin in the treatment of patients with hepatocellular carcinoma).
Our clinical development program for HEPZATO was comprised of the FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (the “FOCUS Trial”), a global registration clinical trial that investigated objective response rate in metastatic ocular melanoma (“mOM”). We are currently reviewing the incidence, unmet need, available efficacy data and development requirements for a broad set of liver cancers in order to select a portfolio of follow-on indications that will maximize the value of the HEPZATO platform. In addition to HEPZATO’s use to treat mOM, we believe that HEPZATO has the potential to treat other liver dominant cancers, such as Metastatic Colorectal Cancer and Cholangiocarcinoma, and plan to begin the study of HEPZATO to treat such conditions in the near future. We believe that the disease states we are investigating and intend to investigate are unmet medical needs that represent significant market opportunities.
Upon launch, we believe we believe we will have sufficient stock for HEPZATO KIT to meet the first year of our forecasted demand and intend to manage supply chain risk through stockpiled inventory and contracting with multiple suppliers for critical components.
As we prepare for the launch of HEPZATO, we continue our expanded access programs (“EAP”) in the United States to make HEPZATO readily available to mOM patients. We are focused on continuing to treat patients enrolled in the EAP sites.
On February 28, 2022, CHEMOSAT received Medical Device Regulation (MDR) certification under the European Medical Devices Regulation (2017/745/EU), which may be considered by jurisdictions when evaluating reimbursement. As of March 1, 2022, we have assumed direct responsibility for sales, marketing and distribution of CHEMOSAT in Europe.
24

Results of Operations
Three months ended September 30,Nine months ended September 30,
(In thousands)2023202220232022
Total revenues$434 $906 $1,526 $2,080 
Cost of goods sold(133)(235)(464)(449)
Gross profit301 671 1,062 1,631 
Research and development expenses4,662 4,065 12,793 14,152 
Selling, general and administrative expenses6,195 4,779 15,147 13,477 
Total operating expenses10,857 8,844 27,940 27,629 
Operating loss(10,556)(8,173)(26,878)(25,998)
Interest and other income (expense)(9,784)(704)(9,664)(2,038)
Net loss$(20,340)$(8,877)$(36,542)$(28,036)
Revenue
The decrease in total revenue for the three and nine months ended September 30, 2023 compared to the same periods in 2022 was primarily due to lower demand for CHEMOSAT.
Cost of Goods Sold
The change in cost of goods sold for the three and nine months ended September 30, 2023 compared to the same periods in 2022 is directly related to changes in demand for product revenue.
Research and Development Expenses
Research and development expenses are incurred for the development of HEPZATO and consist primarily of payroll and payments to contract research and development companies. In 2022, these costs primarily related to generating pre-clinical data and the cost of manufacturing HEPZATO for clinical trials and conducting clinical trials. The increase for the three months ended September 30, 2023 compared to the same period in 2022 is due to activities related to the FDA inspection and other requests in advance of the approval of HEPZATO. The decrease in the nine months ended September 30, 2023 compared to the same period in 2022 relates to completion of clinical trial activities in the prior period in 2022 and higher expenses for the preparation for the pre-NDA meeting in April 2022.
Selling, General and Administrative Expenses
Selling, general and administrative expenses consist primarily of payroll, rent and professional services such as accounting, legal, marketing and commercial preparation services. For the three and nine months ended September 30, 2023 compared to the same periods in 2022, selling, general and administrative expenses have increased due to activities to prepare for commercial launch.
Interest and other Income/Expense
Interest and other income (expense) in 2023 is primarily related to the change in fair value of the Tranche A Warrants (as defined below) at exercise, the Tranche B Warrants (as defined below) liability, interest income associated with marketable securities offset by interest expense related to our debt instruments. There was a decrease in interest expense for the three and nine months ended September 30, 2023 compared to the same periods in 2022 related to the principal loan payments during the 2023 as we paid $6.3 million of principal payments.
Liquidity and Capital Resources
At September 30, 2023, we had cash, cash equivalents and restricted cash totaling $40.5 million, as compared to cash, cash equivalents and restricted cash totaling $11.8 million at December 31, 2022. During the nine months ended September 30, 2023, we used $23.1 million of cash for operating activities compared to $17.6 million during the nine months ended September 30, 2022, and $6.3 million for principal payments during the nine months ended September 30, 2023, compared to no principal payments during the nine months ended September 30, 2022. At September 30, 2022, we had cash, cash equivalents and restricted cash totaling $14.0 million.
Our future results are subject to substantial risks and uncertainties. We have operated at a loss for our entire history and there can be no assurance that we will ever achieve or maintain profitability. We have historically funded our operations primarily with
25

proceeds from sales of common stock, warrants and prefunded warrants for the purchase of common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements.
We currently believe that our current cash and cash equivalents will enable us to have sufficient cash through the launch of HEPZATO. If there is a substantial delay in the launch of HEPZATO we expect to need to raise additional capital under structures available to us, including debt and/or equity offerings, which may not be on terms favorable to us. In a substantially delayed launch scenario, we will not have sufficient funds to meet its obligations within twelve months from the issuance date of these condensed consolidated financial statements. As such, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt about our ability to continue as a going concern. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves. In a delayed approval scenario, our ability to continue as a going concern depends on our ability to raise additional capital through the sale of equity or debt securities, or through partnering or licensing transactions in which we receive cash to support our future operations. If we are unable to secure additional capital or if additional capital is not available on favorable terms for us, we may be required to take measures to reduce costs in order to conserve our cash.
We also expect to use cash and cash equivalents to fund activities relating to the launch of HEPZATO and the continued commercial support for CHEMOSAT and any future clinical research trials and operating activities. Our future liquidity and capital requirements will depend on numerous factors, including the initiation and progress of clinical trials and research and product development programs; obtaining regulatory approvals and complying with applicable laws and regulations; the timing and effectiveness of product commercialization activities, including marketing arrangements; the timing and costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; and the effect of competing technological and market developments.
Our capital commitments over the next twelve months include (a) $6.0 million to satisfy accounts payable, accrued expenses and lease liabilities and (b) $8.6 million of loan principal payments. Additional capital commitments beyond the next twelve months include (a) $0.1 million of lease liabilities; (b) $1.0 million for settlement of litigation with medac; (c) $2.0 million of convertible note principal payments, if the holders do not elect to convert the notes into equity.
ATM Sales Agreement
We entered into a Controlled Equity OfferingSM Sales Agreement (“ATM Sales Agreement”), with Cantor Fitzgerald & Co. (the “Sales Agent”), pursuant to which we may offer and sell, at our sole discretion through the Sales Agent, shares of common stock having an aggregate offering price of up to $17.0 million. To date, we have sold approximately $4.0 million of our common stock, prior to issuance costs, under the ATM Sales Agreement. No sales were made during the three and nine months ended September 30, 2023.
Avenue Loan Agreement
On August 6, 2021, we entered into the Avenue Loan Agreement with Avenue Venture Opportunities Fund, L.P. (the “Lender,” or “Avenue”) for a term loan in an aggregate principal amount of up to $20 million (the “Avenue Loan”). The Avenue Loan bears interest at an annual rate equal to the greater of (a) the sum of 7.7% plus the prime rate as reported in The Wall Street Journal and (b) 10.95%. The interest rate at September 30, 2023 was 16.20%. The Avenue Loan is secured by all of our assets globally, including intellectual property. The Avenue Loan matures on August 1, 2024. On March 15, 2023, we returned to Avenue $4.0 million held in the restricted cash to pay down a portion of the outstanding loan balance, principal payments of $2.1 million and an incremental 4.25% of the final payment of $0.2 million. On March 31, 2023, we reached an agreement to amend the existing loan agreement with Avenue to defer the interest only period to September 30, 2023. In exchange for this extension, the Company has agreed to provide Avenue with 34,072 warrants to purchase shares of common stock. The exercise price of the warrants is $0.01. On August 14, 2023, the Company received the FDA approval for the HEPZATO KIT and subsequently received over $10 million from the exercise of warrants. At our option, we have since elected to extend the interest only period to December 31, 2023 and principal payments are deferred until January 2024.
Private Placements, Common Offering and Warrants
26

On March 27, 2023, we entered into a securities purchase agreement with certain accredited investors (the “Preferred Purchase Agreement”), pursuant to which we agreed to issue and sell, in a private placement (the “Series F Preferred Offering”), (i) 24,900 shares of our Series F-1 Convertible Preferred Stock, par value $0.01 per share (the “Series F-1 Preferred Stock”), (ii) tranche A warrants (the “Preferred Tranche A Warrant”) to acquire 34,859 shares of Series F-3 Convertible Preferred Stock, par value $0.01 per share (the “Series F-3 Preferred Stock”) and (iii) tranche B warrants (the “Preferred Tranche B Warrant,” together with the Preferred Tranche A Warrant, the “Preferred Warrants”) to acquire 24,900 shares of Series F-4 Convertible Preferred Stock, par value $0.01 per share (the “Series F-4 Preferred Stock”) for an aggregate offering price of $24.9 million before deducting the fees paid to the placement agent and the financial advisors and other financing expenses payable by us.
Also on March 27, 2023, we entered into a securities purchase agreement with the our Chief Executive Officer, Gerard Michel, pursuant to which we agreed to issue and sell, in a private placement (the “Common Offering”, and together with the Series F Preferred Offering, the “Private Placements”), (i) 19,646 shares of common stock, (ii) tranche A warrants to acquire 31,110 shares of common stock (the “Common Tranche A Warrants”, and together with the Preferred Tranche A Warrants, the “Tranche A Warrants”) and (iii) tranche B warrants to acquire 16,666 shares of common stock (the “Common Tranche B Warrants”, and together with the Preferred Tranche B Warrants, the “Tranche B Warrants”) for an approximate aggregate offering price of $0.1 million.
On June 12, 2023, the stockholders approved the Private Placements at the annual general meeting of stockholders and therefore, the Preferred Warrants and Common Warrants issued in the Private Placements are exercisable. The exercise of all such Preferred Warrants and Common Warrants would generate approximately $60.0 million in proceeds. There can be no guarantee that all such Warrants are ever exercised, and if so, there is no guarantee that we will ever receive the full $60.0 million in proceeds. During the nine months ended September 30, 2023, all of the Preferred Tranche A Warrants were exercised for an aggregate exercise price of $34.9 million into 34,859 shares of Series F-3 Preferred Stock and all of the Common Tranche A Warrants were exercised for an aggregate exercise price of $0.1 million into 31,110 shares of common stock.

As of September 30, 2023, 33,229 shares of our Series F-1, F-2 and F-3 Preferred Stock were converted into 9,000,582 shares of common stock.

Critical Accounting Estimates
Other than the accounting for the valuation of warrant liability and Series F-1 Preferred Stock, during the three and nine months ended September 30, 2023, there were no other material changes to critical accounting estimates as reported in our Annual Report.
The valuations of the warrant liability and Series F-1 Preferred Stock were determined using option pricing models. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. In addition, we used probabilities of recording at least $10 million in quarterly U.S. revenue from the commercialization of HEPZATO as inputs in the model to determine the fair value of warrants liability and Series F-1 Preferred Stock. We adjust the fair value of the warranty liability at the end of each reporting period.

Application of Critical Accounting Policies
Our financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America. Other than the policies described in our notes Note 1 to the Notes to the Condensed Consolidated Financial Statements included elsewhere in this quarterly report on 10-Q for the three and nine months ended September 30, 2023, there were no material changes to our critical accounting policies as reported in our Annual Report. A description of certain accounting policies that may have a significant impact on amounts reported in the financial statements is disclosed in “Note 3 – Summary of Accounting Policies” to the notes to the consolidated financial statements contained in the Annual Report.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
Not required.


27

Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
As of September 30, 2023, our management, under the supervision of our Chief Executive Officer and our Principal Accounting Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Principal Accounting Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and Principal Officer determined that as a result of the material weaknesses in our internal control over financial reporting previously disclosed in our Annual Report, our disclosure controls and procedures were not effective as of September 30, 2023.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
28

PART II: OTHER INFORMATION
Item 1.    Legal Proceedings
From time to time, claims are made against the Company in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties, or injunctions prohibiting us from selling our products or engaging in other activities.
medac Matter
In April 2021, the Company’s wholly owned subsidiary, Delcath Systems Ltd, issued to medac GmbH, a privately held, multi-national pharmaceutical company based in Germany (“medac”), an invoice for a €1 million milestone payment under a License, Supply and Marketing Agreement dated December 10, 2018 (the “medac Agreement”) between medac and the Company. The medac Agreement provided to medac the exclusive right to market and sell CHEMOSAT in certain designated countries for which the Company was entitled to a combination of upfront and success-based milestone payments as well as a fixed transfer price per unit of CHEMOSAT and specified royalties.
In response to medac’s subsequent dispute and non-payment of the invoice, on October 12, 2021, the Company notified medac in writing that it was terminating the medac Agreement due to medac’s nonpayment of the €1 million milestone payment, with the effective date of termination of the medac Agreement being April 12, 2022. On December 16, 2021, the Company initiated an arbitration proceeding pursuant to the dispute resolution procedures of the medac Agreement for the non-payment of the invoice.
On December 30, 2022, the parties reached a final settlement of the matter and the Company agreed to pay medac either (a) a royalty on sales of CHEMOSAT units over a defined minimum for a period of five years or until a maximum payment has been reached, or (b) a minimum annual payment of $0.2 million in the event the annual royalty payment does not reach the agreed minimum payment amount. The Company has estimated the fair value of the settlement to be $1.3 million as of September 30, 2023 and recorded $1.1 million as other liabilities, non-current and $0.2 million as accrued expenses on the Company’s condensed consolidated balance sheet as of September 30, 2023.
Lachman Consulting Services, Inc.
On January 24, 2023, Lachman Consultant Services, Inc (“Lachman”) served the Company with a complaint alleging that Delcath owed Lachman approximately $0.9 million in unpaid consulting fees plus interest, costs and attorneys’ fees. The dispute arose from a July 22, 2021 agreement between Lachman and Delcath under which Lachman provided assistance to the Company in regard to preparing for a FDA inspection and good manufacturing practices, training and support. A settlement was reached on July 5, 2023, under which the Company paid Lachman $0.9 million.


29

Item 1A.    Risk Factors
Our business is subject to various risks and uncertainties that may have a material adverse effect on our business, financial condition or results of operations. You should carefully consider the risks and uncertainties described below, together with all of the other information included in this Quarterly Report on Form 10-Q and in the Annual Report on Form 10-K. Our business faces significant risks and uncertainties, and those described below may not be the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also significantly impair our business, financial condition or results of operations. If any of these risks or uncertainties occur, our business, financial condition or results of operations could suffer, the market price of our common stock could decline and you could lose all or part of your investment in our common stock.

Risk Factor Summary
Below is a summary of material factors that make an investment in our common stock speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider this summary to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. An additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, are described below, and this summary is qualified in its entirety by that description. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time, and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations. You should carefully consider the risks and uncertainties described below as part of your evaluation of an investment in our common stock.
Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. If there is a delay in the commercialization of HEPZATO or lower than anticipated revenue from such commercialization, we will be unable to continue to operate for the foreseeable future without additional capital;

If there is a substantial delay in the commercialization of HEPZATO, including lower than anticipated revenue from any HEPZATO commercialization, we will need additional capital to maintain our operations. If we cannot raise additional capital, our potential to generate future revenues will be significantly limited since we may not be able to further commercialize CHEMOSAT and HEPZATO, complete our clinical trials or conduct future product development and clinical trials;

We do not expect to generate significant revenue for the foreseeable future;

Continuing losses may exhaust our capital resources;

Our failure to obtain, or delays in obtaining, regulatory approvals may have a material adverse effect on our business, financial condition and results of operations;

We have obtained the right to affix the CE Mark for the CHEMOSAT Hepatic Delivery System as a medical device for the delivery of melphalan. Since we may only promote the device within this specific indication, if physicians are unwilling to obtain melphalan separately for use with CHEMOSAT, our ability to commercialize CHEMOSAT in the EU will be significantly limited;

We are subject to significant ongoing regulatory obligations and oversight in the EU and will be subject to such obligations in any other country where we receive marketing authorization or approval;

The development and approval process in the United States is time consuming, requires substantial resources and may not lead to the approval of our product candidates by the FDA for use in the United States.

If future clinical trials are unsuccessful, significantly delayed or not completed, we may not be able to market HEPZATO for other indications;

We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates;

30

We rely on third parties to conduct certain elements of the clinical trials for CHEMOSAT and HEPZATO, and if these third parties do not perform their obligations to us, we may not be able to obtain regulatory approvals for our system;

Purchasers of CHEMOSAT in the EU may not receive third-party reimbursement or such reimbursement may be inadequate. Without adequate reimbursement, commercialization of CHEMOSAT in the EU may not be successful. The success of any of our products may be harmed if the government, private health insurers or other third-party payers do not provide sufficient coverage or reimbursement;

CHEMOSAT and HEPZATO may not achieve sufficient acceptance by the medical community to sustain our business;

We may be subject, directly or indirectly, to federal and state health care fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties;

Compliance with laws and regulations pertaining to the privacy and security of health information may be time consuming, difficult and costly for us, particularly in light of increased focus on privacy issues in countries around the world, including the U.S. and in the EU;

Changes in health care law and governmental policies and initiatives with respect to health care, including government restrictions on pricing and reimbursement and other health care payor cost-containment initiatives, may have a material adverse effect on us;

Changes in general market, economic, and political conditions, as well as uncertainty resulting from geopolitical tensions, and other macroeconomic conditions;

Consolidation in the healthcare industry could lead to demands for price concessions;

We may not be able to enter into or maintain acceptable arrangements for the supply of components and/or raw materials needed for the manufacture of HEPZATO and/or CHEMOSAT;

We must maintain or enter into acceptable arrangements for the production of melphalan and other critical components of HEPZATO, we may not be able to ensure adequate supply impacting our ability to successfully commercialize HEPZATO in the United States or complete any future clinical trials;

If we cannot successfully manufacture CHEMOSAT and HEPZATO, our ability to develop and commercialize the system would be impaired;

We may be unsuccessful in commercializing our product in markets outside the EU, because of inadequate infrastructure or an ineffective commercialization strategy; and

Any of our plans to use collaborative arrangements with third parties to help finance and to market and sell CHEMOSAT and HEPZATO may not be successful.

31

Risks Related to Our Business and Financial Condition
Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern as of December 31, 2022.

Our independent registered public accounting firm issued a report dated March 27, 2023 in connection with the audit of our financial statements as of December 31, 2022, which included an explanatory paragraph describing the existence of conditions that raise substantial doubt about our ability to continue as a going concern including our significant working capital deficiency, significant losses and need to raise additional funds to meet our obligations and sustain our operations. In addition, the notes to our financial statements for the year ended December 31, 2022 and quarter ended September 30, 2023, included in our Annual Report on Form 10-K and Quarterly Report on Form 10-Q, respectively, contain disclosures describing the existence of conditions that raise substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern was dependent upon our ability to obtain substantial additional funding in connection with our continuing operations. We anticipate that our existing cash and cash equivalents will enable us to maintain our current operations through the launch of HEPZATO. If we are unable to raise sufficient capital or otherwise when needed, our business, financial condition and results of operations will be materially and adversely affected, and we will need to significantly modify our operational plans to continue as a going concern. If we are not able to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our consolidated financial statements and/or seek protection under federal bankruptcy law or enter into a receivership, and it is likely that holders of our common stock and holders of securities convertible into our common stock will lose all of their investment. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding on commercially reasonable terms or at all.
As such, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt about our ability to continue as a going concern.
We will need additional capital to maintain our operations. If we cannot raise additional capital, our potential to generate future revenues will be significantly limited since we will not be able to further commercialize CHEMOSAT and HEPZATO, complete our clinical trials or conduct future product development and clinical trials.
Developing and commercializing pharmaceutical products, including conducting preclinical testing and clinical trials and preparing for commercial launch are long, expensive, and highly uncertain processes and failure can unexpectedly occur at any stage of clinical development. Drug development is very risky, and it takes several years to complete clinical trials. The start or end of a clinical trial is often delayed or halted due to changing regulatory requirements, manufacturing challenges, required clinical trial administrative actions, slower than anticipated patient enrollment, changing standards of care, availability, or prevalence of use of a comparator treatment or required prior therapy, clinical outcomes including insufficient efficacy, safety concerns, or our own financial constraints.
We expect our expenses to increase, particularly as we commercialize HEPZATO in the United States, including expenses related to product sales, marketing, manufacturing and distribution. We will require additional substantial financing to complete our clinical trial programs or seek other approvals, to conduct future development and clinical trials and to further commercialize our products in the EU and any other markets where we may receive approval for our products. In the absence of potential proceeds from cash exercises of currently outstanding warrants, we will require substantial additional funding to complete product development projects or clinical trials. If we are unable to raise additional capital, our ability to complete product development projects or clinical trials will be impaired. We do not know if additional financing will be available on commercially reasonable terms or at all. In addition, we may not be able to access a portion of our existing cash, cash equivalents and investments due to market conditions.
Our liquidity and capital requirements will depend on numerous factors, including:
our ability to successfully commercialize and sell HEPZATO in the United States;
the outcome of clinical studies;
the timing and costs of our various United States and foreign regulatory filings, obtaining approvals and complying with regulations;
our ability to secure the continuous supply of melphalan and other critical components of HEPZATO and CHEMOSAT from facilities in compliance with applicable manufacturing regulations;
our ability to secure commercially reasonable terms for the supply of melphalan and other critical components of HEPZATO and CHEMOSAT;
32

the timing, costs and regulatory approval processes associated with developing our and/or our partners’ manufacturing operations;
the timing of product commercialization activities, including marketing and distribution arrangements;
market acceptance of any approved product candidates, including product pricing and product reimbursement by third-party payors;
executive compensation, including the cost of attracting senior executives;
the timing and costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; and
the impact of competing technological and market developments.
Insufficient capital may require us to curtail or stop our commercialization activities, regulatory submissions or ongoing activities for regulatory approval, research and development and clinical trials, which will significantly limit our potential to generate future revenues.
If we are not in compliance with the terms and conditions of the Avenue Loan Agreement, our business and financial condition may be adversely affected.
On August 6, 2021, we entered into the Loan and Security Agreement (the “Avenue Loan Agreement”) with Avenue Venture Opportunities Fund, L.P. for a term loan in an aggregate principal amount of up to $20.0 million, pursuant to which, we have borrowed $15 million as of the date hereof. Pursuant to the Avenue Loan Agreement, we made monthly interest-only payments during the first fifteen months of the term of the Avenue Loan Agreement and began principal payments in December 2022. On March 31, 2023, we reached an agreement to amend the Avenue Loan Agreement to defer the interest only to September 30, 2023. At our option, we have since elected to extend the interest only period to December 31, 2023 and principal payments have been deferred until January 2024.
The Avenue Loan Agreement bears interest at an annual rate equal to the greater of (a) the sum of 7.7% plus the prime rate as reported in The Wall Street Journal and (b) 10.95%. The interest rate at September 30, 2023 was 16.20%. The Avenue Loan Agreement is secured by all of our assets globally, including intellectual property. The amount borrowed pursuant to the Avenue Loan Agreement matures on August 1, 2024.
The Avenue Loan Agreement contains customary events of default, including, among other things, our failure to fulfill certain of our obligations under the Avenue Loan Agreement and the occurrence of a material adverse change in our business, operations or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, the failure to deliver an unqualified audit report and board approved financial projections within time periods set forth in the Avenue Loan Agreement, or a material impairment in the perfection or priority of Lender’s lien in the collateral or in the value of such collateral. In the event of default by us under the Avenue Loan Agreement, the Lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all amounts then outstanding under the Avenue Loan Agreement, which could harm our business, operations and financial condition.
If we do not make our required monthly repayment on January 1, 2024, in accordance with the March 2023 amendment to the Avenue Loan Agreement, we would be in default of the Avenue Loan Agreement. If we were to be in default of the Avenue Loan Agreement, our business and financial condition may be adversely impacted and result in us losing rights to certain or our assets, including intellectual property that is secured by the Avenue Loan Agreement. Furthermore, if we default on any installment under the Avenue Loan Agreement, we will not be eligible to use Form S-3 registration statements for an extended period of time, which could further adversely impact our ability to raise additional financing.
Drug development is an inherently uncertain process with a high risk of failure at every stage of development. If clinical trials of our product candidates fail to satisfactorily demonstrate safety and efficacy to the FDA and other regulators, we, may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of these product candidates.

We are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities, such as the EMA, impose similar requirements. We have received approval for HEPZATO for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma in the United States, but there is no assurance that we will receive regulatory approvals for HEPZATO for the treatment in other jurisdictions, or for other indications in any jurisdiction. Similarly, we have received approval for CHEMOSAT in Europe, but there is no assurance that we will receive regulatory approvals for CHEMOSAT in other jurisdictions.

33

Raising additional capital, or the exercise or conversion of securities exercisable or convertible into shares of common stock, may cause dilution to our existing stockholders and raising funds through lending and licensing arrangements may restrict our operations or require it to relinquish proprietary rights.
Significant additional capital will be needed in the future to continue our planned operations. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, exercise of our outstanding warrants and conversion of outstanding preferred stock, strategic alliances and license and development agreements in connection with any collaborations. To the extent that we raise additional capital by issuing equity securities, existing stockholders’ ownership may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of a common stockholder. In addition, the exercise of outstanding warrants and options will also cause dilution. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, creating liens, redeeming its stock or making investments.
If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, or through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties on acceptable terms, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise develop and market.
Continuing losses may exhaust our capital resources.
As of September 30, 2023, we had $40.5 million in cash and cash equivalents. We have had minimal revenue to date, and have a substantial accumulated deficit, recurring operating losses and negative cash flow. We are not profitable and have incurred losses in each year since commencing operations. For the nine months ended September 30, 2023 and years ended December 31, 2022 and 2021, we incurred net losses of approximately $36.5 million, $36.5 million and $25.6 million, respectively, and expect to continue to incur losses in 2023. To date, we have funded operations through a combination of private placements and public offerings of our securities, debt financing including convertible notes. If we continue to incur losses, we may exhaust our capital resources, and as a result may be unable to engage in product development and the commercialization of CHEMOSAT and HEPZATO or any other versions of these products. If we are unable to raise capital or generate sufficient revenue, we may not be able to pay our debts when they become due and may have to seek protection under federal bankruptcy law or enter into a receivership.
Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders’ equity and working capital. In addition, we will not be able to generate product revenue unless and until one of our product candidates successfully completes clinical trials, receives regulatory approval and is successfully commercialized. In addition, we will not be able to generate product revenue until one of our products or product candidates is successfully commercialized. Our ability to generate any product revenue from our current or future product candidates also depends on a number of additional factors, including our ability to:
successfully commercialize HEPZATO in the United States;
successfully complete research and clinical development of current and future product candidates and obtain regulatory approval for those product candidates;
establish and maintain supply and manufacturing relationships, under commercially reasonable terms, with third parties, and ensure adequate, scaled up and legally compliant manufacturing of necessary components, including melphalan, bulk drug substances and drug products to maintain sufficient supply;
launch and commercialize any product candidates for which marketing approval is obtained, if any, and, if launched independently by us without a partner, successfully establish a sales force and marketing and distribution infrastructure;
demonstrate the necessary safety data (and, if accelerated approval is obtained, verify the clinical benefit) post-approval to ensure continued regulatory approval;
obtain coverage and adequate product reimbursement from third-party payors, including government payors, for any approved products;
achieve market acceptance for any approved products;
establish, maintain, protect and enforce our intellectual property rights; and
attract, hire and retain qualified personnel.
Because of the numerous risks and uncertainties associated with pharmaceutical product development, including that our product candidates may not advance through development or be approved for commercial sale, we are unable to predict if or when we will
34

generate product revenue or achieve or maintain profitability. Even if we successfully complete development and regulatory processes for any product candidates that we take forward, we anticipate incurring significant costs associated with launching and commercializing any products. If we fail to become profitable or do not sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce or cease our operations.
We have in the past, and may in the future, become subject to litigation or claims arising in or outside the ordinary course of business that could negatively affect our business operations and financial condition.
We have in the past, and may in the future, become subject to litigation or claims arising in or outside the ordinary course of business (other than intellectual property infringement actions) that could negatively affect our business operations and financial condition, including securities class actions and shareholder derivative actions, both of which are typically expensive to defend. Such claims and litigation proceedings may be brought by third parties, including our competitors, advisors, service providers, partners or collaborators, employees, and governmental or regulatory bodies. For information on past legal proceedings, please see “Part I - Item 1. Legal Proceedings.” Any claims and lawsuits, and the disposition of such claims and lawsuits, could be time-consuming and expensive to resolve, divert management attention and resources, and lead to attempts on the part of other parties to pursue similar claims. We may not be able to determine the amount of any potential losses and other costs we may incur due to the inherent uncertainties of litigation and settlement negotiations. In the event we are required or decide to pay amounts in connection with any claims or lawsuits, such amounts could be significant and could have a material adverse impact on our liquidity, business, financial condition and results of operations. In addition, depending on the nature and timing of any such dispute, a resolution of a legal matter could materially affect our future operating results, our cash flows or both. Additionally, we may be unable to maintain our existing directors’ and officers’ liability insurance in the future at satisfactory rates or adequate coverage amounts and may incur significant increases in insurance costs.
We do not expect to generate significant revenue for the foreseeable future.
Our entire focus has been on developing, commercializing, and obtaining regulatory authorizations and approvals of CHEMOSAT and HEPZATO and we have only developed these products for the treatment of cancers in the liver. If CHEMOSAT and HEPZATO for the treatment of cancers in the liver fail as commercial products, we have no other products to sell. In addition, since CHEMOSAT currently is approved for commercialization solely in the European Union (the “EU”), and limited other jurisdictions (including the United Kingdom) and HEPZATO is approved only in the United States, if we are unsuccessful in commercializing the products in the EU and the United States, we will have no means of generating revenue.
Our business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises, political crises, global geopolitical conflicts, or other macroeconomic conditions, which have in the past and may in the future negatively impact our business and financial performance.
The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, severely diminished liquidity and credit availability, declines in economic growth, supply chain shortages and disruptions, increases in inflation rates, higher interest rates and uncertainty about economic stability.
The Federal Reserve has raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with the risk of government shutdowns reduced government spending and volatility in financial markets may increase economic uncertainty and affect consumer spending. Similarly, public health crises and ongoing global geopolitical conflict has created extreme volatility in the global capital markets and is expected to have further global economic consequences, including disruptions of the global supply chain and energy markets. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity and credit markets deteriorate, or do not improve, including as a result of political unrest or war, it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more dilutive.
Further downgrades of the U.S. credit rating, automatic spending cuts, or a government shutdown could negatively impact our liquidity, financial condition and earnings.
The U.S. debt ceiling and budget deficit concerns have increased the possibility of credit-rating downgrades and economic slowdowns, or a recession in the United States. Although U.S. lawmakers have previously passed legislation to raise the federal debt ceiling on multiple occasions, there is a history of ratings agencies lowering or threatening to lower the long-term sovereign credit rating on the United States given such uncertainty. On August 1, 2023, Fitch Ratings downgraded the United States’ long-term foreign currency issuer default rating to AA+ from AAA as a result of these repeated debt ceiling and budget deficit concerns. The impact of this or any further downgrades to the U.S. government’s sovereign credit rating or its perceived creditworthiness could adversely affect the U.S. and global financial markets and economic conditions. Moreover, these developments could cause interest rates and borrowing costs to rise, which may negatively impact our ability to access the debt
35

markets on favorable terms. In addition, disagreement over the federal budget has caused the U.S. federal government to shut down for periods of time. Continued adverse political and economic conditions could have a material adverse effect on our business, financial condition and results of operations.
Risks Related to FDA and Foreign Regulatory Approvals and Regulatory Matters
The development and approval process in the United States could take many years, require substantial resources and may never lead to the approval of our product candidates by the FDA for use in the United States.

We cannot commercialize, sell or market any products in the United States without prior FDA approval. Securing regulatory approval requires the submission of extensive pre-clinical and clinical data and other supporting information for each proposed therapeutic indication in order to establish to the FDA’s satisfaction the product’s safety, efficacy, potency and purity for each intended use. Clinical development is a long, expensive and uncertain process and is subject to delays. We may encounter delays or rejections for various reasons.

The pre-clinical testing and clinical trials of HEPZATO with melphalan complied with the regulations of the FDA and other federal, state and local government authorities in the United States. However, approval policies or regulations may change. If we do not maintain regulatory approval for HEPZATO and the use of melphalan or other chemotherapeutic agents, our business, results of operations, financial condition and prospects would be materially and adversely affected. In addition, our failure to successfully complete clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any of our product candidates would significantly harm our business.

Our ability to market HEPZATO is limited to those uses that are approved.
The FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, dissemination of off-label information, industry-sponsored scientific and educational activities and promotional activities involving the Internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved label. Our ability to market and promote HEPZATO is limited to the approved indication and may only be promoted in this limited market. Physicians may prescribe legally available drugs for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers’ communications regarding off-label use, and FDA approval may otherwise limit our sales practices and our ability to promote, sell and distribute the product. Thus, we may only market HEPZATO for its approved indication and could be subject to enforcement action for off-label marketing. Further, if there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, we may be required to submit and obtain FDA approval of a new or supplemental NDA, which may require us to develop additional data or conduct additional preclinical studies and clinical trials. Failure to comply with these requirements can result in adverse publicity, FDA warning letters, corrective advertising and potential civil and criminal penalties.
If future clinical trials are unsuccessful, significantly delayed or not completed, we may not be able to market HEPZATO for other indications.
HEPZATO is now approved for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma. The approval was based primarily on the results of the FOCUS trial, a Phase 3, single arm, multicenter, open label study.
We plan to begin the study of HEPZATO for other indications in the future and failure can occur at any stage of development, for many reasons, including:
any pre-clinical or clinical test may fail to produce results satisfactory to the FDA or foreign regulatory authorities;
we may not be able to establish and maintain the supply of necessary components, including melphalan, bulk drug substances and drug products to maintain sufficient supply to conduct such clinical studies;
pre-clinical or clinical data can be interpreted in different ways, which could delay, limit or prevent regulatory approval;
negative or inconclusive results from a pre-clinical study or clinical trial or adverse medical events during a clinical trial could cause a pre-clinical study or clinical trial to be repeated or a program to be terminated, even if other studies or trials relating to the program are successful;
the FDA or foreign regulatory authorities can place a clinical hold on a trial if, among other reasons, it finds that patients enrolled in the trial are or would be exposed to an unreasonable and significant risk of illness or injury;
we may encounter delays or rejections based on changes in regulatory agency policies during the period in which we are developing a system, or the period required for review of any application for regulatory agency approval;
36

enrollment in any additional clinical trials may proceed more slowly than expected;
any other clinical trials may not demonstrate the safety and efficacy of any system or result in marketable products;
the FDA or a foreign regulatory authority may change its approval policies or adopt new regulations that may negatively affect or delay our ability to bring a system to market or require additional clinical trials; and
a system may not be approved for all the requested indications.
The failure or delay of clinical trials could cause an increase in the cost of product development, delay filing of a NDA for marketing approval or cause us to cease the development of HEPZATO for other indications. If we are unable to develop HEPZATO for other indications, the future growth of our business could be negatively impacted. In addition, we have limited clinical data relating to the effectiveness of HEPZATO in certain types of cancer. Such limited data could slow the adoption of CHEMOSAT and HEPZATO and significantly reduce our ability to commercialize CHEMOSAT and HEPZATO.
We have obtained the right to affix the CE Mark for the CHEMOSAT Hepatic Delivery System as a medical device for the delivery of melphalan. Since we may only promote the device within this specific indication, if physicians are unwilling to obtain melphalan separately for use with CHEMOSAT, our ability to commercialize CHEMOSAT in the EU will be significantly limited.
In the EU, CHEMOSAT is regulated as a Class III medical device indicated for the intra-arterial administration of a chemotherapeutic agent, melphalan hydrochloride, to the liver with additional extracorporeal filtration of the venous blood return. Our ability to market and promote CHEMOSAT is limited to this approved indication. To the extent that our promotion of CHEMOSAT is found to be outside the scope of its approved indication, we may be subject to fines or other regulatory action, limiting our ability to commercialize CHEMOSAT in the EU.
We are limited to marketing CHEMOSAT in the EU as a medical device for the delivery of melphalan. If physicians are unwilling to obtain melphalan separately for use with CHEMOSAT, our ability to commercialize CHEMOSAT in the EU will be significantly limited. Our product instructions and indication reference the chemotherapeutic agent melphalan. However, no melphalan labels in the EU reference our product, and the labels vary from country to country with respect to the approved indication of the drug and its mode of administration. As a result, the delivery of melphalan with our device may not be within the applicable label with respect to some indications in some Member States of the EU where the drugs are authorized for marketing. Physicians intending to use CHEMOSAT must obtain melphalan separately for use with CHEMOSAT and must use melphalan independently at their discretion. If physicians are unwilling to obtain melphalan separately from CHEMOSAT and/or to prescribe the use of melphalan independently, our sales opportunities in the EU will be significantly limited.
We are subject to significant ongoing regulatory obligations and oversight in the EU and will be subject to such obligations in the United States and any other country where we receive marketing authorization or approval.
In April 2012, we obtained the required certification from a designated EU Notified Body, enabling us to complete an EC Declaration of Conformity with the essential requirements of the EU Medical Device Directive and affix the CE Mark to the Generation Two version of CHEMOSAT. More recently, on February 28, 2022, we obtained Medical Device Regulation certification under the new European Medical Devices Regulation (2017/745/EU). In order to maintain the right to affix the CE Mark in the EU, we are subject to compliance obligations, and any material changes to the approved product, such as manufacturing changes, product improvements or revised labeling, may require further regulatory review. Additionally, we are subject to ongoing audits by the European Notified Body, and the right to affix the CE Mark to the Generation Two version of CHEMOSAT may be withdrawn for a number of reasons, including the later discovery of previously unknown problems with the product.
We are subject to ongoing regulatory obligations and oversight in the countries where HEPZATO and CHEMOSAT have been approved. For example, we may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. With HEPZATO's approval, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product are subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current good manufacturing practice (“cGMPs”), good clinical practices (“GCPs”), and good laboratory practices, which are regulations and guidelines enforced by the FDA for all products in clinical development, for any pre-clinical or clinical trials that we conduct post-approval. In addition, post-marketing requirements for HEPZATO include implementation of a risk evaluation and mitigation strategies (“REMS”) program to ensure that the benefits of the product outweigh its risks. We must implement and ensure compliance with the HEPZATO REMS.
37

Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:
refusals or delays in the approval of NDAs or supplements to approved NDAs;
refusal of a regulatory authority to review pending market approval applications or supplements to approved NDAs;
restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls or seizures;
fines, FDA warning letters or untitled letters, or holds on clinical trials;
import or export restrictions;
injunctions or the imposition of civil or criminal penalties;
restrictions on product administration, requirements for additional clinical trials or changes to product labeling or REMS programs; or
recommendations by regulatory authorities against entering into governmental contracts with us.
If we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and may not achieve or sustain profitability, which would have a material adverse effect on our business, results of operations, financial condition and prospects.
We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates.
The FDA has granted us six orphan drug designations and we may seek additional orphan drug designations in the future.
Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States.
Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the European Medicines Agency (“EMA”) from approving another marketing application for the same indication for that drug during that time period. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or the EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.
We cannot assure you that any future application for orphan drug designation with respect to any product candidate will be granted. If we are unable to obtain orphan drug designation in the United States, we will not be eligible to obtain the period of market exclusivity that could result from orphan drug designation or be afforded the financial incentives associated with orphan drug designation. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.
We rely on third parties to conduct certain elements of the clinical trials for CHEMOSAT and HEPZATO, and if they do not perform their obligations to us, we may not be able to obtain future regulatory approvals for our system.
We design the clinical trials for our products, but rely on academic institutions, corporate partners, contract research organizations and other third parties to assist in managing, monitoring and otherwise carrying out these trials. We rely heavily on these parties for the execution of our clinical studies and control only certain aspects of their activities. Accordingly, we may have less control over the timing and other aspects of these clinical trials than if we conducted them entirely on our own. We rely on third parties to conduct monitoring and data collection of our future clinical trials. Although we rely on these third parties to manage the data from these clinical trials, we are responsible for confirming that each of our clinical trials is conducted in accordance with our general investigational plan and protocol. Moreover, the FDA and foreign regulatory agencies require us to comply with GCPs for conducting, recording and reporting the results of clinical trials to assure that the data and results are credible and accurate and that the trial participants are adequately protected. The FDA enforces these GCP regulations through periodic inspections of trial sponsors, principal investigators and trial sites. Our reliance on third parties does not relieve us of these responsibilities and requirements and if we or the third parties upon whom we rely for our clinical trials fail to comply with the applicable GCPs, the data generated in our clinical trials may be deemed unreliable and the FDA or other foreign regulatory agencies may require us to
38

perform additional trials before approving our marketing application. We cannot assure you that, upon inspection, the FDA will determine that any of our clinical trials comply or complied with GCPs. In addition, our clinical trials must be conducted with product that complies with the FDA’s cGMP requirements and we are dependent on third-party manufacturing and supply of critical components necessary for such clinical trial supply. To the extent a critical component relies on a single-sourced manufacture/supplier our ability to mitigate this risk decreases. Our failure, or any failure by such third party partners, to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process, and may result in a failure to obtain regulatory approval for HEPZATO for other indications if these requirements are not met.

Purchasers of CHEMOSAT in Europe may not receive third-party reimbursement or such reimbursement may be inadequate. Without adequate reimbursement, commercialization of CHEMOSAT in Europe may not be successful.
We have obtained the right to affix the CE Mark for CHEMOSAT, and we intend to seek third-party or government reimbursement within those countries in Europe where we expect to market and sell CHEMOSAT. In Germany, we had received a ZE diagnostic-related group code (“ZE Code”) which, beginning in 2016, permits hospitals in Germany to obtain reimbursement for CHEMOSAT procedures. Negotiations on the amount of reimbursement to be received under the ZE Code were concluded in 2016 and the procedure was reimbursed under the ZE Code in 2017. Reimbursement negotiations under the ZE system are conducted annually. Consequently, reimbursement obtained may not be for the full amount sought. In countries where we are able to obtain reimbursement, local policy could limit our ability to obtain adequate and consistent reimbursement and limit other sales opportunities in those countries.
In other countries, until we obtain government reimbursement, we will rely on private payors or local pre-approved funds where available. There are also no assurances that third-party payors or government health agencies in Europe will reimburse use of CHEMOSAT in the long term or at all. Further, each country has its own protocols regarding reimbursement, so successfully obtaining third party or government health agency reimbursement in one country does not necessarily translate to similar reimbursement in another European country. Physicians, hospitals and other health care providers may be reluctant to purchase CHEMOSAT if they do not receive substantial reimbursement for the cost of using the product from third-party payors or government entities. The lack of adequate reimbursement may significantly limit sales opportunities in Europe.
The success of our products may be harmed if the government, private health insurers or other third-party payers do not provide sufficient coverage or reimbursement.
Our ability to commercialize CHEMOSAT and HEPZATO successfully will depend in part on the extent to which reimbursement for the costs of such products and related treatments will be available from government health administration authorities, private health insurers and other third-party payors. We will seek reimbursement by third-party payors of the cost of HEPZATO but there are no assurances that adequate third-party coverage will be adequate for us to realize an appropriate return on our investment in developing new therapies. Government, private health insurers and other third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for new therapeutic products approved for marketing. Accordingly, even if coverage and reimbursement are provided by government, private health insurers and third-party payors for uses of our products, market acceptance of these products would be adversely affected if the reimbursement available proves to be unprofitable for healthcare providers.
Further implementation of healthcare reforms in the United States and in significant overseas markets may limit the ability to commercialize CHEMOSAT and HEPZATO and the demand for CHEMOSAT and HEPZATO.
Healthcare providers may respond to such cost-containment pressures by choosing lower cost products or other therapies.
CHEMOSAT and HEPZATO may not achieve sufficient acceptance by the medical community to sustain our business.
The commercial success of CHEMOSAT and HEPZATO will depend upon their acceptance by the medical community and third-party payers as clinically useful, cost effective and safe. Acceptance by the medical community may depend on the extent to which leaders in the scientific and medical communities publish scientific papers in reputable academic journals. If testing and clinical practice do not confirm the safety and efficacy of CHEMOSAT and HEPZATO or even if further testing and clinical practice produce positive results but the medical community does not view these favorably, our efforts to market CHEMOSAT and HEPZATO may fail, which would cause us to cease operation.
We may be subject, directly or indirectly, to federal and state health care fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
Our operations are directly, or indirectly through our customers, subject to various federal and state fraud and abuse laws. These laws may affect, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to
39

patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include, but are not limited to:
the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal health care program, such as Medicare and Medicaid programs;
federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent;
the federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) which created additional federal criminal statutes that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payers and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services;
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, (“HITECH”) and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information;
the federal transparency requirements under the Patient Protection and Affordable Care Act of 2010, which requires manufacturers of drugs, devices, biologics and medical supplies to report to the Department of Health and Human Services information related to certain payments and other transfers of value provided to physicians, (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, as well as certain ownership and investment interests held by physicians and their immediate family members; and
state law and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including exclusion from payment by federal health care programs, civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly.
Compliance with laws and regulations pertaining to the privacy and security of health information may be time consuming, difficult and costly, particularly in light of increased focus on privacy issues in countries around the world, including the United States and the European Union.
We are subject to various domestic and international privacy and security regulations. The confidentiality, collection, use and disclosure of personal data, including clinical trial patient-specific information, are subject to governmental regulation generally in the country where the personal data were collected or used. In the United States we are subject to various state and federal privacy and data security regulations, including but not limited to, HIPAA as amended by HITECH. HIPAA mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common health care transactions, as well as standards relating to the privacy and security of individually identifiable health information, which require the adoption of administrative, physical and technical safeguards to protect such information. In the European Union, personal data includes any information that relates to an identified or identifiable natural person with health information carrying additional obligations, including obtaining the explicit consent from the individual for collection, use or disclosure of the information. In addition, we are subject to EU regulation with respect to protection of and cross-border transfers of such data out of the European Union, and this regulation became more stringent in May 2018 when the EU’s General Data Protection Regulation (GDPR) came into effect. Furthermore, the legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues. The United States and the European Union and its member states continue to issue new privacy and data protection rules and regulations that relate to personal data and health information.
Compliance with these laws may be time consuming, difficult and costly. If we fail to comply with applicable laws, regulations or duties relating to the use, privacy or security of personal data we could be subject to the imposition of significant civil and criminal penalties, be forced to alter our business practices and suffer reputational harm.
40

Changes in health care law and implementing regulations, including government restrictions on pricing and reimbursement, as well as health care policy and other health care payor cost-containment initiatives, may have a material adverse effect on us.
In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the health care system and efforts to control health care costs, including drug prices, that could have a significant negative impact on our business, including preventing, limiting or delaying regulatory approval of our drug candidates and reducing the sales and profits derived from our products once they are approved.
For example, in the United States, the Patient Protection and Affordable Care Act of 2010 (“ACA”) substantially changed the way health care is financed by both governmental and private insurers and significantly affects the pharmaceutical industry. The ACA, among other things, subjected manufacturers to new annual fees and taxes for specified branded prescription drugs, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, expanded health care fraud and abuse laws, revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs under the Medicaid Drug Rebate Program are calculated, imposed an additional rebate similar to an inflation penalty on new formulations of drugs, extended the Medicaid Drug Rebate Program to Medicaid managed care organizations, expanded the 340B program, which caps the price at which manufacturers can sell covered outpatient pharmaceuticals to specified hospitals, clinics and community health centers, and provided incentives to programs that increase the federal government’s comparative effectiveness research. Since its enactment, there have been judicial and Congressional challenges and amendments to certain aspects of ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 (the “Tax Act”) includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate.” On June 17, 2021, the United States Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress. Congressional actions to repeal and replace provisions of the law and litigation and legislation over the ACA is likely to continue with unpredictable and uncertain results.
More recently, on August 16, 2022, the Inflation Reduction Act of 2022 (“IRA”) was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Department of Health and Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated “maximum fair price” under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.
At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
Consolidation in the healthcare industry could lead to demands for price concessions.
The cost of healthcare has risen significantly over the past decade and numerous initiatives and reforms initiated by legislators, regulators and third-party payors to curb these costs have resulted in a consolidation trend in the medical device industry. Group purchasing organizations, independent delivery networks and large single accounts in the United States and foreign markets may result in a consolidation of purchasing decisions for potential healthcare provider customers. We expect that market demand, government regulation, third-party reimbursement policies and societal pressures will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances which may exert further downward pressure on the price of CHEMOSAT and HEPZATO and adversely impact our business, financial condition and results of operations.

41

Risks Related to Manufacturing, Commercialization and Market Acceptance of CHEMOSAT and HEPZATO
We must maintain or enter into acceptable arrangements for the production of melphalan and other critical components of HEPZATO and we may not be able to ensure adequate supply impacting our ability to successfully commercialize HEPZATO in the United States or complete any future clinical trials.
Each manufacturer/supplier of components for the production of HEPZATO and CHEMOSAT must be in compliance with cGMPs. Our supply of critical components of HEPZATO and CHEMOSAT includes the use of one contracted supplier. In order to successfully commercialize HEPZATO, we also must be able to enter into long-term supply agreements for critical components, including melphalan, under commercially reasonable terms.
Under the current regulatory scheme in the European Union, CHEMOSAT is approved for marketing as a device only, and doctors will separately obtain melphalan for use with CHEMOSAT. Although melphalan has been approved in the European Union for over a decade, we are aware that there are currently three approved manufacturers of melphalan in certain countries of the European Union. If any of these manufacturers fails to provide end-users with adequate supplies of melphalan or fails to comply with the requirements of regulatory authorities, we may be unable to successfully commercialize our product in the European Union. Additionally, melphalan is not available in certain foreign countries outside the European Union where we may seek to market CHEMOSAT. If supply of melphalan remains limited or unavailable, we will be unable to commercialize CHEMOSAT in these markets, thereby limiting future sales opportunities.
FDA inspections of our suppliers/manufacturers, even for products other than those supplied to us, may result in the supplier/manufacturer being shut down or unable to deliver critical components to us in a timely manner. Such risks are increased for those components for which we have one contractual supplier.
We currently have an agreement with one supplier of melphalan and, with the goal of minimizing the risk of a supply interruption, are in discussions with several melphalan ANDA holders who have indicated interest in supplying melphalan to us. We are aware that FDA issued our current melphalan manufacturer 483 observations as a result of an inspection unrelated to the HEPZATO and the manufacturer is working to address these observations. We understand that the manufacturer is planning to suspend its operations beginning in December 2023 for several months to perform facility maintenance, but we do not believe the shutdown will impact the Company’s supply of melphalan for the HEPZATO KIT. Upon launch, we believe we will have sufficient stock for HEPZATO KIT to meet the first year of our forecasted demand and intend to manage supply chain risk through stockpiled inventory and contracting with multiple suppliers for critical components.
Although we are pursuing a variety of strategies to mitigate the risk of a supply interruption of commercial supply for our product, we cannot assure you that such shutdown and related matters will not result in a loss of supply in the event the shutdown is longer than anticipated or in the event regulatory action is taken against the supplier.
We may pursue agreements with additional contract manufacturers to produce melphalan and other critical components for use in any future clinical trial programs and for the production of CHEMOSAT and HEPZATO, as well as for labeling and finishing services. We may not be able to enter into such arrangements on commercially reasonable terms or at all. To manufacture melphalan or other chemotherapeutic agents on our own, we would have to develop a manufacturing facility that complies with FDA regulations for the production of melphalan and each other chemotherapeutic agent we choose to manufacture for use with our system. Developing these resources would be an expensive and lengthy process and would have a material adverse effect on our revenues and profitability. If we are unable to obtain sufficient melphalan and labeling services on acceptable terms or encounter delays or difficulties in our relationships with current and future suppliers or if current and future suppliers of melphalan do not comply with applicable regulations for the manufacturing and production of melphalan, our business, financial condition and results of operations may be materially harmed.
If we cannot successfully manufacture CHEMOSAT and HEPZATO, our ability to develop and commercialize the system would be impaired.
We manufacture certain components of our products, including our proprietary filter media, and assemble and package CHEMOSAT and HEPZATO at our facility in Queensbury, New York. We have established our European headquarters in Galway, Ireland and conduct finishing operations, assembly, packaging, labeling and distribution at this facility. We currently utilize third parties to manufacture some components of CHEMOSAT and HEPZATO. We may have difficulty obtaining components for our products from our third-party suppliers in a timely manner or at all, which may adversely affect our ability to deliver CHEMOSAT and HEPZATO to purchasers.
In addition to limiting sales opportunities, delays in manufacturing CHEMOSAT and HEPZATO may adversely affect our ability to obtain regulatory approval for other indications in the United States and other jurisdictions. Our ability to conduct timely clinical trials in the United States and abroad depends on our ability to manufacture the system, including sourcing the chemotherapeutic agents or other compounds through third parties in accordance with FDA and other regulatory requirements. If
42

we are unable to manufacture CHEMOSAT and HEPZATO in a timely manner, we may not be able to conduct additional clinical trials required to obtain regulatory approval and commercialize our product for other indications.
We have implemented quality systems throughout our organization designed to enable us to satisfy the various international quality system regulations, including those of the FDA with respect to products sold in the United States and those established by the International Standards Organization (“ISO”) with respect to products sold in the European Union. We are required to maintain ISO 13485 certification for medical devices to be sold in the European Union, which requires, among other items, an implemented quality system that applies to component quality, supplier control, product design and manufacturing operations. All of our facilities are presently ISO 13485:2016 certified. If our Queensbury, New York facility fails to maintain compliance with ISO 13485 and FDA cGMP or fails to pass facility inspection or audits, our ability to manufacture at the facility could be limited or terminated. In the future, we may manufacture and assemble CHEMOSAT and HEPZATO in our Galway, Ireland facility or elsewhere in the European Union, and any facilities in the European Union would have to obtain and maintain similar approvals or certifications of compliance.
Although we are not aware of any direct impacts of the war between the Ukraine and the Russian Federation, the conflict in the Middle East, or any other global conflict on our supply chain, such current or future conflicts could adversely impact our ability to obtain components and/or significantly increase the cost of obtaining such components for our products from its third-party suppliers in a timely manner or at all. In addition, at this time, although we are not aware of any direct impacts, any increase in COVID cases and associated restrictions could adversely impact our ability to obtain components and/or significantly increase the cost of obtaining such components for our products from our third-party suppliers in a timely manner or at all. A rise in COVID cases and the associated absences from work of internal and external resources may also impact our ability to meet anticipated timelines.

We do not have written contracts with all of our suppliers for the manufacture of components for CHEMOSAT and HEPZATO.
While we have written contracts and supply agreements for key components for CHEMOSAT and HEPZATO, we do not have written contracts with all suppliers for the manufacture of components for CHEMOSAT and HEPZATO. If we are unable to obtain an adequate supply of the necessary components or negotiate acceptable terms, we may not be able to manufacture CHEMOSAT and HEPZATO in commercial quantities or in a cost-effective manner, and commercialization of CHEMOSAT and HEPZATO in the United States, the European Union and elsewhere may be delayed. In addition, certain components are available from only a limited number of sources. Components of CHEMOSAT and HEPZATO are currently manufactured for us in small quantities. We may require significantly greater quantities to further commercialize the product. We may not be able to find alternate sources of comparable components. If we are unable to obtain adequate supplies of components from existing suppliers or need to switch to an alternate supplier and obtain FDA or other regulatory agency approval of that supplier, commercialization of CHEMOSAT and HEPZATO may be delayed.
We may be unsuccessful in commercializing CHEMOSAT and HEPZATO because of inadequate infrastructure or an ineffective commercialization strategy.
Our ability to commercialize CHEMOSAT and HEPZATO may be limited due to our inexperience in developing a sales, marketing and distribution infrastructure. If we are unable to develop this infrastructure in the United States or elsewhere or to collaborate with an alliance partner to market our products in the United States or foreign countries, particularly in Asia, our efforts to commercialize CHEMOSAT and HEPZATO or any other product may not succeed.
We may not be successful in our efforts to expand the commercialization of CHEMOSAT in the European Union, and we may not be successful in commercializing HEPZATO in the United States and CHEMOSAT or HEPZATO in other foreign countries. Each country requires a different commercialization strategy. Without a successful commercialization strategy tailored for each market, our efforts to promote and market CHEMOSAT and HEPZATO in each of our target markets may fail in any or all of those markets. If we are unsuccessful in accomplishing our objectives, or if our commercialization efforts do not develop as planned, we may not be able to successfully commercialize HEPZATO or any future approved products, we may require significant additional capital and financial resources, we may not become profitable, and we may not be able to compete against more established companies in our industry. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.
We may use collaborative arrangements with third parties to help finance and to market and sell CHEMOSAT and HEPZATO, but it may not be successful.
We may be unable to enter into collaborative agreements without additional clinical data or unable to continue a collaborative agreement as a result of unsuccessful future clinical trials. Additionally, we may face competition in the search for alliances. As a result, we may not be able to enter into alliances on acceptable terms, if at all. Our collaborative relationships may never result in the successful development or commercialization of CHEMOSAT and HEPZATO or any other product. The success of any
43

collaboration will depend upon our ability to perform our obligations under any agreements as well as factors beyond our control, such as the commitment of our collaborators and the timely performance of their obligations. The terms of any such collaboration may permit our collaborators to abandon the alliance at any time for any reason or prevent us from terminating arrangements with collaborators who do not perform in accordance with our expectations, or our collaborators may breach their agreements with us. In addition, any third parties with whom we collaborate may have significant control over important aspects of the development and commercialization of our products, including research and development, market identification, marketing methods, pricing, composition of sales force and promotional activities. We will not control the amount and timing of resources that any collaborator may devote to our research and development programs or the commercialization, marketing or distribution of our products. We may not be able to prevent any collaborators from pursuing alternative technologies or products that could result in the development of products that compete with CHEMOSAT and HEPZATO or the withdrawal of their support for our products. The failure of any such collaboration could have a material adverse effect on our business.
If we fail to overcome the challenges inherent in international operations, our business and results of operations may be materially adversely affected.
Currently we have only received authorization to market CHEMOSAT in the European Union and intend to seek similar authorization or approvals in other foreign countries. To accommodate our international sales, we will need to further invest financial and management resources to develop an international infrastructure that will meet the needs of our customers. Accordingly, we will face additional risks resulting from our international operations including:
difficulties in enforcing agreements and collecting receivables in a timely manner through the legal systems of many countries outside the United States;
the failure to satisfy foreign regulatory requirements to market our products on a timely basis or at all;
availability of, and changes in, reimbursement within prevailing foreign healthcare payment systems;
difficulties in managing foreign relationships and operations, including any relationships that we establish with foreign sales or marketing employees and agents;
limited protection for intellectual property rights in some countries;
fluctuations in currency exchange rates;
the possibility that foreign countries may impose additional withholding taxes or otherwise tax our foreign income, impose tariffs or adopt other restrictions on foreign trade;
the possibility of any material shipping delays;
significant changes in the political, regulatory, safety or economic conditions in a country or region;
protectionist laws and business practices that favor local competitors; and
trade restrictions, including the imposition of, or significant changes to, the level of tariffs, customs duties and export quotas.
If we fail to overcome the challenges inherent in international operations, our business and results of operations may be materially adversely affected.

Rapid technological developments in treatment methods for liver cancer and competition with other forms of liver cancer treatments could affect our ability to achieve meaningful revenues or profit.
Competition in the cancer treatment industry is intense. CHEMOSAT and HEPZATO compete with all forms of liver cancer treatments that are alternatives to surgical resection. Many of our competitors have substantially greater resources and considerable experience in conducting clinical trials and obtaining regulatory approvals. If these competitors develop more effective or more affordable products or treatment methods, or achieve earlier product development, our revenues or profitability will be substantially reduced.
If another company has orphan drug designations for the same drug and indication as us and receives marketing approval before we do, then we will be blocked from marketing approval for seven years from the date of its approval for the same indication of use unless we can make a showing of the clinical superiority of our drug.
Risks Related to our Intellectual Property
Intellectual property rights may not provide adequate protection, which may permit third parties to compete against us more effectively.
Our success depends significantly on our ability to maintain and protect our proprietary rights in the technologies and inventions used in or embodied by our products. To protect our proprietary technology, we rely on patent protection, as well as a combination of copyright, trade secret and trademark laws, as well as nondisclosure, confidentiality, license and other contractual
44

restrictions in our employment, manufacturing, consulting and other third-party agreements. These legal means may afford only limited protection, however, and may not adequately protect our rights or permit us to gain or keep any competitive advantage.
We have not and may not be able to adequately protect our intellectual property rights throughout the world.
Filing, prosecuting and defending patents on our products and technologies in all countries throughout the world could be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some foreign countries may not protect our intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from copying our inventions in foreign countries to the extent we can in the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection that covers the commercial products to develop their own competing products that are the same or substantially the same as our commercial product and, further, may export otherwise infringing products to territories where we have patent protection, but judicial systems do not adequately enforce patents to cause infringing activities to be ceased.
We do not have patent rights in certain foreign countries in which a market for our product and technologies exists or may exist in the future. Moreover, in foreign jurisdictions where we do have patent rights, proceedings to enforce such rights could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. The complexity and uncertainty of European patent laws have increased in recent years. In Europe, a new unitary patent system will likely be introduced by the end of 2023, which would significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications will soon have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (UPC). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in foreign countries products that are the same as or similar to our product and technologies.
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
The United States Patent and Trademark Office (USPTO), and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product or procedures, we may not be able to stop a competitor from marketing products that are the same as or similar to our product and technologies.
Our success depends in part on our ability to obtain patents, which can be an expensive, time consuming, and uncertain process, and the value of the patents is dependent in part on the breadth of coverage and the relationship between the coverage and the commercial product.
The patent position of medical drug and device companies is generally highly uncertain. The degree of patent protection we require may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us sufficient exclusivity, or to gain or keep our competitive advantage. For example:
we might not have been the first to invent or the first to file patent applications on the inventions covered by each of our pending patent applications and issued patents;
others may independently develop similar or alternative technologies or duplicate any of our technologies;
the patents of others may have an adverse effect on our business;
45

any patents we obtain or license from others in the future may not encompass commercially viable products, may not provide us with any competitive advantages or may be challenged by third parties; and
any patents we obtain or license from others in the future may not be valid or enforceable.
The process of applying for patent protection itself is time consuming and expensive and we cannot assure you that we have prepared or will be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is possible that innovation over the course of development and commercialization may lead to changes in CHEMOSAT and HEPZATO methods and/or devices that cause such methods and/or devices to fall outside the scope of the patent protection we have obtained and the patent protection we have obtained may become less valuable. It is also possible that we will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. In addition, our patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example, with respect to proper priority claims, inventorship, claim scope or patent term adjustments. Moreover, we cannot assure you that all of our pending patent applications will issue as patents or that, if issued, they will issue in a form that will be advantageous to us.
Our success depends in part on our ability to commercialize CHEMOSAT and HEPZATO prior to the expiration of our patent protection.
Our patent protection for CHEMOSAT and HEPZATO is primarily in the United States and the EU. We currently have patents in the United States and the EU directed to our product, system, components, procedure, and method of treatment, with additional design patent protection in Argentina, Canada, Europe, the UK, and Japan. Our patents provide patent protection for our CHEMOSAT hepatic delivery system, HEPZATO, hemofiltration cartridge apparatus, hemofiltration cartridge design, methods of treatment of a subject with cancer in accordance with various embodiments of our system, embodiments of our system for delivering a high concentration of a small molecule chemotherapeutic agent to a subject while minimizing systemic exposure to the small molecule chemotherapeutic agent, and methods of setting up a filter apparatus for hemofiltration in accordance with our procedures using our proprietary hepatic deliver system. However, patents have a limited lifespan. In the United States and the EU, the ordinary statutory natural expiration of a utility patent is generally 20 years from its filing date. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited.
We may in the future become involved in lawsuits to protect or enforce our intellectual property, or to defend our products against assertion of intellectual property rights by a third party, which could be expensive, time consuming and unsuccessful.
Competitors may infringe our patents or misappropriate or otherwise violate our intellectual property rights. To stop any such infringement or unauthorized use, litigation may be necessary. Our intellectual property has not been tested in litigation. There is no assurance that any of our issued patents will be upheld if later challenged or will provide significant protection or commercial advantage. A court may declare our patents invalid or unenforceable, may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question, or may interpret the claims of our patents narrowly, thereby substantially narrowing the scope of patent protection they afford. Because of the length of time and expense associated with bringing new medical drugs and devices to the market, the healthcare industry has traditionally placed considerable emphasis on patent and trade secret protection for significant new technologies. Other parties may challenge patents, patent claims or patent applications licensed or issued to us, or may design around technologies we have patented, licensed or developed.
In addition, third parties may initiate legal or administrative proceedings against us to challenge the validity or scope of our intellectual property rights, such as inter partes review, post-grant review, re-examination or opposition proceedings before the USPTO, the European Patent Office or other foreign counterparts. Third parties may also allege an ownership right in our patents, as a result of their past employment or consultancy with us. Many of our current and potential competitors have the ability to dedicate substantially greater resources to defend their intellectual property rights than we can. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. Competing products may also be sold in other countries in which our patent coverage might not exist or be as strong. If we lose a foreign patent lawsuit, alleging our infringement of a competitor’s patents, we could be prevented from marketing our product in one or more foreign countries.
Our competitors or other patent holders may assert that our products and the methods employed in our products are covered by their patents. Although we have performed a search for third-party patents and believe we have adequate defenses available if faced with any allegations that we infringe these third-party patents, it is possible that CHEMOSAT and HEPZATO could be found to infringe these patents. It is also possible that our competitors or potential competitors may have patents, or have applied for, will apply for, or will obtain patents that will prevent, limit or interfere with our ability to make, have made, use, sell, offer for
46

sale, import or export our product. If our products or methods are found to infringe, we could be prevented from manufacturing or marketing our product.
Companies in the medical drug/device industry may use intellectual property infringement litigation to gain a competitive advantage. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications are not publicly available until the patent issues. As a result, there may be some uncertainties associated with avoiding patent infringement. Litigation may be necessary to enforce any patents issued or assigned to us or to determine the scope and validity of third-party proprietary rights. Litigation could be costly and could divert our attention from our business. There are no guarantees that we will receive a favorable outcome in any such litigation. If a third-party claims that we infringed its patents, any of the following may occur:
we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a competitor’s patent;
we may become prohibited from selling or licensing our product without a license from the patent holder, which may not be available on commercially acceptable terms or at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and
we may have to redesign our product so that it does not infringe upon others’ patent rights, which may not be possible or could require substantial funds or time.
Litigation related to infringement and other intellectual property claims such as trade secrets, with or without merit, is unpredictable, can be expensive and time-consuming, and can divert management’s attention from our core business. If we lose this kind of litigation, a court could require us to pay substantial damages, treble damages, and attorneys’ fees, and could prohibit us from using technologies essential to our product, any of which would have a material adverse effect on our business, results of operations, and financial condition. If relevant third-party patents are upheld as valid and enforceable and we are found to infringe, we could be prevented from selling our product unless we can obtain licenses to use technology covered by such patents. We do not know whether any necessary licenses would be available to us on satisfactory terms, if at all. If we cannot obtain these licenses, we could be forced to design around those patents at additional cost or abandon the product altogether. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could cause the price of our common stock to decline.
If others have filed patent applications with respect to inventions for which we already have patents issued to us or have patent applications pending, we may be forced to participate in interference or derivation proceedings declared by the USPTO to determine priority of invention, which could also be costly and could divert our attention from our business. If the USPTO declares an interference and determines that our patent or application is not entitled to a priority date earlier than that of the other patent application, our ability to maintain or obtain those patent rights will be curtailed. Similarly, if the USPTO declares a derivation proceeding and determines that the invention covered by our patent application was derived from another, we will not be able to obtain patent coverage of that invention.
Because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before CHEMOSAT and HEPZATO or any other product can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantages of the patent. Not all of our United States patent rights have corresponding patent rights effective in European or other foreign jurisdictions. Similar considerations apply in any other country where we are prosecuting patent applications, have been issued patents, or have decided not to pursue patent protection relating to our technology. The laws of foreign countries may not protect our intellectual property rights to the same extent as do laws of the United States.
Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product and our technologies.
Patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement, and defense of our patents and applications. Furthermore, the United States Supreme Court and the United States Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain and enforce or defend additional patent protection in the future.
47

Our trademarks may be infringed or successfully challenged, resulting in harm to our business.
We rely on our trademarks as one means to distinguish for our customers our products from the products of our competitors, and we have registered or applied to register many of these trademarks. The USPTO or foreign trademark offices may deny our trademark applications, however, and even if published or registered, these trademarks may be ineffective in protecting our brand and goodwill and may be successfully opposed or challenged. Third parties may oppose our trademark applications, or otherwise challenge our use of our trademarks. In addition, third parties may use marks that are confusingly similar to our own, which could result in confusion or a likelihood of confusion among our customers, thereby weakening the strength of our brand or allowing such third parties to capitalize on our goodwill. In such an event, or if our trademarks are successfully challenged, we could be forced to rebrand our product, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademark rights in the face of any such infringement.
We may rely primarily on trade secret protection for important proprietary technologies.
In addition to patent and trademark protection, we also rely on trade secrets, including unpatented know-how, technology, and other proprietary information, to maintain our competitive position. Unlike patents, trade secrets are only recognized under applicable law if they are kept secret by restricting their disclosure to third parties. We protect our trade secrets and proprietary knowledge in part through confidentiality agreements with employees, consultants and other parties. However, certain consultants and third parties with whom we have business relationships, and to whom in some cases we have disclosed trade secrets and other proprietary knowledge, may also provide services to other parties in the medical device industry, including companies, universities and research organizations that are developing competing products. In addition, some of our former employees who were exposed to certain of our trade secrets and other proprietary knowledge in the course of their employment may seek employment with, and become employed by, our competitors. We cannot be assured that consultants, employees and other third parties with whom we have entered into confidentiality agreements will not breach the terms of such agreements by improperly using or disclosing our trade secrets or other proprietary knowledge. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.
Trade secret protection does not prevent independent discovery of the technology or proprietary information or use of the same. Competitors may independently duplicate or exceed our technology in whole or in part. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us in countries where we do not have patent protection.
Similar considerations apply in foreign countries where we receive approval and do not have issued patents for the current version of CHEMOSAT and HEPZATO. In these countries, our ability to successfully commercialize CHEMOSAT and HEPZATO will depend on our ability to maintain trade secret protection in these markets.
We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.
We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other proprietary information of former employers, competitors, or other third parties. Although we endeavor to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may in the future be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. If our defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our product, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers or other third parties. An inability to incorporate technologies or features that are important or essential to our product may prevent us from selling our product. In addition, we may lose valuable intellectual property rights or personnel. Moreover, any such litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our product.

48

Risks Related to Our Common Stock
The market price of our common stock has been, and may continue to be volatile and fluctuate significantly, which could result in substantial losses for investors.
The trading price of our common stock has been, and we expect it to continue to be, volatile. For example, the trading price of our common stock has varied between a high of $7.99 on May 31, 2023 and a low of $3.12 on August 14, 2023. The price at which our common stock trades depends upon a number of factors, including historical and anticipated operating results, our financial situation, announcements of technological innovations or new products by us or our competitors, our ability or inability to raise the additional capital needed and the terms on which it may be raised, and general market and economic conditions. Some of these factors are beyond our control. Broad market fluctuations may lower the market price of our common stock and affect the volume of trading, regardless of our financial condition, results of operations, business or prospects. Among the factors that may cause the market price of our common stock to fluctuate are the risks described elsewhere in this “Risk Factors” section and other factors, including:
fluctuations in our quarterly operating results or the operating results of competitors;
variance in financial performance from the expectations of investors;
changes in the estimation of the future size and growth rate of our markets;
changes in accounting principles or changes in interpretations of existing principles, which could affect financial results;
conditions and trends in the markets served;
changes in general economic, industry and market conditions;
success of competitive products and services;
changes in market valuations or earnings of competitors;
changes in pricing policies or the pricing policies of competitors;
announcements of significant new products, contracts, acquisitions or strategic alliances by us or our competitors;
potentially negative announcements, such as a review of any of our filings by the SEC, changes in accounting treatment or restatements of previously reported financial results or delays in our filings with the SEC;
the commencement or outcome of litigation involving us, our general industry or both;
our filing for protection under federal bankruptcy laws;
changes in capital structure, such as future issuances of securities or the incurrence of additional debt;
actual or expected sales of common stock by stockholders; and
the trading volume of our common stock.
In addition, the stock markets and the market for pharmaceutical companies in particular, may experience a loss of investor confidence. Such loss of investor confidence may result in extreme price and volume fluctuations in our common stock that are unrelated or disproportionate to the operating performance of our business, financial condition or results of operations. These broad market and industry factors may materially harm the market price of our common stock and expose us to securities class action litigation. Such litigation, even if unsuccessful, could be costly to defend and divert management’s attention and resources, which could further materially harm our financial condition and results of operations.
Because of volatility in our trading price and trading volume, we may incur significant costs from class action securities litigation.
Holders of stock in companies that have a volatile stock price frequently bring securities class action litigation against the company that issued the stock. We may be the target of this type of litigation in the future. If any of our stockholders were to bring a lawsuit of this type against us, even if the lawsuit is without merit, we could incur substantial costs defending the lawsuit and the time and attention of our management could be diverted from other business concerns, either of which could seriously harm our business.
Sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the market price of our common stock and could impair our ability to raise additional equity capital.
As of September 30, 2023, 19,688,991 shares of common stock are issued and outstanding, and we had reserved 22,879,228 shares of our common stock for future issuance pursuant to our stock option and equity incentive plans, outstanding warrants and preferred stock.
Future sales of a substantial number of shares of our common stock in the public market or the perception that such sales may occur, or the issuance of our common stock pursuant to outstanding warrants or convertible preferred stock, could cause immediate dilution and adversely affect the market price of our common stock. The sale or issuance of our common stock, as well
49

as the existence of outstanding stock options and shares of common stock reserved for issuance under our equity incentive plans and outstanding warrants and convertible preferred stock, could cause the market price of our common stock to decline and could impair our ability to raise capital through the sale of additional equity securities. We cannot predict the effect that future sales of shares of our common stock or other equity-related securities would have on the market price of our common stock.
We have a history of reverse splits, which have severely impacted our common stock price.
Since our initial public offering in 2000, we have effected five reverse stock splits, for a cumulative ratio since our IPO of 1:31,360,000,000. Each such reverse split has resulted in an effective decline in the price of our common stock. There can be no assurance that we will not be required to effect one or more additional reverse stock splits which could further impact the market price and liquidity of our common stock.
Anti-takeover provisions in our Amended and Restated Certificate of Incorporation and By-laws may reduce the likelihood of a potential change of control or make it more difficult for our stockholders to replace management.
Certain provisions of our Amended and Restated Certificate of Incorporation and By-laws could have the effect of making it more difficult for our stockholders to replace management at a time when a substantial number of stockholders might favor a change in management. These provisions include providing for a staggered board of directors and authorizing the board of directors to fill vacant directorships or increase the size of the board of directors.
Furthermore, our board of directors has the authority to issue up to 10,000,000 shares of preferred stock in one or more series and to determine the rights and preferences of the shares of any such series without stockholder approval. Any series of preferred stock is likely to be senior to the common stock with respect to dividends, liquidation rights and, possibly, voting rights. The board’s ability to issue preferred stock may have the effect of discouraging unsolicited acquisition proposals, thus adversely affecting the market price of our common stock.
We have never declared or paid any dividends to the holders of our common stock and we do not expect to pay cash dividends in the foreseeable future.
We intend to retain all earnings for use in connection with the expansion of our business and for general corporate purposes. The board of directors will have the sole discretion in determining whether to declare and pay dividends in the future. The declaration of dividends will depend on profitability, financial condition, cash requirements, future prospects and other factors deemed relevant by our board of directors. Our ability to pay cash dividends in the future could be limited or prohibited by the terms of financing agreements that we may enter into or by the terms of any preferred stock that may be authorized and issued. For example, the terms of the Avenue Loan Agreement contains negative covenants prohibiting us from issuing cash dividends. We do not expect to pay dividends in the foreseeable future. As a result, holders of our common stock must rely on stock appreciation for any return on their investment.
If we engage in acquisitions, reorganizations or business combinations, we will incur a variety of risks that could adversely affect our business operations or our stockholders.
From time to time, we may consider strategic alternatives, such as acquiring businesses, technologies or products or entering into a business combination with another company. If we do pursue such a strategy, we could, among other things:
issue equity securities that would dilute current stockholders’ percentage ownership;
incur substantial debt that may place strains on our operations;
spend substantial operational, financial and management resources in integrating new businesses, personnel, intellectual property, technologies and products;
assume substantial actual or contingent liabilities;
reprioritize our programs and even cease development and commercialization of CHEMOSAT and HEPZATO;
suffer the loss of key personnel, or
merge with, or otherwise enter into a business combination with, another company in which our stockholders would receive cash or shares of the other company or a combination of both on terms that certain of our stockholders may not deem desirable.
Although we intend to evaluate and consider different strategic alternatives, we have no agreements or understandings with respect to any acquisition, reorganization, or business combination at this time.

50

If securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our market, or if they change their recommendations regarding our securities adversely, the price and trading volume of our securities could decline.
The trading market for our securities will be influenced by the research and reports that industry or securities analysts may publish about us, our business, market or competitors. Securities and industry analysts do not currently, and may never, publish research on us. If no securities or industry analysts commence coverage of us, the price and trading volume of our securities would likely be negatively impacted. If any of the analysts who may cover us change their recommendation regarding our shares of Common Stock adversely, or provide more favorable relative recommendations about our competitors, the price of our shares of Common Stock would likely decline. If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline.
We have identified material weaknesses in our internal control over financial reporting. If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.
Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements would not be prevented or detected on a timely basis. Inadequate internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.
Management determined there was material weaknesses that existed at December 31, 2022. The material weaknesses relate to detection and application of our expense policy on our share-based compensation under the accelerated method. We have commenced measures to remediate this material weaknesses and will design additional key controls in order to ensure our share-based compensation is calculated under the accelerated method. We will continue to assess our finance and accounting staffing needs to ensure remediation of this material weakness. The material weakness will not be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively. If not remediated, this material weakness could result in further material misstatements to our annual or interim consolidated financial statements that might not be prevented or detected on a timely basis, or in delayed filing of required periodic reports. If we are unable to assert that our internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of the stock could be adversely affected, and we could become subject to litigation or investigations by Nasdaq, the SEC, or other regulatory authorities, which could require additional financial and management resources.
Management will be required to assess the effectiveness of our internal controls annually. However, for as long as we are a non-accelerated filer, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act. An independent assessment of the effectiveness of our internal controls could detect problems that our management’s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements requiring us to incur the expense of remediation and could also result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.
General Risk Factors
The loss of key personnel could adversely affect our business.
Our success depends upon the efforts of our employees. The loss of any of our senior executives or other key employees could harm its business. Competition for experienced personnel is intense and, if key individuals leave us, we could be adversely affected if suitable replacement personnel are not quickly identified and hired. Competition for qualified individuals exists in all functional areas, which makes it difficult to attract and retain the qualified employees we need to operate our business. Our success also depends in part on our ability to attract and retain highly qualified scientific, technical, commercial and administrative personnel. If we are unable to attract new employees and retain our current key employees, our ability to compete could be adversely affected and the development and commercialization of our products could be delayed or negatively impacted.
51


We rely on the proper function, availability and security of information technology systems to operate our business and a cyber-attack or other breach of these systems could have a material adverse effect on our business, financial condition or results of operations.
We rely on information technology systems to process, transmit, and store electronic information in our day-to-day operations. Similar to other companies, the size and complexity of our information technology systems makes them vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy, or other significant disruption. Our information systems require an ongoing commitment of significant resources to maintain, protect, and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards. Any failure by us to maintain or protect our information technology systems and data integrity, including from cyber-attacks, intrusions or other breaches, could result in the unauthorized access to personally identifiable information, theft of intellectual property or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Any of these events may cause us to have difficulty preventing, detecting, and controlling fraud, be subject to legal claims and liability, have regulatory sanctions or penalties imposed, have increases in operating expenses, incur expenses or lose revenues as a result of a data privacy breach or theft of intellectual property, or suffer other adverse consequences, any of which could have a material adverse effect on our business, financial condition or results of operations.
We may be the subject of product liability claims or product recalls, and we may be unable to maintain insurance adequate to cover potential liabilities.
Our business exposes us to potential liability risks that may arise from clinical trials and the testing, manufacture, marketing, sale and use of CHEMOSAT and HEPZATO. In addition, because CHEMOSAT and HEPZATO are intended for use in patients with cancer, there is an increased risk of death among the patients treated with our system, which may increase the risk of product liability lawsuits related to clinical trials or commercial sales. We may be subject to claims against us even if the injury is due to the actions of others. For example, if the medical personnel that use our system on patients are not properly trained or are negligent in the use of the system, the patient may be injured, which may subject us to claims. Were such a claim asserted, we would likely incur substantial legal and related expenses even if we prevail on the merits. Claims for damages, whether or not successful, could cause delays in clinical trials and result in the loss of physician endorsement, adverse publicity and/or limit our ability to market and sell the system, resulting in loss of revenue. In addition, it may be necessary for us to recall products that do not meet approved specifications, which would also result in adverse publicity and costs connected to the recall and loss of revenue. A successful products liability claim or product recall would have a material adverse effect on our business, financial condition, and results of operations. While we currently carry product liability and clinical trial insurance coverage, it may be insufficient to cover one or more large claims.
We will continue to incur significant costs as a result of operating as a public company, and our management will continue to devote substantial time to compliance initiatives.
As a public company, we have incurred and will continue to incur significant legal, accounting and other expenses. As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, as well as rules adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel need to continue to devote a substantial amount of time to comply with these requirements. Moreover, these rules and regulations have increased, and will continue to increase, our legal and financial compliance costs and make some activities more time- consuming and costly. The increased costs may increase our net loss. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be forced to accept reduced policy limits or incur substantially higher costs to maintain the same or similar coverage as we did prior to becoming a public company. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in future uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our Board, our board committees or as our executive officers.
We are a “smaller reporting company” and have elected to comply with reduced public company reporting requirements, which could make our Common Stock less attractive to investors.
Because our annual revenue was less than $100.0 million during the most recently completed fiscal year and the market value of our voting and non-voting Common Stock held by non-affiliates was less than $560.0 million measured on the last business day of our second fiscal quarter, we qualify again as a “smaller reporting company” as defined in the Exchange Act. Accordingly, we may provide less public disclosure than larger public companies, including, the inclusion of only two years of audited financial statements and only two years of related selected financial data and management’s discussion and analysis of financial condition
52

and results of operations disclosure. We are also no longer required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests. We cannot predict if investors will find our Common Stock less attractive as a result of our reliance on these exemptions. If some investors find our Common Stock less attractive as a result of any choice we make to reduce disclosure, there may be a less active trading market for our Common Stock and the market price for our Common Stock may be more volatile.

53

Item 6.    Exhibits
Exhibit
No.
Description
3.1
3.2
3.3
3.4
3.5
3.6
3.7
3.8
31.1*
31.2*
32.1*+
32.2*+
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
*Filed herewith.
+ This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,     or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filing, except to the extent the Company specifically incorporates it by reference.
54

DELCATH SYSTEMS, INC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DELCATH SYSTEMS, INC.
November 13, 2023
/s/ Gerard Michel
Gerard Michel
Chief Executive Officer (Principal Executive Officer)
November 13, 2023
/s/ Sandra Pennell
Sandra Pennell
Principal Financial Officer
55
EX-31.1 2 dcth-20230930xexx311.htm EX-31.1 Document

Exhibit 31.1
DELCATH SYSTEMS, INC.
CERTIFICATION
PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002
I, Gerard Michel, certify that:
1)I have reviewed this Quarterly Report on Form 10-Q of Delcath Systems, Inc.;
2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4)The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5)The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
November 13, 2023
/s/ Gerard Michel
Gerard Michel
Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 dcth-20230930xexx312.htm EX-31.2 Document

Exhibit 31.2
DELCATH SYSTEMS, INC.
CERTIFICATION
PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002
I, Sandra Pennell, certify that:
1)I have reviewed this Quarterly Report on Form 10-Q of Delcath Systems, Inc.;
2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4)The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5)The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
November 13, 2023
/s/ Sandra Pennell
Sandra Pennell
Principal Financial Officer

EX-32.1 4 dcth-20230930xexx321.htm EX-32.1 Document

Exhibit 32.1
DELCATH SYSTEMS, INC.
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of DELCATH SYSTEMS, INC. (the “Company”) on Form 10-Q for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gerard Michel, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1)The Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
November 13, 2023
/s/ Gerard Michel
Gerard Michel
Chief Executive Officer (Principal Executive Officer)

EX-32.2 5 dcth-20230930xexx322.htm EX-32.2 Document

Exhibit 32.2
DELCATH SYSTEMS, INC.
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of DELCATH SYSTEMS, INC. (the “Company”) on Form 10-Q for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sandra Pennell, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1)The report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.
November 13, 2023
/s/ Sandra Pennell
Sandra Pennell
Principal Financial Officer

EX-101.SCH 6 dcth-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - General link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Cash, Cash Equivalents and Restricted Cash link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Property, Plant, and Equipment link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Loans and Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Preferred Purchase Agreement link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - General (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - General (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Property, Plant, and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Loans and Convertible Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - General - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - General - Schedule of Error Corrections and Prior Period Adjustments (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Property, Plant, and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Leases - Summary of Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Leases - Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Leases - Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Loans and Convertible Notes Payable - Summary of Remaining Maturities of Company's Loan and Convertible Note Payables (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Loans and Convertible Notes Payable - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Preferred Purchase Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Stockholders' Equity - Equity Offerings and Placements (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Stockholders' Equity - At-the-Market Offering (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Stockholders' Equity - Designated Preferred Shares (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Stockholders' Equity - Authorized Shares and Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Stockholders' Equity - Equity Incentive Plan (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Stockholders' Equity - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Stockholders' Equity - Summary of Stock Option Shares Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Stockholders' Equity - Summary of Recognized Share-based Compensation Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Stockholders' Equity - Summary of Common Stock Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Stockholders' Equity - Summary of Common Stock Warrants Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Stockholders' Equity - Preferred Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Stockholders' Equity - Summary of Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Net Loss per Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Net Loss per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - Net Loss per Share - Summary of Reconciliation of Weighted Average Shares Outstanding Calculation (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - Commitments and contingencies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Outstanding Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - Fair Value Measurements - Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 dcth-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 dcth-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 dcth-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Accrued expenses Total accrued expenses Accrued Liabilities, Current Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Statistical Measurement Statistical Measurement [Domain] Research and development expenses Research and Development Expense Fair value of the warrant liability issued Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Number of shares converted (in shares) Convertible Preferred Stock, Shares Issued upon Conversion Cash, Cash Equivalents and Restricted Cash [Table] Cash, Cash Equivalents and Restricted Cash [Table] Cash, cash equivalents and restricted cash. Loans and Convertible Notes Payable Debt Disclosure [Text Block] Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited) Statement of Stockholders' Equity [Abstract] Series F-1 Series F1 Preferred Stock [Member] Series F1 Preferred Stock. Lease Liabilities Lease Liabilities [Member] Lease liabilities. Accounts payable Accounts Payable, Current Weighted Average Remaining Contractual Term (in years), Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Enterprise hardware and software Computer Equipment [Member] Notes And Loans Payable, Net, Current Notes And Loans Payable, Net, Current Notes And Loans Payable, Net, Current Security for credit cards Security For Credit Cards Restricted Cash Security for credit cards restricted cash. Condition for the Extension of Period of Interest Only Payments Condition For The Extension Of Period OF Interest Only Payments [Member] Condition for the extension of period of interest only payments. Other liabilities, non-current Increase (Decrease) in Other Noncurrent Liabilities Commitments and contingencies (see note 13) Commitments and Contingencies Expected volatility Measurement Input, Price Volatility [Member] As previously reported Previously Reported [Member] Exercisable (in shares) Number of Options Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Initial tranche of loan Initial Tranche Of Loan Initial tranche of loan. Third Party Settlement Third Party Settlement [Member] Third party settlement. Preferred Series E Stock Series E Series E Preferred Stock [Member] Stockholders' Equity Equity [Text Block] Proceeds from the issuance of common stock relating to the employee stock purchase plan Proceeds from Issuance of Common Stock Error Corrections and Prior Period Adjustments Restatement [Line Items] Error Corrections and Prior Period Adjustments Restatement [Line Items] Geographical Geographical [Axis] Loan payable, current Less Current Portion, Net Loans Payable, Current Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Income Taxes Income Tax Disclosure [Text Block] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Series E-1 Series E1 Preferred Stock [Member] Series e1 preferred stock member Warrants exercised (in dollars per share) Class Of Warrant Or Right Weighted Average Exercise Price Exercised Class Of Warrant Or Right Weighted Average Exercise Price Exercised Expected dividends Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Preferred Warrant Liabilities Preferred Warrant Liabilities [Member] Preferred warrant liabilities. Employee Stock Ownership Plan (ESOP) Disclosures [Line Items] Employee Stock Ownership Plan (ESOP) Disclosures [Line Items] Current liabilities Liabilities, Current [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.01 par value; 10,000,000 shares authorized; 37,787 and 11,357 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively Preferred Stock, Value, Issued Details [Axis] Details [Axis] Details. Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Stockholders Equity Note [Table] Stockholders Equity Note [Table] Stockholders equity note. Diluted loss per common share (in dollars per share) Earnings Per Share, Diluted Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Year ended December 31, 2023 December Thirty First Two Thousand Twenty Three [Member] December thirty first two thousand twenty three. Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment [Table] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Noncurrent capital commitments Capital Commitments Non Current Capital commitments non current. Professional fees Prepaid Expense and Other Assets, Current [Abstract] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Total - Loans Payable, Non-Current, Gross Notes And Loans Payable Gross Non Current Notes and loans payable gross non current. Outstanding, beginning of period (in shares) Outstanding, end of period (in shares) Outstanding Number of Options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Liquidity and Going Concern Liquidity And Going Concern Policy [Policy Text Block] Liquidity and going concern. Issuance of common stock related to stock option exercises Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Total change in foreign exchange Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Percentage of final payment included in gross amount Percentage Of Final Payment Included In Gross Amount Percentage of final payment included in gross amount. Granted, Weighted Average Exercise Price Per Share (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Agent [Axis] Agent [Axis] Agent. Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Leases Lessee, Operating Leases [Text Block] Interest on convertible note Interest Payable, Current Accrued Expenses Accrued Expenses [Member] Accrued expenses member. May 2022 Employee Stock Purchase Plan May Two Thousand And Twenty Two Employee Stock Purchase Plan [Member] May two thousand and twenty two employee stock purchase plan member. Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Amortization of debt discount Amortization of Debt Discount (Premium) Preferred Purchase Agreement Disclosure Of Preferred Purchase Agreement [Text Block] Disclosure Of Preferred Purchase Agreement [Text Block]. Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Stockholders’ equity (deficit) Equity, Attributable to Parent [Abstract] Issuance of common stock related to stock option exercises (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Convertible notes payable, non-current Convertible Notes Payable, Noncurrent Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table] Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table] Preferred Purchase Agreement Preferred Purchase Agreement [Member] Preferred Purchase Agreement [Member]. Exercise Price Range Exercise Price Range [Domain] Foreign currency effects on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Summary of Reconciliation of Weighted Average Shares Outstanding Calculation Schedule of Weighted Average Number of Shares [Table Text Block] Rosalind Notes Eight Point Zero Percentage July Two Thousand And Nineteen Notes [Member] Eight point zero percentage july two thousand and nineteen notes. Exercised, Weighted Average Exercise Price Per Share (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Notes And Loans Payable, Net, Noncurrent Notes And Loans Payable, Net, Noncurrent Notes And Loans Payable, Net, Noncurrent Components of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Equity Components Equity Components [Axis] Warrant exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Lessee Lease Description [Table] Lessee, Lease, Description [Table] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross $2.83 - $51.50 Exercise Price Range From Two Point Eight Three To Fifty One Point Five Zero [Member] Exercise Price Range From Two Point Eight Three To Fifty One Point Five Zero. Entity Small Business Entity Small Business Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Selling, general and administrative Selling, General and Administrative Expenses [Member] Warrant Warrants Warrant [Member] Restricted cash Restricted Cash and Cash Equivalents, Current Class of Warrant or Right [Table] Class of Warrant or Right [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Debt Instrument, Name Debt Instrument, Name [Domain] Depreciation expense Depreciation expense (less than) Depreciation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Income Statement Location Income Statement Location [Axis] Summary of Loans and Convertible Notes Payable Schedule of Long-Term Debt Instruments [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Preferred stock, shares designated (in shares) Preferred Stock, Shares, Designated Preferred Stock, Shares, Designated Schedule of Remaining maturity of Operating Leases Excluding Short-Term Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Valuation Technique, Option Pricing Model Valuation Technique, Option Pricing Model [Member] Weighted Average Remaining Life (in years), Outstanding Warrants Exercisable, Weighted Average Remaining Warrant Term (in years) Class Of Warrant Or Right Weighted Average Remaining Contractual Term Weighted average remaining contractual term for each class of warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Number of shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Prepaid Expenses and Other Current Assets Prepaid Expenses And Other Current Assets [Text Block] Prepaid expenses and other current assets. Private placement - issuance of common stock and prefunded warrants, net of expense Issuance Of Common Stock And Pre Funded Warrants In Private Placement Issuance Of Common Stock And Pre Funded Warrants In Private Placement Common Purchase Agreement Common Purchase Agreement [Member] Common Purchase Agreement [Member]. Contingent liability Contingent Liability, Fair Value Disclosure Contingent liabilities fair value. $6.00 Range Of Exercise Prices six Point Zero Range [Member] Range Of Exercise Prices six Point Zero Range Payables and Accruals [Abstract] Payables and Accruals [Abstract] Risk free interest rate Measurement Input, Risk Free Interest Rate [Member] Employee stock purchase plan, offering period Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Antidilutive Securities Excluded from the Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Product and Service Product and Service [Domain] Summary of Lease Costs Lease, Cost [Table Text Block] Inventory Increase (Decrease) in Inventories Research and development Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Assumed conversion of preferred stock Assumed Conversion Of Preferred Stock [Member] Assumed conversion of preferred stock. Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Weighted Average Remaining Life, Exercisable Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Term Class of warrant or right exercisable weighted average remaining contractual term. Supplemental Disclosure of Non-Cash Investing and Financing Activities: Noncash Investing and Financing Items [Abstract] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Share-based compensation arrangement by share-based payment award number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Property, plant and equipment, gross Property, Plant and Equipment, Gross Weighted Average Remaining Contractual Term (in years), Outstanding Weighted Average Remaining Option Term (in years), Options Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Right of use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Less present value discount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Leases Lessee, Finance Leases [Text Block] Milestone payment unpaid Milestone Payment Unpaid Milestone payment unpaid. Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Lease liabilities, current Operating Lease, Liability, Current Aggregate exercise price of preferred warrants Aggregate Exercise Price Of Preferred Warrants Aggregate exercise price of preferred warrants. Series F1, Series F2 and F3 Preferred Stock Series F1, Series F2 and F3 Preferred Stock [Member] Series F1, Series F2 and F3 Preferred Stock Issuance of common stock with the employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Entity Shell Company Entity Shell Company Series D Series D Preferred Stock [Member] Year ended December 31, 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Adjustment Revision of Prior Period, Adjustment [Member] Total - Loans Payable, Non-Current, Discount Discount On Notes And Loans Payable Noncurrent Discount on notes and loans payable noncurrent. Property Plant And Equipment [Line Items] Property, Plant and Equipment [Line Items] Recently Adopted and Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Counterparty Name [Domain] Counterparty Name [Domain] Cash cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Schedule of Designated Preferred Units Schedule of Stock by Class [Table Text Block] Year ended December 31, 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Restricted balance for loan agreement Loan Agreement Restricted Cash Loan Agreement Restricted Cash . Expected term (years) Measurement Input, Expected Term [Member] Loans Payable Loans Payable [Member] Common stock, shares issued (in shares) Common Stock, Shares, Issued Gross profit Gross Profit Summary of Avenue Warrant Valued Using the Black-Scholes Option Pricing Method Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Percentage of excise tax on repurchases of stock Percentage Of Excise Tax On Repurchases Of Stock Percentage of excise tax on repurchases of stock. Preferred And Common Warrants Preferred And Common Warrants [Member] Preferred and common warrants. Selling, general and administrative expenses Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Summary of Stock Option Shares Outstanding and Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block] Stock options Employee Stock Option [Member] Loans Loans Payable Cost expected to be recognized over weighted average period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Maximum Maximum [Member] Total other comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Unrecognized compensation expense related to non-vested share-based compensation awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Loan payable, non-current Total - Loans Payable, Non-Current, Net Loans Payable, Noncurrent Other information Other Lease Information [Abstract] Other lease information. Entity Address, Address Line One Entity Address, Address Line One Tranche B Warrants Tranche B Warrants [Member] Tranche B Warrants [Member]. Entity Address, Address Line Two Entity Address, Address Line Two Outstanding, beginning of period (in dollars per share) Outstanding, ending of period (in dollars per share) Class Of Warrant Or Right Weighted Average Exercise Price Class Of Warrant Or Right Weighted Average Exercise Price Weighted average exercise price for warrants or rights outstanding. Stockholders Equity Note [Line Items] Stockholders Equity Note [Line Items] Stockholders equity note. Warrants exercised (in shares) Warrants exercised (in shares) Class Of Warrant Or Right Exercised Class Of Warrant Or Right Exercised. Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted Average Exercise Price Class Of Warrant Or Right Weighted Average Exercise Price [Abstract] A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Weighted Average Exercise Price Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items] Organization consolidation basis of presentation business description and accounting policies line item. Cash, Cash Equivalents and Restricted Cash consisted of the following: Cash, Cash Equivalents and Restricted Cash consisted of the following [Abstract] Cash, cash equivalents and restricted cash consisted of the following, Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Income Statement [Abstract] Tranche A Warrants Tranche A Warrants [Member] Tranche A Warrants [Member]. Estimated Useful Life Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration] Stock issued during period (in shares) Stock Issued During Period, Shares, New Issues Cancelled/Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Agreement [Axis] Agreement [Axis] Agreement. Less Current Portion, Gross Notes And Loans Payable Gross Current Notes and loans payable gross current. Related Party Related Party, Type [Domain] Warrant liability Derivative Liability Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] As revised As Revised [Member] As revised. Schedule of Fair Value Warrants Schedule of Assumptions for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Inventory Total inventory Inventory, Net Net proceeds from private placement Proceeds from Issuance of Private Placement Statistical Measurement Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Entity Interactive Data Current Entity Interactive Data Current Impact of share-based compensation correction on net income (loss) Impact of Correction of Share Based Compensation on Net Income Loss Impact of correction of share based compensation on net income loss. Product revenue Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Warrants issued (in shares) Class Of Warrant Or Right Issued The number of each class of warrants or rights issued during the period. Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Term over which the royalty is to be paid Term Over Which The Royalty Is To Be Paid Term over which the royalty is to be paid. Assumed conversion of preferred stock warrants Assumed Conversation Of Preferred Stock Warrants [Member] Assumed conversation of preferred stock warrants. Preferred F-1 Stock Preferred F1 Stock [Member] Preferred F-1 stock member. Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Principal payments Debt Instrument, Repaid, Principal Accumulated deficit Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Exercise Price Range Exercise Price Range [Axis] Preferred Purchase Agreement [Abstract] Preferred Purchase Agreement [Abstract] Preferred Purchase Agreement [Abstract]. Debt instrument, principal face amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Counterparty Name [Axis] Counterparty Name [Axis] Warrant Liabilities Derivatives, Policy [Policy Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Class of Warrant or Right Class of Warrant or Right [Domain] Gross Notes And Loans Payable Gross Notes and loans payable gross. Operating cash flows for operating leases Operating Lease, Payments Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Debt instrument, conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Change due to warrant exercise Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 Debt Instrument Redemption [Table] Debt Instrument Redemption [Table] Convertible notes payable, current Convertible Notes Payable, Current Convertible Notes Notes Payable Beginning Balance (in shares) Ending Balance (in shares) Shares, Outstanding Preferred F-3 Stock Series F-3 Series F3 Preferred Stock [Member] Series F3 Preferred Stock. Warrants issued (in dollars per share) Class Of Warrant Or Right Weighted Average Exercise Price Issued Weighted average exercise price for the number of warrants or rights issued for the unvested, forfeitable warrants or rights in period. Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Weighted Average Remaining Contractual Term (in years), Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Remaining Contractual Term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Remaining Contractual Term Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock Class of Stock [Domain] Details [Domain] Details [Domain] Details. Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Debt Instrument Debt Instrument [Axis] Schedule of Error Corrections and Prior Period Adjustments Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Warrant liability Derivative Liability, Noncurrent Repayment of debt Principal payment Repayments of Debt Operating lease liabilities included in the condensed consolidated balance sheets at September 30, 2023 Operating Lease, Liability Measurement Input Type Measurement Input Type [Domain] Letters of credit Letters Of Credit Restricted Cash Letters of credit restricted cash. Series B Series B Preferred Stock [Member] Summary of Remaining Maturities of Company's Loan and Convertible Note Payables Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities Pre-funded penny warrants outstanding Number Of Shares Pre Funded Penny Warrants Outstanding Number of shares pre-funded penny warrants outstanding. Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Common stock, capital shares reserved (in shares) Common Stock, Capital Shares Reserved for Future Issuance Property, Plant, and Equipment Property, Plant and Equipment Disclosure [Text Block] Plan Name [Axis] Plan Name [Axis] Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Non-cash lease expense Amortization Of Right Of Use Assets Amortization of right of use assets. Debt Disclosure [Abstract] Debt Disclosure [Abstract] Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Minimum annual payments Minimum Annual Payments Minimum annual payments. Common share data: Earnings Per Share [Abstract] Avenue Loan Term Loan From Avenue Venture Opportunities Fund LP [Member] Term Loan From Avenue Venture Opportunities Fund LP [Member] Common stock, $0.01 par value; 80,000,000 shares authorized; 19,688,991 shares and 10,046,571 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively Sale of stock consideration received on the transaction Common Stock, Value, Issued Range of Exercise Prices (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Lachman Lachman [Member] Lachman member. Professional fees Accrued Professional Fees, Current Total current assets Assets, Current Preferred Stock Preferred Stock [Member] Accounts receivable Accounts Receivable, after Allowance for Credit Loss Restricted Cash Restricted cash Restricted Cash Supplemental Disclosure of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Corporate alternative minimum tax (as a percent) Corporate Alternative Minimum Tax Corporate alternative minimum tax. Other income (expense) Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Warrants Warrants Outstanding Roll Forward A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. Short-Term Debt, Type [Domain] Short-Term Debt, Type [Domain] Summary of Stock Option Activity Schedule of Stock Options Roll Forward [Table Text Block] Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Expected dividends Measurement Input, Expected Dividend Rate [Member] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Outstanding, beginning of period (in shares) Outstanding, end of period (in shares) Outstanding Number of Warrants (in shares) Class of Warrant or Right, Outstanding Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Buildings Building [Member] Insurance premiums Prepaid Insurance Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Ireland IRELAND Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Table] Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Table] Organization consolidation basis of presentation business description and accounting policies table. Schedule of Prepaid Expenses and Other Current Assets Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Operating Activities Aggregate Intrinsic Value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Class of Stock Class of Stock [Axis] Compensation expense for issuance of stock options APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Other Other Accrued Liabilities, Current Change in fair value of warrant liability Warrant liability fair value adjustment Other expense related to the change in fair value of the warrant liability Fair Value Adjustment of Warrants Settlement amount Litigation Settlement, Amount Awarded to Other Party Furniture Furniture and Fixtures [Member] Contingent liabilities Contingent Liabilities [Member] Contingent liabilities. Interest rate Debt Instrument, Interest Rate, Stated Percentage Unpaid consulting fees Unpaid Consulting Fees Unpaid consulting fees. Balance Sheet for September 30, 2022 (unaudited) Statement of Financial Position [Abstract] Proceeds from exercise of warrants Proceeds from Warrant Exercises Total stockholders’ equity (deficit) Beginning Balance Ending Balance Equity, Attributable to Parent Stock option compensation expense Stock Option Compensation Income Expense Stock option compensation (income) expense. Leaseholds Leaseholds and Leasehold Improvements [Member] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Professional services Prepaid Professional Services Current Prepaid professional services current. Schedule of Financial Assets Carried at Fair Value Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Convertible Notes Payable Convertible Notes Payable [Member] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Common stock warrants Common stock warrants [Member] Common stock warrants. Expected terms (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Conversion of mezzanine equity to common shares Conversion Of Temporary Equity To Common Shares Conversion Of Temporary Equity To Common Shares Revision of Prior Period [Domain] Revision of Prior Period [Domain] Loan Principal Payments Loan Principal Payments [Member] Loan principal payments. Warrants measurement input Warrants and Rights Outstanding, Measurement Input Compensation expense for issuance of employee stock purchase plan APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited) Statement of Operations and Comprehensive Loss [Abstract] Statement of operations and comprehensive loss. Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Conversion of shares (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Warrants issued to purchase of common stock (in shares) Warrants Issued To Purchase Of Common Stock Warrants issued to purchase of common stock. Capital Commitments [Domain] Capital Commitements [Domain] Capital commitements. Entity Emerging Growth Company Entity Emerging Growth Company Finished goods Inventory, Finished Goods, Gross Conversion of mezzanine equity to preferred shares Conversion Of Temporary Equity To Preferred Shares Conversion Of Temporary Equity To Preferred Shares Disclosure Of Preferred Purchase Agreement [Line Items] Disclosure Of Preferred Purchase Agreement [Line Items] Disclosure Of Preferred Purchase Agreement [Line Item]. Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Cash paid during the periods for: Interest Paid, Including Capitalized Interest, Operating and Investing Activities [Abstract] Year ended December 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Common stock, aggregate offering price Common Stock, Value, Subscriptions Antidilutive Securities [Axis] Antidilutive Securities [Axis] Outstanding, Weighted Average Exercise Price Per Share, beginning of period (in dollars per share) Outstanding, Weighted Average Exercise Price Per Share, end of period (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease expense Operating Lease, Expense Convertible Note Principal Payments Convertibe Note Principal Payments [Member] Convertibe note principal payments. Interest expense accrued related to convertible notes Paid-in-Kind Interest Common Stock Common Stock [Member] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net Loss per Share Earnings Per Share [Text Block] Product and Service Product and Service [Axis] Income Statement Location Income Statement Location [Domain] Clinical expenses Accrued Clinical Expenses Current Accrued Clinical Expenses Current Schedule of Level 3 Investments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Geographical Geographical [Domain] Lease term Lessee, Operating Lease, Term of Contract Schedule of Information Related to Stock Warrants Outstanding and Exercisable Schedule Of Information Related To Stock Warrants Outstanding And Exercisable [Table Text Block] Schedule of Information Related to Stock Warrants Outstanding and Exercisable. Minimum Minimum [Member] Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net General Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Medac Medac [Member] Medac. Cash Cash Summary of Warrant Activity Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited) Statement of Cash Flows [Abstract] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Assets Assets [Abstract] Disclosure Of Preferred Purchase Agreement [Table] Disclosure Of Preferred Purchase Agreement [Table] Disclosure Of Preferred Purchase Agreement [Table]. Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Fair value of warrant liabilities Total liabilities Liabilities, Fair Value Disclosure Clinical trial expenses Prepaid Clinical Trial Expenses Current Prepaid clinical trial expenses current. Other revenue Product and Service, Other [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Number of common shares remained available to be issued (in shares) Number Of Common Shares Remained Available To Be Issued Number of common shares remained available to be issued. Lessee Lease Description [Line Items] Lessee, Lease, Description [Line Items] Agent [Domain] Agent [Domain] Agent. Accumulated Deficit Retained Earnings [Member] Summary of Recognized Share-based Compensation Cost Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Basic loss per common share (in dollars per share) Earnings Per Share, Basic Right-of-use assets Operating Lease, Right-of-Use Asset Debt Instrument [Table] Schedule of Long-Term Debt Instruments [Table] Issuance of common stock with the employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Accounting Policies [Abstract] Accounting Policies [Abstract] Warrants exercisable, period Expected term Warrants and Rights Outstanding, Term Year ended December 31, 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Number of warrants outstanding (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Entity Address, City or Town Entity Address, City or Town Schedule of Cash, Cash Equivalents, and Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Cantor Fitzgerald & Co Cantor Fitzgerald And Co [Member] Cantor fitzgerald and co [Member]. Private placement -issuance of common shares, net of expenses (in shares) Issuance Of Common Stock In Private Placement Shares Issuance of common stock in private placement shares. $0.01 Range Of Exercise Prices Point Zero One Range [Member] Range of exercise prices Point zero one range. Document Transition Report Document Transition Report Interest expense incurred (less than) Interest Expense, Borrowings Year ended December 31, 2024 December Thirty First Two Thousand Twenty Four [Member] December thirty first two thousand twenty four. Common stock, shares authorized (in shares) Common Stock, Shares Authorized Secured Convertible Notes Payable Secured Convertible Notes Payable [Member] Secured convertible notes payable. Raw materials Inventory, Raw Materials, Gross $10.00 Range Of Exercise Prices Ten Point Zero Range [Member] Range of exercise prices Ten point zero range. Buildings and land Land, Buildings and Improvements [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Current capital commitments Capital Commitments Current Capital commitments current. Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Liability Class [Axis] Liability Class [Axis] Measurement Input Type Measurement Input Type [Axis] Weighted average pre-funded warrants (in shares) Weighted Average Number Of Shares Pre Funded Warrants Weighted average number of shares pre funded warrants 1. Debt instrument, incremental final payment, percentage Debt Instrument Incremental Final Payment Percentage Debt instrument, incremental final payment, percentage. Private placement - issuance of common stock and prefunded warrants, net of expense (in shares) Issuance Of Common Stock And Pre Funded Warrants In Private Placement Shares Issuance Of Common Stock And Pre Funded Warrants In Private Placement Shares $51.50+ Exercise Price Range Above Fifty One Point Five Zero [Member] Exercise Price Range Above Fifty One Point Five Zero. Additional paid-in capital Additional Paid in Capital Preferred Tranche A Warrant Preferred Tranche A Warrant [Member] Preferred tranche a warrant [Member]. Proceeds from exercise of stock options Proceeds from Stock Options Exercised Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Convertible Debt Convertible Debt [Member] Short-Term Debt, Type [Axis] Short-Term Debt, Type [Axis] Cancelled-Forfeited, Weighted Average Exercise Price Per Share (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid expenses and other current assets Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Work-in-process Inventory, Work in Process, Gross Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Deferred revenue Deferred Revenue Related Party Related Party, Type [Axis] Aggregate Intrinsic Value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Preferred Warrants Preferred Warrants [Member] Preferred Warrants Minimum accounting profit required for preceding three financial year Minimum Accounting Profit Required For Preceding Three Financial Year Minimum accounting profit required for preceding three financial year. Entity Registrant Name Entity Registrant Name Accounts Payable Accrued Expenses And Lease Liabilities Accounts Payable Accrued Expenses And Lease Liabilities [Member] Accounts payable accrued expenses and lease liabilities. Estimated minimum proceeds on issue of common stock for extension of due date of interest only interest payments Estimated Minimum Proceeds On Issue Of Common Stock For Extension Of Due Date Of Interest Only Interest Payments Estimated minimum proceeds on issue of common stock for extension of due date of interest only interest payments. Cost of goods sold Cost of Sales [Member] Document Period End Date Document Period End Date Warrant exercise period Class Of Warrant Or Right, Exercise Period Class Of Warrant Or Right, Exercise Period Net Notes And Loans Payable Net Notes and loans payable net. Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Weighted Average Exercise Price, Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key Amortization of debt discount Amortization of Debt Issuance Costs and Discounts Liabilities [Abstract] Liabilities, Fair Value Disclosure [Abstract] Loss contingency accrual Loss Contingency Accrual Class of Warrant or Right Class of Warrant or Right [Axis] Share-based compensation expense Share-Based Payment Arrangement, Expense Total Notes and Loans Payable Total Cash, Cash Equivalents and Restricted Cash: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract] Compensation, excluding taxes Employee-related Liabilities, Current Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Fair Value Measurements Fair Value Disclosures [Text Block] Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Total comprehensive income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Private placement -issuance of common shares, net of expenses Issuance Of Common Stock In Private Placement Issuance of common stock in private placement. Agreement [Domain] Agreement [Domain] Agreement. Stock issued during the period Stock Issued During Period, Value, New Issues Equity [Abstract] Inventory Inventory Disclosure [Text Block] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Amendment Flag Amendment Flag Weighted Average Remaining Life (in years) Class of Warrant or Right Outstanding, Additional Information [Abstract] Class of Warrant or Right Outstanding, Additional Information Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Number of exercisable preferred warrants (in shares) Number Of Exercisable Preferred Warrants Number of exercisable preferred warrants. Weighted average discount rate - operating leases Operating Lease, Weighted Average Discount Rate, Percent Interest expense Interest Paid, Excluding Capitalized Interest, Operating Activities Final payment Final Payment Final payment. Debt instrument, interest rate Debt Instrument, Basis Spread on Variable Rate Estimated Useful Life Property, Plant and Equipment, Useful Life Weighted average number of diluted shares outstanding (in shares) Weighted average number of diluted shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Capital Commitments [Axis] Capital Commitements [Axis] Capital commitements. Interest expense, net Interest Income (Expense), Nonoperating, Net Increase in shares available under equity incentive plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Operating expenses: Operating Expenses [Abstract] Weighted average shares issued (in shares) Weighted Average Number of Shares Issued, Basic Purchase of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Additional Paid in Capital Additional Paid-in Capital [Member] Preferred Tranche B Warrant Preferred Tranche B Warrant [Member] Preferred tranche b warrant [Member]. Balance Sheet Location [Axis] Balance Sheet Location [Axis] Expired, Weighted Average Exercise Price Per Share (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Commitments and Contingencies Commitments Disclosure [Text Block] Beginning of period End of period Total cash, cash equivalents and restricted cash shown in the statements of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Total assets Assets Other Liabilities Other Liabilities [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Revision of Prior Period [Axis] Revision of Prior Period [Axis] Cover [Abstract] Cover [Abstract] Exercisable, (in dollars per share) Warrants Exercisable, Weighted Average Exercise Price Class Of Warrant Or Right Exercisable Weighted Average Exercise Price Class of warrant or right exercisable weighted average exercise price. Series F-4 Series F4 Preferred Stock [Member] Series F4 Preferred Stock. Equipment Equipment [Member] Proceeds from issuance of warrants Proceeds from Issuance of Warrants Other Other Prepaid Expense, Current U.S. UNITED STATES Class Of Warrant Or Right Outstanding [Roll Forward] Class Of Warrant Or Right Outstanding [Roll Forward] Class Of Warrant Or Right Outstanding Series A Series A Preferred Stock [Member] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Other liabilities, non-current Other Liabilities, Noncurrent Total Lessee, Operating Lease, Liability, to be Paid Number of exercisable common warrants (in shares) Number Of Exercisable Common Warrants Number of exercisable common warrants. Total operating expenses Operating Expenses Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents Disclosure [Text Block] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Schedule of Error Corrections and Prior Period Adjustment Restatement [Table] Net increase (decrease) in total cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Equity Component Equity Component [Domain] Share-based compensation arrangement by share-based payment award purchase price of common stock (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent $4.50 Range Of Exercise Prices Four Point Five Zero Range [Member] Range Of Exercise Prices Four Point Five Zero Range Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted average number of basic shares outstanding (in shares) Weighted average number of basic shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Controlled Equity Offering Sales Agreement Controlled Equity Offering Sales Agreement [Member] Controlled equity offering sales agreement. Loan amount funded into restricted account Tranche Loan Funded Into Restricted Account Tranche loan funded into restricted account. Discount Discount On Notes And Loans Payable Discount on notes and loans payable. Operating loss Operating Income (Loss) Assumed conversion of convertible notes Assumed Conversion Of Convertible Notes [Member] Assumed conversion of convertible notes. Revision of Previously Issued Quarterly Financial Statements Reclassification, Comparability Adjustment [Policy Text Block] Preferred F-2 Stock Series F-2 Series F2 Preferred Stock [Member] Series F2 Preferred Stock. Series C Series C Preferred Stock [Member] Cost of goods sold Cost of Revenue Statement [Line Items] Statement [Line Items] Conversion of shares Stock Issued During Period, Value, Conversion of Convertible Securities Exercisable, end of period (in shares) Warrants Exercisable, Number of Warrants (in shares) Class Of Warrant Or Right Exercisable Class of warrant or right exercisable. Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Common Warrants Common Warrants [Member] Common Warrants Weighted Average Remaining Contractual Term (in years) and Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Less Current Portion, Discount Discount On Notes And Loans Payable Current Discount on notes and loans payable current. Risks and Uncertainties Risk And Uncertainties Policy [Policy Text Block] Risk and uncertainties. Useful Life, Shorter of Lease Term or Asset Utility [Member] EX-101.PRE 10 dcth-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover Page - shares
9 Months Ended
Sep. 30, 2023
Nov. 08, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-16133  
Entity Registrant Name DELCATH SYSTEMS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 06-1245881  
Entity Address, Address Line One 1633 Broadway  
Entity Address, Address Line Two Suite 22C  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10019  
City Area Code 212  
Local Phone Number 489-2100  
Title of 12(b) Security Common stock, $0.01 par value per share  
Trading Symbol DCTH  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   22,046,101
Entity Central Index Key 0000872912  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 40,462 $ 7,671
Restricted cash 50 4,151
Accounts receivable, net 205 366
Inventory 2,667 1,998
Prepaid expenses and other current assets 2,712 1,969
Total current assets 46,096 16,155
Property, plant and equipment, net 1,374 1,422
Right-of-use assets 107 285
Total assets 47,577 17,862
Current liabilities    
Accounts payable 753 2,018
Accrued expenses 5,230 4,685
Lease liabilities, current 35 186
Loan payable, current 5,080 7,846
Convertible notes payable, current 2,876 0
Total current liabilities 13,974 14,735
Warrant liability 5,773 0
Other liabilities, non-current 1,111 1,144
Loan payable, non-current 0 3,070
Convertible notes payable, non-current 2,000 4,772
Total liabilities 22,858 23,721
Commitments and contingencies (see note 13)
Stockholders’ equity (deficit)    
Preferred stock, $0.01 par value; 10,000,000 shares authorized; 37,787 and 11,357 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively 0 0
Common stock, $0.01 par value; 80,000,000 shares authorized; 19,688,991 shares and 10,046,571 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively 197 100
Additional paid-in capital 518,607 451,608
Accumulated deficit (494,026) (457,484)
Accumulated other comprehensive loss (59) (83)
Total stockholders’ equity (deficit) 24,719 (5,859)
Total liabilities and stockholders’ equity $ 47,577 $ 17,862
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 37,787 11,357
Preferred stock, shares outstanding (in shares) 37,787 11,357
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 80,000,000 80,000,000
Common stock, shares issued (in shares) 19,688,991 10,046,571
Common stock, shares outstanding (in shares) 19,688,991 10,046,571
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total revenues $ 434 $ 906 $ 1,526 $ 2,080
Cost of goods sold (133) (235) (464) (449)
Gross profit 301 671 1,062 1,631
Operating expenses:        
Research and development expenses 4,662 4,065 12,793 14,152
Selling, general and administrative expenses 6,195 4,779 15,147 13,477
Total operating expenses 10,857 8,844 27,940 27,629
Operating loss (10,556) (8,173) (26,878) (25,998)
Change in fair value of warrant liability (9,384) 0 (8,224) 0
Interest expense, net (395) (730) (1,454) (2,040)
Other income (expense) (5) 26 14 2
Net loss (20,340) (8,877) (36,542) (28,036)
Other comprehensive income:        
Foreign currency translation adjustments 5 (46) 24 (82)
Total other comprehensive loss $ (20,335) $ (8,923) $ (36,518) $ (28,118)
Common share data:        
Basic loss per common share (in dollars per share) $ (1.14) $ (0.96) $ (2.61) $ (3.29)
Diluted loss per common share (in dollars per share) $ (1.14) $ (0.96) $ (2.61) $ (3.29)
Weighted average number of basic shares outstanding (in shares) 17,863,078 9,215,786 13,985,248 8,536,006
Weighted average number of diluted shares outstanding (in shares) 17,863,078 9,215,786 13,985,248 8,536,006
Product revenue        
Total revenues $ 434 $ 906 $ 1,526 $ 1,909
Other revenue        
Total revenues $ 0 $ 0 $ 0 $ 171
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Total
Preferred F-1 Stock
Preferred F-2 Stock
Preferred F-3 Stock
Common Stock
Common Stock
Preferred F-1 Stock
Common Stock
Preferred F-2 Stock
Common Stock
Preferred F-3 Stock
Common Stock
Preferred Series E Stock
Preferred Stock
Preferred Stock
Preferred F-2 Stock
Preferred Stock
Preferred F-3 Stock
Preferred Stock
Preferred Series E Stock
Additional Paid in Capital
Additional Paid in Capital
Preferred F-1 Stock
Additional Paid in Capital
Preferred F-2 Stock
Additional Paid in Capital
Preferred F-3 Stock
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Beginning Balance (in shares) at Dec. 31, 2021         7,906,728         11,357                  
Beginning Balance at Dec. 31, 2021 $ 11,952       $ 79         $ 0       $ 432,831       $ (420,976) $ 18
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Compensation expense for issuance of stock options 2,271                         2,271          
Net loss (9,000)                                 (9,000)  
Total comprehensive income 2                                   2
Ending Balance (in shares) at Mar. 31, 2022         7,906,728         11,357                  
Ending Balance at Mar. 31, 2022 5,225       $ 79         $ 0       435,102       (429,976) 20
Beginning Balance (in shares) at Dec. 31, 2021         7,906,728         11,357                  
Beginning Balance at Dec. 31, 2021 11,952       $ 79         $ 0       432,831       (420,976) 18
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Net loss (28,036)                                    
Ending Balance (in shares) at Sep. 30, 2022         8,597,682         11,357                  
Ending Balance at Sep. 30, 2022 (5,246)       $ 86         $ 0       443,737       (449,012) (57)
Beginning Balance (in shares) at Mar. 31, 2022         7,906,728         11,357                  
Beginning Balance at Mar. 31, 2022 5,225       $ 79         $ 0       435,102       (429,976) 20
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Compensation expense for issuance of stock options 2,119                         2,119          
Net loss (10,159)                                 (10,159)  
Total comprehensive income (31)                                   (31)
Ending Balance (in shares) at Jun. 30, 2022         7,906,728         11,357                  
Ending Balance at Jun. 30, 2022 (2,846)       $ 79         $ 0       437,221       (440,135) (11)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Compensation expense for issuance of stock options 1,627                         1,627          
Private placement - issuance of common stock and prefunded warrants, net of expense (in shares)         690,954                            
Private placement - issuance of common stock and prefunded warrants, net of expense 4,896       $ 7                 4,889          
Net loss (8,877)                                 (8,877)  
Total comprehensive income (46)                                   (46)
Ending Balance (in shares) at Sep. 30, 2022         8,597,682         11,357                  
Ending Balance at Sep. 30, 2022 (5,246)       $ 86         $ 0       443,737       (449,012) (57)
Beginning Balance (in shares) at Dec. 31, 2022         10,046,571         11,357                  
Beginning Balance at Dec. 31, 2022 (5,859)       $ 100         $ 0       451,608       (457,484) (83)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Compensation expense for issuance of stock options 1,661                         1,661          
Private placement -issuance of common shares, net of expenses (in shares)         19,646                            
Private placement -issuance of common shares, net of expenses 56       $ 1                 55          
Issuance of common stock with the employee stock purchase plan (in shares)         15,417                            
Issuance of common stock with the employee stock purchase plan 47                         47          
Net loss (9,000)                                 (9,000)  
Total comprehensive income 19                                   19
Ending Balance (in shares) at Mar. 31, 2023         10,081,634         11,357                  
Ending Balance at Mar. 31, 2023 (13,076)       $ 101         $ 0       453,371       (466,484) (64)
Beginning Balance (in shares) at Dec. 31, 2022         10,046,571         11,357                  
Beginning Balance at Dec. 31, 2022 $ (5,859)       $ 100         $ 0       451,608       (457,484) (83)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Issuance of common stock related to stock option exercises (in shares) 819                                    
Net loss $ (36,542)                                    
Ending Balance (in shares) at Sep. 30, 2023         19,688,991         37,787                  
Ending Balance at Sep. 30, 2023 24,719       $ 197         $ 0       518,607       (494,026) (59)
Beginning Balance (in shares) at Mar. 31, 2023         10,081,634         11,357                  
Beginning Balance at Mar. 31, 2023 (13,076)       $ 101         $ 0       453,371       (466,484) (64)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Compensation expense for issuance of stock options 1,661                         1,661          
Stock issued during period (in shares)                     9,624                
Stock issued during the period     $ 7,099                         $ 7,099      
Conversion of shares (in shares)         538,828 4,629,539                          
Conversion of shares 5 $ 11,269     $ 5 $ 47                 $ 11,222        
Issuance of common stock related to stock option exercises (in shares)         468                            
Issuance of common stock related to stock option exercises 2                         2          
Net loss (7,202)                                 (7,202)  
Total comprehensive income 0                                   0
Ending Balance (in shares) at Jun. 30, 2023         15,250,469         20,981                  
Ending Balance at Jun. 30, 2023 (242)       $ 153         $ 0       473,355       (473,686) (64)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                      
Compensation expense for issuance of stock options 2,783                         2,783          
Stock issued during period (in shares)                       34,859              
Stock issued during the period       $ 42,388                         $ 42,388    
Conversion of shares (in shares)         31,110   1,430,603 2,940,440 10,000   (4,721) (13,232) (100)            
Conversion of shares     $ 0 $ 1     $ 14 $ 30               $ (14) $ (29)    
Issuance of common stock with the employee stock purchase plan (in shares)         26,018                            
Issuance of common stock with the employee stock purchase plan 76                         76          
Issuance of common stock related to stock option exercises (in shares)         351                            
Issuance of common stock related to stock option exercises 1                         1          
Compensation expense for issuance of employee stock purchase plan 47                         47          
Net loss (20,340)                                 (20,340)  
Total comprehensive income 5                                   5
Ending Balance (in shares) at Sep. 30, 2023         19,688,991         37,787                  
Ending Balance at Sep. 30, 2023 $ 24,719       $ 197         $ 0       $ 518,607       $ (494,026) $ (59)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) - $ / shares
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Statement of Stockholders' Equity [Abstract]                
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01
Common stock, par value (in dollars per share) $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net loss $ (36,542) $ (28,036)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock option compensation expense 6,152 6,016
Depreciation expense 87 98
Warrant liability fair value adjustment 8,224 0
Non-cash lease expense 262 339
Amortization of debt discount 582 574
Interest expense accrued related to convertible notes 120 120
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (743) 708
Accounts receivable 161 (493)
Inventory (669) (515)
Accounts payable and accrued expenses (437) 2,907
Other liabilities, non-current (270) 861
Deferred revenue 0 (170)
Net cash used in operating activities (23,073) (17,591)
Cash flows from investing activities:    
Purchase of property, plant and equipment (39) (209)
Net cash used in investing activities (39) (209)
Cash flows from financing activities:    
Net proceeds from private placement 22,960 4,896
Proceeds from the issuance of common stock relating to the employee stock purchase plan 123 0
Repayment of debt (6,313) 0
Proceeds from exercise of warrants 35,004 0
Proceeds from exercise of stock options 3 0
Net cash provided by financing activities 51,777 4,896
Foreign currency effects on cash 25 (67)
Net increase (decrease) in total cash 28,690 (12,971)
Total Cash, Cash Equivalents and Restricted Cash:    
Beginning of period 11,822 26,953
End of period 40,512 13,982
Cash, Cash Equivalents and Restricted Cash consisted of the following:    
Cash 40,462 9,831
Restricted Cash 50 4,151
Total cash, cash equivalents and restricted cash shown in the statements of cash flows 40,512 13,982
Cash paid during the periods for:    
Interest expense 1,122 1,337
Supplemental Disclosure of Non-Cash Investing and Financing Activities:    
Right of use assets obtained in exchange for lease obligations 84 0
Conversion of mezzanine equity to common shares 11,269 0
Conversion of mezzanine equity to preferred shares $ 7,099 $ 0
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
General
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
General General
The unaudited interim condensed consolidated financial statements of Delcath Systems, Inc. (“Delcath” or the “Company”) as of and for the three and nine months ended September 30, 2023 and 2022 should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Annual Report”), which was filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2023 and may also be found on the Company’s website (www.delcath.com). In these notes to the interim condensed consolidated financial statements the terms “us”, “we” or “our” refer to Delcath and its consolidated subsidiaries.
Description of Business
The Company is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company’s lead product, the HEPZATO KITTM (“HEPZATO” melphalan for Injection/Hepatic Delivery System), a drug/device combination product, was approved by the U.S. Food and Drug Administration (the “FDA”) on August 14, 2023 indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver with no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.
In the United States, HEPZATO is considered a combination drug and device product and is regulated as a drug by the FDA. Primary jurisdiction for regulation of HEPZATO has been assigned to the FDA’s Center for Drug Evaluation and Research. The FDA has granted Delcath six orphan drug designations (five for melphalan in the treatment of patients with ocular (uveal) melanoma, cutaneous melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and neuroendocrine tumor indications and one for doxorubicin in the treatment of patients with hepatocellular carcinoma).
The Company’s clinical development program for HEPZATO was comprised of the FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (the “FOCUS Trial”), a global registration clinical trial that investigated objective response rate in metastatic ocular melanoma (“mOM”). The Company is currently reviewing the incidence, unmet need, available efficacy data and development requirements for a broad set of liver cancers in order to select a portfolio of follow-on indications that will maximize the value of the HEPZATO platform. In addition to HEPZATO’s approved use to treat mOM, the Company believes that HEPZATO has the potential to treat other liver dominant cancers, such as Metastatic Colorectal Cancer and Cholangiocarcinoma, and plans to begin the study of HEPZATO to treat such conditions in the near future. The Company believes that the disease states it is investigating and intends to investigate are unmet medical needs that represent significant market opportunities.
As the Company prepares for commercial launch of HEPZATO, the Company continues its expanded access program (“EAP”) in the United States to make HEPZATO readily available to mOM patients. The Company is focused on continuing to treat these patients enrolled in the EAP sites.
On February 28, 2022, CHEMOSAT received Medical Device Regulation (“MDR”) certification under the European Medical Devices Regulation (2017/745/EU), which may be considered by jurisdictions when evaluating reimbursement. As of March 1, 2022, the Company has assumed direct responsibility for sales, marketing and distribution of CHEMOSAT in Europe.
Risks and Uncertainties
The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully launching and commercializing its drug/device combination products, the Company's ability to obtain regulatory approval of its such products in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians and consumers, and significant competition.
In addition, high rates of inflation have resulted in the U.S. Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks and financial institutions enter receivership or
become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our or our partners’ ability to access existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on our business and financial condition, including our ability to access additional capital on favorable terms, or at all, which could in the future negatively affect our ability to pursue our business strategy.
Liquidity and Going Concern
On September 30, 2023, the Company had cash, cash equivalents and restricted cash totaling $40.5 million, as compared to cash, cash equivalents and restricted cash totaling $11.8 million at December 31, 2022. During the nine months ended September 30, 2023, the Company used $23.1 million of cash in its operating activities and $6.3 million for principal payments.
The Company’s future results are subject to substantial risks and uncertainties. The Company has operated at a loss for its entire history and there can be no assurance that it will ever achieve or maintain profitability. The Company has historically funded its operations primarily with proceeds from sales of common stock, warrants and prefunded warrants for the purchase of common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements.
The Company believes that current cash and cash equivalents will enable the Company to have sufficient cash through the launch of HEPZATO. If there is a substantial delay in the launch of HEPZATO, the Company expects to need to raise additional capital under structures available to the Company, including debt and/or equity offerings, which may not be on favorable terms. If commercialization were significantly delayed, the Company would not have sufficient funds to meet its obligations within twelve months from the issuance date of these condensed consolidated financial statements. As such, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt about our ability to continue as a going concern.
The Company’s capital commitments over the next twelve months include (a) $6.0 million to satisfy accounts payable, accrued expenses and lease liabilities and (b) $8.6 million of loan principal payments. Additional capital commitments beyond the next twelve months include (a) $0.1 million of lease liabilities; (b) $1.0 million for settlement of litigation with medac; and (c) $2.0 million of convertible note principal payments, if the holders do not elect to convert the notes into equity.
Basis of Presentation
These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all wholly owned subsidiaries and all significant inter-company accounts and transactions have been eliminated in consolidation.
The preparation of interim condensed consolidated financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended September 30, 2023 and 2022; however, certain information and footnote disclosures normally included in our audited consolidated financial statements included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.
Significant Accounting Policies
Other than the policies listed below, there have been no material changes to our significant accounting policies as set forth in Note 3 Summary of Significant Accounting Policies to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
Warrant Liabilities
The Company determined the warrant liability was not in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, which classifies and measures certain financial instruments with characteristics of both liability and equity. Entities must consider whether to classify contracts that may be settled in its own stock, such as warrants, as equity of the entity or as an asset or liability. If an event that is not within the entity’s control could require net cash settlement,
then the contract should be classified as an asset or a liability at their fair value at issuance with subsequent changes in fair value recorded in earnings.
The Company has accounted for the Preferred Warrants as derivative instruments in accordance with ASC 815, Derivatives and Hedging. The Company classified the Preferred Warrants issued in conjunction with the Preferred Purchase Agreement (defined below) and the Common Warrants issued in conjunction with the Common Purchase Agreement (as defined below) as a liability due to the existence of a pre-specified volatility input to the Black-Scholes calculation which would be used to calculate the repurchase price of the Preferred Warrants and Common Warrants in the event of a Fundamental Transaction, as defined.
The valuations of the warrant liability and Series F-1 Preferred Stock (defined below) were determined using option pricing models. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. In addition, the Company used probabilities of the FDA approval of the HEPZATO KIT (“FDA Approval”) and of recording at least $10 million in quarterly U.S. revenue from the commercialization of HEPZATO as inputs to determine the fair value of warrants liability and Series F-1 Preferred Stock. The Company intends to adjust the fair value of the warranty liability at the end of each reporting period.
Recently Adopted and Issued Accounting Pronouncements
We have not been required to adopt any accounting standards that had a significant impact on our consolidated financial statements in the two years ended December 31, 2022. We do not expect any recently issued accounting standards to have a significant impact on our consolidated financial statements.
Revision of Previously Issued Quarterly Financial Statements
In preparation of the Company's audited financial statements as of and for year ended December 31, 2022, the Company determined it needed to correct previously reported share-based compensation expense for each quarter during 2022. The correction for share-based compensation increased the net loss in amount of $0.8 million for the first quarter of 2022, $0.5 million for the second quarter of 2022 and $0.4 million for the third quarter of fiscal 2022. The share-based compensation adjustment is a non-cash adjustment and did not have any impact on the cash balances for the Company.
The following tables contain the financial information for the periods previously reported and have been updated to reflect the revisions of the Company’s financial statements. The revisions do not have an impact on the Company’s cash position. The Company has not amended its previously filed Quarterly Reports on Form 10-Q for the three quarterly periods ended September 30, 2022. The impact of the revision on the Company’s financial statements for the three and nine months ended September 30, 2022 is reflected in the following table:
(In thousands)As previously reported
Adjustment
As revised
Balance Sheet for September 30, 2022 (unaudited)
Additional paid-in capital$442,066 $1,671 $443,737 
Accumulated deficit$(447,341)$(1,671)$(449,012)
Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)
Research and development expenses$3,953 $112 $4,065 
Selling, general and administrative expenses4,519 260 4,779 
Total operating expenses8,472 372 8,844 
Operating loss(7,801)(372)(8,173)
Net loss(8,505)(372)(8,877)
Total other comprehensive loss(8,551)(372)(8,923)
Basic and diluted loss per common share$(0.92)$(0.04)$(0.96)
Consolidated Statement of Operations and Comprehensive Loss for the nine months September 30, 2022 (unaudited)
Research and development expenses$13,649 $503 $14,152 
Selling, general and administrative expenses12,309 1,168 13,477 
Total operating expenses25,958 1,671 27,629 
Operating loss(24,327)(1,671)(25,998)
Net loss(26,365)(1,671)(28,036)
Total other comprehensive loss(26,447)(1,671)(28,118)
Basic and diluted loss per common share$(3.09)$(0.20)$(3.29)
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)
Compensation expense for issuance of stock options$1,255 $372 $1,627 
Net loss$(8,505)$(372)$(8,877)
Consolidated statement of Stockholders’ Equity (Deficit) for the nine months ended September 30, 2022 (unaudited)
Compensation expense for issuance of stock options$4,345 $1,671 $6,016 
Net loss$(26,365)$(1,671)$(28,036)
Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)
Net loss$(26,365)$(1,671)$(28,036)
Stock option compensation expense$4,345 $1,671 $6,016 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Cash, Cash Equivalents and Restricted Cash
9 Months Ended
Sep. 30, 2023
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded in Restricted Cash on the balance sheets.
Cash, cash equivalents, and restricted cash balances were as follows:
(In thousands)September 30,
2023
December 31,
2022
Cash and cash equivalents$40,462 $7,671 
Restricted balance for loan agreement— 4,000 
Letters of credit— 101 
Security for credit cards50 50 
Total cash, cash equivalents and restricted cash shown in the statements of cash flows$40,512 $11,822 
On March 15, 2023, the Company returned to Avenue (as defined below) the $4.0 million held in restricted cash to pay down a portion of the outstanding Avenue Loan (defined below) balance. On March 31, 2023, the letter of credit for the sub-lease agreement for office space at 1633 Broadway, New York, NY expired.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Inventory
9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Inventory InventoryInventory consists of the following:
(In thousands)September 30,
2023
December 31,
2022
Raw materials$924 $763 
Work-in-process1,582 1,102 
Finished goods161 133 
Total inventory$2,667 $1,998 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Prepaid Expenses and Other Current Assets
9 Months Ended
Sep. 30, 2023
Prepaid Expense and Other Assets, Current [Abstract]  
Prepaid Expenses and Other Current Assets Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following:
(In thousands)September 30,
2023
December 31,
2022
Clinical trial expenses$1,630 $1,630 
Insurance premiums71 123 
Professional services655 121 
Other356 95 
Total prepaid expenses and other current assets$2,712 $1,969 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Property, Plant, and Equipment
9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
Property, Plant, and Equipment Property, Plant, and Equipment
Property, plant, and equipment consist of the following:
(In thousands)September 30, 2023December 31, 2022Estimated Useful Life
Buildings and land$1,301 $1,301 
30 years - Buildings
Enterprise hardware and software1,855 1,855 3 years
Leaseholds1,772 1,774 Lesser of lease term or estimated useful life
Equipment1,262 1,222 7 years
Furniture201 201 5 years
Property, plant and equipment, gross6,391 6,353 
Accumulated depreciation(5,017)(4,931)
Property, plant and equipment, net$1,374 $1,422 
Depreciation expense for the three and nine months ended September 30, 2023 and 2022 was less than $0.1 million for each period.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Accrued Expenses
9 Months Ended
Sep. 30, 2023
Payables and Accruals [Abstract]  
Accrued Expenses Accrued ExpensesAccrued expenses consist of the following:
(In thousands)September 30,
2023
December 31,
2022
Clinical expenses$2,105 $1,470 
Compensation, excluding taxes1,535 1,040 
Professional fees61 1,087 
Interest on convertible note673 553 
Other856 535 
Total accrued expenses$5,230 $4,685 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Leases
9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Leases Leases
The Company recognizes right-of-use (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company leases its facilities under non-cancellable operating and financing leases. The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the ROU asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.
For the three and nine months ended September 30, 2023 and 2022, the Company recognized $0.1 million and $0.3 million, respectively, of operating lease expense in the U.S. and less than $0.1 million of operating lease expense in Ireland for the same periods.
As of September 30, 2023:
(In thousands)U.S.IrelandTotal
Operating cash flows for operating leases$238 $24 $262 
Weighted average remaining lease term0.02.8
Weighted average discount rate - operating leases%%
As of August 31, 2023, the lease of office space at 1633 Broadway, New York, NY was converted to a month-to-month lease. No ROU assets or lease liabilities are recognized on the balance sheet for this arrangement.
Remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows:
U.S.IrelandTotal
Year ended December 31, 2023$— $11 $11 
Year ended December 31, 2024— 42 42 
Year ended December 31, 2025— 42 42 
Year ended December 31, 2026— 25 25 
Total— 120 120 
Less present value discount— (13)(13)
Operating lease liabilities included in the condensed consolidated balance sheets at September 30, 2023$— $107 $107 
Leases Leases
The Company recognizes right-of-use (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company leases its facilities under non-cancellable operating and financing leases. The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the ROU asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.
For the three and nine months ended September 30, 2023 and 2022, the Company recognized $0.1 million and $0.3 million, respectively, of operating lease expense in the U.S. and less than $0.1 million of operating lease expense in Ireland for the same periods.
As of September 30, 2023:
(In thousands)U.S.IrelandTotal
Operating cash flows for operating leases$238 $24 $262 
Weighted average remaining lease term0.02.8
Weighted average discount rate - operating leases%%
As of August 31, 2023, the lease of office space at 1633 Broadway, New York, NY was converted to a month-to-month lease. No ROU assets or lease liabilities are recognized on the balance sheet for this arrangement.
Remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows:
U.S.IrelandTotal
Year ended December 31, 2023$— $11 $11 
Year ended December 31, 2024— 42 42 
Year ended December 31, 2025— 42 42 
Year ended December 31, 2026— 25 25 
Total— 120 120 
Less present value discount— (13)(13)
Operating lease liabilities included in the condensed consolidated balance sheets at September 30, 2023$— $107 $107 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Loans and Convertible Notes Payable
9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Loans and Convertible Notes Payable Loans and Convertible Notes Payable
September 30, 2023December 31, 2022
Gross
Discount
Net
Gross
Discount
Net
Loans Payable, Current5,610 (530)5,080 8,570 (724)7,846 
Loans Payable, Non-Current— — — 3,353 (284)3,070 
Total - Loans Payable1
$5,610 $(530)$5,080 $11,923 $(1,008)$10,916 
Convertible Notes Payable - Current$3,000 $(124)$2,876 $— $— $— 
Convertible Notes Payable - Non-Current$2,000 $— $2,000 $5,000 $(228)$4,772 
Total - Convertible Notes Payable$5,000 $(124)$4,876 $5,000 $(228)$4,772 
Total - Loans and Notes Payable10,610 16,923 
1 The gross amount includes the 4.25% final payment of $0.5 million.
Remaining maturities of the Company’s loan and convertible note payables are as follows:
(In thousands)LoansConvertible
Notes
Total
Year ended December 31, 2023$— $— $— 
Year ended December 31, 20245,610 5,000 10,610 
Total$5,610 $5,000 $10,610 
Term Loan from Avenue Venture Opportunities Fund, L.P.
On August 6, 2021, the Company entered into a Loan and Security Agreement (the “Avenue Loan Agreement”) with Avenue Venture Opportunities Fund, L.P. (the “Lender,” or “Avenue”) for a term loan in an aggregate principal amount of up to $20.0 million (the “Avenue Loan”). The Avenue Loan bears interest at an annual rate equal to the greater of (a) the sum of 7.70% plus the prime rate as reported in The Wall Street Journal and (b) 10.95%. The interest rate at September 30, 2023 was 16.20%. The Avenue Loan is secured by all of the Company’s assets globally, including intellectual property. The Avenue Loan matures on August 1, 2024.

The initial tranche of the Avenue Loan was $15.0 million, including $4.0 million that was funded into a restricted account. On March 15, 2023, the Company returned to Avenue $4.0 million held in the restricted cash to pay down a portion of the
outstanding loan balance, principal payments of $2.1 million and an incremental 4.25% of the final payment of $0.2 million. On March 31, 2023, the Avenue Loan Agreement was amended (the “Avenue Amendment”) to defer the interest only period to September 30, 2023, with an additional extension option upon FDA Approval for the HEPZATO KIT and subsequent receipt of at least $10 million from the sale and issuance of equity securities. On August 14, 2023, the Company received FDA approval and has subsequently received over $10 million from the exercise of Tranche A Preferred Warrants. At the Company’s option, it has elected to extend the interest only period to December 31, 2023 and principal payments are deferred until January 2024.
Up to $3.0 million of the principal amount of the Avenue Loan outstanding may be converted, at Avenue's option, into shares of the Company’s common stock at a conversion price of $11.98 per share.
The Avenue Loan Agreement requires the Company to make and maintain representations and warranties and other agreements that are customary in loan agreements of this type. The Avenue Loan Agreement also contains customary events of default, including non-payment of principal or interest, violations of covenants, bankruptcy and material judgements.
In connection with the initial entry into the Avenue Loan Agreement, the Company issued warrants to Avenue (the “Initial Avenue Warrant”) to purchase 127,755 shares of common stock at an exercise price per share equal to $0.01. The Initial Avenue Warrant is exercisable until August 31, 2026. Additionally, in connection with the Avenue Amendment, the Company issued to Avenue a warrant to purchase 34,072 shares of common stock at an exercise price per share equal to $0.01.
The Company determined that the embedded conversion option associated with the Avenue Loan did not require bifurcation and met the criteria for equity classification. In addition, the amendment was recorded under debt modification guidance. Aggregate debt discount amortization of $0.2 million and $0.6 million was recorded during the three and nine months ended September 30, 2023 and 2022, respectively. Interest expense incurred was $0.3 million and $0.4 million for the three months ended September 30, 2023 and 2022, respectively and $1.1 million and $1.3 million for the nine months ended September 30, 2023 and 2022, respectively.
Convertible Notes Payable
The Company has $2.0 million of principal outstanding related to Senior Secured Promissory Notes (the “Rosalind Notes”) which bear interest at 8% per annum. Pursuant to the original terms, the Rosalind Notes were convertible into Series E Preferred Stock at a price of $1,500 per share and were to mature on July 16, 2021. Interest expense was $0.1 million for the nine months ended September 30, 2023 and 2022, respectively.
On August 6, 2021, the Company executed an agreement to amend the Rosalind Notes to (i) reduce the conversion price to $1,198 per share of the Company’s Series E Preferred Stock; and (ii) extend the maturity date to October 30, 2024. In addition, the holders of the Rosalind Notes agreed to subordinate all of the Company’s indebtedness and obligations to Avenue and all of the holders’ security interest, to the Avenue Loan and Avenue’s security interest in the Company’s property.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Preferred Purchase Agreement
9 Months Ended
Sep. 30, 2023
Preferred Purchase Agreement [Abstract]  
Preferred Purchase Agreement Preferred Purchase Agreement
On March 27, 2023, we entered into a securities purchase agreement with certain accredited investors (the “Preferred Purchase Agreement”), pursuant to which on March 29, 2023, the Company issued and sold, in a private placement (the “Series F Preferred Offering”), (i) 24,900 shares of Series F-1 Convertible Preferred Stock, par value $0.01 per share (the “Series F-1 Preferred Stock”), (ii) tranche A warrants (the “Preferred Tranche A Warrants”) to acquire 34,859 shares of Series F-3 Convertible Preferred Stock, par value $0.01 per share (the “Series F-3 Preferred Stock”) and (iii) tranche B warrants (the “Preferred Tranche B Warrants,” together with the Preferred Tranche A Warrant, the “Preferred Warrants”) to acquire 24,900 shares of Series F-4 Convertible Preferred Stock, par value $0.01 per share (the “Series F-4 Preferred Stock”) for an aggregate offering price of $24.9 million before deducting the fees paid to the placement agent and the financial advisors and other financing expenses payable by the Company.
The gross proceeds of $24.9 million from the Series F Preferred Offering have been allocated first to the Preferred Warrant liabilities at their fair value of $4.9 million, with the residual of $20.0 million being allocated to the Series F-1 Preferred Stock.
During the three months ended September 30, 2023, all of the Preferred Tranche A Warrants were exercised for an aggregate exercise price of $34.9 million into 34,859 shares of Series F-3 Preferred Stock and 13,232 shares of Series F-3
Preferred Stock were concurrently converted into 2,940,440 shares of common stock (in accordance with the beneficial ownership limitations then in effect). The Preferred Tranche B Warrants are exercisable for 24,900 shares of Series F-4 Preferred Stock, with an aggregate exercise price of $24.9 million until the earlier of (i) 21 days following the Company's announcement of receipt of at least $10 million in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026.
Following stockholder approval, pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series F Convertible Voting Preferred Stock (the “Certificate of Designation”), each share of Series F-1 Preferred Stock automatically converted into shares of common stock and/or, if applicable (in accordance with the beneficial ownership limitations then in effect), shares of Series F-2 Preferred Stock, par value $0.01 per share (the “Series F-2 Preferred Stock” and, together with the Series F-1 Preferred Stock, the Series F-3 Preferred Stock and the Series F-4 Preferred Stock, the “Series F Preferred Stock”) in lieu of common stock. Subject to limitations set forth in the Certificate of Designation, the shares of Series F-2, F-3 and F-4 Preferred Stock are convertible into common stock at the option of the holder at the conversion price of $3.30 per share, $4.50 per share and $6.00 per share, respectively, rounded down to the nearest whole share, and in each case subject to the terms and limitations contained in the Certificate of Designation. As of September 30, 2023, 33,229 shares of the Company's Series F-1, F-2 and F-3 Preferred Stock were converted into 9,000,582 shares of common stock. As of September 30, 2023, there were 4,903 shares of Series F-2 Preferred Stock, 21,627 shares of Series F-3 Preferred Stock and no shares of Series F-4 Preferred Stock outstanding.
The Series F-2, F-3 and F-4 Preferred Stock are not mandatorily redeemable, redeemable at the holder’s election or contingently redeemable at the holder’s election (at this point, a Deemed Liquidation Event would potentially trigger pro rata liquidation payments to the preferred and common stockholders on a pro rata “as converted” basis). Accordingly, the Series F-2, F-3 and F-4 Preferred are now classified as permanent equity.
The Company determined that the outstanding Preferred Warrants should be liability-classified. See “Note 1 – Warrant Liabilities” for a discussion of the accounting treatment of the Common Warrants and Preferred Warrants.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity
9 Months Ended
Sep. 30, 2023
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Stockholders’ Equity
Public and Private Placements
Common Purchase Agreement
On March 27, 2023, the Company entered into a securities purchase agreement (the “Common Purchase Agreement”) with the Company’s Chief Executive Officer, Gerard Michel, pursuant to which the Company agreed to issue and sell, in a private placement (the “Common Offering”) shares of common stock, tranche A warrants (“Common Tranche A Warrants”) to acquire 31,110 shares of common stock, tranche B warrants (“Common Tranche B Warrants”, together with the Common Tranche A Warrants, the “Common Warrants”) to acquire 16,666 shares of common stock. On March 29, 2023, the Company closed the Common Offering.
The aggregate exercise price of the Common Tranche A Warrants issued pursuant to the Common Offering is approximately $0.1 million.
On August 14, 2023, the Company announced the receipt of the FDA Approval and all Common Tranche A Warrants were exercised and converted into 31,110 shares of common stock.
The aggregate exercise price of the Common Tranche B Warrants issued in the Common Offering is approximately $0.1 million. The Common Tranche B Warrants are exercisable for an aggregate of 16,666 shares of common stock until the earlier of 21 days following the Company’s announcement of receipt of recording at least $10 million in quarterly U.S. revenue from the commercialization of HEPZATO and March 31, 2026.
The Company determined that the outstanding Common Warrants should be liability-classified. See “Note 1 – Warrant Liabilities” for a discussion of the accounting treatment of the Common Warrants and Preferred Warrants.
Registration Rights for Preferred and Common Offerings
Pursuant to the Preferred Purchase Agreement and the Common Purchase Agreement (collectively, the “Purchase Agreements”), the Company filed a registration statement on Form S-3 (the “Resale Registration Statement”) providing for
the resale by the investors party thereto of the common stock issuable upon conversion of the Registrable Shares (as defined in the Purchase Agreements). The Resale Registration Statement became effective on June 28, 2023.
There is no established public trading market for the Series F Preferred Stock, the Preferred Warrants, or the Common Warrants and the Company does not intend to list such securities on any national securities exchange or nationally recognized trading system.
At-the-Market Offering
The Company has entered into a Controlled Equity OfferingSM Sales Agreement (“ATM Sales Agreement”), with Cantor Fitzgerald & Co. (the “Sales Agent”), pursuant to which the Company may offer and sell, at its sole discretion through the Sales Agent, shares of common stock having an aggregate offering price of up to $17.0 million. To date, the Company has sold approximately $4.0 million of its common stock, prior to issuance costs, under the ATM Sales Agreement. No sales were made during the three and nine months ended September 30, 2023.
Authorized Shares
In June 2023, stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of its common stock authorized for issuance from 40 million shares to 80 million shares. The Company is authorized to issue 80 million shares of common stock, $0.01 par value, and 10 million shares of preferred stock, $0.01 par value. As of September 30, 2023, the Company has designated the following preferred stock:

Designated Preferred SharesSeptember 30, 2023
Series A4,200 
Series B2,360 
Series C590 
Series D10,000 
Series E 40,000 
Series E-112,960 
Series F-1 24,900 
Series F-224,900 
Series F-334,860 
Series F-424,900 
Total179,670 
Preferred Stock
As of September 30, 2023, there were an aggregate of 11,257 shares of Series E and Series E-1, 4,903 Series F-2 and 21,627 Series F-3 Convertible Preferred Stock outstanding, respectively.
Omnibus Equity Incentive Plan
On September 30, 2020, the Company’s 2020 Omnibus Equity Incentive Plan (the “2020 Plan”) was adopted by the Company’s Board of Directors. On November 23, 2020, the Company’s stockholders approved the 2020 Plan. The 2020 Plan will continue in effect until the tenth anniversary of the date of its adoption by the Board or until earlier terminated by the Board. The 2020 Plan is administered by the Board of Directors or a committee designated by the Board of Directors. On June 12, 2023, the stockholders approved the amendment to the Company’s 2020 Plan to increase the number of shares of common stock available under the plan by 2.65 million shares. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, as well as other stock-based awards or cash awards that are deemed to be consistent with the purposes of the plan to Company employees, directors and consultants. As of September 30, 2023, there are 5,125,000 shares of common stock reserved under the 2020 Plan, of which 1,802,841 remained available to be issued.
In addition to options granted from the 2020 Plan, the Company also grants employment inducement grants pursuant to Listing Rule 5635(c) of the corporate governance rules of the NASDAQ Stock Market. These inducement grants are intended to provide incentive to certain individuals to enter into employment with the Company. Inducement grants are
granted outside of the 2020 Plan, however they are governed in all respects as if they were issued under the 2020 Plan. These grants do not reduce the number of options available for issuance under the 2020 Plan.
Stock Options
The following tables include information for all options granted including inducement grants that are granted outside of the 2020 Plan.
The Company values stock options using the Black-Scholes option pricing model and used the following assumptions, on a weighted-average basis, during the reporting periods:
 Nine Months Ended September 30,
 20232022
Expected terms (years)5.75.4
Expected volatility160.4%164.3%
Risk-free interest rate3.99%1.86%
Expected dividends0.00%0.00%
The following is a summary of stock option activity for the nine months ended September 30, 2023:
Number of Options Weighted Average
Exercise Price Per Share
Weighted Average
Remaining
Contractual Term
(in years)
Aggregate Intrinsic
Value
Outstanding at January 1, 20232,235,052$10.30 7.8$35,875 
Granted2,122,7576.08 9.1
Exercised(819)4.67 
Expired(115,772)8.80 
Cancelled/Forfeited(104,390)7.22 
Outstanding at September 30, 20234,136,828$8.26 8.5$72,850 
Exercisable at September 30, 20232,020,026$10.29 7.7$— 
The following table summarizes information for stock option shares outstanding and exercisable at September 30, 2023:
Options Outstanding
Range of Exercise PricesOutstanding Number of
Options
Weighted Average
Remaining Option Term
(in years)
Number of Options
$2.83 - $51.50
4,136,3298.54,136,329
$51.50+
4995.3499
4,136,8288.54,136,828
The following is a summary of share-based compensation expense in the statement of operations for the three and nine months ended September 30, 2023:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
Selling, general and administrative$1,674 $1,117 $3,774 $3,984 
Research and development1,027 458 2,095 1,872 
Cost of goods sold129 52 283 160 
Total$2,830 $1,627 $6,152 $6,016 
At September 30, 2023, there was $7.7 million of aggregate unrecognized compensation expense related employee and board stock option grants. The cost is expected to be recognized over a weighted average period of 2.4 years.
Common Stock Warrants
The following is a summary of common stock warrant activity for the nine months ended September 30, 2023:
 Warrants
Weighted Average Exercise Price
Weighted Average
Remaining Life
(in years)
Outstanding at January 1, 20235,153,291$7.01 
Warrants issued81,8482.94 
Warrants exercised(569,938)0.26 
Outstanding at September 30, 20234,665,201$7.76 1.9
Exercisable at September 30, 20234,665,201$7.76 1.9
The following table presents information related to common stock warrants outstanding at September 30, 2023:
Warrants Exercisable
Range of Exercise PricesOutstanding
Number of
Warrants
Weighted Average
Remaining Warrant Term
(in years)
Number of Warrants
$0.011,037,7923.41,037,792
$6.00
16,6662.516,666
$10.003,610,7431.43,610,743
4,665,2011.94,665,201
As of September 30, 2023, there were 538,828 warrants priced at $0.01 and 31,110 warrants priced at $4.50 exercised for 569,938 common shares.
Preferred Stock Warrants
The following is a summary of preferred stock warrant activity for the nine months ended September 30, 2023:
WarrantsWeighted Average Exercise PriceWeighted Average
Remaining Life
(in years)
Outstanding at January 1, 2023— $— 
Warrants issued59,7591,000 
Warrants exercised(34,859)1,000 
Outstanding at September 30, 202324,900$1,000 2.5
Exercisable at September 30, 202324,900$1,000 2.5
Employee Stock Purchase Plan
In August 2021, the Company’s Board of Directors, with shareholder approval in May 2022, adopted the Employee Stock Purchase Plan (the “ESPP”). The ESPP provides for a maximum of 260,295 shares of common stock to be purchased by participating employees. Employees who elect to participate in the ESPP will be able to purchase common stock at the lower of 85% of the fair market value of common stock on the first or last day of the applicable six-month offering period. In January 2023, an aggregate of 15,417 shares were purchased by participating employees for the offering period of July 1, 2022 to December 31, 2022. In July 2023, an aggregate of 26,018 shares were purchased by participating employees for the offering period of January 1, 2023 to June 30, 2023.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss per Share
9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Net Loss per Share Net Loss per Share
Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period, without consideration of potentially dilutive securities, except for those shares that are issuable for little or no cash consideration. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options, convertible preferred shares, and preferred and common warrants are generally deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal.
The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2023 and 2022 because their effects would be anti-dilutive:
September 30,
20232022
Common stock warrants3,627,4094,461,249
Assumed conversion of preferred stock warrants4,149,994
Assumed conversion of preferred stock7,417,4731,135,721
Assumed conversion of convertible notes488,031488,031
Stock options4,136,8282,249,955
Total19,819,7358,334,956

At September 30, 2023, the Company had 1,037,792 pre-funded warrants outstanding. The following table provides a reconciliation of the weighted average shares outstanding calculation for the three and nine months ended September 30, 2023 and 2022:
Three months ended September 30,Nine months ended September 30,
2023202220232022
Weighted average shares issued16,825,2868,470,00612,745,0358,096,551
Weighted average pre-funded warrants1,037,792745,7801,240,213439,455
Weighted average shares outstanding17,863,0789,215,78613,985,2488,536,006
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes
9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
As discussed in “Note 14—Income Taxes” to the notes to the consolidated financial statements contained in the Annual Report, the Company has a valuation allowance against the full amount of its net deferred tax assets. The Company currently provides a valuation allowance against deferred tax assets when it is more likely than not that some portion or all of its deferred tax assets will not be realized. The Company has not recognized any unrecognized tax benefits in its balance sheet.
The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. Additional information regarding the statutes of limitations can be found in Note 14 Income Taxes of the Company’s Annual Report.
The Inflation Reduction Act of 2022 included tax legislation that became effective in the first quarter of 2023. Significant legislation for corporate taxpayers includes a corporate alternative minimum tax of 15% for companies with $1 billion or more in average net financial statement profits over the three previous years, as well as a 1% indirect excise tax on the repurchase of shares by a publicly traded company. The Company does not expect this legislation to have an effect on the tax provision as of September 30, 2023, however the Company will continue to evaluate the effect on the tax provision each reporting period.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
medac Matter
In April 2021, the Company’s wholly owned subsidiary, Delcath Systems Ltd, issued to medac GmbH, a privately held, multi-national pharmaceutical company based in Germany (“medac”), an invoice for a €1 million milestone payment under a License, Supply and Marketing Agreement dated December 10, 2018 (the “medac Agreement”) between medac and the Company. The medac Agreement provided to medac the exclusive right to market and sell CHEMOSAT in certain designated countries for which the Company was entitled to a combination of upfront and success-based milestone payments as well as a fixed transfer price per unit of CHEMOSAT and specified royalties.
In response to medac’s subsequent dispute and non-payment of the invoice, on October 12, 2021, the Company notified medac in writing that it was terminating the medac Agreement due to medac’s nonpayment of the €1 million milestone payment, with the effective date of termination of the medac Agreement being April 12, 2022. On December 16, 2021, the Company initiated an arbitration proceeding pursuant to the dispute resolution procedures of the medac Agreement for the non-payment of the invoice.
On December 30, 2022, the parties reached a final settlement of the matter and the Company agreed to pay medac either (a) a royalty on sales of CHEMOSAT units over a defined minimum for a period of five years or until a maximum payment has been reached, or (b) a minimum annual payment of $0.2 million in the event the annual royalty payment does not reach the agreed minimum payment amount. The Company has estimated the fair value of the settlement to be $1.3 million as of September 30, 2023 and recorded $1.1 million as other liabilities, non-current and $0.2 million as accrued expenses on the Company’s condensed consolidated balance sheet as of September 30, 2023.
Lachman Consulting Services, Inc.
On January 24, 2023, Lachman Consultant Services, Inc (“Lachman”) served the Company with a complaint alleging that Delcath owed Lachman approximately $0.9 million in unpaid consulting fees plus interest, costs and attorneys’ fees. The dispute arose from a July 22, 2021 agreement between Lachman and Delcath under which Lachman provided assistance to the Company in regard to preparing for a FDA inspection and good manufacturing practices, training and support. A settlement was reached on July 5, 2023, under which the Company paid Lachman $0.9 million.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements
9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The table below presents activity within Level 3 of the fair value hierarchy, our liabilities carried at fair value for the nine months ended September 30, 2023:
Level 3
(In thousands)Contingent
liabilities
WarrantsTotal
Balance at January 1, 2023$1,280 $— $1,280 
Total change in foreign exchange(9)— (9)
Fair value of the warrant liability issued— 4,940 4,940 
Warrant liability fair value adjustment— 8,224 8,224 
Change due to warrant exercise$— $(7,391)$(7,391)
Balance at September 30, 2023$1,271 $5,773 $7,044 
Contingent liabilities are re-measured to fair value each reporting period using projected financial targets, discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected financial targets are based on our most recent internal operational budgets and may take into consideration alternate scenarios that could result in more or less profitability for the respective service line. Increases or decreases in projected financial targets and probabilities of payment may result in significant changes in the fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs in isolation may result in a significantly lower or higher fair value measurement.
As disclosed in Note 9 and Note 10 of the Company’s consolidated financial statements, the Company allocated part of the proceeds of the Series F Preferred Offering to warrant liability issued in connection with the transaction. The valuations of the warrants were determined using option pricing models. The Company concluded that the Preferred Warrants were not in the scope of Accounting Standards Codification (ASC 480), Distinguishing Liabilities from Equity (ASC 480,) since the
Preferred Warrants are not mandatorily redeemable; and do not have obligations to issue a variable number of shares of preferred stock. The Company determined the Preferred Warrants met the definition of a derivative in accordance with ASC 815 but were not considered indexed to the Company’s common stock since the warrants require early settlement by repurchasing the preferred warrants for cash in an amount equal to the Black-Scholes value in the event of a Fundamental Transaction at pre-specified volatility of 100% as an input to the Black-Scholes calculation. The Company determined to record the Preferred Warrants at fair value with subsequent changes in fair value recorded in earnings at the end of each reporting period. For the three and nine months ended September 30, 2023, the Company recorded other expense of $9.4 million and $8.2 million, respectively, related to the change in fair value of the warrant liability and Tranche A Warrant exercises. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. The Company has classified the warrants as a long-term liability due to certain provisions relating to the holders’ ability to exercise the warrants beyond twelve months of the reporting date.
The fair value of the preferred and common warrants at September 30, 2023 and March 29, 2023 was determined by using option pricing models assuming the following:
March 29, 2023September 30, 2023
Risk free interest rate
3.80% - 4.80%
 4.80%
Expected term (years)
0.5 - 3.0
 2.5
Expected volatility
70% - 75%
 70%
Expected dividends0.00%0.00%
Additionally, the Company has determined that the warrant liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing models against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of the Company’s stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of the Company’s stock over that term; annual rate of dividends; and the risk-free rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of the Company’s stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The risk-free rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, the Company determined the warrant liability is most appropriately classified within Level 3 of the fair value hierarchy.
The following tables present information about the Company’s financial assets and liabilities that have been measured at fair value as of September 30, 2023 and December 31, 2022 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. In general, the fair values were determined using Level 3:
(In thousands)
Quoted Prices in
Active Markets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
September 30,
2023
Liabilities:    
Contingent liability$— $— $1,271 $1,271 
Warrant liability— — 5,773 5,773 
Total liabilities$— $— $7,044 $7,044 
(In thousands)Quoted Prices in
Active Markets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
December 31,
2022
Liabilities:    
Contingent liability$— $— $1,280 $1,280 
Total liabilities$— $— $1,280 $1,280 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
General (Policies)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Risks and Uncertainties
Risks and Uncertainties
The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully launching and commercializing its drug/device combination products, the Company's ability to obtain regulatory approval of its such products in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians and consumers, and significant competition.
In addition, high rates of inflation have resulted in the U.S. Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks and financial institutions enter receivership or
become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our or our partners’ ability to access existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on our business and financial condition, including our ability to access additional capital on favorable terms, or at all, which could in the future negatively affect our ability to pursue our business strategy.
Liquidity and Going Concern
Liquidity and Going Concern
On September 30, 2023, the Company had cash, cash equivalents and restricted cash totaling $40.5 million, as compared to cash, cash equivalents and restricted cash totaling $11.8 million at December 31, 2022. During the nine months ended September 30, 2023, the Company used $23.1 million of cash in its operating activities and $6.3 million for principal payments.
The Company’s future results are subject to substantial risks and uncertainties. The Company has operated at a loss for its entire history and there can be no assurance that it will ever achieve or maintain profitability. The Company has historically funded its operations primarily with proceeds from sales of common stock, warrants and prefunded warrants for the purchase of common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements.
The Company believes that current cash and cash equivalents will enable the Company to have sufficient cash through the launch of HEPZATO. If there is a substantial delay in the launch of HEPZATO, the Company expects to need to raise additional capital under structures available to the Company, including debt and/or equity offerings, which may not be on favorable terms. If commercialization were significantly delayed, the Company would not have sufficient funds to meet its obligations within twelve months from the issuance date of these condensed consolidated financial statements. As such, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt about our ability to continue as a going concern.
The Company’s capital commitments over the next twelve months include (a) $6.0 million to satisfy accounts payable, accrued expenses and lease liabilities and (b) $8.6 million of loan principal payments. Additional capital commitments beyond the next twelve months include (a) $0.1 million of lease liabilities; (b) $1.0 million for settlement of litigation with medac; and (c) $2.0 million of convertible note principal payments, if the holders do not elect to convert the notes into equity.
Basis of Presentation
Basis of Presentation
These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all wholly owned subsidiaries and all significant inter-company accounts and transactions have been eliminated in consolidation.
The preparation of interim condensed consolidated financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended September 30, 2023 and 2022; however, certain information and footnote disclosures normally included in our audited consolidated financial statements included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.
Warrant Liabilities
Warrant Liabilities
The Company determined the warrant liability was not in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, which classifies and measures certain financial instruments with characteristics of both liability and equity. Entities must consider whether to classify contracts that may be settled in its own stock, such as warrants, as equity of the entity or as an asset or liability. If an event that is not within the entity’s control could require net cash settlement,
then the contract should be classified as an asset or a liability at their fair value at issuance with subsequent changes in fair value recorded in earnings.
The Company has accounted for the Preferred Warrants as derivative instruments in accordance with ASC 815, Derivatives and Hedging. The Company classified the Preferred Warrants issued in conjunction with the Preferred Purchase Agreement (defined below) and the Common Warrants issued in conjunction with the Common Purchase Agreement (as defined below) as a liability due to the existence of a pre-specified volatility input to the Black-Scholes calculation which would be used to calculate the repurchase price of the Preferred Warrants and Common Warrants in the event of a Fundamental Transaction, as defined.
The valuations of the warrant liability and Series F-1 Preferred Stock (defined below) were determined using option pricing models. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. In addition, the Company used probabilities of the FDA approval of the HEPZATO KIT (“FDA Approval”) and of recording at least $10 million in quarterly U.S. revenue from the commercialization of HEPZATO as inputs to determine the fair value of warrants liability and Series F-1 Preferred Stock. The Company intends to adjust the fair value of the warranty liability at the end of each reporting period.
Recently Adopted and Issued Accounting Pronouncements Recently Adopted and Issued Accounting Pronouncements We have not been required to adopt any accounting standards that had a significant impact on our consolidated financial statements in the two years ended December 31, 2022. We do not expect any recently issued accounting standards to have a significant impact on our consolidated financial statements.
Revision of Previously Issued Quarterly Financial Statements
Revision of Previously Issued Quarterly Financial Statements
In preparation of the Company's audited financial statements as of and for year ended December 31, 2022, the Company determined it needed to correct previously reported share-based compensation expense for each quarter during 2022. The correction for share-based compensation increased the net loss in amount of $0.8 million for the first quarter of 2022, $0.5 million for the second quarter of 2022 and $0.4 million for the third quarter of fiscal 2022. The share-based compensation adjustment is a non-cash adjustment and did not have any impact on the cash balances for the Company.
The following tables contain the financial information for the periods previously reported and have been updated to reflect the revisions of the Company’s financial statements. The revisions do not have an impact on the Company’s cash position. The Company has not amended its previously filed Quarterly Reports on Form 10-Q for the three quarterly periods ended September 30, 2022. The impact of the revision on the Company’s financial statements for the three and nine months ended September 30, 2022 is reflected in the following table:
(In thousands)As previously reported
Adjustment
As revised
Balance Sheet for September 30, 2022 (unaudited)
Additional paid-in capital$442,066 $1,671 $443,737 
Accumulated deficit$(447,341)$(1,671)$(449,012)
Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)
Research and development expenses$3,953 $112 $4,065 
Selling, general and administrative expenses4,519 260 4,779 
Total operating expenses8,472 372 8,844 
Operating loss(7,801)(372)(8,173)
Net loss(8,505)(372)(8,877)
Total other comprehensive loss(8,551)(372)(8,923)
Basic and diluted loss per common share$(0.92)$(0.04)$(0.96)
Consolidated Statement of Operations and Comprehensive Loss for the nine months September 30, 2022 (unaudited)
Research and development expenses$13,649 $503 $14,152 
Selling, general and administrative expenses12,309 1,168 13,477 
Total operating expenses25,958 1,671 27,629 
Operating loss(24,327)(1,671)(25,998)
Net loss(26,365)(1,671)(28,036)
Total other comprehensive loss(26,447)(1,671)(28,118)
Basic and diluted loss per common share$(3.09)$(0.20)$(3.29)
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)
Compensation expense for issuance of stock options$1,255 $372 $1,627 
Net loss$(8,505)$(372)$(8,877)
Consolidated statement of Stockholders’ Equity (Deficit) for the nine months ended September 30, 2022 (unaudited)
Compensation expense for issuance of stock options$4,345 $1,671 $6,016 
Net loss$(26,365)$(1,671)$(28,036)
Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)
Net loss$(26,365)$(1,671)$(28,036)
Stock option compensation expense$4,345 $1,671 $6,016 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
General (Tables)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Schedule of Error Corrections and Prior Period Adjustments The impact of the revision on the Company’s financial statements for the three and nine months ended September 30, 2022 is reflected in the following table:
(In thousands)As previously reported
Adjustment
As revised
Balance Sheet for September 30, 2022 (unaudited)
Additional paid-in capital$442,066 $1,671 $443,737 
Accumulated deficit$(447,341)$(1,671)$(449,012)
Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)
Research and development expenses$3,953 $112 $4,065 
Selling, general and administrative expenses4,519 260 4,779 
Total operating expenses8,472 372 8,844 
Operating loss(7,801)(372)(8,173)
Net loss(8,505)(372)(8,877)
Total other comprehensive loss(8,551)(372)(8,923)
Basic and diluted loss per common share$(0.92)$(0.04)$(0.96)
Consolidated Statement of Operations and Comprehensive Loss for the nine months September 30, 2022 (unaudited)
Research and development expenses$13,649 $503 $14,152 
Selling, general and administrative expenses12,309 1,168 13,477 
Total operating expenses25,958 1,671 27,629 
Operating loss(24,327)(1,671)(25,998)
Net loss(26,365)(1,671)(28,036)
Total other comprehensive loss(26,447)(1,671)(28,118)
Basic and diluted loss per common share$(3.09)$(0.20)$(3.29)
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)
Compensation expense for issuance of stock options$1,255 $372 $1,627 
Net loss$(8,505)$(372)$(8,877)
Consolidated statement of Stockholders’ Equity (Deficit) for the nine months ended September 30, 2022 (unaudited)
Compensation expense for issuance of stock options$4,345 $1,671 $6,016 
Net loss$(26,365)$(1,671)$(28,036)
Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)
Net loss$(26,365)$(1,671)$(28,036)
Stock option compensation expense$4,345 $1,671 $6,016 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Cash, Cash Equivalents and Restricted Cash (Tables)
9 Months Ended
Sep. 30, 2023
Cash and Cash Equivalents [Abstract]  
Schedule of Cash, Cash Equivalents, and Restricted Cash Cash, cash equivalents, and restricted cash balances were as follows:
(In thousands)September 30,
2023
December 31,
2022
Cash and cash equivalents$40,462 $7,671 
Restricted balance for loan agreement— 4,000 
Letters of credit— 101 
Security for credit cards50 50 
Total cash, cash equivalents and restricted cash shown in the statements of cash flows$40,512 $11,822 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Inventory (Tables)
9 Months Ended
Sep. 30, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventory Inventory consists of the following:
(In thousands)September 30,
2023
December 31,
2022
Raw materials$924 $763 
Work-in-process1,582 1,102 
Finished goods161 133 
Total inventory$2,667 $1,998 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Prepaid Expenses and Other Current Assets (Tables)
9 Months Ended
Sep. 30, 2023
Prepaid Expense and Other Assets, Current [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following:
(In thousands)September 30,
2023
December 31,
2022
Clinical trial expenses$1,630 $1,630 
Insurance premiums71 123 
Professional services655 121 
Other356 95 
Total prepaid expenses and other current assets$2,712 $1,969 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Property, Plant, and Equipment (Tables)
9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
Components of Property, Plant and Equipment Property, plant, and equipment consist of the following:
(In thousands)September 30, 2023December 31, 2022Estimated Useful Life
Buildings and land$1,301 $1,301 
30 years - Buildings
Enterprise hardware and software1,855 1,855 3 years
Leaseholds1,772 1,774 Lesser of lease term or estimated useful life
Equipment1,262 1,222 7 years
Furniture201 201 5 years
Property, plant and equipment, gross6,391 6,353 
Accumulated depreciation(5,017)(4,931)
Property, plant and equipment, net$1,374 $1,422 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Accrued Expenses (Tables)
9 Months Ended
Sep. 30, 2023
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses Accrued expenses consist of the following:
(In thousands)September 30,
2023
December 31,
2022
Clinical expenses$2,105 $1,470 
Compensation, excluding taxes1,535 1,040 
Professional fees61 1,087 
Interest on convertible note673 553 
Other856 535 
Total accrued expenses$5,230 $4,685 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Tables)
9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Summary of Lease Costs As of September 30, 2023:
(In thousands)U.S.IrelandTotal
Operating cash flows for operating leases$238 $24 $262 
Weighted average remaining lease term0.02.8
Weighted average discount rate - operating leases%%
Schedule of Remaining maturity of Operating Leases Excluding Short-Term Leases
Remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows:
U.S.IrelandTotal
Year ended December 31, 2023$— $11 $11 
Year ended December 31, 2024— 42 42 
Year ended December 31, 2025— 42 42 
Year ended December 31, 2026— 25 25 
Total— 120 120 
Less present value discount— (13)(13)
Operating lease liabilities included in the condensed consolidated balance sheets at September 30, 2023$— $107 $107 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Loans and Convertible Notes Payable (Tables)
9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Summary of Loans and Convertible Notes Payable
September 30, 2023December 31, 2022
Gross
Discount
Net
Gross
Discount
Net
Loans Payable, Current5,610 (530)5,080 8,570 (724)7,846 
Loans Payable, Non-Current— — — 3,353 (284)3,070 
Total - Loans Payable1
$5,610 $(530)$5,080 $11,923 $(1,008)$10,916 
Convertible Notes Payable - Current$3,000 $(124)$2,876 $— $— $— 
Convertible Notes Payable - Non-Current$2,000 $— $2,000 $5,000 $(228)$4,772 
Total - Convertible Notes Payable$5,000 $(124)$4,876 $5,000 $(228)$4,772 
Total - Loans and Notes Payable10,610 16,923 
1 The gross amount includes the 4.25% final payment of $0.5 million.
Summary of Remaining Maturities of Company's Loan and Convertible Note Payables Remaining maturities of the Company’s loan and convertible note payables are as follows:
(In thousands)LoansConvertible
Notes
Total
Year ended December 31, 2023$— $— $— 
Year ended December 31, 20245,610 5,000 10,610 
Total$5,610 $5,000 $10,610 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2023
Stockholders' Equity Note [Abstract]  
Schedule of Designated Preferred Units As of September 30, 2023, the Company has designated the following preferred stock:
Designated Preferred SharesSeptember 30, 2023
Series A4,200 
Series B2,360 
Series C590 
Series D10,000 
Series E 40,000 
Series E-112,960 
Series F-1 24,900 
Series F-224,900 
Series F-334,860 
Series F-424,900 
Total179,670 
Summary of Avenue Warrant Valued Using the Black-Scholes Option Pricing Method The Company values stock options using the Black-Scholes option pricing model and used the following assumptions, on a weighted-average basis, during the reporting periods:
 Nine Months Ended September 30,
 20232022
Expected terms (years)5.75.4
Expected volatility160.4%164.3%
Risk-free interest rate3.99%1.86%
Expected dividends0.00%0.00%
Summary of Stock Option Activity
The following is a summary of stock option activity for the nine months ended September 30, 2023:
Number of Options Weighted Average
Exercise Price Per Share
Weighted Average
Remaining
Contractual Term
(in years)
Aggregate Intrinsic
Value
Outstanding at January 1, 20232,235,052$10.30 7.8$35,875 
Granted2,122,7576.08 9.1
Exercised(819)4.67 
Expired(115,772)8.80 
Cancelled/Forfeited(104,390)7.22 
Outstanding at September 30, 20234,136,828$8.26 8.5$72,850 
Exercisable at September 30, 20232,020,026$10.29 7.7$— 
Summary of Stock Option Shares Outstanding and Exercisable The following table summarizes information for stock option shares outstanding and exercisable at September 30, 2023:
Options Outstanding
Range of Exercise PricesOutstanding Number of
Options
Weighted Average
Remaining Option Term
(in years)
Number of Options
$2.83 - $51.50
4,136,3298.54,136,329
$51.50+
4995.3499
4,136,8288.54,136,828
Summary of Recognized Share-based Compensation Cost The following is a summary of share-based compensation expense in the statement of operations for the three and nine months ended September 30, 2023:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2023202220232022
Selling, general and administrative$1,674 $1,117 $3,774 $3,984 
Research and development1,027 458 2,095 1,872 
Cost of goods sold129 52 283 160 
Total$2,830 $1,627 $6,152 $6,016 
Summary of Warrant Activity The following is a summary of common stock warrant activity for the nine months ended September 30, 2023:
 Warrants
Weighted Average Exercise Price
Weighted Average
Remaining Life
(in years)
Outstanding at January 1, 20235,153,291$7.01 
Warrants issued81,8482.94 
Warrants exercised(569,938)0.26 
Outstanding at September 30, 20234,665,201$7.76 1.9
Exercisable at September 30, 20234,665,201$7.76 1.9
The following is a summary of preferred stock warrant activity for the nine months ended September 30, 2023:
WarrantsWeighted Average Exercise PriceWeighted Average
Remaining Life
(in years)
Outstanding at January 1, 2023— $— 
Warrants issued59,7591,000 
Warrants exercised(34,859)1,000 
Outstanding at September 30, 202324,900$1,000 2.5
Exercisable at September 30, 202324,900$1,000 2.5
Schedule of Information Related to Stock Warrants Outstanding and Exercisable The following table presents information related to common stock warrants outstanding at September 30, 2023:
Warrants Exercisable
Range of Exercise PricesOutstanding
Number of
Warrants
Weighted Average
Remaining Warrant Term
(in years)
Number of Warrants
$0.011,037,7923.41,037,792
$6.00
16,6662.516,666
$10.003,610,7431.43,610,743
4,665,2011.94,665,201
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss per Share (Tables)
9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Antidilutive Securities Excluded from the Computation of Earnings Per Share The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2023 and 2022 because their effects would be anti-dilutive:
September 30,
20232022
Common stock warrants3,627,4094,461,249
Assumed conversion of preferred stock warrants4,149,994
Assumed conversion of preferred stock7,417,4731,135,721
Assumed conversion of convertible notes488,031488,031
Stock options4,136,8282,249,955
Total19,819,7358,334,956
Summary of Reconciliation of Weighted Average Shares Outstanding Calculation The following table provides a reconciliation of the weighted average shares outstanding calculation for the three and nine months ended September 30, 2023 and 2022:
Three months ended September 30,Nine months ended September 30,
2023202220232022
Weighted average shares issued16,825,2868,470,00612,745,0358,096,551
Weighted average pre-funded warrants1,037,792745,7801,240,213439,455
Weighted average shares outstanding17,863,0789,215,78613,985,2488,536,006
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Level 3 Investments The table below presents activity within Level 3 of the fair value hierarchy, our liabilities carried at fair value for the nine months ended September 30, 2023:
Level 3
(In thousands)Contingent
liabilities
WarrantsTotal
Balance at January 1, 2023$1,280 $— $1,280 
Total change in foreign exchange(9)— (9)
Fair value of the warrant liability issued— 4,940 4,940 
Warrant liability fair value adjustment— 8,224 8,224 
Change due to warrant exercise$— $(7,391)$(7,391)
Balance at September 30, 2023$1,271 $5,773 $7,044 
Schedule of Fair Value Warrants The fair value of the preferred and common warrants at September 30, 2023 and March 29, 2023 was determined by using option pricing models assuming the following:
March 29, 2023September 30, 2023
Risk free interest rate
3.80% - 4.80%
 4.80%
Expected term (years)
0.5 - 3.0
 2.5
Expected volatility
70% - 75%
 70%
Expected dividends0.00%0.00%
Schedule of Financial Assets Carried at Fair Value The following tables present information about the Company’s financial assets and liabilities that have been measured at fair value as of September 30, 2023 and December 31, 2022 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. In general, the fair values were determined using Level 3:
(In thousands)
Quoted Prices in
Active Markets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
September 30,
2023
Liabilities:    
Contingent liability$— $— $1,271 $1,271 
Warrant liability— — 5,773 5,773 
Total liabilities$— $— $7,044 $7,044 
(In thousands)Quoted Prices in
Active Markets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
December 31,
2022
Liabilities:    
Contingent liability$— $— $1,280 $1,280 
Total liabilities$— $— $1,280 $1,280 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
General - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Mar. 29, 2023
Dec. 31, 2022
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]              
Cash cash equivalents and restricted cash       $ 40,500     $ 11,800
Net Cash Provided by (Used in) Operating Activities       (23,073) $ (17,591)    
Principal payments       6,300      
Deferred revenue       10,000   $ 10,000  
Impact of share-based compensation correction on net income (loss) $ 400 $ 500 $ 800        
Accounts Payable Accrued Expenses And Lease Liabilities              
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]              
Current capital commitments       6,000      
Loan Principal Payments              
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]              
Current capital commitments       8,600      
Lease Liabilities              
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]              
Noncurrent capital commitments       100      
Third Party Settlement              
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]              
Noncurrent capital commitments       1,000      
Convertible Note Principal Payments              
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]              
Noncurrent capital commitments       $ 2,000      
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
General - Schedule of Error Corrections and Prior Period Adjustments (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Balance Sheet for September 30, 2022 (unaudited)                  
Additional paid-in capital $ 518,607           $ 518,607   $ 451,608
Accumulated deficit (494,026)           (494,026)   $ (457,484)
Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)                  
Research and development expenses 4,662     $ 4,065     12,793 $ 14,152  
Selling, general and administrative expenses 6,195     4,779     15,147 13,477  
Total operating expenses 10,857     8,844     27,940 27,629  
Operating loss (10,556)     (8,173)     (26,878) (25,998)  
Net loss (20,340) $ (7,202) $ (9,000) (8,877) $ (10,159) $ (9,000) (36,542) (28,036)  
Total other comprehensive loss $ (20,335)     $ (8,923)     $ (36,518) $ (28,118)  
Basic loss per common share (in dollars per share) $ (1.14)     $ (0.96)     $ (2.61) $ (3.29)  
Diluted loss per common share (in dollars per share) $ (1.14)     $ (0.96)     $ (2.61) $ (3.29)  
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)                  
Compensation expense for issuance of stock options $ 2,783 1,661 1,661 $ 1,627 2,119 2,271      
Net loss (20,340) (7,202) (9,000) (8,877) (10,159) (9,000) $ (36,542) $ (28,036)  
Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)                  
Net loss $ (20,340) $ (7,202) $ (9,000) (8,877) $ (10,159) $ (9,000) (36,542) (28,036)  
Stock option compensation expense             $ 6,152 6,016  
As previously reported                  
Balance Sheet for September 30, 2022 (unaudited)                  
Additional paid-in capital       442,066       442,066  
Accumulated deficit       (447,341)       (447,341)  
Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)                  
Research and development expenses       3,953       13,649  
Selling, general and administrative expenses       4,519       12,309  
Total operating expenses       8,472       25,958  
Operating loss       (7,801)       (24,327)  
Net loss       (8,505)       (26,365)  
Total other comprehensive loss       $ (8,551)       $ (26,447)  
Basic loss per common share (in dollars per share)       $ (0.92)       $ (3.09)  
Diluted loss per common share (in dollars per share)       $ (0.92)       $ (3.09)  
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)                  
Compensation expense for issuance of stock options       $ 1,255       $ 4,345  
Net loss       (8,505)       (26,365)  
Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)                  
Net loss       (8,505)       (26,365)  
Stock option compensation expense               4,345  
Adjustment                  
Balance Sheet for September 30, 2022 (unaudited)                  
Additional paid-in capital       1,671       1,671  
Accumulated deficit       (1,671)       (1,671)  
Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)                  
Research and development expenses       112       503  
Selling, general and administrative expenses       260       1,168  
Total operating expenses       372       1,671  
Operating loss       (372)       (1,671)  
Net loss       (372)       (1,671)  
Total other comprehensive loss       $ (372)       $ (1,671)  
Basic loss per common share (in dollars per share)       $ (0.04)       $ (0.20)  
Diluted loss per common share (in dollars per share)       $ (0.04)       $ (0.20)  
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)                  
Compensation expense for issuance of stock options       $ 372       $ 1,671  
Net loss       (372)       (1,671)  
Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)                  
Net loss       (372)       (1,671)  
Stock option compensation expense               1,671  
As revised                  
Balance Sheet for September 30, 2022 (unaudited)                  
Additional paid-in capital       443,737       443,737  
Accumulated deficit       (449,012)       (449,012)  
Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)                  
Research and development expenses       4,065       14,152  
Selling, general and administrative expenses       4,779       13,477  
Total operating expenses       8,844       27,629  
Operating loss       (8,173)       (25,998)  
Net loss       (8,877)       (28,036)  
Total other comprehensive loss       $ (8,923)       $ (28,118)  
Basic loss per common share (in dollars per share)       $ (0.96)       $ (3.29)  
Diluted loss per common share (in dollars per share)       $ (0.96)       $ (3.29)  
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)                  
Compensation expense for issuance of stock options       $ 1,627       $ 6,016  
Net loss       (8,877)       (28,036)  
Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)                  
Net loss       $ (8,877)       (28,036)  
Stock option compensation expense               $ 6,016  
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Cash, Cash Equivalents and Restricted Cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Dec. 31, 2021
Cash and Cash Equivalents [Abstract]        
Cash and cash equivalents $ 40,462 $ 7,671    
Restricted balance for loan agreement 0 4,000    
Letters of credit 0 101    
Security for credit cards 50 50    
Total cash, cash equivalents and restricted cash shown in the statements of cash flows $ 40,512 $ 11,822 $ 13,982 $ 26,953
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Cash, Cash Equivalents and Restricted Cash - Narrative (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Mar. 15, 2023
Sep. 30, 2022
Cash and Cash Equivalents [Line Items]      
Restricted cash $ 50   $ 4,151
Avenue Loan      
Cash and Cash Equivalents [Line Items]      
Restricted cash   $ 4,000  
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Inventory (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 924 $ 763
Work-in-process 1,582 1,102
Finished goods 161 133
Total inventory $ 2,667 $ 1,998
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Prepaid Expense and Other Assets, Current [Abstract]    
Clinical trial expenses $ 1,630 $ 1,630
Insurance premiums 71 123
Professional services 655 121
Other 356 95
Total prepaid expenses and other current assets $ 2,712 $ 1,969
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross $ 6,391 $ 6,353
Accumulated depreciation (5,017) (4,931)
Property, plant and equipment, net 1,374 1,422
Buildings and land    
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross $ 1,301 1,301
Buildings    
Property Plant And Equipment [Line Items]    
Estimated Useful Life 30 years  
Enterprise hardware and software    
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross $ 1,855 1,855
Estimated Useful Life 3 years  
Leaseholds    
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross $ 1,772 1,774
Estimated Useful Life Useful Life, Shorter of Lease Term or Asset Utility [Member]  
Equipment    
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross $ 1,262 1,222
Estimated Useful Life 7 years  
Furniture    
Property Plant And Equipment [Line Items]    
Property, plant and equipment, gross $ 201 $ 201
Estimated Useful Life 5 years  
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Property, Plant, and Equipment - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Property, Plant and Equipment [Abstract]        
Depreciation expense (less than) $ 100 $ 100 $ 87 $ 98
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Accrued Expenses (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Clinical expenses $ 2,105 $ 1,470
Compensation, excluding taxes 1,535 1,040
Professional fees 61 1,087
Interest on convertible note 673 553
Other 856 535
Total accrued expenses $ 5,230 $ 4,685
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Lessee Lease Description [Line Items]        
Lease term 12 months   12 months  
U.S.        
Lessee Lease Description [Line Items]        
Operating lease expense $ 100 $ 300 $ 100 $ 300
Ireland        
Lessee Lease Description [Line Items]        
Operating lease expense $ 100 $ 100 $ 100 $ 100
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Summary of Lease Costs (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2023
USD ($)
Other information  
Operating cash flows for operating leases $ 262
U.S.  
Other information  
Operating cash flows for operating leases $ 238
Weighted average remaining lease term 0 years
Weighted average discount rate - operating leases 8.00%
Ireland  
Other information  
Operating cash flows for operating leases $ 24
Weighted average remaining lease term 2 years 9 months 18 days
Weighted average discount rate - operating leases 8.00%
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Lessee Lease Description [Line Items]  
Year ended December 31, 2023 $ 11
Year ended December 31, 2024 42
Year ended December 31, 2025 42
Year ended December 31, 2026 25
Total 120
Less present value discount (13)
Operating lease liabilities included in the condensed consolidated balance sheets at September 30, 2023 107
U.S.  
Lessee Lease Description [Line Items]  
Year ended December 31, 2023 0
Year ended December 31, 2024 0
Year ended December 31, 2025 0
Year ended December 31, 2026 0
Total 0
Less present value discount 0
Operating lease liabilities included in the condensed consolidated balance sheets at September 30, 2023 0
Ireland  
Lessee Lease Description [Line Items]  
Year ended December 31, 2023 11
Year ended December 31, 2024 42
Year ended December 31, 2025 42
Year ended December 31, 2026 25
Total 120
Less present value discount (13)
Operating lease liabilities included in the condensed consolidated balance sheets at September 30, 2023 $ 107
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Gross $ 10,610 $ 16,923
Less Current Portion, Net 5,080 7,846
Total - Loans Payable, Non-Current, Net $ 0 $ 3,070
Percentage of final payment included in gross amount 4.25% 4.25%
Final payment $ 500 $ 500
Loans Payable    
Debt Instrument [Line Items]    
Gross 5,610 11,923
Discount (530) (1,008)
Net 5,080 10,916
Less Current Portion, Gross 5,610 8,570
Less Current Portion, Discount (530) (724)
Less Current Portion, Net 5,080 7,846
Total - Loans Payable, Non-Current, Gross 0 3,353
Total - Loans Payable, Non-Current, Discount 0 (284)
Total - Loans Payable, Non-Current, Net 0 3,070
Convertible Notes Payable    
Debt Instrument [Line Items]    
Gross 5,000 5,000
Discount (124) (228)
Net 4,876 4,772
Notes And Loans Payable, Net, Current 2,876 0
Less Current Portion, Gross 3,000 0
Less Current Portion, Discount (124) 0
Notes And Loans Payable, Net, Noncurrent 2,000 4,772
Total - Loans Payable, Non-Current, Gross 2,000 5,000
Total - Loans Payable, Non-Current, Discount $ 0 $ (228)
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Loans and Convertible Notes Payable - Summary of Remaining Maturities of Company's Loan and Convertible Note Payables (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Debt Instrument [Line Items]  
Loans $ 5,610
Convertible Notes 5,000
Total 10,610
Year ended December 31, 2023  
Debt Instrument [Line Items]  
Loans 0
Convertible Notes 0
Total 0
Year ended December 31, 2024  
Debt Instrument [Line Items]  
Loans 5,610
Convertible Notes 5,000
Total $ 10,610
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Loans and Convertible Notes Payable - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2023
Aug. 14, 2023
Mar. 31, 2023
Mar. 15, 2023
Aug. 06, 2021
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Debt Instrument [Line Items]                    
Restricted Cash $ 50         $ 50 $ 4,151 $ 50 $ 4,151  
Principal payment               6,313 0  
Final payment               500   $ 500
Proceeds from exercise of warrants               35,004 0  
Interest expense incurred (less than)           $ 300 400 $ 1,100 1,300  
Preferred Tranche A Warrant                    
Debt Instrument [Line Items]                    
Proceeds from exercise of warrants   $ 10,000                
Series E                    
Debt Instrument [Line Items]                    
Debt instrument, conversion price (in dollars per share) $ 1,500         $ 1,500   $ 1,500    
Secured Convertible Notes Payable                    
Debt Instrument [Line Items]                    
Debt instrument, principal face amount $ 2,000         $ 2,000   $ 2,000    
Secured Convertible Notes Payable | Series E                    
Debt Instrument [Line Items]                    
Debt instrument, conversion price (in dollars per share)         $ 1,198          
Avenue Loan                    
Debt Instrument [Line Items]                    
Debt instrument, principal face amount         $ 3,000          
Interest rate         7.70%          
Debt instrument, interest rate 16.20%       10.95%          
Initial tranche of loan         $ 15,000          
Loan amount funded into restricted account         $ 4,000          
Restricted Cash       $ 4,000            
Principal payment       $ 2,100            
Debt instrument, incremental final payment, percentage       4.25%            
Final payment       $ 200            
Debt instrument, conversion price (in dollars per share)         $ 11.98          
Amortization of debt discount           $ 200 $ 200 600 600  
Avenue Loan | Warrant                    
Debt Instrument [Line Items]                    
Warrants issued to purchase of common stock (in shares)         127,755          
Warrant exercise price (in dollars per share)         $ 0.01          
Avenue Loan | Condition for the Extension of Period of Interest Only Payments                    
Debt Instrument [Line Items]                    
Estimated minimum proceeds on issue of common stock for extension of due date of interest only interest payments     $ 10,000              
Warrant exercise price (in dollars per share)     $ 0.01              
Number of warrants outstanding (in shares)     34,072              
Rosalind Notes | Convertible Debt                    
Debt Instrument [Line Items]                    
Interest expense incurred (less than)               $ 100 $ 100  
Rosalind Notes | Convertible Notes Payable                    
Debt Instrument [Line Items]                    
Interest rate 8.00%         8.00%   8.00%    
Maximum | Avenue Loan                    
Debt Instrument [Line Items]                    
Debt instrument, principal face amount         $ 20,000          
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Preferred Purchase Agreement (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 29, 2023
Sep. 30, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Preferred stock, par value (in dollars per share)   $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01
Fair value of warrant liabilities   $ 7,044 $ 7,044     $ 1,280        
Deferred revenue $ 10,000 $ 10,000 $ 10,000              
Preferred stock, shares outstanding (in shares)   37,787 37,787     11,357        
Preferred Warrant Liabilities                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Proceeds from issuance of warrants 24,900                  
Fair value of warrant liabilities $ 4,900                  
Preferred Purchase Agreement | Preferred Tranche A Warrant                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Number of exercisable preferred warrants (in shares)   34,859                
Aggregate exercise price of preferred warrants   $ 34,900                
Preferred Purchase Agreement | Preferred Tranche B Warrant                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Number of exercisable preferred warrants (in shares) 24,900                  
Aggregate exercise price of preferred warrants   $ 24,900                
Warrant exercise period   21 days                
Preferred Purchase Agreement | Series F-1                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Number of exercisable preferred warrants (in shares) 24,900                  
Preferred Purchase Agreement | Series F-4                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Number of exercisable preferred warrants (in shares)   24,900                
Series F-1 | Preferred Warrant Liabilities                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Proceeds from issuance of warrants $ 20,000                  
Series F-1 | Preferred Purchase Agreement                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Preferred stock, par value (in dollars per share) $ 0.01                  
Series F-3                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Preferred stock, par value (in dollars per share)   $ 4.50 $ 4.50              
Preferred stock, shares outstanding (in shares)   21,627 21,627              
Series F-3 | Preferred Tranche A Warrant                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Number of exercisable preferred warrants (in shares) 34,859                  
Series F-3 | Preferred Purchase Agreement                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Preferred stock, par value (in dollars per share) $ 0.01                  
Series F1, Series F2 and F3 Preferred Stock                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Conversion of shares (in shares)     33,229              
Common Stock                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Number of shares converted (in shares)   9,000,582 9,000,582              
Common Stock | Preferred Purchase Agreement                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Number of shares converted (in shares)   2,940,440 2,940,440              
Common Stock | Preferred Purchase Agreement | Preferred Tranche A Warrant                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Conversion of shares (in shares)   13,232                
Series F-4                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Preferred stock, par value (in dollars per share)   $ 6.00 $ 6.00              
Preferred stock, shares outstanding (in shares)   0 0              
Series F-4 | Preferred Purchase Agreement                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Preferred stock, par value (in dollars per share) $ 0.01                  
Series F-2                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Preferred stock, par value (in dollars per share)   $ 3.30 $ 3.30              
Preferred stock, shares outstanding (in shares)   4,903 4,903              
Series F-2 | Preferred Purchase Agreement                    
Disclosure Of Preferred Purchase Agreement [Line Items]                    
Preferred stock, par value (in dollars per share)   $ 0.01 $ 0.01              
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Equity Offerings and Placements (Details) - USD ($)
$ in Millions
Aug. 14, 2023
Mar. 29, 2023
Mar. 27, 2023
Sep. 30, 2023
Stockholders Equity Note [Line Items]        
Deferred revenue   $ 10.0   $ 10.0
Tranche A Warrants | Common Purchase Agreement        
Stockholders Equity Note [Line Items]        
Number of exercisable common warrants (in shares) 31,110   31,110  
Aggregate exercise price of preferred warrants   $ 0.1    
Tranche B Warrants | Common Purchase Agreement        
Stockholders Equity Note [Line Items]        
Number of exercisable common warrants (in shares)   16,666 16,666  
Aggregate exercise price of preferred warrants   $ 0.1    
Warrants exercisable, period       21 days
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - At-the-Market Offering (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2023
Dec. 31, 2022
Stockholders Equity Note [Line Items]      
Sale of stock consideration received on the transaction $ 197 $ 197 $ 100
Number of shares sold (in shares) 0 0  
Controlled Equity Offering Sales Agreement | Cantor Fitzgerald & Co      
Stockholders Equity Note [Line Items]      
Common stock, aggregate offering price $ 17,000 $ 17,000  
Sale of stock consideration received on the transaction $ 4,000 $ 4,000  
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Designated Preferred Shares (Details)
Sep. 30, 2023
shares
Class of Stock [Line Items]  
Preferred stock, shares designated (in shares) 179,670
Series A  
Class of Stock [Line Items]  
Preferred stock, shares designated (in shares) 4,200
Series B  
Class of Stock [Line Items]  
Preferred stock, shares designated (in shares) 2,360
Series C  
Class of Stock [Line Items]  
Preferred stock, shares designated (in shares) 590
Series D  
Class of Stock [Line Items]  
Preferred stock, shares designated (in shares) 10,000
Series E  
Class of Stock [Line Items]  
Preferred stock, shares designated (in shares) 40,000
Series E-1  
Class of Stock [Line Items]  
Preferred stock, shares designated (in shares) 12,960
Series F-1  
Class of Stock [Line Items]  
Preferred stock, shares designated (in shares) 24,900
Series F-2  
Class of Stock [Line Items]  
Preferred stock, shares designated (in shares) 24,900
Series F-3  
Class of Stock [Line Items]  
Preferred stock, shares designated (in shares) 34,860
Series F-4  
Class of Stock [Line Items]  
Preferred stock, shares designated (in shares) 24,900
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Authorized Shares and Preferred Stock (Details) - $ / shares
Sep. 30, 2023
Jun. 30, 2023
May 31, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2021
Stockholders Equity Note [Line Items]                  
Common stock, shares authorized (in shares) 80,000,000 80,000,000 40,000,000   80,000,000        
Common stock, par value (in dollars per share) $ 0.01 $ 0.01   $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 10,000,000       10,000,000        
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01   $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01 $ 0.01
Preferred stock, shares outstanding (in shares) 37,787       11,357        
Series E                  
Stockholders Equity Note [Line Items]                  
Preferred stock, shares outstanding (in shares) 11,257                
Series E-1                  
Stockholders Equity Note [Line Items]                  
Preferred stock, shares outstanding (in shares) 11,257                
Series F-2                  
Stockholders Equity Note [Line Items]                  
Preferred stock, par value (in dollars per share) $ 3.30                
Preferred stock, shares outstanding (in shares) 4,903                
Series F-3                  
Stockholders Equity Note [Line Items]                  
Preferred stock, par value (in dollars per share) $ 4.50                
Preferred stock, shares outstanding (in shares) 21,627                
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Equity Incentive Plan (Details) - shares
Jun. 12, 2023
Sep. 30, 2023
Stockholders' Equity Note [Abstract]    
Increase in shares available under equity incentive plan (in shares) 2,650,000  
Common stock, capital shares reserved (in shares)   5,125,000
Number of common shares remained available to be issued (in shares)   1,802,841
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Stockholders' Equity Note [Abstract]    
Expected volatility 160.40% 164.30%
Risk-free interest rate 3.99% 1.86%
Expected dividends 0.00% 0.00%
Expected terms (years) 5 years 8 months 12 days 5 years 4 months 24 days
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Summary of Stock Option Activity (Details)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Number of Options    
Outstanding, beginning of period (in shares) | shares 2,235,052  
Granted (in shares) | shares 2,122,757  
Exercised (in shares) | shares (819)  
Expired (in shares) | shares (115,772)  
Cancelled/Forfeited (in shares) | shares (104,390)  
Outstanding, end of period (in shares) | shares 4,136,828 2,235,052
Exercisable (in shares) | shares 2,020,026  
Weighted Average Exercise Price Per Share    
Outstanding, Weighted Average Exercise Price Per Share, beginning of period (in dollars per share) | $ / shares $ 10.30  
Granted, Weighted Average Exercise Price Per Share (in dollars per share) | $ / shares 6.08  
Exercised, Weighted Average Exercise Price Per Share (in dollars per share) | $ / shares 4.67  
Expired, Weighted Average Exercise Price Per Share (in dollars per share) | $ / shares 8.80  
Cancelled-Forfeited, Weighted Average Exercise Price Per Share (in dollars per share) | $ / shares 7.22  
Outstanding, Weighted Average Exercise Price Per Share, end of period (in dollars per share) | $ / shares 8.26 $ 10.30
Weighted Average Exercise Price, Exercisable (in dollars per share) | $ / shares $ 10.29  
Weighted Average Remaining Contractual Term (in years) and Aggregate Intrinsic Value    
Weighted Average Remaining Contractual Term (in years), Outstanding 8 years 6 months 7 years 9 months 18 days
Weighted Average Remaining Contractual Term (in years), Granted 9 years 1 month 6 days  
Weighted Average Remaining Contractual Term (in years), Exercisable 7 years 8 months 12 days  
Aggregate Intrinsic Value, Outstanding | $ $ 72,850 $ 35,875
Aggregate Intrinsic Value, Exercisable | $ $ 0  
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Summary of Stock Option Shares Outstanding and Exercisable (Details) - $ / shares
9 Months Ended 12 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Outstanding Number of Options (in shares) 4,136,828 2,235,052
Weighted Average Remaining Option Term (in years), Options Outstanding 8 years 6 months 7 years 9 months 18 days
Number of Options Exercisable (in shares) 2,020,026  
$2.83 - $51.50    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Outstanding Number of Options (in shares) 4,136,329  
Weighted Average Remaining Option Term (in years), Options Outstanding 8 years 6 months  
$2.83 - $51.50 | Maximum    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Range of Exercise Prices (in dollars per share) $ 51.50  
$2.83 - $51.50 | Minimum    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Range of Exercise Prices (in dollars per share) 2.83  
$51.50+    
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]    
Range of Exercise Prices (in dollars per share) $ 51.50  
Outstanding Number of Options (in shares) 499  
Weighted Average Remaining Option Term (in years), Options Outstanding 5 years 3 months 18 days  
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Summary of Recognized Share-based Compensation Cost (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based compensation expense $ 2,830 $ 1,627 $ 6,152 $ 6,016
Unrecognized compensation expense related to non-vested share-based compensation awards 7,700   $ 7,700  
Cost expected to be recognized over weighted average period     2 years 4 months 24 days  
Selling, general and administrative        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based compensation expense 1,674 1,117 $ 3,774 3,984
Research and development        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based compensation expense 1,027 458 2,095 1,872
Cost of goods sold        
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based compensation expense $ 129 $ 52 $ 283 $ 160
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Summary of Common Stock Warrant Activity (Details) - Common Warrants
9 Months Ended
Sep. 30, 2023
$ / shares
shares
Class Of Warrant Or Right Outstanding [Roll Forward]  
Outstanding, beginning of period (in shares) | shares 5,153,291
Warrants issued (in shares) | shares 81,848
Warrants exercised (in shares) | shares (569,938)
Outstanding, end of period (in shares) | shares 4,665,201
Exercisable, end of period (in shares) | shares 4,665,201
Weighted Average Exercise Price  
Outstanding, beginning of period (in dollars per share) | $ / shares $ 7.01
Warrants issued (in dollars per share) | $ / shares 2.94
Warrants exercised (in dollars per share) | $ / shares 0.26
Outstanding, ending of period (in dollars per share) | $ / shares 7.76
Exercisable, (in dollars per share) | $ / shares $ 7.76
Weighted Average Remaining Life (in years)  
Weighted Average Remaining Life (in years), Outstanding 1 year 10 months 24 days
Weighted Average Remaining Life, Exercisable 1 year 10 months 24 days
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Summary of Common Stock Warrants Outstanding and Exercisable (Details) - $ / shares
9 Months Ended
Aug. 14, 2023
Mar. 27, 2023
Sep. 30, 2023
Dec. 31, 2022
Common Warrants        
Class of Warrant or Right [Line Items]        
Outstanding Number of Warrants (in shares)     4,665,201 5,153,291
Warrants Exercisable, Weighted Average Remaining Warrant Term (in years)     1 year 10 months 24 days  
Warrants Exercisable, Number of Warrants (in shares)     4,665,201  
Warrants exercised (in shares)     569,938  
Tranche A Warrants | Common Purchase Agreement        
Class of Warrant or Right [Line Items]        
Number of exercisable common warrants (in shares) 31,110 31,110    
$0.01        
Class of Warrant or Right [Line Items]        
Warrant exercise price (in dollars per share)     $ 0.01  
Outstanding Number of Warrants (in shares)     538,828  
$0.01 | Common Warrants        
Class of Warrant or Right [Line Items]        
Outstanding Number of Warrants (in shares)     1,037,792  
Warrants Exercisable, Weighted Average Remaining Warrant Term (in years)     3 years 4 months 24 days  
Warrants Exercisable, Number of Warrants (in shares)     1,037,792  
$6.00        
Class of Warrant or Right [Line Items]        
Warrant exercise price (in dollars per share)     $ 6.00  
$6.00 | Common Warrants        
Class of Warrant or Right [Line Items]        
Outstanding Number of Warrants (in shares)     16,666  
Warrants Exercisable, Weighted Average Remaining Warrant Term (in years)     2 years 6 months  
Warrants Exercisable, Number of Warrants (in shares)     16,666  
$10.00        
Class of Warrant or Right [Line Items]        
Warrant exercise price (in dollars per share)     $ 10  
$10.00 | Common Warrants        
Class of Warrant or Right [Line Items]        
Outstanding Number of Warrants (in shares)     3,610,743  
Warrants Exercisable, Weighted Average Remaining Warrant Term (in years)     1 year 4 months 24 days  
Warrants Exercisable, Number of Warrants (in shares)     3,610,743  
$4.50        
Class of Warrant or Right [Line Items]        
Warrant exercise price (in dollars per share)     $ 4.50  
Outstanding Number of Warrants (in shares)     31,110  
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Preferred Stock Warrants (Details) - Preferred Warrants - $ / shares
9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Class of Warrant or Right [Line Items]    
Outstanding Number of Warrants (in shares) 24,900 0
Class Of Warrant Or Right Weighted Average Exercise Price $ 1,000 $ 0
Warrants issued (in shares) 59,759  
Warrants issued (in dollars per share) $ 1,000  
Warrants exercised (in shares) 34,859  
Warrants exercised (in dollars per share) $ 1,000  
Warrants Exercisable, Weighted Average Remaining Warrant Term (in years) 2 years 6 months  
Warrants Exercisable, Number of Warrants (in shares) 24,900  
Warrants Exercisable, Weighted Average Exercise Price $ 1,000  
Weighted Average Remaining Life, Exercisable 2 years 6 months  
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Summary of Employee Stock Purchase Plan (Details) - shares
1 Months Ended 9 Months Ended
Aug. 31, 2021
Sep. 30, 2023
Jul. 31, 2023
Jan. 31, 2023
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]        
Employee stock purchase plan, offering period   6 months    
May 2022 Employee Stock Purchase Plan        
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]        
Share-based compensation arrangement by share-based payment award number of shares authorized (in shares) 260,295   26,018 15,417
Share-based compensation arrangement by share-based payment award purchase price of common stock (as a percent) 85.00%      
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss per Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 19,819,735 8,334,956
Common stock warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 3,627,409 4,461,249
Assumed conversion of preferred stock warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 4,149,994 0
Assumed conversion of preferred stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 7,417,473 1,135,721
Assumed conversion of convertible notes    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 488,031 488,031
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of earnings per share (in shares) 4,136,828 2,249,955
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss per Share - Narrative (Details)
9 Months Ended
Sep. 30, 2023
shares
Earnings Per Share [Abstract]  
Pre-funded penny warrants outstanding 1,037,792
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss per Share - Summary of Reconciliation of Weighted Average Shares Outstanding Calculation (Details) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Earnings Per Share [Abstract]        
Weighted average shares issued (in shares) 16,825,286 8,470,006 12,745,035 8,096,551
Weighted average pre-funded warrants (in shares) 1,037,792 745,780 1,240,213 439,455
Weighted average number of basic shares outstanding (in shares) 17,863,078 9,215,786 13,985,248 8,536,006
Weighted average number of diluted shares outstanding (in shares) 17,863,078 9,215,786 13,985,248 8,536,006
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes (Details)
$ in Billions
9 Months Ended
Sep. 30, 2023
USD ($)
Income Tax Disclosure [Abstract]  
Corporate alternative minimum tax (as a percent) 15.00%
Minimum accounting profit required for preceding three financial year $ 1
Percentage of excise tax on repurchases of stock 1.00%
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and contingencies - Additional Information (Details)
€ in Millions, $ in Millions
Jul. 05, 2023
USD ($)
Dec. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Jan. 24, 2023
USD ($)
Oct. 12, 2021
EUR (€)
Apr. 30, 2021
EUR (€)
Loss Contingencies [Line Items]            
Milestone payment unpaid | €         € 1  
Medac            
Loss Contingencies [Line Items]            
Accounts receivable | €           € 1
Term over which the royalty is to be paid   5 years        
Minimum annual payments   $ 0.2        
Lachman            
Loss Contingencies [Line Items]            
Settlement amount $ 0.9          
Unpaid consulting fees       $ 0.9    
Other Liabilities | Medac            
Loss Contingencies [Line Items]            
Loss contingency accrual     $ 1.3      
Other Noncurrent Liabilities | Medac            
Loss Contingencies [Line Items]            
Loss contingency accrual     1.1      
Accrued Expenses | Medac            
Loss Contingencies [Line Items]            
Loss contingency accrual     $ 0.2      
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning balance     $ 1,280  
Total change in foreign exchange     (9)  
Fair value of the warrant liability issued     4,940  
Warrant liability fair value adjustment $ 9,384 $ 0 8,224 $ 0
Change due to warrant exercise     (7,391)  
Ending balance 7,044   7,044  
Contingent liabilities        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning balance     1,280  
Total change in foreign exchange     (9)  
Fair value of the warrant liability issued     0  
Warrant liability fair value adjustment     0  
Change due to warrant exercise     0  
Ending balance 1,271   1,271  
Warrants        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Beginning balance     0  
Total change in foreign exchange     0  
Fair value of the warrant liability issued     4,940  
Ending balance $ 5,773   $ 5,773  
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Fair Value Disclosures [Abstract]        
Other expense related to the change in fair value of the warrant liability $ 9,384 $ 0 $ 8,224 $ 0
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Schedule of Fair Value of Outstanding Warrants (Details) - Valuation Technique, Option Pricing Model - Preferred And Common Warrants
Sep. 30, 2023
Mar. 29, 2023
Risk free interest rate | Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input   0.0380
Risk free interest rate | Maximum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 0.0480 0.0480
Expected term (years) | Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Expected term   6 months
Expected term (years) | Maximum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Expected term 2 years 6 months 3 years
Expected volatility | Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input   0.70
Expected volatility | Maximum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 0.70 0.75
Expected dividends    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 0.0000 0.0000
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value Measurements - Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Liabilities [Abstract]    
Contingent liability $ 1,271 $ 1,280
Warrant liability 5,773  
Total liabilities 7,044 1,280
Quoted Prices in Active Markets (Level 1)    
Liabilities [Abstract]    
Contingent liability 0 0
Warrant liability 0  
Total liabilities 0 0
Significant Other Observable Inputs (Level 2)    
Liabilities [Abstract]    
Contingent liability 0 0
Warrant liability 0  
Total liabilities 0 0
Significant Unobservable Inputs (Level 3)    
Liabilities [Abstract]    
Contingent liability 1,271 1,280
Warrant liability 5,773  
Total liabilities $ 7,044 $ 1,280
XML 82 dcth-20230930_htm.xml IDEA: XBRL DOCUMENT 0000872912 2023-01-01 2023-09-30 0000872912 2023-11-08 0000872912 2023-09-30 0000872912 2022-12-31 0000872912 us-gaap:ProductMember 2023-07-01 2023-09-30 0000872912 us-gaap:ProductMember 2022-07-01 2022-09-30 0000872912 us-gaap:ProductMember 2023-01-01 2023-09-30 0000872912 us-gaap:ProductMember 2022-01-01 2022-09-30 0000872912 us-gaap:ProductAndServiceOtherMember 2023-07-01 2023-09-30 0000872912 us-gaap:ProductAndServiceOtherMember 2022-07-01 2022-09-30 0000872912 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-09-30 0000872912 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-09-30 0000872912 2023-07-01 2023-09-30 0000872912 2022-07-01 2022-09-30 0000872912 2022-01-01 2022-09-30 0000872912 2023-03-31 0000872912 2023-06-30 0000872912 us-gaap:PreferredStockMember 2022-12-31 0000872912 us-gaap:CommonStockMember 2022-12-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000872912 us-gaap:RetainedEarningsMember 2022-12-31 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000872912 2023-01-01 2023-03-31 0000872912 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000872912 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000872912 us-gaap:PreferredStockMember 2023-03-31 0000872912 us-gaap:CommonStockMember 2023-03-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000872912 us-gaap:RetainedEarningsMember 2023-03-31 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000872912 2023-04-01 2023-06-30 0000872912 dcth:PreferredF1StockMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000872912 dcth:PreferredF1StockMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000872912 dcth:PreferredF1StockMember 2023-04-01 2023-06-30 0000872912 dcth:SeriesF2PreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0000872912 dcth:SeriesF2PreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0000872912 dcth:SeriesF2PreferredStockMember 2023-04-01 2023-06-30 0000872912 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000872912 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000872912 us-gaap:PreferredStockMember 2023-06-30 0000872912 us-gaap:CommonStockMember 2023-06-30 0000872912 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000872912 us-gaap:RetainedEarningsMember 2023-06-30 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000872912 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000872912 dcth:SeriesF2PreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0000872912 dcth:SeriesF2PreferredStockMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000872912 dcth:SeriesF2PreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000872912 dcth:SeriesF2PreferredStockMember 2023-07-01 2023-09-30 0000872912 dcth:SeriesF3PreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0000872912 dcth:SeriesF3PreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000872912 dcth:SeriesF3PreferredStockMember 2023-07-01 2023-09-30 0000872912 dcth:SeriesF3PreferredStockMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000872912 us-gaap:SeriesEPreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0000872912 us-gaap:SeriesEPreferredStockMember us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000872912 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000872912 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000872912 us-gaap:PreferredStockMember 2023-09-30 0000872912 us-gaap:CommonStockMember 2023-09-30 0000872912 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000872912 us-gaap:RetainedEarningsMember 2023-09-30 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000872912 2022-06-30 0000872912 2022-03-31 0000872912 2022-09-30 0000872912 2021-12-31 0000872912 us-gaap:PreferredStockMember 2021-12-31 0000872912 us-gaap:CommonStockMember 2021-12-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000872912 us-gaap:RetainedEarningsMember 2021-12-31 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000872912 2022-01-01 2022-03-31 0000872912 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000872912 us-gaap:PreferredStockMember 2022-03-31 0000872912 us-gaap:CommonStockMember 2022-03-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000872912 us-gaap:RetainedEarningsMember 2022-03-31 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000872912 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0000872912 2022-04-01 2022-06-30 0000872912 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000872912 us-gaap:PreferredStockMember 2022-06-30 0000872912 us-gaap:CommonStockMember 2022-06-30 0000872912 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000872912 us-gaap:RetainedEarningsMember 2022-06-30 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000872912 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000872912 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0000872912 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000872912 us-gaap:PreferredStockMember 2022-09-30 0000872912 us-gaap:CommonStockMember 2022-09-30 0000872912 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000872912 us-gaap:RetainedEarningsMember 2022-09-30 0000872912 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000872912 dcth:AccountsPayableAccruedExpensesAndLeaseLiabilitiesMember 2023-09-30 0000872912 dcth:LoanPrincipalPaymentsMember 2023-09-30 0000872912 dcth:LeaseLiabilitiesMember 2023-09-30 0000872912 dcth:ThirdPartySettlementMember 2023-09-30 0000872912 dcth:ConvertibeNotePrincipalPaymentsMember 2023-09-30 0000872912 srt:ScenarioPreviouslyReportedMember 2022-09-30 0000872912 srt:RestatementAdjustmentMember 2022-09-30 0000872912 dcth:AsRevisedMember 2022-09-30 0000872912 srt:ScenarioPreviouslyReportedMember 2022-07-01 2022-09-30 0000872912 srt:RestatementAdjustmentMember 2022-07-01 2022-09-30 0000872912 dcth:AsRevisedMember 2022-07-01 2022-09-30 0000872912 srt:ScenarioPreviouslyReportedMember 2022-01-01 2022-09-30 0000872912 srt:RestatementAdjustmentMember 2022-01-01 2022-09-30 0000872912 dcth:AsRevisedMember 2022-01-01 2022-09-30 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2023-03-15 0000872912 us-gaap:LandBuildingsAndImprovementsMember 2023-09-30 0000872912 us-gaap:LandBuildingsAndImprovementsMember 2022-12-31 0000872912 us-gaap:BuildingMember 2023-09-30 0000872912 us-gaap:ComputerEquipmentMember 2023-09-30 0000872912 us-gaap:ComputerEquipmentMember 2022-12-31 0000872912 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2023-09-30 0000872912 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2022-12-31 0000872912 us-gaap:EquipmentMember 2023-09-30 0000872912 us-gaap:EquipmentMember 2022-12-31 0000872912 us-gaap:FurnitureAndFixturesMember 2023-09-30 0000872912 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000872912 country:US 2023-07-01 2023-09-30 0000872912 country:US 2023-01-01 2023-09-30 0000872912 country:US 2022-07-01 2022-09-30 0000872912 country:US 2022-01-01 2022-09-30 0000872912 country:IE 2023-07-01 2023-09-30 0000872912 country:IE 2022-07-01 2022-09-30 0000872912 country:IE 2022-01-01 2022-09-30 0000872912 country:IE 2023-01-01 2023-09-30 0000872912 country:US 2023-09-30 0000872912 country:IE 2023-09-30 0000872912 us-gaap:LoansPayableMember 2023-09-30 0000872912 us-gaap:LoansPayableMember 2022-12-31 0000872912 us-gaap:ConvertibleNotesPayableMember 2023-09-30 0000872912 us-gaap:ConvertibleNotesPayableMember 2022-12-31 0000872912 2022-01-01 2022-12-31 0000872912 dcth:DecemberThirtyFirstTwoThousandTwentyThreeMember 2023-09-30 0000872912 dcth:DecemberThirtyFirstTwoThousandTwentyFourMember 2023-09-30 0000872912 srt:MaximumMember dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2021-08-06 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2021-08-06 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2021-08-06 2021-08-06 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2023-09-30 2023-09-30 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2023-03-15 2023-03-15 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember dcth:ConditionForTheExtensionOfPeriodOfInterestOnlyPaymentsMember 2023-03-31 2023-03-31 0000872912 dcth:PreferredTrancheAWarrantMember 2023-08-14 2023-08-14 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember us-gaap:WarrantMember 2021-08-06 2021-08-06 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember us-gaap:WarrantMember 2021-08-06 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember dcth:ConditionForTheExtensionOfPeriodOfInterestOnlyPaymentsMember 2023-03-31 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2022-07-01 2022-09-30 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2023-07-01 2023-09-30 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2022-01-01 2022-09-30 0000872912 dcth:TermLoanFromAvenueVentureOpportunitiesFundLpMember 2023-01-01 2023-09-30 0000872912 dcth:SecuredConvertibleNotesPayableMember 2023-09-30 0000872912 dcth:EightPointZeroPercentageJulyTwoThousandAndNineteenNotesMember us-gaap:ConvertibleNotesPayableMember 2023-09-30 0000872912 us-gaap:SeriesEPreferredStockMember 2023-09-30 0000872912 dcth:EightPointZeroPercentageJulyTwoThousandAndNineteenNotesMember us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0000872912 dcth:EightPointZeroPercentageJulyTwoThousandAndNineteenNotesMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0000872912 dcth:SecuredConvertibleNotesPayableMember us-gaap:SeriesEPreferredStockMember 2021-08-06 0000872912 dcth:SeriesF1PreferredStockMember dcth:PreferredPurchaseAgreementMember 2023-03-29 2023-03-29 0000872912 dcth:SeriesF1PreferredStockMember dcth:PreferredPurchaseAgreementMember 2023-03-29 0000872912 dcth:PreferredTrancheAWarrantMember dcth:SeriesF3PreferredStockMember 2023-03-29 2023-03-29 0000872912 dcth:SeriesF3PreferredStockMember dcth:PreferredPurchaseAgreementMember 2023-03-29 0000872912 dcth:PreferredTrancheBWarrantMember dcth:PreferredPurchaseAgreementMember 2023-03-29 2023-03-29 0000872912 dcth:SeriesF4PreferredStockMember dcth:PreferredPurchaseAgreementMember 2023-03-29 0000872912 dcth:PreferredWarrantLiabilitiesMember 2023-03-29 2023-03-29 0000872912 dcth:PreferredWarrantLiabilitiesMember 2023-03-29 0000872912 dcth:PreferredWarrantLiabilitiesMember dcth:SeriesF1PreferredStockMember 2023-03-29 2023-03-29 0000872912 dcth:PreferredTrancheAWarrantMember dcth:PreferredPurchaseAgreementMember 2023-07-01 2023-09-30 0000872912 dcth:PreferredTrancheAWarrantMember us-gaap:CommonStockMember dcth:PreferredPurchaseAgreementMember 2023-07-01 2023-09-30 0000872912 us-gaap:CommonStockMember dcth:PreferredPurchaseAgreementMember 2023-09-30 0000872912 dcth:SeriesF4PreferredStockMember dcth:PreferredPurchaseAgreementMember 2023-07-01 2023-09-30 0000872912 dcth:PreferredTrancheBWarrantMember dcth:PreferredPurchaseAgreementMember 2023-07-01 2023-09-30 0000872912 dcth:SeriesF2PreferredStockMember dcth:PreferredPurchaseAgreementMember 2023-09-30 0000872912 dcth:SeriesF2PreferredStockMember 2023-09-30 0000872912 dcth:SeriesF3PreferredStockMember 2023-09-30 0000872912 dcth:SeriesF4PreferredStockMember 2023-09-30 0000872912 dcth:SeriesF1SeriesF2AndF3PreferredStockMember 2023-01-01 2023-09-30 0000872912 us-gaap:CommonStockMember 2023-09-30 0000872912 dcth:TrancheAWarrantsMember dcth:CommonPurchaseAgreementMember 2023-03-27 2023-03-27 0000872912 dcth:TrancheBWarrantsMember dcth:CommonPurchaseAgreementMember 2023-03-27 2023-03-27 0000872912 dcth:TrancheAWarrantsMember dcth:CommonPurchaseAgreementMember 2023-03-29 2023-03-29 0000872912 dcth:TrancheAWarrantsMember dcth:CommonPurchaseAgreementMember 2023-08-14 2023-08-14 0000872912 dcth:TrancheBWarrantsMember dcth:CommonPurchaseAgreementMember 2023-03-29 2023-03-29 0000872912 dcth:TrancheBWarrantsMember dcth:CommonPurchaseAgreementMember 2023-09-30 0000872912 2023-03-29 0000872912 dcth:CantorFitzgeraldAndCoMember dcth:ControlledEquityOfferingSalesAgreementMember 2023-09-30 0000872912 2023-05-31 0000872912 us-gaap:SeriesAPreferredStockMember 2023-09-30 0000872912 us-gaap:SeriesBPreferredStockMember 2023-09-30 0000872912 us-gaap:SeriesCPreferredStockMember 2023-09-30 0000872912 us-gaap:SeriesDPreferredStockMember 2023-09-30 0000872912 dcth:SeriesE1PreferredStockMember 2023-09-30 0000872912 dcth:SeriesF1PreferredStockMember 2023-09-30 0000872912 2023-06-12 2023-06-12 0000872912 srt:MinimumMember dcth:ExercisePriceRangeFromTwoPointEightThreeToFiftyOnePointFiveZeroMember 2023-09-30 0000872912 srt:MaximumMember dcth:ExercisePriceRangeFromTwoPointEightThreeToFiftyOnePointFiveZeroMember 2023-09-30 0000872912 dcth:ExercisePriceRangeFromTwoPointEightThreeToFiftyOnePointFiveZeroMember 2023-09-30 0000872912 dcth:ExercisePriceRangeFromTwoPointEightThreeToFiftyOnePointFiveZeroMember 2023-01-01 2023-09-30 0000872912 dcth:ExercisePriceRangeAboveFiftyOnePointFiveZeroMember 2023-09-30 0000872912 dcth:ExercisePriceRangeAboveFiftyOnePointFiveZeroMember 2023-01-01 2023-09-30 0000872912 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0000872912 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0000872912 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0000872912 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0000872912 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0000872912 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0000872912 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0000872912 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0000872912 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0000872912 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000872912 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0000872912 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0000872912 dcth:CommonWarrantsMember 2022-12-31 0000872912 dcth:CommonWarrantsMember 2023-01-01 2023-09-30 0000872912 dcth:CommonWarrantsMember 2023-09-30 0000872912 dcth:RangeOfExercisePricesPointZeroOneRangeMember 2023-09-30 0000872912 dcth:CommonWarrantsMember dcth:RangeOfExercisePricesPointZeroOneRangeMember 2023-09-30 0000872912 dcth:CommonWarrantsMember dcth:RangeOfExercisePricesPointZeroOneRangeMember 2023-01-01 2023-09-30 0000872912 dcth:RangeOfExercisePricesSixPointZeroRangeMember 2023-09-30 0000872912 dcth:CommonWarrantsMember dcth:RangeOfExercisePricesSixPointZeroRangeMember 2023-09-30 0000872912 dcth:CommonWarrantsMember dcth:RangeOfExercisePricesSixPointZeroRangeMember 2023-01-01 2023-09-30 0000872912 dcth:RangeOfExercisePricesTenPointZeroRangeMember 2023-09-30 0000872912 dcth:CommonWarrantsMember dcth:RangeOfExercisePricesTenPointZeroRangeMember 2023-09-30 0000872912 dcth:CommonWarrantsMember dcth:RangeOfExercisePricesTenPointZeroRangeMember 2023-01-01 2023-09-30 0000872912 dcth:RangeOfExercisePricesFourPointFiveZeroRangeMember 2023-09-30 0000872912 dcth:PreferredWarrantsMember 2022-12-31 0000872912 dcth:PreferredWarrantsMember 2023-01-01 2023-09-30 0000872912 dcth:PreferredWarrantsMember 2023-09-30 0000872912 dcth:MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember 2021-08-31 0000872912 dcth:MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember 2021-08-01 2021-08-31 0000872912 dcth:MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember 2023-01-31 0000872912 dcth:MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember 2023-07-31 0000872912 dcth:CommonStockWarrantsMember 2023-01-01 2023-09-30 0000872912 dcth:CommonStockWarrantsMember 2022-01-01 2022-09-30 0000872912 dcth:AssumedConversationOfPreferredStockWarrantsMember 2023-01-01 2023-09-30 0000872912 dcth:AssumedConversationOfPreferredStockWarrantsMember 2022-01-01 2022-09-30 0000872912 dcth:AssumedConversionOfPreferredStockMember 2023-01-01 2023-09-30 0000872912 dcth:AssumedConversionOfPreferredStockMember 2022-01-01 2022-09-30 0000872912 dcth:AssumedConversionOfConvertibleNotesMember 2023-01-01 2023-09-30 0000872912 dcth:AssumedConversionOfConvertibleNotesMember 2022-01-01 2022-09-30 0000872912 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0000872912 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0000872912 dcth:MedacMember 2021-04-30 0000872912 2021-10-12 0000872912 dcth:MedacMember 2022-12-30 2022-12-30 0000872912 dcth:MedacMember 2022-12-30 0000872912 dcth:MedacMember us-gaap:OtherLiabilitiesMember 2023-09-30 0000872912 dcth:MedacMember us-gaap:OtherNoncurrentLiabilitiesMember 2023-09-30 0000872912 dcth:MedacMember dcth:AccruedExpensesMember 2023-09-30 0000872912 dcth:LachmanMember 2023-01-24 0000872912 dcth:LachmanMember 2023-07-05 2023-07-05 0000872912 dcth:ContingentLiabilitiesMember 2022-12-31 0000872912 us-gaap:WarrantMember 2022-12-31 0000872912 dcth:ContingentLiabilitiesMember 2023-01-01 2023-09-30 0000872912 us-gaap:WarrantMember 2023-01-01 2023-09-30 0000872912 dcth:ContingentLiabilitiesMember 2023-09-30 0000872912 us-gaap:WarrantMember 2023-09-30 0000872912 srt:MinimumMember dcth:PreferredAndCommonWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-03-29 0000872912 srt:MaximumMember dcth:PreferredAndCommonWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-03-29 0000872912 srt:MaximumMember dcth:PreferredAndCommonWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-09-30 0000872912 srt:MinimumMember dcth:PreferredAndCommonWarrantsMember us-gaap:MeasurementInputExpectedTermMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-03-29 0000872912 srt:MaximumMember dcth:PreferredAndCommonWarrantsMember us-gaap:MeasurementInputExpectedTermMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-03-29 0000872912 srt:MaximumMember dcth:PreferredAndCommonWarrantsMember us-gaap:MeasurementInputExpectedTermMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-09-30 0000872912 srt:MinimumMember dcth:PreferredAndCommonWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-03-29 0000872912 srt:MaximumMember dcth:PreferredAndCommonWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-03-29 0000872912 srt:MaximumMember dcth:PreferredAndCommonWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-09-30 0000872912 dcth:PreferredAndCommonWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-03-29 0000872912 dcth:PreferredAndCommonWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-09-30 0000872912 us-gaap:FairValueInputsLevel1Member 2023-09-30 0000872912 us-gaap:FairValueInputsLevel2Member 2023-09-30 0000872912 us-gaap:FairValueInputsLevel3Member 2023-09-30 0000872912 us-gaap:FairValueInputsLevel1Member 2022-12-31 0000872912 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000872912 us-gaap:FairValueInputsLevel3Member 2022-12-31 shares iso4217:USD iso4217:USD shares pure iso4217:EUR 0000872912 --12-31 2023 Q3 false http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember 10-Q true 2023-09-30 false 001-16133 DELCATH SYSTEMS, INC. DE 06-1245881 1633 Broadway Suite 22C New York NY 10019 212 489-2100 Common stock, $0.01 par value per share DCTH NASDAQ Yes Yes Non-accelerated Filer true false false 22046101 40462000 7671000 50000 4151000 205000 366000 2667000 1998000 2712000 1969000 46096000 16155000 1374000 1422000 107000 285000 47577000 17862000 753000 2018000 5230000 4685000 35000 186000 5080000 7846000 2876000 0 13974000 14735000 5773000 0 1111000 1144000 0 3070000 2000000 4772000 22858000 23721000 0.01 0.01 10000000 10000000 37787 37787 11357 11357 0 0 0.01 0.01 80000000 80000000 19688991 19688991 10046571 10046571 197000 100000 518607000 451608000 -494026000 -457484000 -59000 -83000 24719000 -5859000 47577000 17862000 434000 906000 1526000 1909000 0 0 0 171000 434000 906000 1526000 2080000 133000 235000 464000 449000 301000 671000 1062000 1631000 4662000 4065000 12793000 14152000 6195000 4779000 15147000 13477000 10857000 8844000 27940000 27629000 -10556000 -8173000 -26878000 -25998000 9384000 0 8224000 0 -395000 -730000 -1454000 -2040000 -5000 26000 14000 2000 -20340000 -8877000 -36542000 -28036000 5000 -46000 24000 -82000 -20335000 -8923000 -36518000 -28118000 -1.14 -1.14 -0.96 -0.96 -2.61 -2.61 -3.29 -3.29 17863078 17863078 9215786 9215786 13985248 13985248 8536006 8536006 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 11357 0 10046571 100000 451608000 -457484000 -83000 -5859000 1661000 1661000 19646 1000 55000 56000 15417 47000 47000 -9000000 -9000000 19000 19000 11357 0 10081634 101000 453371000 -466484000 -64000 -13076000 1661000 1661000 4629539 47000 11222000 11269000 9624 7099000 7099000 538828 5000 5000 468 2000 2000 -7202000 -7202000 0 0 20981 0 15250469 153000 473355000 -473686000 -64000 -242000 2783000 2783000 -4721 1430603 14000 -14000 0 34859 42388000 42388000 -13232 2940440 30000 -29000 1000 -100 10000 31110 26018 76000 76000 351 1000 1000 47000 47000 -20340000 -20340000 5000 5000 37787 0 19688991 197000 518607000 -494026000 -59000 24719000 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 11357 0 7906728 79000 432831000 -420976000 18000 11952000 2271000 2271000 -9000000 -9000000 2000 2000 11357 0 7906728 79000 435102000 -429976000 20000 5225000 2119000 2119000 -10159000 -10159000 -31000 -31000 11357 0 7906728 79000 437221000 -440135000 -11000 -2846000 1627000 1627000 690954 7000 4889000 4896000 -8877000 -8877000 -46000 -46000 11357 0 8597682 86000 443737000 -449012000 -57000 -5246000 -36542000 -28036000 6152000 6016000 87000 98000 8224000 0 262000 339000 582000 574000 120000 120000 743000 -708000 -161000 493000 669000 515000 -437000 2907000 -270000 861000 0 -170000 -23073000 -17591000 39000 209000 -39000 -209000 22960000 4896000 123000 0 6313000 0 35004000 0 3000 0 51777000 4896000 25000 -67000 28690000 -12971000 11822000 26953000 40512000 13982000 40462000 9831000 50000 4151000 40512000 13982000 1122000 1337000 84000 0 11269000 0 7099000 0 General<div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements of Delcath Systems, Inc. (“Delcath” or the “Company”) as of and for the three and nine months ended September 30, 2023 and 2022 should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Annual Report”), which was filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2023 and may also be found on the Company’s website (www.delcath.com). In these notes to the interim condensed consolidated financial statements the terms “us”, “we” or “our” refer to Delcath and its consolidated subsidiaries. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company’s lead product, the HEPZATO KIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“HEPZATO” melphalan for Injection/Hepatic Delivery System), a drug/device combination product, was approved by the U.S. Food and Drug Administration (the “FDA”) on August 14, 2023 indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver with no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, HEPZATO is considered a combination drug and device product and is regulated as a drug by the FDA. Primary jurisdiction for regulation of HEPZATO has been assigned to the FDA’s Center for Drug Evaluation and Research. The FDA has granted Delcath six orphan drug designations (five for melphalan in the treatment of patients with ocular (uveal) melanoma, cutaneous melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and neuroendocrine tumor indications and one for doxorubicin in the treatment of patients with hepatocellular carcinoma). </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s clinical development program for HEPZATO was comprised of the FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma (the “FOCUS Trial”), a global registration clinical trial that investigated objective response rate in metastatic ocular melanoma (“mOM”). The Company is currently reviewing the incidence, unmet need, available efficacy data and development requirements for a broad set of liver cancers in order to select a portfolio of follow-on indications that will maximize the value of the HEPZATO platform. In addition to HEPZATO’s approved use to treat mOM, the Company believes that HEPZATO has the potential to treat other liver dominant cancers, such as Metastatic Colorectal Cancer and Cholangiocarcinoma, and plans to begin the study of HEPZATO to treat such conditions in the near future. The Company believes that the disease states it is investigating and intends to investigate are unmet medical needs that represent significant market opportunities. </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As the Company prepares for commercial launch of HEPZATO, the Company continues its expanded access program (“EAP”) in the United States to make HEPZATO readily available to mOM patients. The Company is focused on continuing to treat these patients enrolled in the EAP sites. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2022, CHEMOSAT received Medical Device Regulation (“MDR”) certification under the European Medical Devices Regulation (2017/745/EU), which may be considered by jurisdictions when evaluating reimbursement. As of March 1, 2022, the Company has assumed direct responsibility for sales, marketing and distribution of CHEMOSAT in Europe. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully launching and commercializing its drug/device combination products, the Company's ability to obtain regulatory approval of its such produ</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians and consumers, and significant competition. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, high rates of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inflation have resulted in the U.S. Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks and financial institutions enter receivership or </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our or our partners’ ability to access existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on our business and financial condition, including our ability to access additional capital on favorable terms, or at all, which could in the future negatively affect our ability to pursue our business strategy.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2023, the Company had cash, cash equivalents and restricted cash totaling $40.5 million, as compared to cash, cash equivalents and restricted cash totaling $11.8 million at December 31, 2022. During the nine months ended September 30, 2023, the Company used $23.1 million of cash in its operating activities and $6.3 million for principal payments. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future results are subject to substantial risks and uncertainties. The Company has operated at a loss for its entire history and there can be no assurance that it will ever achieve or maintain profitability. The Company has historically funded its operations primarily with proceeds from sales of common stock, warrants and prefunded warrants for the purchase of common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that current cash and cash equivalents will enable the Company to have sufficient cash through the launch of HEPZATO. If there is a substantial delay in the launch of HEPZATO, the Company expects to need to raise additional capital under structures available to the Company, including debt and/or equity offerings, which may not be on favorable terms. If commercialization were significantly delayed, the Company would not have sufficient funds to meet its obligations within twelve months from the issuance date of these condensed consolidated financial statements. As such, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt about our ability to continue as a going concern.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s capital commitments over the next twelve months include (a) $6.0 million to satisfy accounts payable, accrued expenses and lease liabilities and (b) $8.6 million of loan principal payments. Additional capital commitments beyond the next twelve months include (a) $0.1 million of lease liabilities; (b) $1.0 million for settlement of litigation with medac; and (c) $2.0 million of convertible note principal payments, if the holders do not elect to convert the notes into equity. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all wholly owned subsidiaries and all significant inter-company accounts and transactions have been eliminated in consolidation. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of interim condensed consolidated financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended September 30, 2023 and 2022; however, certain information and footnote disclosures normally included in our audited consolidated financial statements included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the policies listed below, there have been no material changes to our significant accounting policies as set forth in Note 3 Summary of Significant Accounting Policies to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liabilities </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the warrant liability was not in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, which classifies and measures certain financial instruments with characteristics of both liability and equity. Entities must consider whether to classify contracts that may be settled in its own stock, such as warrants, as equity of the entity or as an asset or liability. If an event that is not within the entity’s control could require net cash settlement, </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">then the contract should be classified as an asset or a liability at their fair value at issuance with subsequent changes in fair value recorded in earnings. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the Preferred Warrants as derivative instruments in accordance with ASC 815, Derivatives and Hedging. The Company classified the Preferred Warrants issued in conjunction with the Preferred Purchase Agreement (defined below) and the Common Warrants issued in conjunction with the Common Purchase Agreement (as defined below) as a liability due to the existence of a pre-specified volatility input to the Black-Scholes calculation which would be used to calculate the repurchase price of the Preferred Warrants and Common Warrants in the event of a Fundamental Transaction, as defined. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuations of the warrant liability and Series F-1 Preferred Stock (defined below) were determined using option pricing models. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. In addition, the Company used probabilities of the FDA approval of the HEPZATO KIT (“FDA Approval”) and of recording at least $10 million in quarterly U.S. revenue from the commercialization of HEPZATO as inputs to determine the fair value of warrants liability and Series F-1 Preferred Stock. The Company intends to adjust the fair value of the warranty liability at the end of each reporting period. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted and Issued Accounting Pronouncements </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been required to adopt any accounting standards that had a significant impact on our consolidated financial statements in the two years ended December 31, 2022. We do not expect any recently issued accounting standards to have a significant impact on our consolidated financial statements. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revision of Previously Issued Quarterly Financial Statements </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparation of the Company's audited financial statements as of and for year ended December 31, 2022, the Company determined it needed to correct previously reported share-based compensation expense for each quarter during 2022. The correction for share-based compensation increased the net loss in amount of $0.8 million for the first quarter of 2022, $0.5 million for the second quarter of 2022 and $0.4 million for the third quarter of fiscal 2022. The share-based compensation adjustment is a non-cash adjustment and did not have any impact on the cash balances for the Company. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables contain the financial information for the periods previously reported and have been updated to reflect the revisions of the Company’s financial statements. The revisions do not have an impact on the Company’s cash position. The Company has not amended its previously filed Quarterly Reports on Form 10-Q for the three quarterly periods ended September 30, 2022. The impact of the revision on the Company’s financial statements for the three and nine months ended September 30, 2022 is reflected in the following table: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:59.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As previously reported </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As revised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheet for September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">443,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(447,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(449,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">372 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,844 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,801)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,923)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Operations and Comprehensive Loss for the nine months September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,998)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,036)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense for issuance of stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated statement of Stockholders’ Equity (Deficit) for the nine months ended September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense for issuance of stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,016 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,036)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,365)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option compensation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully launching and commercializing its drug/device combination products, the Company's ability to obtain regulatory approval of its such produ</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians and consumers, and significant competition. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, high rates of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inflation have resulted in the U.S. Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks and financial institutions enter receivership or </span></div>become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our or our partners’ ability to access existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on our business and financial condition, including our ability to access additional capital on favorable terms, or at all, which could in the future negatively affect our ability to pursue our business strategy. <div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2023, the Company had cash, cash equivalents and restricted cash totaling $40.5 million, as compared to cash, cash equivalents and restricted cash totaling $11.8 million at December 31, 2022. During the nine months ended September 30, 2023, the Company used $23.1 million of cash in its operating activities and $6.3 million for principal payments. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future results are subject to substantial risks and uncertainties. The Company has operated at a loss for its entire history and there can be no assurance that it will ever achieve or maintain profitability. The Company has historically funded its operations primarily with proceeds from sales of common stock, warrants and prefunded warrants for the purchase of common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that current cash and cash equivalents will enable the Company to have sufficient cash through the launch of HEPZATO. If there is a substantial delay in the launch of HEPZATO, the Company expects to need to raise additional capital under structures available to the Company, including debt and/or equity offerings, which may not be on favorable terms. If commercialization were significantly delayed, the Company would not have sufficient funds to meet its obligations within twelve months from the issuance date of these condensed consolidated financial statements. As such, there is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt about our ability to continue as a going concern.</span></div>The Company’s capital commitments over the next twelve months include (a) $6.0 million to satisfy accounts payable, accrued expenses and lease liabilities and (b) $8.6 million of loan principal payments. Additional capital commitments beyond the next twelve months include (a) $0.1 million of lease liabilities; (b) $1.0 million for settlement of litigation with medac; and (c) $2.0 million of convertible note principal payments, if the holders do not elect to convert the notes into equity. 40500000 11800000 -23100000 6300000 6000000 8600000 100000 1000000 2000000 <div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (GAAP) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all wholly owned subsidiaries and all significant inter-company accounts and transactions have been eliminated in consolidation. </span></div>The preparation of interim condensed consolidated financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended September 30, 2023 and 2022; however, certain information and footnote disclosures normally included in our audited consolidated financial statements included in our Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period. <div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liabilities </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the warrant liability was not in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, which classifies and measures certain financial instruments with characteristics of both liability and equity. Entities must consider whether to classify contracts that may be settled in its own stock, such as warrants, as equity of the entity or as an asset or liability. If an event that is not within the entity’s control could require net cash settlement, </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">then the contract should be classified as an asset or a liability at their fair value at issuance with subsequent changes in fair value recorded in earnings. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for the Preferred Warrants as derivative instruments in accordance with ASC 815, Derivatives and Hedging. The Company classified the Preferred Warrants issued in conjunction with the Preferred Purchase Agreement (defined below) and the Common Warrants issued in conjunction with the Common Purchase Agreement (as defined below) as a liability due to the existence of a pre-specified volatility input to the Black-Scholes calculation which would be used to calculate the repurchase price of the Preferred Warrants and Common Warrants in the event of a Fundamental Transaction, as defined. </span></div>The valuations of the warrant liability and Series F-1 Preferred Stock (defined below) were determined using option pricing models. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. In addition, the Company used probabilities of the FDA approval of the HEPZATO KIT (“FDA Approval”) and of recording at least $10 million in quarterly U.S. revenue from the commercialization of HEPZATO as inputs to determine the fair value of warrants liability and Series F-1 Preferred Stock. The Company intends to adjust the fair value of the warranty liability at the end of each reporting period. 10000000 Recently Adopted and Issued Accounting Pronouncements We have not been required to adopt any accounting standards that had a significant impact on our consolidated financial statements in the two years ended December 31, 2022. We do not expect any recently issued accounting standards to have a significant impact on our consolidated financial statements. <div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revision of Previously Issued Quarterly Financial Statements </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparation of the Company's audited financial statements as of and for year ended December 31, 2022, the Company determined it needed to correct previously reported share-based compensation expense for each quarter during 2022. The correction for share-based compensation increased the net loss in amount of $0.8 million for the first quarter of 2022, $0.5 million for the second quarter of 2022 and $0.4 million for the third quarter of fiscal 2022. The share-based compensation adjustment is a non-cash adjustment and did not have any impact on the cash balances for the Company. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables contain the financial information for the periods previously reported and have been updated to reflect the revisions of the Company’s financial statements. The revisions do not have an impact on the Company’s cash position. The Company has not amended its previously filed Quarterly Reports on Form 10-Q for the three quarterly periods ended September 30, 2022. The impact of the revision on the Company’s financial statements for the three and nine months ended September 30, 2022 is reflected in the following table: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:59.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As previously reported </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As revised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheet for September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">443,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(447,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(449,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">372 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,844 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,801)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,923)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Operations and Comprehensive Loss for the nine months September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,998)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,036)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense for issuance of stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated statement of Stockholders’ Equity (Deficit) for the nine months ended September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense for issuance of stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,016 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,036)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,365)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option compensation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 800000 500000 400000 The impact of the revision on the Company’s financial statements for the three and nine months ended September 30, 2022 is reflected in the following table: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:59.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As previously reported </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As revised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheet for September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">442,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">443,737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(447,341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(449,012)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,065 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,519 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,779 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">372 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,844 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,801)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,173)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(372)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,923)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.04)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Operations and Comprehensive Loss for the nine months September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,649 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27,629 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,998)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,036)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense for issuance of stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,255 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,627 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated statement of Stockholders’ Equity (Deficit) for the nine months ended September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense for issuance of stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,345 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,016 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,036)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,365)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option compensation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,345 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,671 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 442066000 1671000 443737000 -447341000 -1671000 -449012000 3953000 112000 4065000 4519000 260000 4779000 8472000 372000 8844000 -7801000 -372000 -8173000 -8505000 -372000 -8877000 -8551000 -372000 -8923000 -0.92 -0.92 -0.04 -0.04 -0.96 -0.96 13649000 503000 14152000 12309000 1168000 13477000 25958000 1671000 27629000 -24327000 -1671000 -25998000 -26365000 -1671000 -28036000 -26447000 -1671000 -28118000 -3.09 -3.09 -0.20 -0.20 -3.29 -3.29 1255000 372000 1627000 -8505000 -372000 -8877000 4345000 1671000 6016000 -26365000 -1671000 -28036000 -26365000 -1671000 -28036000 4345000 1671000 6016000 Cash, Cash Equivalents and Restricted Cash<div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents that are restricted as to withdrawal or use under the terms of certain contractual agreements are recorded in Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash balances were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted balance for loan agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Letters of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security for credit cards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash shown in the statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,512 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,822 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>On March 15, 2023, the Company returned to Avenue (as defined below) the $4.0 million held in restricted cash to pay down a portion of the outstanding Avenue Loan (defined below) balance. On March 31, 2023, the letter of credit for the sub-lease agreement for office space at 1633 Broadway, New York, NY expired. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash balances were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,462 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted balance for loan agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Letters of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Security for credit cards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash shown in the statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,512 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,822 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 40462000 7671000 0 4000000 0 101000 50000 50000 40512000 11822000 4000000 Inventory<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">924 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">763 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,582 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,667 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,998 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consists of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">924 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">763 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,582 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,667 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,998 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 924000 763000 1582000 1102000 161000 133000 2667000 1998000 Prepaid Expenses and Other Current Assets <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,630 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,630 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance premiums</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,712 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,969 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,630 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,630 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance premiums</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">356 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,712 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,969 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1630000 1630000 71000 123000 655000 121000 356000 95000 2712000 1969000 Property, Plant, and Equipment<div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment consist of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:49.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings and land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,301 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,301 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30 years - Buildings</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enterprise hardware and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leaseholds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,774 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-547">Lesser of lease term or estimated useful life</span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,391 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,353 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,931)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,374 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,422 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three and nine months ended September 30, 2023 and 2022 was less than $0.1 million for each period.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant, and equipment consist of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:49.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.175%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings and land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,301 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,301 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">30 years - Buildings</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enterprise hardware and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leaseholds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,772 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,774 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-547">Lesser of lease term or estimated useful life</span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">201 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,391 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,353 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,017)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,931)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-0.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,374 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,422 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table> 1301000 1301000 P30Y 1855000 1855000 P3Y 1772000 1774000 1262000 1222000 P7Y 201000 201000 P5Y 6391000 6353000 5017000 4931000 1374000 1422000 100000 100000 100000 100000 Accrued Expenses<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation, excluding taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,040 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on convertible note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,230 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,685 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation, excluding taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,040 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on convertible note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">856 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,230 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,685 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2105000 1470000 1535000 1040000 61000 1087000 673000 553000 856000 535000 5230000 4685000 Leases<div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes right-of-use (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company leases its facilities under non-cancellable operating and financing leases. The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the ROU asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023 and 2022, the Company recognized $0.1 million and $0.3 million, respectively, of operating lease expense in the U.S. and less than $0.1 million of operating lease expense in Ireland for the same periods. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:58.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ireland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows for operating leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">238 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August 31, 2023, the lease of office space at 1633 Broadway, New York, NY was converted to a month-to-month lease. No ROU assets or lease liabilities are recognized on the balance sheet for this arrangement. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:57.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ireland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities included in the condensed consolidated balance sheets at September 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> Leases<div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes right-of-use (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company leases its facilities under non-cancellable operating and financing leases. The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the ROU asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023 and 2022, the Company recognized $0.1 million and $0.3 million, respectively, of operating lease expense in the U.S. and less than $0.1 million of operating lease expense in Ireland for the same periods. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:58.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ireland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows for operating leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">238 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of August 31, 2023, the lease of office space at 1633 Broadway, New York, NY was converted to a month-to-month lease. No ROU assets or lease liabilities are recognized on the balance sheet for this arrangement. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:57.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ireland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities included in the condensed consolidated balance sheets at September 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P12M 100000 100000 300000 300000 100000 100000 100000 100000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:58.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ireland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows for operating leases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">238 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average discount rate - operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table> 238000 24000 262000 P0Y P2Y9M18D 0.08 0.08 <div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows: </span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:57.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Ireland</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less present value discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities included in the condensed consolidated balance sheets at September 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 11000 11000 0 42000 42000 0 42000 42000 0 25000 25000 0 120000 120000 0 13000 13000 0 107000 107000 Loans and Convertible Notes Payable<div style="margin-top:18pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.683%"><tr><td style="width:1.0%"></td><td style="width:29.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Discount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Discount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans Payable, Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,610 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(530)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,080 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(724)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,846 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans Payable, Non-Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total - Loans Payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,610 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(530)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,080 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,923 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,008)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,916 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 28pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible Notes Payable - Current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible Notes Payable - Non-Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total - Convertible Notes Payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(124)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(228)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total - Loans and Notes Payable</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,610 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,923 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross amount includes the 4.25% final payment of $0.5 million. </span></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining maturities of the Company’s loan and convertible note payables are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.683%"><tr><td style="width:1.0%"></td><td style="width:58.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.950%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.950%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Convertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,610 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,610 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Term Loan from Avenue Venture Opportunities Fund, L.P. </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 6, 2021, the Company entered into a Loan and Security Agreement (the “Avenue Loan Agreement”) with Avenue Venture Opportunities Fund, L.P. (the “Lender,” or “Avenue”) for a term loan in an aggregate principal amount of up to $20.0 million (the “Avenue Loan”). The Avenue Loan bears interest at an annual rate equal to the greater of (a) the sum of 7.70% plus the prime rate as reported in The Wall Street Journal and (b) 10.95%. The interest rate at September 30, 2023 was 16.20%. The Avenue Loan is secured by all of the Company’s assets globally, including intellectual property. The Avenue Loan matures on August 1, 2024. </span></div><div style="padding-left:27pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial tranche of the Avenue Loan was $15.0 million, including $4.0 million that was funded into a restricted account. On March 15, 2023, the Company returned to Avenue $4.0 million held in the restricted cash to pay down a portion of the </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding loan balance, principal payments of $2.1 million and an incremental 4.25% of the final payment of $0.2 million. On March 31, 2023, the Avenue Loan Agreement was amended (the “Avenue Amendment”) to defer the interest only period to September 30, 2023, with an additional extension option upon FDA Approval for the HEPZATO KIT and subsequent receipt of at least $10 million from the sale and issuance of equity securities. On August 14, 2023, the Company received FDA approval and has subsequently received over $10 million from the exercise of Tranche A Preferred Warrants. At the Company’s option, it has elected to extend the interest only period to December 31, 2023 and principal payments are deferred until January 2024.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up to $3.0 million of the principal amount of the Avenue Loan outstanding may be converted, at Avenue's option, into shares of the Company’s common stock at a conversion price of $11.98 per share. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Avenue Loan Agreement requires the Company to make and maintain representations and warranties and other agreements that are customary in loan agreements of this type. The Avenue Loan Agreement also contains customary events of default, including non-payment of principal or interest, violations of covenants, bankruptcy and material judgements. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the initial entry into the Avenue Loan Agreement, the Company issued warrants to Avenue (the “Initial Avenue Warrant”) to purchase 127,755 shares of common stock at an exercise price per share equal to $0.01. The Initial Avenue Warrant is exercisable until August 31, 2026. Additionally, in connection with the Avenue Amendment, the Company issued to Avenue a warrant to purchase 34,072 shares of common stock at an exercise price per share equal to $0.01. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the embedded conversion option associated with the Avenue Loan did not require bifurcation and met the criteria for equity classification. In addition, the amendment was recorded under debt modification guidance. Aggregate debt discount amortization of $0.2 million and $0.6 million was recorded during the three and nine months ended September 30, 2023 and 2022, respectively. Interest expense incurred was $0.3 million and $0.4 million for the three months ended September 30, 2023 and 2022, respectively and $1.1 million and $1.3 million for the nine months ended September 30, 2023 and 2022, respectively. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes Payable </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has $2.0 million of principal outstanding related to Senior Secured Promissory Notes (the “Rosalind Notes”) which bear interest at 8% per annum. Pursuant to the original terms, the Rosalind Notes were convertible into Series E Preferred Stock at a price of $1,500 per share and were to mature on July 16, 2021. Interest expense was $0.1 million for the nine months ended September 30, 2023 and 2022, respectively. </span></div>On August 6, 2021, the Company executed an agreement to amend the Rosalind Notes to (i) reduce the conversion price to $1,198 per share of the Company’s Series E Preferred Stock; and (ii) extend the maturity date to October 30, 2024. In addition, the holders of the Rosalind Notes agreed to subordinate all of the Company’s indebtedness and obligations to Avenue and all of the holders’ security interest, to the Avenue Loan and Avenue’s security interest in the Company’s property. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.683%"><tr><td style="width:1.0%"></td><td style="width:29.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Discount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Discount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans Payable, Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,610 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(530)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,080 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,570 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(724)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,846 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans Payable, Non-Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,353 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,070 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total - Loans Payable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,610 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(530)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,080 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,923 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,008)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,916 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 28pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible Notes Payable - Current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,876 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible Notes Payable - Non-Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,772 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total - Convertible Notes Payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(124)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(228)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total - Loans and Notes Payable</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,610 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,923 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table>1 The gross amount includes the 4.25% final payment of $0.5 million. 5610000 530000 5080000 8570000 724000 7846000 0 0 0 3353000 284000 3070000 5610000 530000 5080000 11923000 1008000 10916000 3000000 124000 2876000 0 0 0 2000000 0 2000000 5000000 228000 4772000 5000000 124000 4876000 5000000 228000 4772000 10610000 16923000 0.0425 0.0425 500000 500000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining maturities of the Company’s loan and convertible note payables are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.683%"><tr><td style="width:1.0%"></td><td style="width:58.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.950%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.950%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Loans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Convertible<br/>Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Year ended December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,610 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,610 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 0 0 0 5610000 5000000 10610000 5610000 5000000 10610000 20000000 0.0770 0.1095 0.1620 15000000 4000000 4000000 2100000 0.0425 200000 10000000 10000000 3000000 11.98 127755 0.01 34072 0.01 200000 200000 600000 600000 300000 400000 1100000 1300000 2000000 0.08 1500 100000 100000 1198 Preferred Purchase Agreement<div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2023, we entered into a securities purchase agreement with certain accredited investors (the “Preferred Purchase Agreement”), pursuant to which on March 29, 2023, the Company issued and sold, in a private placement (the “Series F Preferred Offering”), (i) 24,900 shares of Series F-1 Convertible Preferred Stock, par value $0.01 per share (the “Series F-1 Preferred Stock”), (ii) tranche A warrants (the “Preferred Tranche A Warrants”) to acquire 34,859 shares of Series F-3 Convertible Preferred Stock, par value $0.01 per share (the “Series F-3 Preferred Stock”) and (iii) tranche B warrants (the “Preferred Tranche B Warrants,” together with the Preferred Tranche A Warrant, the “Preferred Warrants”) to acquire 24,900 shares of Series F-4 Convertible Preferred Stock, par value $0.01 per share (the “Series F-4 Preferred Stock”) for an aggregate offering price of $24.9 million before deducting the fees paid to the placement agent and the financial advisors and other financing expenses payable by the Company. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross proceeds of $24.9 million from the Series F Preferred Offering have been allocated first to the Preferred Warrant liabilities at their fair value of $4.9 million, with the residual of $20.0 million being allocated to the Series F-1 Preferred Stock. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2023, all of the Preferred Tranche A Warrants were exercised for an aggregate exercise price of $34.9 million into 34,859 shares of Series F-3 Preferred Stock and 13,232 shares of Series F-3 </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Stock were concurrently converted into 2,940,440 shares of common stock (in accordance with the beneficial ownership limitations then in effect). The Preferred Tranche B Warrants are exercisable for 24,900 shares of Series F-4 Preferred Stock, with an aggregate exercise price of $24.9 million until the earlier of (i) 21 days following the Company's announcement of receipt of at least $10 million in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following stockholder approval, pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series F Convertible Voting Preferred Stock (the “Certificate of Designation”), each share of Series F-1 Preferred Stock automatically converted into shares of common stock and/or, if applicable (in accordance with the beneficial ownership limitations then in effect), shares of Series F-2 Preferred Stock, par value $0.01 per share (the “Series F-2 Preferred Stock” and, together with the Series F-1 Preferred Stock, the Series F-3 Preferred Stock and the Series F-4 Preferred Stock, the “Series F Preferred Stock”) in lieu of common stock. Subject to limitations set forth in the Certificate of Designation, the shares of Series F-2, F-3 and F-4 Preferred Stock are convertible into common stock at the option of the holder at the conversion price of $3.30 per share, $4.50 per share and $6.00 per share, respectively, rounded down to the nearest whole share, and in each case subject to the terms and limitations contained in the Certificate of Designation. As of September 30, 2023, 33,229 shares of the Company's Series F-1, F-2 and F-3 Preferred Stock were converted into 9,000,582 shares of common stock. As of September 30, 2023, there were 4,903 shares of Series F-2 Preferred Stock, 21,627 shares of Series F-3 Preferred Stock and no shares of Series F-4 Preferred Stock outstanding. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series F-2, F-3 and F-4 Preferred Stock are not mandatorily redeemable, redeemable at the holder’s election or contingently redeemable at the holder’s election (at this point, a Deemed Liquidation Event would potentially trigger pro rata liquidation payments to the preferred and common stockholders on a pro rata “as converted” basis). Accordingly, the Series F-2, F-3 and F-4 Preferred are now classified as permanent equity. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the outstanding Preferred Warrants should be liability-classified. See “Note 1 – Warrant Liabilities” for a discussion of the accounting treatment of the Common Warrants and Preferred Warrants.</span></div> 24900 0.01 34859 0.01 24900 0.01 24900000 24900000 4900000 20000000 34900000 34859 13232 2940440 24900 24900000 P21D 10000000 0.01 3.30 4.50 6.00 33229 9000582 4903 21627 0 Stockholders’ Equity<div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public and Private Placements </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Purchase Agreement </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2023, the Company entered into a securities purchase agreement (the “Common Purchase Agreement”) with the Company’s Chief Executive Officer, Gerard Michel, pursuant to which the Company agreed to issue and sell, in a private placement (the “Common Offering”) shares of common stock, tranche A warrants (“Common Tranche A Warrants”) to acquire 31,110 shares of common stock, tranche B warrants (“Common Tranche B Warrants”, together with the Common Tranche A Warrants, the “Common Warrants”) to acquire 16,666 shares of common stock. On March 29, 2023, the Company closed the Common Offering. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate exercise price of the Common Tranche A Warrants issued pursuant to the Common Offering is approximately $0.1 million. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 14, 2023, the Company announced the receipt of the FDA Approval and all Common Tranche A Warrants were exercised and converted into 31,110 shares of common stock.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate exercise price of the Common Tranche B Warrants issued in the Common Offering is approximately $0.1 million. The Common Tranche B Warrants are exercisable for an aggregate of 16,666 shares of common stock until the earlier of 21 days following the Company’s announcement of receipt of recording at least $10 million in quarterly U.S. revenue from the commercialization of HEPZATO and March 31, 2026.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the outstanding Common Warrants should be liability-classified. See “Note 1 – Warrant Liabilities” for a discussion of the accounting treatment of the Common Warrants and Preferred Warrants.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registration Rights for Preferred and Common Offerings </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Preferred Purchase Agreement and the Common Purchase Agreement (collectively, the “Purchase Agreements”), the Company filed a registration statement on Form S-3 (the “Resale Registration Statement”) providing for </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the resale by the investors party thereto of the common stock issuable upon conversion of the Registrable Shares (as defined in the Purchase Agreements). The Resale Registration Statement became effective on June 28, 2023. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no established public trading market for the Series F Preferred Stock, the Preferred Warrants, or the Common Warrants and the Company does not intend to list such securities on any national securities exchange or nationally recognized trading system. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-the-Market Offering </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into a Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (“ATM Sales Agreement”), with Cantor Fitzgerald &amp; Co. (the “Sales Agent”), pursuant to which the Company may offer and sell, at its sole discretion through the Sales Agent, shares of common stock having an aggregate offering price of up to $17.0 million. To date, the Company has sold approximately $4.0 million of its common stock, prior to issuance costs, under the ATM Sales Agreement. No sales were made during the three and nine months ended September 30, 2023. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Authorized Shares </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of its common stock authorized for issuance from 40 million shares to 80 million shares. The Company is authorized to issue 80 million shares of common stock, $0.01 par value, and 10 million shares of preferred stock, $0.01 par value. As of September 30, 2023, the Company has designated the following preferred stock:</span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.212%"><tr><td style="width:1.0%"></td><td style="width:67.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Designated Preferred Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series E </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series E-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series F-1 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series F-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series F-3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,860 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series F-4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, there were an aggregate of 11,257 shares of Series E and Series E-1, 4,903 Series F-2 and 21,627 Series F-3 Convertible Preferred Stock outstanding, respectively. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Omnibus Equity Incentive Plan </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2020, the Company’s 2020 Omnibus Equity Incentive Plan (the “2020 Plan”) was adopted by the Company’s Board of Directors. On November 23, 2020, the Company’s stockholders approved the 2020 Plan. The 2020 Plan will continue in effect until the tenth anniversary of the date of its adoption by the Board or until earlier terminated by the Board. The 2020 Plan is administered by the Board of Directors or a committee designated by the Board of Directors. On June 12, 2023, the stockholders approved the amendment to the Company’s 2020 Plan to increase the number of shares of common stock available under the plan by 2.65 million shares. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, as well as other stock-based awards or cash awards that are deemed to be consistent with the purposes of the plan to Company employees, directors and consultants. As of September 30, 2023, there are 5,125,000 shares of common stock reserved under the 2020 Plan, of which 1,802,841 remained available to be issued. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to options granted from the 2020 Plan, the Company also grants employment inducement grants pursuant to Listing Rule 5635(c) of the corporate governance rules of the NASDAQ Stock Market. These inducement grants are intended to provide incentive to certain individuals to enter into employment with the Company. Inducement grants are </span></div>granted outside of the 2020 Plan, however they are governed in all respects as if they were issued under the 2020 Plan. These grants do not reduce the number of options available for issuance under the 2020 Plan. <div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables include information for all options granted including inducement grants that are granted outside of the 2020 Plan. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values stock options using the Black-Scholes option pricing model and used the following assumptions, on a weighted-average basis, during the reporting periods: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected terms (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160.4%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164.3%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.99%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.86%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.00%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.00%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity for the nine months ended September 30, 2023: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Options </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining<br/>Contractual Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,235,052</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,122,757</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(819)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(115,772)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled/Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(104,390)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,136,828</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,850 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,020,026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.29 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information for stock option shares outstanding and exercisable at September 30, 2023: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:57.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining Option Term<br/>(in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Options</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.83 - $51.50</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,136,329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,136,329</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$51.50+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">499</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">499</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,136,828</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,136,828</span></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of share-based compensation expense in the statement of operations for the three and nine months ended September 30, 2023: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,674 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,117 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,774 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,984 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,095 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,830 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,627 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,152 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,016 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2023, there was $7.7 million of aggregate unrecognized compensation expense related employee and board stock option grants. The cost is expected to be recognized over a weighted average period of 2.4 years. </span></div><div style="margin-top:18pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of common stock warrant activity for the nine months ended September 30, 2023: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,153,291</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.01 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,848</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(569,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,665,201</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.76 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,665,201</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.76 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9</span></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information related to common stock warrants outstanding at September 30, 2023: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrants Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Range of Exercise Prices</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Number of<br/>Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining Warrant Term<br/>(in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.01</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,037,792</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,037,792</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,666</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,666</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,610,743</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,610,743</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,665,201</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,665,201</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, there were 538,828 warrants priced at $0.01 and 31,110 warrants priced at $4.50 exercised for 569,938 common shares.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock Warrants </span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of preferred stock warrant activity for the nine months ended September 30, 2023: </span></div><div style="margin-bottom:9pt;margin-top:18pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,759</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34,859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,900</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,900</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company’s Board of Directors, with shareholder approval in May 2022, adopted the Employee Stock Purchase Plan (the “ESPP”). The ESPP provides for a maximum of 260,295 shares of common stock to be purchased by participating employees. Employees who elect to participate in the ESPP will be able to purchase common stock at the lower of 85% of the fair market value of common stock on the first or last day of the applicable six-month offering period. In January 2023, an aggregate of 15,417 shares were purchased by participating employees for the offering period of July 1, 2022 to December 31, 2022. In July 2023, an aggregate of 26,018 shares were purchased by participating employees for the offering period of January 1, 2023 to June 30, 2023.</span></div> 31110 16666 100000 31110 100000 16666 P21D 10000000 17000000 4000000 0 0 40000000 80000000 80000000 0.01 10000000 0.01 As of September 30, 2023, the Company has designated the following preferred stock:<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.212%"><tr><td style="width:1.0%"></td><td style="width:67.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Designated Preferred Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,360 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series C</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series D</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series E </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series E-1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,960 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series F-1 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,900 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series F-2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series F-3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,860 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series F-4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179,670 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 4200 2360 590 10000 40000 12960 24900 24900 34860 24900 179670 11257 11257 4903 21627 2650000 5125000 1802841 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values stock options using the Black-Scholes option pricing model and used the following assumptions, on a weighted-average basis, during the reporting periods: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected terms (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160.4%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164.3%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.99%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.86%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.00%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.00%</span></td></tr></table> P5Y8M12D P5Y4M24D 1.604 1.643 0.0399 0.0186 0.0000 0.0000 <div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity for the nine months ended September 30, 2023: </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;padding-right:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Options </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining<br/>Contractual Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,235,052</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,875 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,122,757</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(819)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(115,772)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cancelled/Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(104,390)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,136,828</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.26 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,850 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,020,026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.29 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2235052 10.30 P7Y9M18D 35875000 2122757 6.08 P9Y1M6D 819 4.67 115772 8.80 104390 7.22 4136828 8.26 P8Y6M 72850000 2020026 10.29 P7Y8M12D 0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information for stock option shares outstanding and exercisable at September 30, 2023: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:57.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options Outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding Number of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining Option Term<br/>(in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Options</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.83 - $51.50</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,136,329</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,136,329</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:5pt;padding-right:5pt;text-align:center;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$51.50+</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">499</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">499</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,136,828</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,136,828</span></td></tr></table> 2.83 51.50 4136329 P8Y6M 4136329 51.50 499 P5Y3M18D 499 4136828 P8Y6M 4136828 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of share-based compensation expense in the statement of operations for the three and nine months ended September 30, 2023: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,674 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,117 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,774 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,984 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">458 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,095 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,830 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,627 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,152 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,016 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1674000 1117000 3774000 3984000 1027000 458000 2095000 1872000 129000 52000 283000 160000 2830000 1627000 6152000 6016000 7700000 P2Y4M24D <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of common stock warrant activity for the nine months ended September 30, 2023: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,153,291</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.01 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,848</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(569,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,665,201</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.76 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,665,201</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.76 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9</span></td></tr></table><div style="margin-bottom:9pt;margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of preferred stock warrant activity for the nine months ended September 30, 2023: </span></div><div style="margin-bottom:9pt;margin-top:18pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining Life<br/>(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,759</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34,859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at September 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,900</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,900</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5</span></td></tr></table></div> 5153291 7.01 81848 2.94 569938 0.26 4665201 7.76 P1Y10M24D 4665201 7.76 P1Y10M24D <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information related to common stock warrants outstanding at September 30, 2023: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrants Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Range of Exercise Prices</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding<br/>Number of<br/>Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining Warrant Term<br/>(in years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.01</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,037,792</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,037,792</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,666</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,666</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11pt;text-align:left;text-indent:-10pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,610,743</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,610,743</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,665,201</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,665,201</span></td></tr></table> 0.01 1037792 P3Y4M24D 1037792 6.00 16666 P2Y6M 16666 10 3610743 P1Y4M24D 3610743 4665201 P1Y10M24D 4665201 538828 0.01 31110 4.50 569938 0 0 59759 1000 34859 1000 24900 1000 P2Y6M 24900 1000 P2Y6M 260295 0.85 P6M 15417 26018 Net Loss per Share<div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period, without consideration of potentially dilutive securities, except for those shares that are issuable for little or no cash consideration. Diluted net loss per share is determined by dividing net loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options, convertible preferred shares, and preferred and common warrants are generally deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2023 and 2022 because their effects would be anti-dilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,627,409</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,461,249</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed conversion of preferred stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,149,994</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed conversion of preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,417,473</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,135,721</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed conversion of convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">488,031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">488,031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,136,828</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,249,955</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,819,735</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,334,956</span></td></tr></table></div><div style="margin-top:12pt;padding-left:27pt"><span><br/></span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At September 30, 2023, the Company had 1,037,792 pre-funded warrants outstanding. The following table provides a reconciliation of the weighted average shares outstanding calculation for the three and nine months ended September 30, 2023 and 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares issued</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,825,286</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,470,006</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,745,035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,096,551</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average pre-funded warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,037,792</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">745,780</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,240,213</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439,455</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,863,078</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,215,786</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,985,248</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,536,006</span></td></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities were excluded from the computation of earnings per share as of September 30, 2023 and 2022 because their effects would be anti-dilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,627,409</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,461,249</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed conversion of preferred stock warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,149,994</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed conversion of preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,417,473</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,135,721</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumed conversion of convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">488,031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">488,031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,136,828</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,249,955</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,819,735</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,334,956</span></td></tr></table> 3627409 4461249 4149994 0 7417473 1135721 488031 488031 4136828 2249955 19819735 8334956 1037792 The following table provides a reconciliation of the weighted average shares outstanding calculation for the three and nine months ended September 30, 2023 and 2022: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares issued</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,825,286</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,470,006</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,745,035</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,096,551</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average pre-funded warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,037,792</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">745,780</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,240,213</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">439,455</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,863,078</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,215,786</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,985,248</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,536,006</span></td></tr></table> 16825286 8470006 12745035 8096551 1037792 745780 1240213 439455 17863078 17863078 9215786 9215786 13985248 13985248 8536006 8536006 Income Taxes<div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in “Note 14—Income Taxes” to the notes to the consolidated financial statements contained in the Annual Report, the Company has a valuation allowance against the full amount of its net deferred tax assets. The Company currently provides a valuation allowance against deferred tax assets when it is more likely than not that some portion or all of its deferred tax assets will not be realized. The Company has not recognized any unrecognized tax benefits in its balance sheet. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to income tax in the U.S., as well as various state and international jurisdictions. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. Additional information regarding the statutes of limitations can be found in Note 14 Income Taxes of the Company’s Annual Report. </span></div>The Inflation Reduction Act of 2022 included tax legislation that became effective in the first quarter of 2023. Significant legislation for corporate taxpayers includes a corporate alternative minimum tax of 15% for companies with $1 billion or more in average net financial statement profits over the three previous years, as well as a 1% indirect excise tax on the repurchase of shares by a publicly traded company. The Company does not expect this legislation to have an effect on the tax provision as of September 30, 2023, however the Company will continue to evaluate the effect on the tax provision each reporting period. 0.15 1000000000 0.01 Commitments and Contingencies<div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">medac Matter </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company’s wholly owned subsidiary, Delcath Systems Ltd, issued to medac GmbH, a privately held, multi-national pharmaceutical company based in Germany (“medac”), an invoice for a €1 million milestone payment under a License, Supply and Marketing Agreement dated December 10, 2018 (the “medac Agreement”) between medac and the Company. The medac Agreement provided to medac the exclusive right to market and sell CHEMOSAT in certain designated countries for which the Company was entitled to a combination of upfront and success-based milestone payments as well as a fixed transfer price per unit of CHEMOSAT and specified royalties. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to medac’s subsequent dispute and non-payment of the invoice, on October 12, 2021, the Company notified medac in writing that it was terminating the medac Agreement due to medac’s nonpayment of the €1 million milestone payment, with the effective date of termination of the medac Agreement being April 12, 2022. On December 16, 2021, the Company initiated an arbitration proceeding pursuant to the dispute resolution procedures of the medac Agreement for the non-payment of the invoice.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2022, the parties reached a final settlement of the matter and the Company agreed to pay medac either (a) a royalty on sales of CHEMOSAT units over a defined minimum for a period of five years or until a maximum payment has been reached, or (b) a minimum annual payment of $0.2 million in the event the annual royalty payment does not reach the agreed minimum payment amount. The Company has estimated the fair value of the settlement to be $1.3 million as of September 30, 2023 and recorded $1.1 million as other liabilities, non-current and $0.2 million as accrued expenses on the Company’s condensed consolidated balance sheet as of September 30, 2023. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lachman Consulting Services, Inc.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2023, Lachman Consultant Services, Inc (“Lachman”) served the Company with a complaint alleging that Delcath owed Lachman approximately $0.9 million in unpaid consulting fees plus interest, costs and attorneys’ fees. The dispute arose from a July 22, 2021 agreement between Lachman and Delcath under which Lachman provided assistance to the Company in regard to preparing for a FDA inspection and good manufacturing practices, training and support. A settlement was reached on July 5, 2023, under which the Company paid Lachman $0.9 million.</span></div> 1000000 1000000 P5Y 200000 1300000 1100000 200000 900000 900000 Fair Value Measurements<div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents activity within Level 3 of the fair value hierarchy, our liabilities carried at fair value for the nine months ended September 30, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contingent<br/>liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at January 1, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total change in foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the warrant liability issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability fair value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change due to warrant exercise</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at September 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,271 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,773 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,044 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent liabilities are re-measured to fair value each reporting period using projected financial targets, discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected financial targets are based on our most recent internal operational budgets and may take into consideration alternate scenarios that could result in more or less profitability for the respective service line. Increases or decreases in projected financial targets and probabilities of payment may result in significant changes in the fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs in isolation may result in a significantly lower or higher fair value measurement. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in Note 9 and Note 10 of the Company’s consolidated financial statements, the Company allocated part of the proceeds of the Series F Preferred Offering to warrant liability issued in connection with the transaction. The valuations of the warrants were determined using option pricing models. The Company concluded that the Preferred Warrants were not in the scope of Accounting Standards Codification (ASC 480), Distinguishing Liabilities from Equity (ASC 480,) since the </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Warrants are not mandatorily redeemable; and do not have obligations to issue a variable number of shares of preferred stock. The Company determined the Preferred Warrants met the definition of a derivative in accordance with ASC 815 but were not considered indexed to the Company’s common stock since the warrants require early settlement by repurchasing the preferred warrants for cash in an amount equal to the Black-Scholes value in the event of a Fundamental Transaction at pre-specified volatility of 100% as an input to the Black-Scholes calculation. The Company determined to record the Preferred Warrants at fair value with subsequent changes in fair value recorded in earnings at the end of each reporting period. For the three and nine months ended September 30, 2023, the Company recorded other expense of $9.4 million and $8.2 million, respectively, related to the change in fair value of the warrant liability and Tranche A Warrant exercises. These models use inputs such as the underlying price of the shares issued at the measurement date, volatility, risk free interest rate and expected life of the instrument. The Company has classified the warrants as a long-term liability due to certain provisions relating to the holders’ ability to exercise the warrants beyond twelve months of the reporting date.</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the preferred and common warrants at September 30, 2023 and March 29, 2023 was determined by using option pricing models assuming the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.80% - 4.80%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 4.80%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 - 3.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2.5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70% - 75% </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 70%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.00%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company has determined that the warrant liability should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the option pricing models against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification as called for in ASC 820. There are six inputs: closing price of the Company’s stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of the Company’s stock over that term; annual rate of dividends; and the risk-free rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of the Company’s stock would fall under Level 1 of the fair-value hierarchy as it is a quoted price in an active market (ASC 820-10). The risk-free rate of return is a Level 2 input as defined in ASC 820-10, while the historical volatility is a Level 3 input as defined in ASC 820. Since the lowest level input is a Level 3, the Company determined the warrant liability is most appropriately classified within Level 3 of the fair value hierarchy. </span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company’s financial assets and liabilities that have been measured at fair value as of September 30, 2023 and December 31, 2022 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. In general, the fair values were determined using Level 3: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,044 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,044 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents activity within Level 3 of the fair value hierarchy, our liabilities carried at fair value for the nine months ended September 30, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contingent<br/>liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at January 1, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total change in foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the warrant liability issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability fair value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change due to warrant exercise</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at September 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,271 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,773 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,044 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1280000 0 1280000 -9000 0 -9000 0 4940000 4940000 0 8224000 8224000 0 7391000 7391000 1271000 5773000 7044000 9400000 8200000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the preferred and common warrants at September 30, 2023 and March 29, 2023 was determined by using option pricing models assuming the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.80% - 4.80%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 4.80%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 - 3.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2.5</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70% - 75% </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 70%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.00%</span></td></tr></table> 0.0380 0.0480 0.0480 P0Y6M P3Y P2Y6M 0.70 0.75 0.70 0.0000 0.0000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company’s financial assets and liabilities that have been measured at fair value as of September 30, 2023 and December 31, 2022 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. In general, the fair values were determined using Level 3: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.827%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,773 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,044 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,044 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Level 2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,280 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 0 0 1271000 1271000 0 0 5773000 5773000 0 0 7044000 7044000 0 0 1280000 1280000 0 0 1280000 1280000 EXCEL 83 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

0!?Z MMJHQ2P4 ,XN / " ?:> 0!X;"]W;W)K8F]O:RYX;6Q0 M2P$"% ,4 " "@FU7L 4 O38" <*@ &@ @ %NI $ M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "@FU7X XML 84 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 85 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 86 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 282 307 1 false 93 0 false 5 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.delcath.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) Sheet http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnauditedParenthetical Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 0000008 - Disclosure - General Sheet http://www.delcath.com/role/General General Notes 8 false false R9.htm 0000009 - Disclosure - Cash, Cash Equivalents and Restricted Cash Sheet http://www.delcath.com/role/CashCashEquivalentsandRestrictedCash Cash, Cash Equivalents and Restricted Cash Notes 9 false false R10.htm 0000010 - Disclosure - Inventory Sheet http://www.delcath.com/role/Inventory Inventory Notes 10 false false R11.htm 0000011 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 11 false false R12.htm 0000012 - Disclosure - Property, Plant, and Equipment Sheet http://www.delcath.com/role/PropertyPlantandEquipment Property, Plant, and Equipment Notes 12 false false R13.htm 0000013 - Disclosure - Accrued Expenses Sheet http://www.delcath.com/role/AccruedExpenses Accrued Expenses Notes 13 false false R14.htm 0000014 - Disclosure - Leases Sheet http://www.delcath.com/role/Leases Leases Notes 14 false false R15.htm 0000015 - Disclosure - Loans and Convertible Notes Payable Notes http://www.delcath.com/role/LoansandConvertibleNotesPayable Loans and Convertible Notes Payable Notes 15 false false R16.htm 0000016 - Disclosure - Preferred Purchase Agreement Sheet http://www.delcath.com/role/PreferredPurchaseAgreement Preferred Purchase Agreement Notes 16 false false R17.htm 0000017 - Disclosure - Stockholders' Equity Sheet http://www.delcath.com/role/StockholdersEquity Stockholders' Equity Notes 17 false false R18.htm 0000018 - Disclosure - Net Loss per Share Sheet http://www.delcath.com/role/NetLossperShare Net Loss per Share Notes 18 false false R19.htm 0000019 - Disclosure - Income Taxes Sheet http://www.delcath.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 0000020 - Disclosure - Commitments and Contingencies Sheet http://www.delcath.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 20 false false R21.htm 0000021 - Disclosure - Fair Value Measurements Sheet http://www.delcath.com/role/FairValueMeasurements Fair Value Measurements Notes 21 false false R22.htm 9954471 - Disclosure - General (Policies) Sheet http://www.delcath.com/role/GeneralPolicies General (Policies) Policies 22 false false R23.htm 9954472 - Disclosure - General (Tables) Sheet http://www.delcath.com/role/GeneralTables General (Tables) Tables http://www.delcath.com/role/General 23 false false R24.htm 9954473 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables) Sheet http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashTables Cash, Cash Equivalents and Restricted Cash (Tables) Tables http://www.delcath.com/role/CashCashEquivalentsandRestrictedCash 24 false false R25.htm 9954474 - Disclosure - Inventory (Tables) Sheet http://www.delcath.com/role/InventoryTables Inventory (Tables) Tables http://www.delcath.com/role/Inventory 25 false false R26.htm 9954475 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssets 26 false false R27.htm 9954476 - Disclosure - Property, Plant, and Equipment (Tables) Sheet http://www.delcath.com/role/PropertyPlantandEquipmentTables Property, Plant, and Equipment (Tables) Tables http://www.delcath.com/role/PropertyPlantandEquipment 27 false false R28.htm 9954477 - Disclosure - Accrued Expenses (Tables) Sheet http://www.delcath.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://www.delcath.com/role/AccruedExpenses 28 false false R29.htm 9954478 - Disclosure - Leases (Tables) Sheet http://www.delcath.com/role/LeasesTables Leases (Tables) Tables http://www.delcath.com/role/Leases 29 false false R30.htm 9954479 - Disclosure - Loans and Convertible Notes Payable (Tables) Notes http://www.delcath.com/role/LoansandConvertibleNotesPayableTables Loans and Convertible Notes Payable (Tables) Tables http://www.delcath.com/role/LoansandConvertibleNotesPayable 30 false false R31.htm 9954480 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.delcath.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.delcath.com/role/StockholdersEquity 31 false false R32.htm 9954481 - Disclosure - Net Loss per Share (Tables) Sheet http://www.delcath.com/role/NetLossperShareTables Net Loss per Share (Tables) Tables http://www.delcath.com/role/NetLossperShare 32 false false R33.htm 9954482 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.delcath.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.delcath.com/role/FairValueMeasurements 33 false false R34.htm 9954483 - Disclosure - General - Narrative (Details) Sheet http://www.delcath.com/role/GeneralNarrativeDetails General - Narrative (Details) Details 34 false false R35.htm 9954484 - Disclosure - General - Schedule of Error Corrections and Prior Period Adjustments (Details) Sheet http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails General - Schedule of Error Corrections and Prior Period Adjustments (Details) Details 35 false false R36.htm 9954485 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) Sheet http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashScheduleofCashCashEquivalentsandRestrictedCashDetails Cash, Cash Equivalents and Restricted Cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) Details 36 false false R37.htm 9954486 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Narrative (Details) Sheet http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashNarrativeDetails Cash, Cash Equivalents and Restricted Cash - Narrative (Details) Details 37 false false R38.htm 9954487 - Disclosure - Inventory (Details) Sheet http://www.delcath.com/role/InventoryDetails Inventory (Details) Details http://www.delcath.com/role/InventoryTables 38 false false R39.htm 9954488 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) Details http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsTables 39 false false R40.htm 9954489 - Disclosure - Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) Sheet http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details) Details 40 false false R41.htm 9954490 - Disclosure - Property, Plant, and Equipment - Narrative (Details) Sheet http://www.delcath.com/role/PropertyPlantandEquipmentNarrativeDetails Property, Plant, and Equipment - Narrative (Details) Details 41 false false R42.htm 9954491 - Disclosure - Accrued Expenses (Details) Sheet http://www.delcath.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://www.delcath.com/role/AccruedExpensesTables 42 false false R43.htm 9954492 - Disclosure - Leases - Narrative (Details) Sheet http://www.delcath.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 43 false false R44.htm 9954493 - Disclosure - Leases - Summary of Lease Costs (Details) Sheet http://www.delcath.com/role/LeasesSummaryofLeaseCostsDetails Leases - Summary of Lease Costs (Details) Details 44 false false R45.htm 9954494 - Disclosure - Leases - Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases (Details) Sheet http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails Leases - Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases (Details) Details 45 false false R46.htm 9954495 - Disclosure - Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details) Notes http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details) Details 46 false false R47.htm 9954496 - Disclosure - Loans and Convertible Notes Payable - Summary of Remaining Maturities of Company's Loan and Convertible Note Payables (Details) Notes http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofRemainingMaturitiesofCompanysLoanandConvertibleNotePayablesDetails Loans and Convertible Notes Payable - Summary of Remaining Maturities of Company's Loan and Convertible Note Payables (Details) Details 47 false false R48.htm 9954497 - Disclosure - Loans and Convertible Notes Payable - Narrative (Details) Notes http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails Loans and Convertible Notes Payable - Narrative (Details) Details 48 false false R49.htm 9954498 - Disclosure - Preferred Purchase Agreement (Details) Sheet http://www.delcath.com/role/PreferredPurchaseAgreementDetails Preferred Purchase Agreement (Details) Details http://www.delcath.com/role/PreferredPurchaseAgreement 49 false false R50.htm 9954499 - Disclosure - Stockholders' Equity - Equity Offerings and Placements (Details) Sheet http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails Stockholders' Equity - Equity Offerings and Placements (Details) Details 50 false false R51.htm 9954500 - Disclosure - Stockholders' Equity - At-the-Market Offering (Details) Sheet http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails Stockholders' Equity - At-the-Market Offering (Details) Details 51 false false R52.htm 9954501 - Disclosure - Stockholders' Equity - Designated Preferred Shares (Details) Sheet http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails Stockholders' Equity - Designated Preferred Shares (Details) Details 52 false false R53.htm 9954502 - Disclosure - Stockholders' Equity - Authorized Shares and Preferred Stock (Details) Sheet http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails Stockholders' Equity - Authorized Shares and Preferred Stock (Details) Details 53 false false R54.htm 9954503 - Disclosure - Stockholders' Equity - Equity Incentive Plan (Details) Sheet http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanDetails Stockholders' Equity - Equity Incentive Plan (Details) Details 54 false false R55.htm 9954504 - Disclosure - Stockholders' Equity - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details) Sheet http://www.delcath.com/role/StockholdersEquityScheduleofAssumptionstoEstimateFairValueofStockOptionsUsingBlackScholesOptionPricingModelDetails Stockholders' Equity - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details) Details 55 false false R56.htm 9954505 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details) Sheet http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails Stockholders' Equity - Summary of Stock Option Activity (Details) Details 56 false false R57.htm 9954506 - Disclosure - Stockholders' Equity - Summary of Stock Option Shares Outstanding and Exercisable (Details) Sheet http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails Stockholders' Equity - Summary of Stock Option Shares Outstanding and Exercisable (Details) Details 57 false false R58.htm 9954507 - Disclosure - Stockholders' Equity - Summary of Recognized Share-based Compensation Cost (Details) Sheet http://www.delcath.com/role/StockholdersEquitySummaryofRecognizedSharebasedCompensationCostDetails Stockholders' Equity - Summary of Recognized Share-based Compensation Cost (Details) Details 58 false false R59.htm 9954508 - Disclosure - Stockholders' Equity - Summary of Common Stock Warrant Activity (Details) Sheet http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails Stockholders' Equity - Summary of Common Stock Warrant Activity (Details) Details 59 false false R60.htm 9954509 - Disclosure - Stockholders' Equity - Summary of Common Stock Warrants Outstanding and Exercisable (Details) Sheet http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails Stockholders' Equity - Summary of Common Stock Warrants Outstanding and Exercisable (Details) Details 60 false false R61.htm 9954510 - Disclosure - Stockholders' Equity - Preferred Stock Warrants (Details) Sheet http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails Stockholders' Equity - Preferred Stock Warrants (Details) Details 61 false false R62.htm 9954511 - Disclosure - Stockholders' Equity - Summary of Employee Stock Purchase Plan (Details) Sheet http://www.delcath.com/role/StockholdersEquitySummaryofEmployeeStockPurchasePlanDetails Stockholders' Equity - Summary of Employee Stock Purchase Plan (Details) Details 62 false false R63.htm 9954512 - Disclosure - Net Loss per Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://www.delcath.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails Net Loss per Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 63 false false R64.htm 9954513 - Disclosure - Net Loss per Share - Narrative (Details) Sheet http://www.delcath.com/role/NetLossperShareNarrativeDetails Net Loss per Share - Narrative (Details) Details 64 false false R65.htm 9954514 - Disclosure - Net Loss per Share - Summary of Reconciliation of Weighted Average Shares Outstanding Calculation (Details) Sheet http://www.delcath.com/role/NetLossperShareSummaryofReconciliationofWeightedAverageSharesOutstandingCalculationDetails Net Loss per Share - Summary of Reconciliation of Weighted Average Shares Outstanding Calculation (Details) Details 65 false false R66.htm 9954515 - Disclosure - Income Taxes (Details) Sheet http://www.delcath.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.delcath.com/role/IncomeTaxes 66 false false R67.htm 9954516 - Disclosure - Commitments and contingencies - Additional Information (Details) Sheet http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails Commitments and contingencies - Additional Information (Details) Details 67 false false R68.htm 9954517 - Disclosure - Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details) Sheet http://www.delcath.com/role/FairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details) Details 68 false false R69.htm 9954518 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.delcath.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 69 false false R70.htm 9954519 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Outstanding Warrants (Details) Sheet http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails Fair Value Measurements - Schedule of Fair Value of Outstanding Warrants (Details) Details 70 false false R71.htm 9954520 - Disclosure - Fair Value Measurements - Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value (Details) Sheet http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails Fair Value Measurements - Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value (Details) Details 71 false false All Reports Book All Reports dcth-20230930.htm dcth-20230930.xsd dcth-20230930_cal.xml dcth-20230930_def.xml dcth-20230930_lab.xml dcth-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 88 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "dcth-20230930.htm": { "nsprefix": "dcth", "nsuri": "http://www.delcath.com/20230930", "dts": { "inline": { "local": [ "dcth-20230930.htm" ] }, "schema": { "local": [ "dcth-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "dcth-20230930_cal.xml" ] }, "definitionLink": { "local": [ "dcth-20230930_def.xml" ] }, "labelLink": { "local": [ "dcth-20230930_lab.xml" ] }, "presentationLink": { "local": [ "dcth-20230930_pre.xml" ] } }, "keyStandard": 242, "keyCustom": 65, "axisStandard": 23, "axisCustom": 4, "memberStandard": 42, "memberCustom": 46, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 1 }, "contextCount": 282, "entityCount": 1, "segmentCount": 93, "elementCount": 539, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 790, "http://xbrl.sec.gov/dei/2023": 30 }, "report": { "R1": { "role": "http://www.delcath.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R3": { "role": "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R4": { "role": "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-73", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-77", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R6": { "role": "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnauditedParenthetical", "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dcth:AmortizationOfRightOfUseAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R8": { "role": "http://www.delcath.com/role/General", "longName": "0000008 - Disclosure - General", "shortName": "General", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCash", "longName": "0000009 - Disclosure - Cash, Cash Equivalents and Restricted Cash", "shortName": "Cash, Cash Equivalents and Restricted Cash", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.delcath.com/role/Inventory", "longName": "0000010 - Disclosure - Inventory", "shortName": "Inventory", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssets", "longName": "0000011 - Disclosure - Prepaid Expenses and Other Current Assets", "shortName": "Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "dcth:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dcth:PrepaidExpensesAndOtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.delcath.com/role/PropertyPlantandEquipment", "longName": "0000012 - Disclosure - Property, Plant, and Equipment", "shortName": "Property, Plant, and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.delcath.com/role/AccruedExpenses", "longName": "0000013 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.delcath.com/role/Leases", "longName": "0000014 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.delcath.com/role/LoansandConvertibleNotesPayable", "longName": "0000015 - Disclosure - Loans and Convertible Notes Payable", "shortName": "Loans and Convertible Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.delcath.com/role/PreferredPurchaseAgreement", "longName": "0000016 - Disclosure - Preferred Purchase Agreement", "shortName": "Preferred Purchase Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "dcth:DisclosureOfPreferredPurchaseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dcth:DisclosureOfPreferredPurchaseAgreementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.delcath.com/role/StockholdersEquity", "longName": "0000017 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.delcath.com/role/NetLossperShare", "longName": "0000018 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.delcath.com/role/IncomeTaxes", "longName": "0000019 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.delcath.com/role/CommitmentsandContingencies", "longName": "0000020 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.delcath.com/role/FairValueMeasurements", "longName": "0000021 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.delcath.com/role/GeneralPolicies", "longName": "9954471 - Disclosure - General (Policies)", "shortName": "General (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "dcth:RiskAndUncertaintiesPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dcth:RiskAndUncertaintiesPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.delcath.com/role/GeneralTables", "longName": "9954472 - Disclosure - General (Tables)", "shortName": "General (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashTables", "longName": "9954473 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)", "shortName": "Cash, Cash Equivalents and Restricted Cash (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.delcath.com/role/InventoryTables", "longName": "9954474 - Disclosure - Inventory (Tables)", "shortName": "Inventory (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsTables", "longName": "9954475 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.delcath.com/role/PropertyPlantandEquipmentTables", "longName": "9954476 - Disclosure - Property, Plant, and Equipment (Tables)", "shortName": "Property, Plant, and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.delcath.com/role/AccruedExpensesTables", "longName": "9954477 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.delcath.com/role/LeasesTables", "longName": "9954478 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.delcath.com/role/LoansandConvertibleNotesPayableTables", "longName": "9954479 - Disclosure - Loans and Convertible Notes Payable (Tables)", "shortName": "Loans and Convertible Notes Payable (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.delcath.com/role/StockholdersEquityTables", "longName": "9954480 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.delcath.com/role/NetLossperShareTables", "longName": "9954481 - Disclosure - Net Loss per Share (Tables)", "shortName": "Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.delcath.com/role/FairValueMeasurementsTables", "longName": "9954482 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.delcath.com/role/GeneralNarrativeDetails", "longName": "9954483 - Disclosure - General - Narrative (Details)", "shortName": "General - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "dcth:LiquidityAndGoingConcernPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "dcth:LiquidityAndGoingConcernPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails", "longName": "9954484 - Disclosure - General - Schedule of Error Corrections and Prior Period Adjustments (Details)", "shortName": "General - Schedule of Error Corrections and Prior Period Adjustments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AdditionalPaidInCapital", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-112", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R36": { "role": "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashScheduleofCashCashEquivalentsandRestrictedCashDetails", "longName": "9954485 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)", "shortName": "Cash, Cash Equivalents and Restricted Cash - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "dcth:LoanAgreementRestrictedCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R37": { "role": "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashNarrativeDetails", "longName": "9954486 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Narrative (Details)", "shortName": "Cash, Cash Equivalents and Restricted Cash - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://www.delcath.com/role/InventoryDetails", "longName": "9954487 - Disclosure - Inventory (Details)", "shortName": "Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsDetails", "longName": "9954488 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "dcth:PrepaidClinicalTrialExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "dcth:PrepaidClinicalTrialExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails", "longName": "9954489 - Disclosure - Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details)", "shortName": "Property, Plant, and Equipment - Components of Property, Plant, and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.delcath.com/role/PropertyPlantandEquipmentNarrativeDetails", "longName": "9954490 - Disclosure - Property, Plant, and Equipment - Narrative (Details)", "shortName": "Property, Plant, and Equipment - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "us-gaap:Depreciation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.delcath.com/role/AccruedExpensesDetails", "longName": "9954491 - Disclosure - Accrued Expenses (Details)", "shortName": "Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "dcth:AccruedClinicalExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "dcth:AccruedClinicalExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.delcath.com/role/LeasesNarrativeDetails", "longName": "9954492 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-130", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R44": { "role": "http://www.delcath.com/role/LeasesSummaryofLeaseCostsDetails", "longName": "9954493 - Disclosure - Leases - Summary of Lease Costs (Details)", "shortName": "Leases - Summary of Lease Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails", "longName": "9954494 - Disclosure - Leases - Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases (Details)", "shortName": "Leases - Schedule of Remaining Maturity of Operating Leases Excluding Short-Term Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails", "longName": "9954495 - Disclosure - Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details)", "shortName": "Loans and Convertible Notes Payable - Summary of Loans and Convertible Notes Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "dcth:NotesAndLoansPayableGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "dcth:NotesAndLoansPayableGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofRemainingMaturitiesofCompanysLoanandConvertibleNotePayablesDetails", "longName": "9954496 - Disclosure - Loans and Convertible Notes Payable - Summary of Remaining Maturities of Company's Loan and Convertible Note Payables (Details)", "shortName": "Loans and Convertible Notes Payable - Summary of Remaining Maturities of Company's Loan and Convertible Note Payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LoansPayable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LoansPayable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "longName": "9954497 - Disclosure - Loans and Convertible Notes Payable - Narrative (Details)", "shortName": "Loans and Convertible Notes Payable - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:InterestExpenseBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R49": { "role": "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "longName": "9954498 - Disclosure - Preferred Purchase Agreement (Details)", "shortName": "Preferred Purchase Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-173", "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R50": { "role": "http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails", "longName": "9954499 - Disclosure - Stockholders' Equity - Equity Offerings and Placements (Details)", "shortName": "Stockholders' Equity - Equity Offerings and Placements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-193", "name": "us-gaap:DeferredRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-189", "name": "dcth:AggregateExercisePriceOfPreferredWarrants", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R51": { "role": "http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails", "longName": "9954500 - Disclosure - Stockholders' Equity - At-the-Market Offering (Details)", "shortName": "Stockholders' Equity - At-the-Market Offering (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R52": { "role": "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails", "longName": "9954501 - Disclosure - Stockholders' Equity - Designated Preferred Shares (Details)", "shortName": "Stockholders' Equity - Designated Preferred Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-3", "name": "dcth:PreferredStockSharesDesignated", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "dcth:PreferredStockSharesDesignated", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails", "longName": "9954502 - Disclosure - Stockholders' Equity - Authorized Shares and Preferred Stock (Details)", "shortName": "Stockholders' Equity - Authorized Shares and Preferred Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-17", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R54": { "role": "http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanDetails", "longName": "9954503 - Disclosure - Stockholders' Equity - Equity Incentive Plan (Details)", "shortName": "Stockholders' Equity - Equity Incentive Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-202", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-202", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-4", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.delcath.com/role/StockholdersEquityScheduleofAssumptionstoEstimateFairValueofStockOptionsUsingBlackScholesOptionPricingModelDetails", "longName": "9954504 - Disclosure - Stockholders' Equity - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)", "shortName": "Stockholders' Equity - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails", "longName": "9954505 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)", "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R57": { "role": "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails", "longName": "9954506 - Disclosure - Stockholders' Equity - Summary of Stock Option Shares Outstanding and Exercisable (Details)", "shortName": "Stockholders' Equity - Summary of Stock Option Shares Outstanding and Exercisable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-205", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R58": { "role": "http://www.delcath.com/role/StockholdersEquitySummaryofRecognizedSharebasedCompensationCostDetails", "longName": "9954507 - Disclosure - Stockholders' Equity - Summary of Recognized Share-based Compensation Cost (Details)", "shortName": "Stockholders' Equity - Summary of Recognized Share-based Compensation Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails", "longName": "9954508 - Disclosure - Stockholders' Equity - Summary of Common Stock Warrant Activity (Details)", "shortName": "Stockholders' Equity - Summary of Common Stock Warrant Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-221", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-222", "name": "dcth:ClassOfWarrantOrRightIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R60": { "role": "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails", "longName": "9954509 - Disclosure - Stockholders' Equity - Summary of Common Stock Warrants Outstanding and Exercisable (Details)", "shortName": "Stockholders' Equity - Summary of Common Stock Warrants Outstanding and Exercisable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-223", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-224", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "unique": true } }, "R61": { "role": "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "longName": "9954510 - Disclosure - Stockholders' Equity - Preferred Stock Warrants (Details)", "shortName": "Stockholders' Equity - Preferred Stock Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-236", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-236", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.delcath.com/role/StockholdersEquitySummaryofEmployeeStockPurchasePlanDetails", "longName": "9954511 - Disclosure - Stockholders' Equity - Summary of Employee Stock Purchase Plan (Details)", "shortName": "Stockholders' Equity - Summary of Employee Stock Purchase Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "dcth:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dcth:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.delcath.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "longName": "9954512 - Disclosure - Net Loss per Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "Net Loss per Share - Anti-Dilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.delcath.com/role/NetLossperShareNarrativeDetails", "longName": "9954513 - Disclosure - Net Loss per Share - Narrative (Details)", "shortName": "Net Loss per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "dcth:NumberOfSharesPreFundedPennyWarrantsOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dcth:NumberOfSharesPreFundedPennyWarrantsOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.delcath.com/role/NetLossperShareSummaryofReconciliationofWeightedAverageSharesOutstandingCalculationDetails", "longName": "9954514 - Disclosure - Net Loss per Share - Summary of Reconciliation of Weighted Average Shares Outstanding Calculation (Details)", "shortName": "Net Loss per Share - Summary of Reconciliation of Weighted Average Shares Outstanding Calculation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.delcath.com/role/IncomeTaxesDetails", "longName": "9954515 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-1", "name": "dcth:CorporateAlternativeMinimumTax", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dcth:CorporateAlternativeMinimumTax", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails", "longName": "9954516 - Disclosure - Commitments and contingencies - Additional Information (Details)", "shortName": "Commitments and contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-252", "name": "dcth:MilestonePaymentUnpaid", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-252", "name": "dcth:MilestonePaymentUnpaid", "unitRef": "eur", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.delcath.com/role/FairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails", "longName": "9954517 - Disclosure - Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details)", "shortName": "Fair Value Measurements - Fair Value Measurements Using Significant Unobservable Inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.delcath.com/role/FairValueMeasurementsNarrativeDetails", "longName": "9954518 - Disclosure - Fair Value Measurements - Narrative (Details)", "shortName": "Fair Value Measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:FairValueAdjustmentOfWarrants", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true }, "uniqueAnchor": null }, "R70": { "role": "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails", "longName": "9954519 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Outstanding Warrants (Details)", "shortName": "Fair Value Measurements - Schedule of Fair Value of Outstanding Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-266", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-266", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "longName": "9954520 - Disclosure - Fair Value Measurements - Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value (Details)", "shortName": "Fair Value Measurements - Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-3", "name": "dcth:ContingentLiabilityFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "dcth:ContingentLiabilityFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "dcth-20230930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r4", "r17" ] }, "dcth_ClassOfWarrantOrRightWeightedAverageExercisePriceIssued": { "xbrltype": "perShareItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceIssued", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued (in dollars per share)", "label": "Class Of Warrant Or Right Weighted Average Exercise Price Issued", "documentation": "Weighted average exercise price for the number of warrants or rights issued for the unvested, forfeitable warrants or rights in period." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (years)", "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r703" ] }, "us-gaap_ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAssumptionsForFairValueAsOfBalanceSheetDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Warrants", "label": "Schedule of Assumptions for Fair Value as of Balance Sheet Date of Assets or Liabilities that relate to Transferor's Continuing Involvement [Table Text Block]", "documentation": "Tabular disclosure of all information related to the key inputs and assumptions (including, at a minimum, but not limited to, and if applicable, quantitative information about discount rates, expected prepayments including the expected weighted-average life of prepayable financial assets, and anticipated credit losses) used in measuring the fair value of assets or liabilities that relate to the transferor's continuing involvement with transferred financial assets, as of the balance sheet date." } } }, "auth_ref": [ "r719" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration", "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Useful Life", "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]", "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value." } } }, "auth_ref": [ "r663" ] }, "dcth_NumberOfExercisablePreferredWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "NumberOfExercisablePreferredWarrants", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of exercisable preferred warrants (in shares)", "label": "Number Of Exercisable Preferred Warrants", "documentation": "Number of exercisable preferred warrants." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividends", "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r703" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r618" ] }, "us-gaap_LoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayable", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofRemainingMaturitiesofCompanysLoanandConvertibleNotePayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans", "label": "Loans Payable", "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": [ "r20", "r127", "r725" ] }, "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOwnershipPlanESOPDisclosuresLineItems", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]", "label": "Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]", "label": "Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]", "documentation": "Describes the details pertaining to each employee stock ownership plan." } } }, "auth_ref": [ "r64" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r209", "r210", "r211", "r214", "r215", "r219", "r220", "r222", "r294", "r295", "r406" ] }, "us-gaap_LoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableCurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan payable, current", "totalLabel": "Less Current Portion, Net", "label": "Loans Payable, Current", "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r27" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Expected volatility", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r703" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "presentation": [ "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet for September 30, 2022 (unaudited)", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r14" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate", "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r703" ] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r14" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofRecognizedSharebasedCompensationCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_LoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableMember", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loans Payable", "label": "Loans Payable [Member]", "documentation": "Borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "dcth_ImpactOfCorrectionOfShareBasedCompensationOnNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ImpactOfCorrectionOfShareBasedCompensationOnNetIncomeLoss", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of share-based compensation correction on net income (loss)", "label": "Impact of Correction of Share Based Compensation on Net Income Loss", "documentation": "Impact of correction of share based compensation on net income loss." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Professional fees", "label": "Prepaid Expense and Other Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofRecognizedSharebasedCompensationCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r333", "r338" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r641" ] }, "us-gaap_ValuationTechniqueOptionPricingModelMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueOptionPricingModelMember", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Technique, Option Pricing Model", "label": "Valuation Technique, Option Pricing Model [Member]", "documentation": "Valuation technique calculating price of option." } } }, "auth_ref": [ "r703" ] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.delcath.com/role/Inventory" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r230" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofRecognizedSharebasedCompensationCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r617" ] }, "us-gaap_InterestExpenseBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseBorrowings", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense incurred (less than)", "label": "Interest Expense, Borrowings", "documentation": "Aggregate amount of interest expense on all borrowings." } } }, "auth_ref": [ "r130" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofRecognizedSharebasedCompensationCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense related to non-vested share-based compensation awards", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r334" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, interest rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r109", "r142", "r431" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r15" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r8", "r421", "r431", "r600" ] }, "dcth_DecemberThirtyFirstTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "DecemberThirtyFirstTwoThousandTwentyThreeMember", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofRemainingMaturitiesofCompanysLoanandConvertibleNotePayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year ended December 31, 2023", "label": "December Thirty First Two Thousand Twenty Three [Member]", "documentation": "December thirty first two thousand twenty three." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Loans and Convertible Notes Payable", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r30", "r54", "r57", "r75", "r76", "r77", "r79", "r115", "r117", "r587", "r589", "r653" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r3" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants measurement input", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r370" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price Range", "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": [ "r61" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price Range", "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation arrangement by share-based payment award number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r598" ] }, "dcth_ConditionForTheExtensionOfPeriodOfInterestOnlyPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ConditionForTheExtensionOfPeriodOfInterestOnlyPaymentsMember", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Condition for the Extension of Period of Interest Only Payments", "label": "Condition For The Extension Of Period OF Interest Only Payments [Member]", "documentation": "Condition for the extension of period of interest only payments." } } }, "auth_ref": [] }, "dcth_StockholdersEquityNoteTable": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "StockholdersEquityNoteTable", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails", "http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails", "http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders Equity Note [Table]", "label": "Stockholders Equity Note [Table]", "documentation": "Stockholders equity note." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 3.0 }, "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.delcath.com/role/FairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails", "http://www.delcath.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in fair value of warrant liability", "verboseLabel": "Warrant liability fair value adjustment", "terseLabel": "Other expense related to the change in fair value of the warrant liability", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r7" ] }, "dcth_SecurityForCreditCardsRestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "SecurityForCreditCardsRestrictedCash", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashScheduleofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security for credit cards", "label": "Security For Credit Cards Restricted Cash", "documentation": "Security for credit cards restricted cash." } } }, "auth_ref": [] }, "dcth_PreferredPurchaseAgreementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "PreferredPurchaseAgreementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Preferred Purchase Agreement [Abstract]", "label": "Preferred Purchase Agreement [Abstract]", "documentation": "Preferred Purchase Agreement [Abstract]." } } }, "auth_ref": [] }, "dcth_DebtInstrumentIncrementalFinalPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "DebtInstrumentIncrementalFinalPaymentPercentage", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, incremental final payment, percentage", "label": "Debt Instrument Incremental Final Payment Percentage", "documentation": "Debt instrument, incremental final payment, percentage." } } }, "auth_ref": [] }, "dcth_ThirdPartySettlementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ThirdPartySettlementMember", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Third Party Settlement", "label": "Third Party Settlement [Member]", "documentation": "Third party settlement." } } }, "auth_ref": [] }, "dcth_CapitalCommitementsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "CapitalCommitementsDomain", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Commitments [Domain]", "label": "Capital Commitements [Domain]", "documentation": "Capital commitements." } } }, "auth_ref": [] }, "dcth_ContingentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ContingentLiabilitiesMember", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent liabilities", "label": "Contingent Liabilities [Member]", "documentation": "Contingent liabilities." } } }, "auth_ref": [] }, "dcth_CashCashEquivalentsAndRestrictedCashConsistedOfTheFollowingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "CashCashEquivalentsAndRestrictedCashConsistedOfTheFollowingAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents and Restricted Cash consisted of the following:", "label": "Cash, Cash Equivalents and Restricted Cash consisted of the following [Abstract]", "documentation": "Cash, cash equivalents and restricted cash consisted of the following," } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails", "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r58" ] }, "dcth_AssumedConversionOfPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "AssumedConversionOfPreferredStockMember", "presentation": [ "http://www.delcath.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assumed conversion of preferred stock", "label": "Assumed Conversion Of Preferred Stock [Member]", "documentation": "Assumed conversion of preferred stock." } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents, Current", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r39", "r141", "r167" ] }, "dcth_CashCashEquivalentsAndRestrictedCashTable": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "CashCashEquivalentsAndRestrictedCashTable", "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents and Restricted Cash [Table]", "label": "Cash, Cash Equivalents and Restricted Cash [Table]", "documentation": "Cash, cash equivalents and restricted cash." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r317" ] }, "dcth_ClassOfWarrantOrRightIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ClassOfWarrantOrRightIssued", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued (in shares)", "label": "Class Of Warrant Or Right Issued", "documentation": "The number of each class of warrants or rights issued during the period." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash, Cash Equivalents, and Restricted Cash", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r19", "r124", "r726" ] }, "dcth_RangeOfExercisePricesPointZeroOneRangeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "RangeOfExercisePricesPointZeroOneRangeMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$0.01", "label": "Range Of Exercise Prices Point Zero One Range [Member]", "documentation": "Range of exercise prices Point zero one range." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cancelled/Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r316" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.delcath.com/role/AccruedExpenses" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r24" ] }, "dcth_AsRevisedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "AsRevisedMember", "presentation": [ "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "As revised", "label": "As Revised [Member]", "documentation": "As revised." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted, Weighted Average Exercise Price Per Share (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r314" ] }, "dcth_LettersOfCreditRestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "LettersOfCreditRestrictedCash", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashScheduleofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit", "label": "Letters Of Credit Restricted Cash", "documentation": "Letters of credit restricted cash." } } }, "auth_ref": [] }, "dcth_EightPointZeroPercentageJulyTwoThousandAndNineteenNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "EightPointZeroPercentageJulyTwoThousandAndNineteenNotesMember", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rosalind Notes", "label": "Eight Point Zero Percentage July Two Thousand And Nineteen Notes [Member]", "documentation": "Eight point zero percentage july two thousand and nineteen notes." } } }, "auth_ref": [] }, "dcth_OtherLeaseInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "OtherLeaseInformationAbstract", "presentation": [ "http://www.delcath.com/role/LeasesSummaryofLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other information", "label": "Other Lease Information [Abstract]", "documentation": "Other lease information." } } }, "auth_ref": [] }, "dcth_CommonStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "CommonStockWarrantsMember", "presentation": [ "http://www.delcath.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock warrants", "label": "Common stock warrants [Member]", "documentation": "Common stock warrants." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised, Weighted Average Exercise Price Per Share (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r315" ] }, "dcth_LoanAgreementRestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "LoanAgreementRestrictedCash", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashScheduleofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashScheduleofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted balance for loan agreement", "label": "Loan Agreement Restricted Cash", "documentation": "Loan Agreement Restricted Cash ." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23", "r600" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r59" ] }, "dcth_SeriesE1PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "SeriesE1PreferredStockMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails", "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series E-1", "label": "Series E1 Preferred Stock [Member]", "documentation": "Series e1 preferred stock member" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning of period (in shares)", "periodEndLabel": "Outstanding, end of period (in shares)", "terseLabel": "Outstanding Number of Options (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r310", "r311" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expired, Weighted Average Exercise Price Per Share (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r317" ] }, "dcth_ClassOfWarrantOrRightExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ClassOfWarrantOrRightExercised", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Warrants exercised (in shares)", "terseLabel": "Warrants exercised (in shares)", "label": "Class Of Warrant Or Right Exercised", "documentation": "Class Of Warrant Or Right Exercised." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, Weighted Average Exercise Price Per Share, beginning of period (in dollars per share)", "periodEndLabel": "Outstanding, Weighted Average Exercise Price Per Share, end of period (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r310", "r311" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price Per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancelled-Forfeited, Weighted Average Exercise Price Per Share (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r316" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r500", "r561", "r606", "r727" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in shares)", "verboseLabel": "Number of Options Exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r312" ] }, "dcth_CapitalCommitementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "CapitalCommitementsAxis", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Commitments [Axis]", "label": "Capital Commitements [Axis]", "documentation": "Capital commitements." } } }, "auth_ref": [] }, "dcth_DetailsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "DetailsDomain", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Details [Domain]", "label": "Details [Domain]", "documentation": "Details." } } }, "auth_ref": [] }, "dcth_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Exercisable, (in dollars per share)", "terseLabel": "Warrants Exercisable, Weighted Average Exercise Price", "label": "Class Of Warrant Or Right Exercisable Weighted Average Exercise Price", "documentation": "Class of warrant or right exercisable weighted average exercise price." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price, Exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r312" ] }, "dcth_ExercisePriceRangeAboveFiftyOnePointFiveZeroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ExercisePriceRangeAboveFiftyOnePointFiveZeroMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "$51.50+", "label": "Exercise Price Range Above Fifty One Point Five Zero [Member]", "documentation": "Exercise Price Range Above Fifty One Point Five Zero." } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r223", "r224" ] }, "dcth_NotesAndLoansPayableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "NotesAndLoansPayableGrossCurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails": { "parentTag": "us-gaap_LoansPayableCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less Current Portion, Gross", "label": "Notes And Loans Payable Gross Current", "documentation": "Notes and loans payable gross current." } } }, "auth_ref": [] }, "dcth_StockOptionCompensationIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "StockOptionCompensationIncomeExpense", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option compensation expense", "label": "Stock Option Compensation Income Expense", "documentation": "Stock option compensation (income) expense." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.delcath.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r366" ] }, "dcth_IssuanceOfCommonStockInPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "IssuanceOfCommonStockInPrivatePlacement", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Private placement -issuance of common shares, net of expenses", "label": "Issuance Of Common Stock In Private Placement", "documentation": "Issuance of common stock in private placement." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range of Exercise Prices (in dollars per share)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } }, "auth_ref": [ "r60" ] }, "dcth_NumberOfCommonSharesRemainedAvailableToBeIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "NumberOfCommonSharesRemainedAvailableToBeIssued", "presentation": [ "http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of common shares remained available to be issued (in shares)", "label": "Number Of Common Shares Remained Available To Be Issued", "documentation": "Number of common shares remained available to be issued." } } }, "auth_ref": [] }, "dcth_RangeOfExercisePricesSixPointZeroRangeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "RangeOfExercisePricesSixPointZeroRangeMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$6.00", "label": "Range Of Exercise Prices six Point Zero Range [Member]", "documentation": "Range Of Exercise Prices six Point Zero Range" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.delcath.com/role/StockholdersEquityScheduleofAssumptionstoEstimateFairValueofStockOptionsUsingBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividends", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r330" ] }, "dcth_CorporateAlternativeMinimumTax": { "xbrltype": "percentItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "CorporateAlternativeMinimumTax", "presentation": [ "http://www.delcath.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate alternative minimum tax (as a percent)", "label": "Corporate Alternative Minimum Tax", "documentation": "Corporate alternative minimum tax." } } }, "auth_ref": [] }, "dcth_DetailsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "DetailsAxis", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Details [Axis]", "label": "Details [Axis]", "documentation": "Details." } } }, "auth_ref": [] }, "dcth_StockholdersEquityNoteLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "StockholdersEquityNoteLineItems", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails", "http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails", "http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders Equity Note [Line Items]", "label": "Stockholders Equity Note [Line Items]", "documentation": "Stockholders equity note." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted loss per common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r162", "r181", "r182", "r184", "r185", "r187", "r195", "r198", "r199", "r200", "r204", "r364", "r365", "r420", "r434", "r581" ] }, "dcth_ClassOfWarrantOrRightExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ClassOfWarrantOrRightExercisable", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Exercisable, end of period (in shares)", "terseLabel": "Warrants Exercisable, Number of Warrants (in shares)", "label": "Class Of Warrant Or Right Exercisable", "documentation": "Class of warrant or right exercisable." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.delcath.com/role/StockholdersEquityScheduleofAssumptionstoEstimateFairValueofStockOptionsUsingBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r329" ] }, "dcth_SeriesF2PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "SeriesF2PreferredStockMember", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails", "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred F-2 Stock", "terseLabel": "Series F-2", "label": "Series F2 Preferred Stock [Member]", "documentation": "Series F2 Preferred Stock." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails", "http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants exercisable, period", "terseLabel": "Expected term", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r704" ] }, "dcth_WeightedAverageNumberOfSharesPreFundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "WeightedAverageNumberOfSharesPreFundedWarrants", "calculation": { "http://www.delcath.com/role/NetLossperShareSummaryofReconciliationofWeightedAverageSharesOutstandingCalculationDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/NetLossperShareSummaryofReconciliationofWeightedAverageSharesOutstandingCalculationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average pre-funded warrants (in shares)", "label": "Weighted Average Number Of Shares Pre Funded Warrants", "documentation": "Weighted average number of shares pre funded warrants 1." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r219", "r406", "r435", "r436", "r437", "r438", "r439", "r440", "r573", "r592", "r601", "r627", "r667", "r668", "r673", "r728" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r59" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.delcath.com/role/StockholdersEquityScheduleofAssumptionstoEstimateFairValueofStockOptionsUsingBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r331" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Level 3 Investments", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r15", "r74" ] }, "dcth_MedacMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "MedacMember", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medac", "label": "Medac [Member]", "documentation": "Medac." } } }, "auth_ref": [] }, "dcth_DisclosureOfPreferredPurchaseAgreementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "DisclosureOfPreferredPurchaseAgreementTextBlock", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreement" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Purchase Agreement", "label": "Disclosure Of Preferred Purchase Agreement [Text Block]", "documentation": "Disclosure Of Preferred Purchase Agreement [Text Block]." } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r262", "r297", "r302", "r368", "r401", "r587", "r588", "r594", "r595", "r596" ] }, "dcth_MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "MayTwoThousandAndTwentyTwoEmployeeStockPurchasePlanMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "May 2022 Employee Stock Purchase Plan", "label": "May Two Thousand And Twenty Two Employee Stock Purchase Plan [Member]", "documentation": "May two thousand and twenty two employee stock purchase plan member." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r350" ] }, "dcth_CapitalCommitmentsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "CapitalCommitmentsCurrent", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current capital commitments", "label": "Capital Commitments Current", "documentation": "Capital commitments current." } } }, "auth_ref": [] }, "dcth_LachmanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "LachmanMember", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lachman", "label": "Lachman [Member]", "documentation": "Lachman member." } } }, "auth_ref": [] }, "dcth_NotesAndLoansPayableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "NotesAndLoansPayableGross", "crdr": "credit", "calculation": { "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails": { "parentTag": "dcth_NotesAndLoansPayableNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross", "label": "Notes And Loans Payable Gross", "documentation": "Notes and loans payable gross." } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance premiums", "label": "Prepaid Insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r577", "r585", "r662" ] }, "dcth_PercentageOfExciseTaxOnRepurchasesOfStock": { "xbrltype": "percentItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "PercentageOfExciseTaxOnRepurchasesOfStock", "presentation": [ "http://www.delcath.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of excise tax on repurchases of stock", "label": "Percentage Of Excise Tax On Repurchases Of Stock", "documentation": "Percentage of excise tax on repurchases of stock." } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r262", "r297", "r302", "r368", "r400", "r594", "r595", "r596" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dcth_RangeOfExercisePricesFourPointFiveZeroRangeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "RangeOfExercisePricesFourPointFiveZeroRangeMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$4.50", "label": "Range Of Exercise Prices Four Point Five Zero Range [Member]", "documentation": "Range Of Exercise Prices Four Point Five Zero Range" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r219", "r406", "r435", "r436", "r437", "r438", "r439", "r440", "r573", "r592", "r601", "r627", "r667", "r668", "r673", "r728" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r619" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332" ] }, "dcth_DiscountOnNotesAndLoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "DiscountOnNotesAndLoansPayable", "crdr": "debit", "calculation": { "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails": { "parentTag": "dcth_NotesAndLoansPayableNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Discount", "label": "Discount On Notes And Loans Payable", "documentation": "Discount on notes and loans payable." } } }, "auth_ref": [] }, "dcth_ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted Average Remaining Life (in years), Outstanding", "terseLabel": "Warrants Exercisable, Weighted Average Remaining Warrant Term (in years)", "label": "Class Of Warrant Or Right Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for each class of warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from the issuance of common stock relating to the employee stock purchase plan", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r4" ] }, "us-gaap_DebtInstrumentRepaidPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRepaidPrincipal", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal payments", "label": "Debt Instrument, Repaid, Principal", "documentation": "Amount of principal of debt repaid." } } }, "auth_ref": [ "r457" ] }, "dcth_PreferredWarrantLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "PreferredWarrantLiabilitiesMember", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Warrant Liabilities", "label": "Preferred Warrant Liabilities [Member]", "documentation": "Preferred warrant liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total change in foreign exchange", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r15" ] }, "dcth_AgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "AgreementAxis", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement [Axis]", "label": "Agreement [Axis]", "documentation": "Agreement." } } }, "auth_ref": [] }, "dcth_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease Liabilities", "label": "Lease Liabilities [Member]", "documentation": "Lease liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r262", "r297", "r298", "r299", "r300", "r301", "r302", "r368", "r402", "r587", "r588", "r594", "r595", "r596" ] }, "dcth_StatementOfOperationsAndComprehensiveLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "StatementOfOperationsAndComprehensiveLossAbstract", "presentation": [ "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)", "label": "Statement of Operations and Comprehensive Loss [Abstract]", "documentation": "Statement of operations and comprehensive loss." } } }, "auth_ref": [] }, "dcth_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Life, Exercisable", "label": "Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Term", "documentation": "Class of warrant or right exercisable weighted average remaining contractual term." } } }, "auth_ref": [] }, "dcth_DecemberThirtyFirstTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "DecemberThirtyFirstTwoThousandTwentyFourMember", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofRemainingMaturitiesofCompanysLoanandConvertibleNotePayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year ended December 31, 2024", "label": "December Thirty First Two Thousand Twenty Four [Member]", "documentation": "December thirty first two thousand twenty four." } } }, "auth_ref": [] }, "dcth_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTable", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Table]", "label": "Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Table]", "documentation": "Organization consolidation basis of presentation business description and accounting policies table." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.delcath.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Warrant Activity", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r58" ] }, "dcth_ConversionOfTemporaryEquityToCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ConversionOfTemporaryEquityToCommonShares", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of mezzanine equity to common shares", "label": "Conversion Of Temporary Equity To Common Shares", "documentation": "Conversion Of Temporary Equity To Common Shares" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r350" ] }, "dcth_AssumedConversationOfPreferredStockWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "AssumedConversationOfPreferredStockWarrantsMember", "presentation": [ "http://www.delcath.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assumed conversion of preferred stock warrants", "label": "Assumed Conversation Of Preferred Stock Warrants [Member]", "documentation": "Assumed conversation of preferred stock warrants." } } }, "auth_ref": [] }, "dcth_MilestonePaymentUnpaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "MilestonePaymentUnpaid", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment unpaid", "label": "Milestone Payment Unpaid", "documentation": "Milestone payment unpaid." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r58" ] }, "dcth_ConvertibeNotePrincipalPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ConvertibeNotePrincipalPaymentsMember", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Note Principal Payments", "label": "Convertibe Note Principal Payments [Member]", "documentation": "Convertibe note principal payments." } } }, "auth_ref": [] }, "dcth_PreferredPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "PreferredPurchaseAgreementMember", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Purchase Agreement", "label": "Preferred Purchase Agreement [Member]", "documentation": "Preferred Purchase Agreement [Member]." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails", "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "dcth_CapitalCommitmentsNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "CapitalCommitmentsNonCurrent", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent capital commitments", "label": "Capital Commitments Non Current", "documentation": "Capital commitments non current." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term (in years), Outstanding", "verboseLabel": "Weighted Average Remaining Option Term (in years), Options Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r119" ] }, "dcth_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacementShares", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Private placement - issuance of common stock and prefunded warrants, net of expense (in shares)", "label": "Issuance Of Common Stock And Pre Funded Warrants In Private Placement Shares", "documentation": "Issuance Of Common Stock And Pre Funded Warrants In Private Placement Shares" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r163", "r165", "r166" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAxis", "presentation": [ "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Axis]", "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": [ "r137", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r186", "r187", "r188", "r189", "r190", "r191", "r204", "r227", "r228", "r345", "r362", "r363", "r364", "r365", "r384", "r395", "r396", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r59" ] }, "dcth_TermLoanFromAvenueVentureOpportunitiesFundLpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "TermLoanFromAvenueVentureOpportunitiesFundLpMember", "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashNarrativeDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Avenue Loan", "label": "Term Loan From Avenue Venture Opportunities Fund LP [Member]", "documentation": "Term Loan From Avenue Venture Opportunities Fund LP [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r603", "r604", "r605", "r607", "r608", "r609", "r610", "r654", "r655", "r701", "r729", "r732" ] }, "dcth_AccountsPayableAccruedExpensesAndLeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "AccountsPayableAccruedExpensesAndLeaseLiabilitiesMember", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable Accrued Expenses And Lease Liabilities", "label": "Accounts Payable Accrued Expenses And Lease Liabilities [Member]", "documentation": "Accounts payable accrued expenses and lease liabilities." } } }, "auth_ref": [] }, "dcth_PrepaidClinicalTrialExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "PrepaidClinicalTrialExpensesCurrent", "crdr": "debit", "calculation": { "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical trial expenses", "label": "Prepaid Clinical Trial Expenses Current", "documentation": "Prepaid clinical trial expenses current." } } }, "auth_ref": [] }, "dcth_CantorFitzgeraldAndCoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "CantorFitzgeraldAndCoMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cantor Fitzgerald & Co", "label": "Cantor Fitzgerald And Co [Member]", "documentation": "Cantor fitzgerald and co [Member]." } } }, "auth_ref": [] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementDomain", "presentation": [ "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Prior Period [Domain]", "label": "Revision of Prior Period [Domain]" } } }, "auth_ref": [ "r137", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r186", "r187", "r188", "r189", "r190", "r191", "r204", "r227", "r228", "r345", "r362", "r363", "r364", "r365", "r384", "r395", "r396", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock issued during the period", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r12", "r83", "r84", "r118", "r460", "r532", "r555", "r612" ] }, "dcth_RangeOfExercisePricesTenPointZeroRangeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "RangeOfExercisePricesTenPointZeroRangeMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$10.00", "label": "Range Of Exercise Prices Ten Point Zero Range [Member]", "documentation": "Range of exercise prices Ten point zero range." } } }, "auth_ref": [] }, "dcth_AgentDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "AgentDomain", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agent [Domain]", "label": "Agent [Domain]", "documentation": "Agent." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock with the employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r12", "r83", "r84", "r118" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.delcath.com/role/StockholdersEquityScheduleofAssumptionstoEstimateFairValueofStockOptionsUsingBlackScholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected terms (years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r328" ] }, "dcth_ConversionOfTemporaryEquityToPreferredShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ConversionOfTemporaryEquityToPreferredShares", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of mezzanine equity to preferred shares", "label": "Conversion Of Temporary Equity To Preferred Shares", "documentation": "Conversion Of Temporary Equity To Preferred Shares" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r367", "r368", "r373" ] }, "dcth_PreferredStockSharesDesignated": { "xbrltype": "sharesItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "PreferredStockSharesDesignated", "presentation": [ "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares designated (in shares)", "label": "Preferred Stock, Shares, Designated", "documentation": "Preferred Stock, Shares, Designated" } } }, "auth_ref": [] }, "dcth_SeriesF3PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "SeriesF3PreferredStockMember", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails", "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred F-3 Stock", "terseLabel": "Series F-3", "label": "Series F3 Preferred Stock [Member]", "documentation": "Series F3 Preferred Stock." } } }, "auth_ref": [] }, "dcth_PreferredWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "PreferredWarrantsMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Warrants", "label": "Preferred Warrants [Member]", "documentation": "Preferred Warrants" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.delcath.com/role/GeneralPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from private placement", "label": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r4" ] }, "dcth_AssumedConversionOfConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "AssumedConversionOfConvertibleNotesMember", "presentation": [ "http://www.delcath.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assumed conversion of convertible notes", "label": "Assumed Conversion Of Convertible Notes [Member]", "documentation": "Assumed conversion of convertible notes." } } }, "auth_ref": [] }, "dcth_ClassOfWarrantOrRightWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ClassOfWarrantOrRightWeightedAverageExercisePrice", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning of period (in dollars per share)", "periodEndLabel": "Outstanding, ending of period (in dollars per share)", "terseLabel": "Class Of Warrant Or Right Weighted Average Exercise Price", "label": "Class Of Warrant Or Right Weighted Average Exercise Price", "documentation": "Weighted average exercise price for warrants or rights outstanding." } } }, "auth_ref": [] }, "dcth_UnpaidConsultingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "UnpaidConsultingFees", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unpaid consulting fees", "label": "Unpaid Consulting Fees", "documentation": "Unpaid consulting fees." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r14" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock related to stock option exercises", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r12", "r35", "r118" ] }, "dcth_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term (in years), Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Remaining Contractual Term", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_LongTermLoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermLoansPayable", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 }, "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan payable, non-current", "totalLabel": "Total - Loans Payable, Non-Current, Net", "label": "Loans Payable, Noncurrent", "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of warrants", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r4" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets Carried at Fair Value", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r14" ] }, "dcth_ClassOfWarrantOrRightOutstandingAdditionalInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ClassOfWarrantOrRightOutstandingAdditionalInformationAbstract", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Life (in years)", "label": "Class of Warrant or Right Outstanding, Additional Information [Abstract]", "documentation": "Class of Warrant or Right Outstanding, Additional Information" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r262", "r297", "r298", "r299", "r300", "r301", "r302", "r400", "r401", "r402", "r587", "r588", "r594", "r595", "r596" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dcth_EstimatedMinimumProceedsOnIssueOfCommonStockForExtensionOfDueDateOfInterestOnlyInterestPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "EstimatedMinimumProceedsOnIssueOfCommonStockForExtensionOfDueDateOfInterestOnlyInterestPayments", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated minimum proceeds on issue of common stock for extension of due date of interest only interest payments", "label": "Estimated Minimum Proceeds On Issue Of Common Stock For Extension Of Due Date Of Interest Only Interest Payments", "documentation": "Estimated minimum proceeds on issue of common stock for extension of due date of interest only interest payments." } } }, "auth_ref": [] }, "dcth_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "CommonWarrantsMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Warrants", "label": "Common Warrants [Member]", "documentation": "Common Warrants" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r614" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Noncurrent Liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r615" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r74", "r123" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r262", "r297", "r298", "r299", "r300", "r301", "r302", "r368", "r400", "r401", "r402", "r587", "r588", "r594", "r595", "r596" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.delcath.com/role/LeasesSummaryofLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate - operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r393", "r599" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r151", "r152", "r374", "r473", "r474", "r475", "r476", "r478", "r479", "r480", "r481", "r482", "r506", "r508", "r509", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r580", "r730" ] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.delcath.com/role/LeasesNarrativeDetails", "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails", "http://www.delcath.com/role/LeasesSummaryofLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Lease Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r389" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r615" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.delcath.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Recognized Share-based Compensation Cost", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r63" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic loss per common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r162", "r181", "r182", "r184", "r185", "r187", "r193", "r195", "r198", "r199", "r200", "r204", "r364", "r365", "r420", "r434", "r581" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r615" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Remaining Maturities of Company's Loan and Convertible Note Payables", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r9" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r616" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r394" ] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "presentation": [ "http://www.delcath.com/role/GeneralTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Error Corrections and Prior Period Adjustments", "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]", "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made." } } }, "auth_ref": [ "r40", "r41", "r42" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning of period (in shares)", "periodEndLabel": "Outstanding, end of period (in shares)", "terseLabel": "Outstanding Number of Warrants (in shares)", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r8" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r303", "r397", "r398", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r484", "r485", "r486", "r487", "r488", "r510", "r512", "r537", "r713" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r615" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year ended December 31, 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r394" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.delcath.com/role/LeasesNarrativeDetails", "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails", "http://www.delcath.com/role/LeasesSummaryofLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Lease Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r389" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r164" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity (deficit)", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property Plant And Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year ended December 31, 2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r394" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r164" ] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants outstanding (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r292" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.delcath.com/role/AccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/AccruedExpensesDetails", "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year ended December 31, 2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r394" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Year ended December 31, 2023", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r710" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "terseLabel": "Net Cash Provided by (Used in) Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r101", "r102", "r103" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.delcath.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Remaining maturity of Operating Leases Excluding Short-Term Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r710" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.delcath.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r114", "r169", "r275", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r287", "r288", "r290", "r293", "r361", "r535", "r536", "r559" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r707" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r125", "r144", "r170", "r208", "r213", "r217", "r225", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r351", "r353", "r375", "r422", "r505", "r600", "r613", "r669", "r670", "r714" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.01 par value; 10,000,000 shares authorized; 37,787 and 11,357 shares issued and outstanding at September\u00a030, 2023 and December\u00a031, 2022, respectively", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r83", "r425", "r600" ] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.delcath.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt discount", "label": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r7", "r75", "r98", "r270" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, capital shares reserved (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.delcath.com/role/AccruedExpensesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Estimated Useful Life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": [ "http://www.delcath.com/role/NetLossperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Reconciliation of Weighted Average Shares Outstanding Calculation", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": [ "r45" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.delcath.com/role/InventoryTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r22", "r90", "r91", "r92" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity (deficit)", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r84", "r87", "r88", "r107", "r493", "r511", "r533", "r534", "r600", "r613", "r652", "r659", "r705", "r732" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r172", "r173", "r252", "r278", "r399", "r579", "r580" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt discount", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r270", "r382", "r589", "r590", "r648" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of warrants", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r645" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.delcath.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.delcath.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r637" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r23" ] }, "dcth_AgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "AgreementDomain", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement [Domain]", "label": "Agreement [Domain]", "documentation": "Agreement." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.delcath.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation expense for issuance of stock options", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.delcath.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r708" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r139", "r150", "r170", "r225", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r351", "r353", "r375", "r600", "r669", "r670", "r714" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation expense for issuance of employee stock purchase plan", "label": "APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition", "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement." } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.delcath.com/role/LeasesNarrativeDetails", "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails", "http://www.delcath.com/role/LeasesSummaryofLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S.", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionTable", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofRemainingMaturitiesofCompanysLoanandConvertibleNotePayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument Redemption [Table]", "label": "Debt Instrument Redemption [Table]", "documentation": "Disclosure of information about debt instruments or arrangements with redemption features. Includes, but is not limited to, description of debt redemption features, percentage price at which debt can be redeemed by the issuer, and period start and end for debt maturity or redemption." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Total comprehensive income", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r5", "r10", "r122", "r154", "r157" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.delcath.com/role/LeasesSummaryofLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r392", "r599" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance (in shares)", "periodEndLabel": "Ending Balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquipmentMember", "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r25" ] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaidInKindInterest", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense accrued related to convertible notes", "label": "Paid-in-Kind Interest", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r7" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r234", "r235", "r236", "r237", "r296", "r304", "r329", "r330", "r331", "r403", "r404", "r441", "r481", "r482", "r538", "r540", "r542", "r543", "r552", "r571", "r572", "r584", "r591", "r597", "r602", "r605", "r664", "r671", "r717", "r718", "r720", "r721", "r722" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r30", "r49" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r208", "r212", "r216", "r218", "r583" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r234", "r235", "r236", "r237", "r304", "r404", "r441", "r481", "r482", "r538", "r540", "r542", "r543", "r552", "r571", "r572", "r584", "r591", "r597", "r602", "r671", "r716", "r717", "r718", "r720", "r721", "r722" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock", "presentation": [ "http://www.delcath.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Option Shares Outstanding and Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r16" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r234", "r235", "r236", "r237", "r296", "r304", "r329", "r330", "r331", "r403", "r404", "r441", "r481", "r482", "r538", "r540", "r542", "r543", "r552", "r571", "r572", "r584", "r591", "r597", "r602", "r605", "r664", "r671", "r717", "r718", "r720", "r721", "r722" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.delcath.com/role/InventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.delcath.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "totalLabel": "Total inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r149", "r576", "r600" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r234", "r235", "r236", "r237", "r304", "r404", "r441", "r481", "r482", "r538", "r540", "r542", "r543", "r552", "r571", "r572", "r584", "r591", "r597", "r602", "r671", "r716", "r717", "r718", "r720", "r721", "r722" ] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredRevenue", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Deferred Revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r634" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.delcath.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r639" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r172", "r173", "r252", "r278", "r399", "r578", "r580" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.delcath.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Summary of Avenue Warrant Valued Using the Black-Scholes Option Pricing Method", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r120" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Cost of goods sold", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r96", "r170", "r225", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r375", "r669" ] }, "us-gaap_ConvertibleNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableMember", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes Payable", "label": "Convertible Notes Payable [Member]", "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r81", "r126" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofRecognizedSharebasedCompensationCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r85", "r600", "r731" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r97" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.delcath.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Lease Costs", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r709" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r30" ] }, "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RestatementAdjustmentMember", "presentation": [ "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment", "label": "Revision of Prior Period, Adjustment [Member]" } } }, "auth_ref": [ "r176", "r177", "r178", "r187", "r188", "r204", "r363", "r364", "r622", "r623", "r624", "r625", "r626", "r630", "r631" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r131", "r424", "r471", "r499", "r600", "r613", "r633" ] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingMember", "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r109" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.delcath.com/role/NetLossperShareSummaryofReconciliationofWeightedAverageSharesOutstandingCalculationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.delcath.com/role/NetLossperShareSummaryofReconciliationofWeightedAverageSharesOutstandingCalculationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of diluted shares outstanding (in shares)", "totalLabel": "Weighted average number of diluted shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r194", "r200" ] }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "presentation": [ "http://www.delcath.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Option Activity", "label": "Schedule of Stock Options Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in stock options." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.delcath.com/role/General" ], "lang": { "en-us": { "role": { "terseLabel": "General", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r104", "r105", "r106", "r121" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.delcath.com/role/GeneralPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant Liabilities", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r13", "r65", "r66", "r67", "r70", "r174" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.delcath.com/role/InventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/InventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r638" ] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrant liabilities", "totalLabel": "Total liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r72" ] }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsDisclosureTextBlock", "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCash" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify." } } }, "auth_ref": [ "r141", "r424" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.delcath.com/role/NetLossperShareSummaryofReconciliationofWeightedAverageSharesOutstandingCalculationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.delcath.com/role/NetLossperShareSummaryofReconciliationofWeightedAverageSharesOutstandingCalculationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of basic shares outstanding (in shares)", "totalLabel": "Weighted average number of basic shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r193", "r200" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r28", "r140", "r170", "r225", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r352", "r353", "r354", "r375", "r600", "r669", "r714", "r715" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant", "verboseLabel": "Warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r603", "r604", "r607", "r608", "r609", "r610" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r112", "r249", "r250", "r260", "r261", "r262", "r266", "r267", "r268", "r269", "r270", "r586", "r587", "r588", "r589", "r590" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r95", "r170", "r208", "r212", "r216", "r218", "r225", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r375", "r583", "r669" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use assets obtained in exchange for lease obligations", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r391", "r599" ] }, "us-gaap_NotesAndLoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansPayable", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofRemainingMaturitiesofCompanysLoanandConvertibleNotePayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Notes and Loans Payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": [ "r20", "r127", "r725" ] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes payable, current", "label": "Convertible Notes Payable, Current", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r27" ] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares sold (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.delcath.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r385" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability", "label": "Derivative Liability, Noncurrent", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r151" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Income (Expense), Nonoperating, Net", "documentation": "The net amount of nonoperating interest income (expense)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r26", "r170", "r225", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r352", "r353", "r354", "r375", "r489", "r582", "r613", "r669", "r714", "r715" ] }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares converted (in shares)", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r21", "r54", "r83", "r116", "r286" ] }, "us-gaap_ConvertibleLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleLongTermNotesPayable", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes payable, non-current", "label": "Convertible Notes Payable, Noncurrent", "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r30" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r314" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r603", "r604", "r607", "r608", "r609", "r610", "r729", "r732" ] }, "country_IE": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "IE", "presentation": [ "http://www.delcath.com/role/LeasesNarrativeDetails", "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails", "http://www.delcath.com/role/LeasesSummaryofLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ireland", "label": "IRELAND" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of debt", "terseLabel": "Principal payment", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r646" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Term (in years) and Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]", "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value." } } }, "auth_ref": [ "r372" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r89", "r128", "r429", "r600", "r652", "r659", "r705" ] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesCPreferredStockMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series C", "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": [ "r635", "r636", "r672" ] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series B", "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r635", "r636", "r672" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders\u2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Disclosure of Non-Cash Investing and Financing Activities:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Abstract]", "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayable" ], "lang": { "en-us": { "role": { "terseLabel": "Loans and Convertible Notes Payable", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r111", "r168", "r248", "r254", "r255", "r256", "r257", "r258", "r259", "r264", "r271", "r272", "r274" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r615" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.delcath.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r46" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "dcth_NotesAndLoansPayableNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "NotesAndLoansPayableNetNoncurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Notes And Loans Payable, Net, Noncurrent", "label": "Notes And Loans Payable, Net, Noncurrent", "documentation": "Notes And Loans Payable, Net, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.delcath.com/role/NetLossperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from the Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r46" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r369" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofRemainingMaturitiesofCompanysLoanandConvertibleNotePayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Domain]", "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": [ "r18" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r615" ] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofRemainingMaturitiesofCompanysLoanandConvertibleNotePayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Redemption, Period [Axis]", "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information about timing of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Property Plant And Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofRemainingMaturitiesofCompanysLoanandConvertibleNotePayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r175", "r249", "r250", "r251", "r252", "r253", "r255", "r260", "r261", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r270", "r273", "r383", "r586", "r587", "r588", "r589", "r590", "r651" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashNarrativeDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r20", "r81", "r82", "r126", "r127", "r175", "r249", "r250", "r251", "r252", "r253", "r255", "r260", "r261", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r270", "r383", "r586", "r587", "r588", "r589", "r590", "r651" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofRecognizedSharebasedCompensationCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r63" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r405", "r647" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r30", "r54", "r57", "r75", "r76", "r77", "r79", "r115", "r117", "r175", "r249", "r250", "r251", "r252", "r253", "r255", "r260", "r261", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r270", "r273", "r383", "r586", "r587", "r588", "r589", "r590", "r651" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.delcath.com/role/PropertyPlantandEquipmentNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "verboseLabel": "Depreciation expense (less than)", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r7", "r47" ] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductAndServiceOtherMember", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other revenue", "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": [ "r674" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.delcath.com/role/NetLossperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r192", "r201", "r202", "r203" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dcth_PreferredTrancheAWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "PreferredTrancheAWarrantMember", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Tranche A Warrant", "label": "Preferred Tranche A Warrant [Member]", "documentation": "Preferred\u00a0tranche a warrant [Member]." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r176", "r177", "r178", "r205", "r406", "r453", "r472", "r483", "r484", "r485", "r486", "r487", "r488", "r491", "r494", "r495", "r496", "r497", "r498", "r501", "r502", "r503", "r504", "r506", "r507", "r508", "r509", "r510", "r512", "r515", "r516", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r532", "r606" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, conversion price (in dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r113", "r251" ] }, "dcth_AccruedExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "AccruedExpensesMember", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses", "label": "Accrued Expenses [Member]", "documentation": "Accrued expenses member." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r68", "r69" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r29", "r250" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r615" ] }, "dcth_AmortizationOfRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "AmortizationOfRightOfUseAssets", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Amortization Of Right Of Use Assets", "documentation": "Amortization of right of use assets." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesMember", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities", "label": "Other Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other liabilities." } } }, "auth_ref": [ "r68", "r71" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r6" ] }, "dcth_DiscountOnNotesAndLoansPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "DiscountOnNotesAndLoansPayableCurrent", "crdr": "debit", "calculation": { "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails": { "parentTag": "dcth_NotesAndLoansPayableNetCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less Current Portion, Discount", "label": "Discount On Notes And Loans Payable Current", "documentation": "Discount on notes and loans payable current." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.delcath.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r46" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r83", "r276" ] }, "us-gaap_CommitmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsDisclosureTextBlock", "presentation": [ "http://www.delcath.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments Disclosure [Text Block]", "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights." } } }, "auth_ref": [ "r110" ] }, "dcth_AccruedClinicalExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "AccruedClinicalExpensesCurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.delcath.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical expenses", "label": "Accrued Clinical Expenses Current", "documentation": "Accrued Clinical Expenses Current" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r367", "r368", "r373" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dcth_SecuredConvertibleNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "SecuredConvertibleNotesPayableMember", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Convertible Notes Payable", "label": "Secured Convertible Notes Payable [Member]", "documentation": "Secured convertible notes payable." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesIssuedBasic", "calculation": { "http://www.delcath.com/role/NetLossperShareSummaryofReconciliationofWeightedAverageSharesOutstandingCalculationDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/NetLossperShareSummaryofReconciliationofWeightedAverageSharesOutstandingCalculationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares issued (in shares)", "label": "Weighted Average Number of Shares Issued, Basic", "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)." } } }, "auth_ref": [ "r43", "r44" ] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r640", "r662" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.delcath.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities [Abstract]", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnauditedParenthetical", "http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r84" ] }, "dcth_InitialTrancheOfLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "InitialTrancheOfLoan", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial tranche of loan", "label": "Initial Tranche Of Loan", "documentation": "Initial tranche of loan." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.delcath.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r201" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofRecognizedSharebasedCompensationCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common share data:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "dcth_DisclosureOfPreferredPurchaseAgreementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "DisclosureOfPreferredPurchaseAgreementLineItems", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Preferred Purchase Agreement [Line Items]", "label": "Disclosure Of Preferred Purchase Agreement [Line Items]", "documentation": "Disclosure Of Preferred Purchase Agreement [Line Item]." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r83", "r491" ] }, "dcth_FinalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "FinalPayment", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Final payment", "label": "Final Payment", "documentation": "Final payment." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r83", "r491", "r511", "r732", "r733" ] }, "dcth_ExercisePriceRangeFromTwoPointEightThreeToFiftyOnePointFiveZeroMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ExercisePriceRangeFromTwoPointEightThreeToFiftyOnePointFiveZeroMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionSharesOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "$2.83 - $51.50", "label": "Exercise Price Range From Two Point Eight Three To Fifty One Point Five Zero [Member]", "documentation": "Exercise Price Range From Two Point Eight Three To Fifty One Point Five Zero." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashNarrativeDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r30", "r175", "r249", "r250", "r251", "r252", "r253", "r255", "r260", "r261", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r270", "r383", "r586", "r587", "r588", "r589", "r590", "r651" ] }, "dcth_ClassOfWarrantOrRightOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ClassOfWarrantOrRightOutstandingRollForward", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class Of Warrant Or Right Outstanding [Roll Forward]", "label": "Class Of Warrant Or Right Outstanding [Roll Forward]", "documentation": "Class Of Warrant Or Right Outstanding" } } }, "auth_ref": [] }, "dcth_NotesAndLoansPayableGrossNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "NotesAndLoansPayableGrossNonCurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails": { "parentTag": "dcth_NotesAndLoansPayableNetNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total - Loans Payable, Non-Current, Gross", "label": "Notes And Loans Payable Gross Non Current", "documentation": "Notes and loans payable gross non current." } } }, "auth_ref": [] }, "dcth_NotesAndLoansPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "NotesAndLoansPayableNet", "crdr": "credit", "calculation": { "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net", "label": "Notes And Loans Payable Net", "documentation": "Notes and loans payable net." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r6" ] }, "dcth_ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceAbstract", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Class Of Warrant Or Right Weighted Average Exercise Price [Abstract]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]", "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r372" ] }, "dcth_AgentAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "AgentAxis", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agent [Axis]", "label": "Agent [Axis]", "documentation": "Agent." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, principal face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r76", "r77", "r249", "r383", "r587", "r588" ] }, "dcth_ControlledEquityOfferingSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ControlledEquityOfferingSalesAgreementMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Controlled Equity Offering Sales Agreement", "label": "Controlled Equity Offering Sales Agreement [Member]", "documentation": "Controlled equity offering sales agreement." } } }, "auth_ref": [] }, "dcth_TermOverWhichTheRoyaltyIsToBePaid": { "xbrltype": "durationItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "TermOverWhichTheRoyaltyIsToBePaid", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term over which the royalty is to be paid", "label": "Term Over Which The Royalty Is To Be Paid", "documentation": "Term over which the royalty is to be paid." } } }, "auth_ref": [] }, "dcth_ContingentLiabilityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ContingentLiabilityFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleoftheCompanysFinancialAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent liability", "label": "Contingent Liability, Fair Value Disclosure", "documentation": "Contingent liabilities fair value." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant exercise price (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r292" ] }, "dcth_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockPlanOfferingPeriod", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan, offering period", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period", "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Stock Plan Offering Period" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of shares", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r12", "r35", "r118" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r335", "r336", "r337", "r460", "r654", "r655", "r656", "r701", "r732" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock issued during period (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r12", "r83", "r84", "r118", "r454", "r532", "r555" ] }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "presentation": [ "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]", "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]", "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments." } } }, "auth_ref": [ "r181", "r182", "r183", "r187", "r188", "r189", "r190", "r204" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofRecognizedSharebasedCompensationCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost expected to be recognized over weighted average period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r334" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r86", "r118", "r428", "r446", "r451", "r458", "r492", "r600" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashNarrativeDetails", "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash", "verboseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r633", "r649", "r724", "r726" ] }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "presentation": [ "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r181", "r182", "r183", "r187", "r188", "r189", "r190", "r204" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.delcath.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r385" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less present value discount", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r394" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenue", "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r592" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in total cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r101" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency effects on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r706" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r39", "r101", "r167" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashScheduleofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashScheduleofCashCashEquivalentsandRestrictedCashDetails", "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning of period", "periodEndLabel": "End of period", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statements of cash flows", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r39", "r101", "r167" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities included in the condensed consolidated balance sheets at September 30, 2023", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r387" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r12", "r35", "r136", "r158", "r159", "r160", "r176", "r177", "r178", "r180", "r188", "r190", "r205", "r226", "r229", "r293", "r335", "r336", "r337", "r344", "r345", "r355", "r356", "r357", "r358", "r359", "r360", "r363", "r376", "r377", "r378", "r379", "r380", "r381", "r396", "r442", "r443", "r444", "r460", "r532" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r233", "r234", "r235", "r238", "r665", "r666" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Total Cash, Cash Equivalents and Restricted Cash:", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsLineItems", "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Line Items]", "label": "Cash and Cash Equivalents [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r136", "r176", "r177", "r178", "r180", "r188", "r190", "r226", "r229", "r335", "r336", "r337", "r344", "r345", "r355", "r357", "r358", "r360", "r363", "r442", "r444", "r460", "r732" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r94", "r103", "r129", "r138", "r153", "r156", "r160", "r170", "r179", "r181", "r182", "r184", "r185", "r189", "r190", "r197", "r208", "r212", "r216", "r218", "r225", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r365", "r375", "r432", "r513", "r530", "r531", "r583", "r611", "r669" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities, current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r387" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock with the employee stock purchase plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r12", "r83", "r84", "r118" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r233", "r234", "r235", "r238", "r665", "r666" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.delcath.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r171", "r340", "r341", "r342", "r343", "r346", "r347", "r348", "r349", "r459" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.delcath.com/role/StockholdersEquitySummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock related to stock option exercises (in shares)", "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r12", "r83", "r84", "r118", "r315" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of shares (in shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r12", "r34", "r54", "r118", "r265" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Line Items]", "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dcth_IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "IssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Private placement - issuance of common stock and prefunded warrants, net of expense", "label": "Issuance Of Common Stock And Pre Funded Warrants In Private Placement", "documentation": "Issuance Of Common Stock And Pre Funded Warrants In Private Placement" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r12", "r136", "r158", "r159", "r160", "r176", "r177", "r178", "r180", "r188", "r190", "r205", "r226", "r229", "r293", "r335", "r336", "r337", "r344", "r345", "r355", "r356", "r357", "r358", "r359", "r360", "r363", "r376", "r377", "r378", "r379", "r380", "r381", "r396", "r442", "r443", "r444", "r460", "r532" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r11", "r37", "r356", "r359", "r396", "r442", "r443", "r642", "r643", "r644", "r654", "r655", "r656" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities, non-current", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r31" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Loss contingency accrual", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r233", "r621" ] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement amount", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofRecognizedSharebasedCompensationCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r231", "r232", "r517" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "presentation": [ "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated statement of Stockholders\u2019 Equity (Deficit) for the three months ended September 30, 2022 (unaudited)", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestPaidAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid during the periods for:", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails", "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r135", "r145", "r146", "r147", "r170", "r195", "r196", "r198", "r200", "r206", "r207", "r225", "r239", "r241", "r242", "r243", "r246", "r247", "r276", "r277", "r280", "r283", "r291", "r375", "r454", "r455", "r456", "r457", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r472", "r491", "r514", "r532", "r554", "r555", "r556", "r557", "r558", "r620", "r650", "r658" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "presentation": [ "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofRecognizedSharebasedCompensationCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r232", "r517" ] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioPreviouslyReportedMember", "presentation": [ "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "As previously reported", "label": "Previously Reported [Member]" } } }, "auth_ref": [ "r137", "r176", "r178", "r179", "r180", "r181", "r182", "r190", "r204", "r345", "r362", "r363", "r364", "r384", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r626", "r628", "r629", "r630", "r657", "r660", "r661", "r702", "r711", "r712" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r99" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/LeasesSummaryofLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows for operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r388", "r390" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r145", "r146", "r147", "r206", "r276", "r277", "r278", "r280", "r283", "r289", "r291", "r454", "r455", "r456", "r457", "r591", "r620", "r650" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r303", "r397", "r398", "r484", "r485", "r486", "r487", "r488", "r510", "r512", "r537" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashScheduleofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0, "order": 1.0 }, "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.delcath.com/role/CashCashEquivalentsandRestrictedCashScheduleofCashCashEquivalentsandRestrictedCashDetails", "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r39", "r141", "r575" ] }, "dcth_NumberOfSharesPreFundedPennyWarrantsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "NumberOfSharesPreFundedPennyWarrantsOutstanding", "presentation": [ "http://www.delcath.com/role/NetLossperShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-funded penny warrants outstanding", "label": "Number Of Shares Pre Funded Penny Warrants Outstanding", "documentation": "Number of shares pre-funded penny warrants outstanding." } } }, "auth_ref": [] }, "us-gaap_SeriesEPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesEPreferredStockMember", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails", "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred Series E Stock", "terseLabel": "Series E", "label": "Series E Preferred Stock [Member]", "documentation": "Series E preferred stock." } } }, "auth_ref": [ "r635", "r636", "r672" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipment" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant, and Equipment", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r108", "r132", "r133", "r134" ] }, "us-gaap_SeriesDPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesDPreferredStockMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series D", "label": "Series D Preferred Stock [Member]", "documentation": "Series D preferred stock." } } }, "auth_ref": [ "r635", "r636", "r672" ] }, "dcth_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesLineItems", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]", "label": "Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]", "documentation": "Organization consolidation basis of presentation business description and accounting policies line item." } } }, "auth_ref": [] }, "dcth_IssuanceOfCommonStockInPrivatePlacementShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "IssuanceOfCommonStockInPrivatePlacementShares", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Private placement -issuance of common shares, net of expenses (in shares)", "label": "Issuance Of Common Stock In Private Placement Shares", "documentation": "Issuance of common stock in private placement shares." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.delcath.com/role/GeneralPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Recently Adopted and Issued Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dcth_CommonPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "CommonPurchaseAgreementMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Purchase Agreement", "label": "Common Purchase Agreement [Member]", "documentation": "Common Purchase Agreement [Member]." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dcth_PrepaidProfessionalServicesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "PrepaidProfessionalServicesCurrent", "crdr": "debit", "calculation": { "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional services", "label": "Prepaid Professional Services Current", "documentation": "Prepaid professional services current." } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.delcath.com/role/LeasesNarrativeDetails", "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails", "http://www.delcath.com/role/LeasesSummaryofLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r220", "r221", "r475", "r477", "r479", "r539", "r541", "r544", "r553", "r560", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r574", "r593", "r605", "r673", "r728" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnauditedParenthetical", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r83", "r276" ] }, "dcth_NumberOfExercisableCommonWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "NumberOfExercisableCommonWarrants", "presentation": [ "http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of exercisable common warrants (in shares)", "label": "Number Of Exercisable Common Warrants", "documentation": "Number of exercisable common warrants." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property, plant and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r100" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r51", "r52", "r53", "r54", "r55", "r56", "r57", "r115", "r117", "r118", "r145", "r146", "r147", "r206", "r276", "r277", "r278", "r280", "r283", "r289", "r291", "r454", "r455", "r456", "r457", "r591", "r620", "r650" ] }, "us-gaap_ScheduleOfStockByClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTextBlock", "presentation": [ "http://www.delcath.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Designated Preferred Units", "label": "Schedule of Stock by Class [Table Text Block]", "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding." } } }, "auth_ref": [ "r21", "r50", "r52", "r53", "r54", "r55", "r56", "r57", "r83", "r84", "r115", "r117", "r118" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.delcath.com/role/NetLossperShareAntiDilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.delcath.com/role/StockholdersEquityEquityIncentivePlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in shares available under equity incentive plan (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "dcth_MinimumAnnualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "MinimumAnnualPayments", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/CommitmentsandcontingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum annual payments", "label": "Minimum Annual Payments", "documentation": "Minimum annual payments." } } }, "auth_ref": [] }, "dcth_TrancheAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "TrancheAWarrantsMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantsOutstandingandExercisableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche A Warrants", "label": "Tranche A Warrants [Member]", "documentation": "Tranche A Warrants [Member]." } } }, "auth_ref": [] }, "dcth_LoanPrincipalPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "LoanPrincipalPaymentsMember", "presentation": [ "http://www.delcath.com/role/GeneralNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan Principal Payments", "label": "Loan Principal Payments [Member]", "documentation": "Loan principal payments." } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.delcath.com/role/LeasesNarrativeDetails", "http://www.delcath.com/role/LeasesScheduleofRemainingMaturityofOperatingLeasesExcludingShortTermLeasesDetails", "http://www.delcath.com/role/LeasesSummaryofLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r220", "r221", "r475", "r477", "r479", "r539", "r541", "r544", "r553", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r574", "r593", "r605", "r673", "r728" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation, excluding taxes", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27" ] }, "dcth_TrancheBWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "TrancheBWarrantsMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche B Warrants", "label": "Tranche B Warrants [Member]", "documentation": "Tranche B Warrants [Member]." } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A", "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r635", "r636", "r672" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofEmployeeStockPurchasePlanDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation arrangement by share-based payment award purchase price of common stock (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of the warrant liability issued", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r73" ] }, "dcth_SeriesF1SeriesF2AndF3PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "SeriesF1SeriesF2AndF3PreferredStockMember", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series F1, Series F2 and F3 Preferred Stock", "label": "Series F1, Series F2 and F3 Preferred Stock [Member]", "documentation": "Series F1, Series F2 and F3 Preferred Stock" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities, non-current", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r109" ] }, "dcth_SeriesF4PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "SeriesF4PreferredStockMember", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series F-4", "label": "Series F4 Preferred Stock [Member]", "documentation": "Series F4 Preferred Stock." } } }, "auth_ref": [] }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdsAndLeaseholdImprovementsMember", "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leaseholds", "label": "Leaseholds and Leasehold Improvements [Member]", "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement." } } }, "auth_ref": [ "r109" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.delcath.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dcth_PrepaidExpensesAndOtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock", "presentation": [ "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid Expenses and Other Current Assets", "label": "Prepaid Expenses And Other Current Assets [Text Block]", "documentation": "Prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r84" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r15" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.delcath.com/role/GeneralPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revision of Previously Issued Quarterly Financial Statements", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r632" ] }, "dcth_PreferredF1StockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "PreferredF1StockMember", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred F-1 Stock", "label": "Preferred F1 Stock [Member]", "documentation": "Preferred\u00a0F-1\u00a0stock member." } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsFairValueMeasurementsUsingSignificantUnobservableInputsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change due to warrant exercise", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3", "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r371" ] }, "us-gaap_LandBuildingsAndImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandBuildingsAndImprovementsMember", "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and land", "label": "Land, Buildings and Improvements [Member]", "documentation": "Real estate held and additions or improvements to real estate held and structures used in the conduct of business." } } }, "auth_ref": [] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofRemainingMaturitiesofCompanysLoanandConvertibleNotePayablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes", "label": "Notes Payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r20", "r127", "r725" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r176", "r177", "r178", "r205", "r406", "r453", "r472", "r483", "r484", "r485", "r486", "r487", "r488", "r491", "r494", "r495", "r496", "r497", "r498", "r501", "r502", "r503", "r504", "r506", "r507", "r508", "r509", "r510", "r512", "r515", "r516", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r532", "r606" ] }, "us-gaap_CommonStockSharesSubscriptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesSubscriptions", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, aggregate offering price", "label": "Common Stock, Value, Subscriptions", "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds." } } }, "auth_ref": [ "r52", "r84" ] }, "dcth_PreferredAndCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "PreferredAndCommonWarrantsMember", "presentation": [ "http://www.delcath.com/role/FairValueMeasurementsScheduleofFairValueofOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred And Common Warrants", "label": "Preferred And Common Warrants [Member]", "documentation": "Preferred and common warrants." } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.delcath.com/role/StockholdersEquityAttheMarketOfferingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.01 par value; 80,000,000 shares authorized; 19,688,991 shares and 10,046,571 shares issued and outstanding at September\u00a030, 2023 and December\u00a031, 2022, respectively", "terseLabel": "Sale of stock consideration received on the transaction", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r84", "r426", "r600" ] }, "dcth_TrancheLoanFundedIntoRestrictedAccount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "TrancheLoanFundedIntoRestrictedAccount", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan amount funded into restricted account", "label": "Tranche Loan Funded Into Restricted Account", "documentation": "Tranche loan funded into restricted account." } } }, "auth_ref": [] }, "dcth_LiquidityAndGoingConcernPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "LiquidityAndGoingConcernPolicyPolicyTextBlock", "presentation": [ "http://www.delcath.com/role/GeneralPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidity and Going Concern", "label": "Liquidity And Going Concern Policy [Policy Text Block]", "documentation": "Liquidity and going concern." } } }, "auth_ref": [] }, "dcth_ClassOfWarrantOrRightWeightedAverageExercisePriceExercised": { "xbrltype": "perShareItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceExercised", "presentation": [ "http://www.delcath.com/role/StockholdersEquityPreferredStockWarrantsDetails", "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercised (in dollars per share)", "label": "Class Of Warrant Or Right Weighted Average Exercise Price Exercised", "documentation": "Class Of Warrant Or Right Weighted Average Exercise Price Exercised" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r84", "r491" ] }, "dcth_NotesAndLoansPayableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "NotesAndLoansPayableNetCurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Notes And Loans Payable, Net, Current", "label": "Notes And Loans Payable, Net, Current", "documentation": "Notes And Loans Payable, Net, Current" } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.delcath.com/role/PrepaidExpensesandOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r12", "r84", "r491", "r511", "r732", "r733" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (see note 13)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r32", "r78", "r423", "r490" ] }, "dcth_WarrantsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "WarrantsOutstandingRollForward", "presentation": [ "http://www.delcath.com/role/StockholdersEquitySummaryofCommonStockWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrants Outstanding Roll Forward", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dcth_PercentageOfFinalPaymentIncludedInGrossAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "PercentageOfFinalPaymentIncludedInGrossAmount", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of final payment included in gross amount", "label": "Percentage Of Final Payment Included In Gross Amount", "documentation": "Percentage of final payment included in gross amount." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r48", "r143", "r430" ] }, "dcth_MinimumAccountingProfitRequiredForPrecedingThreeFinancialYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "MinimumAccountingProfitRequiredForPrecedingThreeFinancialYear", "crdr": "credit", "presentation": [ "http://www.delcath.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum accounting profit required for preceding three financial year", "label": "Minimum Accounting Profit Required For Preceding Three Financial Year", "documentation": "Minimum accounting profit required for preceding three financial year." } } }, "auth_ref": [] }, "dcth_DisclosureOfPreferredPurchaseAgreementTable": { "xbrltype": "stringItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "DisclosureOfPreferredPurchaseAgreementTable", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disclosure Of Preferred Purchase Agreement [Table]", "label": "Disclosure Of Preferred Purchase Agreement [Table]", "documentation": "Disclosure Of Preferred Purchase Agreement [Table]." } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r38", "r155", "r157", "r161", "r419", "r433" ] }, "dcth_DiscountOnNotesAndLoansPayableNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "DiscountOnNotesAndLoansPayableNoncurrent", "crdr": "debit", "calculation": { "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails": { "parentTag": "dcth_NotesAndLoansPayableNetNoncurrent", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableSummaryofLoansandConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Total - Loans Payable, Non-Current, Discount", "label": "Discount On Notes And Loans Payable Noncurrent", "documentation": "Discount on notes and loans payable noncurrent." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r6" ] }, "dcth_ScheduleOfInformationRelatedToStockWarrantsOutstandingAndExercisableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ScheduleOfInformationRelatedToStockWarrantsOutstandingAndExercisableTableTextBlock", "presentation": [ "http://www.delcath.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Information Related to Stock Warrants Outstanding and Exercisable", "label": "Schedule Of Information Related To Stock Warrants Outstanding And Exercisable [Table Text Block]", "documentation": "Schedule of Information Related to Stock Warrants Outstanding and Exercisable." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofStockholdersEquityDeficitUnaudited", "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails", "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "http://www.delcath.com/role/StockholdersEquityAuthorizedSharesandPreferredStockDetails", "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r135", "r145", "r146", "r147", "r170", "r195", "r196", "r198", "r200", "r206", "r207", "r225", "r239", "r241", "r242", "r243", "r246", "r247", "r276", "r277", "r280", "r283", "r291", "r375", "r454", "r455", "r456", "r457", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r472", "r491", "r514", "r532", "r554", "r555", "r556", "r557", "r558", "r620", "r650", "r658" ] }, "dcth_RiskAndUncertaintiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "RiskAndUncertaintiesPolicyPolicyTextBlock", "presentation": [ "http://www.delcath.com/role/GeneralPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Risks and Uncertainties", "label": "Risk And Uncertainties Policy [Policy Text Block]", "documentation": "Risk and uncertainties." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r6" ] }, "dcth_PreferredTrancheBWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "PreferredTrancheBWarrantMember", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Tranche B Warrant", "label": "Preferred Tranche B Warrant [Member]", "documentation": "Preferred tranche b warrant [Member]." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Disclosure of Cash Flow Information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.delcath.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on convertible note", "label": "Interest Payable, Current", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.delcath.com/role/GeneralScheduleofErrorCorrectionsandPriorPeriodAdjustmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r80", "r339", "r723" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r36", "r37", "r93", "r148", "r427", "r447", "r451" ] }, "dcth_SeriesF1PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "SeriesF1PreferredStockMember", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "http://www.delcath.com/role/StockholdersEquityDesignatedPreferredSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series F-1", "label": "Series F1 Preferred Stock [Member]", "documentation": "Series F1 Preferred Stock." } } }, "auth_ref": [] }, "dcth_ClassOfWarrantOrRightExercisePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "ClassOfWarrantOrRightExercisePeriod", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant exercise period", "label": "Class Of Warrant Or Right, Exercise Period", "documentation": "Class Of Warrant Or Right, Exercise Period" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.delcath.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r386" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.delcath.com/role/PropertyPlantandEquipmentComponentsofPropertyPlantandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Enterprise hardware and software", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "dcth_WarrantsIssuedToPurchaseOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "WarrantsIssuedToPurchaseOfCommonStock", "presentation": [ "http://www.delcath.com/role/LoansandConvertibleNotesPayableNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued to purchase of common stock (in shares)", "label": "Warrants Issued To Purchase Of Common Stock", "documentation": "Warrants issued to purchase of common stock." } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.delcath.com/role/AccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.delcath.com/role/AccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r27" ] }, "dcth_AggregateExercisePriceOfPreferredWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.delcath.com/20230930", "localname": "AggregateExercisePriceOfPreferredWarrants", "crdr": "debit", "presentation": [ "http://www.delcath.com/role/PreferredPurchaseAgreementDetails", "http://www.delcath.com/role/StockholdersEquityEquityOfferingsandPlacementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate exercise price of preferred warrants", "label": "Aggregate Exercise Price Of Preferred Warrants", "documentation": "Aggregate exercise price of preferred warrants." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)-(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.7,8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2E" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r620": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-3" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 89 0001628280-23-038618-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-038618-xbrl.zip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�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�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

G9U+RB9KIIBL95P5Y87R1-YT#Q0M=TU-D;$C>=4WR8 MPNGL6U=4BGCWFMNZQP7_[F7_2$L5?ZL#%]I0AH]_/!=-(97J\^J^=JT6:2Q@ M1F@&(@8Y@ ()0%** ,DSF2+5;B@6R$H>_I04JCN8>;N=>7U>MU1U%> M8[%\C*69F7NK\9F^6D)?OW[)A("^!">K*F@MNWH*57WUTFD:J'%N='5<(\'/ M0+@L=>!8PNDK%OB!^&3A 4]=C5LNWFV+I79JVVM3M<\5 HH8)%+7%DTC!C"" M!(2$0IIF*:30BO3OL/FY>9N==);7T*\P,[.HXY'P; P[P3S<%I_6V9'=>=7X MI";CM&*O9_N9IT9O&Y])P3^OJFVIKY46!,5,0 8ULSX"$"8)H$AM&67"0H&9 M5-M(HS+ YSJ8VV3="18\E^*IV#Y9SMHC (TW?*-A\;_%TZ(%.]F<[NA.:NUN M#W?8_-2[MI/*G=BGG7[.W<%/_[0SY1Q%.CN%,IFI":TV6)B2#.",Q43&.*." M77OR,^-3YG-'/_U"JT[/?NQ/FATB^D:G/UY.F0UA\7C^\V9GS(:JFYP 77_" M7',!ER^+SQ\7840D%G$&DI0H/Q[B$."<9X!G),\3Y=S'T,B6[)N/MQ,R?:'_6SL-37)A#L6 MO9M3)WXS@O3CKGP@J^*?]=[ZO=I>KY<%KW^H8R[NI)JQ5<=]\&Y;%2M151]$ MQ@0WWZ'P#M/@#>^P"42Q"0_0?P MW'T &ZVU*]87[\,R2!CCK_?IN&:\(WA 4^._MW$G A_:7<#[=;6IWI/G8D.6 M^@JX/7A0_=;$A$U%KSWA^IY2 >,L)0(IYSZ.<^7F\P30E"! :!P2&$*8QYG- MD<&U LW-B^A3,G2G92VI8U6;BH:4LTO$O!U1C^_J,30[>IAR9#RO])TJ0:W+ M3=#3YJ8;I9O>Z#0Z]0L.^*30< 6TH]..J\69]#C$%7BOSTN?_?R:R7XY]5=QQ;;\N>H56$1RAA'$C.0Y!0"2'@.*(HH8#A!28(Q MY!FRJ69JWK65[9V@U*F2O*X"%&QU^$2Q"O:\QV0GM)VMM1B'E,*$8TV5(G48 M)><(X"S/09CDDJG%D<9V)'&>QF&"-5"/0UU-I)-=1[;\\FLS*'\)=AH$M_Y' MQ6RM\X.UYU7-)2,:.&*@$UZ.2:(GHT)$B4K MJB9[;%,6JZI@=6I8M$!$QGFJUZ$X"]4?D=HH9$D.4BICBC!)P]CJ1M&?J',S MFKW<*7SS^D-P'.+I=5A< M1GKZ$73Z@$^O@)^,^_3;XY4$@VW24WT???M'42T$8U$LP@2@2#O0,%(;F0AQ MD'"61C%+>1+S45R#KWN:F^G?Y>B-J/1^'DY#"^T"),\&]A"?X#2.[96:F^:].6WZIKKQ=5M:VC9-4,K0/I@G6CHF4=^XD^!S.[ M.,-!]FQE;^\_O[\Y[:3NO8;.5=7.*2L%:3\!?4H:]-1R9YPG'@='IGXJJ2== M."8>BM?+T-3=7U'"\9:Q3S-C+D[E'R')#77CXVD04_4F^[&V''!QHN@ MN"S8>+ZSZ0LV7E3\9,'&RV]=292Y-W([.I!J$6N>?1F'NMY0 B"25#FP. 88 M\0C&B)*8Y%TR_ ]SVS'8J=&D.,QM_S&%$_JH/1%]MR4I3'4\;9SC2Y3,5] G)U8]2[1U"(J3,%S]%2=?30=_:HWZO M_E#_^VMT^^B3G0HN,<=2PHQR!G N$8!)D@#$J/KPH?K^"44BM:NCXPSQZ4H= M=WLLG7:@F9;;NG+LS!30O_,Z#UYJ]]2 M[.MMJ"Z'U#Y+63GXTKA5]HM:L1^:'8'8;);UAO;V24=9UB??:@5;US/OGI2; MEP7/&8="YB 1NFARGB6 0,I!F&K0$X@R;!7/8=7[W"S27N2 U#+;&18[Y,T, MC3<\/1N>O=S!7O";H!$]:&77QKY9!6KQW=FB4:@YLDUV?4]JJT;!\MIVC6MD MY(YA6ZZ*S;84MRO^J?A#_ZUJV4$DXZ'Z"B,=@Z'^2+D &*1Z'-,^M MSKO/=S4W*[63U-+M.8^EH<_C!"'?#D\G9!WHW(GI@8/E,AJN?)WS'4WKZ%Q4 M^,C+N?S&B(S2]^LZ7T19G=X!1?LA4Z%VL5G( &3U'[D$5.I$;2XE2K*$2#.J MATL=SP391(>/HC MT/O3Y=\9:'&006?R_-@<.+KYO*HVY;:I@*3,D*@VNNA1'>G M[X7Z+-0W\R 6G#,NTRP&*4L2 $.U_<,)S8#$&4I(AJE$5N&LYEW/S8YVL@:E M<3G%$7B;N5M^4/1L8K70P5[J.KJS050+?A,TH@=[V5TFF-GBY2R5S+CCB9/& M; $Y3@^S;F&$0_?K2N>:Z?SA[5(;PT]"5 M(8\F%Y""#. W*G>IB;Z6EDK!/T&R$#*:Q_;%=DRPNUZMB2O9L,@YE+YAI3T8XM]7QG2LR1/ M\E#8T',<=V%E*R:@X?BA^V@R05HY__5?4!SE_Q6(6M[@%[5]+5BQL797CL"- M$B)XDH0@9"$"D*,44"X00!C%**:A+J-H7ROT.HC?HH[WNS&%GT_@"3&364X1 M4/^/]<$IDS*C.$L,:HT:]SCW#S;[[V,Q8"=R'&T M.% S0MS@X-$UCMYWTQK"1MY#!HQ&XHX T362%D>5KA&=Z.CR_,?Y2U&+_I?N M*W5UG&D#U.#QIE%#TQUWVNAU+(N&2=1ZO-?G6K_)SNA\]/S^7Z9WW@ MT0501)+&J8AS(%!"E7N6<8 H9D!&&8M(DHG<,B39L..YV>R]W)9AR*9 F[EO M/N#S;*KW(M=1@+L?@[[4'F(";:%R%7%LVNVTP<:68!S%&=N^/_(PHZ4ROI,7 MBTA6YZI(-OSS.,8H3U$.D(PX@)*D %.:*0O&6)BH_;O$5A')SB2;FV';L4?? MR8:)(1BF%:N"=R\'#Q[PBMG5(' _[(:;X+<83-\><8\%W(0>KAKDA[LXCO9[ M;M>8N]JJ.Y-KVAV^:SB/#@:<=S#B/*&EOKXOUU)454V^T9)H[.@8),EYCG,, M4D0P@"3! $>Q5"8_3Q@/19@Q\\I#E_N;F_GNBQI4K:P6NUX#A U.#]SBYOUZ MK*F1< !=)^Y%THM1$%H<&[B%*(+$/"[U3>AQU@31J_XU_6J['ZL2\_H]^OO M[X=@CZOB']NVKLR^.HC,XA!%$($0,@J@/A:F2)GT+,0QC9(LBZA5W-4D4L]M M)>@[@/OXHK:NR'NB-%-.'MD$>Q:"L4P-/C\%,P=^=@/L>TVM6N^N?5 M\W;3'*OLM GVZG@M(3/I$#AGJO I\QLQ7DPP#.>9,Z;H?-P*]GZ]^BG*3:&: M_+K>B$KM3W3S[:DKP43(,(U!SI(8P%130=.( HED&(>1()A:D>,-]C:W%:,G M;%!+&[3BVBT,PPB;&71GN'DVQ&D%LU([=>6R.RE*_@U M]=%'*1[%JBI^BN8F[LNZJCZM2U$\K!IGF[W\*,FJTH6?ZGJ*]4_+YK1D1RWT M56SNY _RQT(@RB 2$(@P2Y332R- ,RI G,4B03C%F5ULKQ\QYV:S6DW:/25[ M"39[Z7N\<):W=)Z&V,SVO?W >3::;?W)OH9=F,8O6LF_W 3=L':*!CU-:_^V MIVN//.TFT!6IU(9'*>R8IM3;@+BD-W4OY/2TJ-Z /DFGZJ^WJV\\==3'NY>Z MXD%SF253'B491" 7H2Y\FZ0 IU$,"&%,0,IB".W2T<[W-3@ M*FIIYCNJRH[R)LLARB &E'*HK(94?B7.!8A2EDA*$HD@M*!=.M/-W Q&(VA; M#,0N0>P"G@;77TY0\KYS/0'0.+JELU^>#=F2 \0FHUHZ@9P[IJ4+0%S@63KW M]I0L2Q,6Q=.GIB0N,]L\PMT]=);IGP1IZ^:=HD<H"HR(F ":0 LQ8 M#)(XX1BFC#$^38'1BZ+.S2AWP@6JLZX9M@]Q%HG6=04-1X6-ZZH.AE0?\'I>EZ1\:5+G?JS;Y4U+52U2M7F'E%) I:9&1D@ $O,4H$RD>9222$AL M0X!JUNW<%H&]X'I3^B3^^4^R*E:BR\S>K'664>U@U>+;$7\:CH21#^\!WTEN MHVIH[V2PDSIHQ Y^K(/6=_WN#UH[AE7W$$_'M^H$:FL>5CO$+K&R&K8V*4>K MG8:O&5LMW[8S^%6Y67P35<<"]&']1(K5(N89)1@Q@),TTQ2M:D. (0$QD1'+ M)(DB;E0U^F3K]V6Q+H.F?F'P6R.OX='!:22'[?+5^'@VO^.A M,;8"@Q ,.:CJQ9YSJG[:.Z:GVYQDR@^JT\WLX8=&>&Q?UF2EQF?%BF==O/.E MGW:9$9P0(@E("<=JAP_UK(X$B#%6\YI3FEA0FPYT-+=IK44-=K)V>SD;%V$( M50-_RQ%6GJ?X&9C&G)L.X67A1#G";2*WJ<;O>8??KOBWXN%Q4]UM-\H0UT1%O<#C.NYX@3+.$$FI\H!D M#"!&&& "!6 4$I1 &?+8:'L[IO.YF=-.=K6_W8=G%UI2N]-.JP$P.[_T!:MG MR[M#5$?_-(('/3GO^- >7UB=ZH-L:9LO&UVS\^ M/2_7+T+4EU3WZGM^5$_W IT96IU>S4155M:\)JM0D3K<;M7>USJW/PK)JRL\-O M]?68F?0_P3?A>76XO?_\_N;T;=3^>N F^/C]_EZ7/6&EIBRIOY?W:UW_9*^4 MNU7CC4?%T0+T5EI,NI:]\5"]7A;?6IQ13(\[9O2[9U'6PNAE_2"^5D?6[EC] M198QS),81)%4>X9$,*")BD'"68)X+B(IC:)9QW4_O_5L5:V7!:\K,!W4!MCK M4[N^AV'S6J7:C.G2ZQLUY47PM%YM'JM K'0-7Q>U&D:.K\&9C]=1\QTA83=& M!N4<7(!NQ4?I$?S)R"E[@[ ^' 1V, A+I8@[@LJ1R%U@J[1M=4KJRI$:O^*Q M'-O*Z%(:JIO-R[WZ9C:J'WT1^-S$B?Q0+=[^450+IG9@,HX1()AQM3VC J"8 M$! B$B&1A9A$B65%C4M]SFWI^;)>/8 O"GH>_%#_7N>RU@GYRZV(8I!"=J;AB_.M;>""G*4O#:^VX" M#3Y7U5;P!54V)6+*N& J(8 H)("F+ %QRF&>YZE@S.H4Z'Q7<[,N.TF;0YB; M-JRK/J=1__A+T05Z6<8!#X!M:F5<0.C9N.S1^]Z@U\@9-(*Z-"V7P'!F4NA'-/5(#;YKSI2:5F7!(DXC*G)E M5?*:-R $)%:F!>5((LP0Y=BH?((;<>9F?@ZC35O;,]KH7#E49H9IN@'POD76 MI^Z-)D&C2AL1U=FQF^!P?/IT*GN5'!=ZN1I:ET5AQ@LS?0&9JX$[66SF^E:O MI#)L6-.^B)]B&;?Q-RQG*&1Y"$(.,P!QK,RI*9BU--T]@I5F!W<'=F^.2>-LKM5U:T5S2U&U22E88H8E0P ) MS@%4+B' +,H @3"/$Y$PGAA=$0QW,S>+W0H:-)*V4>Y6*3X78#4PQ4[ \FQ^ M#W$2'H"RR:AT =A4&90M<*PGK#,6E4LX#.=%GGU[PCS(2QH?-K2(HIB M\7&U*38O'Y]$^:!VYG\MU[]O'O5-+5F]++*02@DS# 05%,!,N;84$@PR"27! M&.H:@48F<;B?N=G$1M2@DS5HA U::0TG^P5H+YA%=X!YMHLCL3*?YV9(G-CZ M5H+]^\/ZYW^H%II=K_K+?K-[J=UI3("9H]+$P;#,(N4RV3%5WRZF[F9@$ZXX$%+ M9W?^=09(LZ.OZ^'Q/.%W MX$.Y!J&6_TW*\A#?$'3J3@-(M (O1E)(,)H!3& .49"5E(9!(:T:)9]SPW$W&9 MX.9Y'Q/AE(CE]9"8;+$\ >U[UW61?J47.>$58U=\-U=@/1O*&V/,';+>G,%M M//'-ZP9GPGUS1D]S^IMS#8Q8%SX4%5NN=7;FG=PUVYW(W3Z4HMZ"?E%&[[/: MC5:+*(MCDF$$((_4=I%1"0@F!$@L8T0IYU%N3JIAV?G<5H>]^'H6[6?,[LQ^ MIT+PFU8BJ+6P.4FR'1V#5<(CYIX7BOG!;;%@>(1]HC5C%/S_CZMCP)'X#:X= MMFU.MWR,U/9@!1G;QMB3A281]X-H_ONYN<9Y7"]5&U6S<'U;+Y>?UJ6F\5PP M'B8(JRU&QE(,8):E@'*J"V!PD:89SA&Q8ABQ[']N2\DNC_F73H&_!$5[U=OJ M\&^==_:;UB-H%;$LEF$[3*8'&M[ ]W[2X1SW$6<@H]!S=CABU_O$IR:CH#D^ M3AG7C/U-RX=V+?ZDC"]9-C&0G]2_58N$XB1)E;O,14*4XRQC@,*<@SPB+.4D MBI/8B%ERL)>YF;5.T*"1M"-1K&4UOV,Y#^KE&Q8G4/EV;,>@9'6[Y7+#X_U?=1<$M5&DSKLTK>52Q.E,LQ )$D"8(HHH B% $5< MN:$*YQKJD-_M/663F!JZE'SV"RWFB@K:&__BW^JC57WT$W'2:!^K[/A]>5 5?]TRS;%SSJ MWH248(1C*8<(EL[,M8 M0>9F@_Z7(&7+F*+MSH M.S(J6CM7C\W=ZGP1U2U"[9!L.[,EQDHCHS4 MAE5_4-^1*$Z M09=75*8](FX]KF+X[G45P[MFQ>I1I/]=:-)TP6]_*F_Z07S\0Y2LT'ROREM; MQ*GV::D /%6.+,1A"$@**C]K(/Q4I_7SH@M!&WSG+FZ^62E)7^IR82 M=$PMW"D^);BA.5F>> ML/MQWM?AP>/'IG#( B4R@FI/#7B.(8 $(D#"* %YPFG.9$CR%-ILM4_V,K=- M\OX ?EE',[555.Q6D--XFMG[JU'R;)V/;B@^7D#(VGH.(N#(UIWN8U++-*CF M:SLR_/#H++9-0<77]4:<+?Q)LS1*& (8Y] G7]1B7U<.U SU84/A!TOO5P&=O.=0'%,MU Q.ZV0TA[!.FH56P[O2 M\/HK)FJ%D$&^V:66IDXT,]3L1(:9Z9LC:=3K,D?_LUCQ+G1F01/$(Q%CP)5O M!F"40$!#)@!F(@I9(E,922OZ]*,NYF:,=\%>76T[PEBI^<=*L:QK!&W6 >L9 M;#T7+.D(3N!LYK==AYYG\ZN% \4*:/%VT7 .B=+/ZNZ*(/VX@VF)T<\J>$2( M?O[)JV,TVO6,AFD")80 8UU2F.L""B+, 4[#E. $;E]M2D/=K+A94+=2I M6K+5LJTF+8R9"E:KL<)IJC4_ 44$FY^IM +)98I#2U\9W/]C0W(_!5;)J: MJ\_=U;F=)WT>4C./V@E0OF=_*^,^O"#X3EU^PLPM5N=&5#OF6;>[*MM!W'6J:L2R)8(Q !&$"((HUG[GR#Q(,HR2G M2/+$B#OC7 =SLP*MC'7R8RNFF1DXB^#P['>!B^^CL6-(G$777E)_:)JK=WM3 M7/VTG]YGFYUD5E]2JIO,%Y\;38^S?A*[JLE?-/C%>M72PN<8IWDB0L SK-;W ML"[YEW* "*0YE6J+G5GR[P[T-K?9W0@;[.M_=^):,]L,(&RVW#O#S?/L/PO9 MY6H%8]AI+F/BCHMFH*^IF61,QE)"&- LP2J74&F[$<4A M8*;+06B"X2M7%@OM4M4+4?U-$$V4R.]6WW1^D$Z4?D>JHOIUM=Y5S*RK#:I? M*Y756_6'UCNA$8A"$5,@PUA98)Y30 B* !8BSDB,2))9%87W(>3<3/=W]BCX M=EG77FMJ:B8MMXU%@)K7437S&M]ZK#PO'?T2J#T-@T[%0+F=.R6#6LN;H*]G M4S@U.-0T^.U'_3LO)U4^1\1U 5:7(KY-Y58/()\M^>JCKVM9'C6K34-'2'&> M(Q8)0%FHB\,*'=X"(8@S03-]>TZX67G!\WW,S8B_YBZL*7ZNXG?LX! M2)ZMYPA\KF!V/$+ :_COLTW8G4\4NH\I^/QH_9'[M_%@V[PKV+]4)+G1^V MMH=(*:$Y)KE0_ET8 9CH8[HPSD&L)GJ:1"C$W.B8;K"7N4WPOH3FI^[G0;Q\ M].X$&L_3NB^N?Q%]^V!WKX@]1/ND2Q*N&9U2D M&<1(YB D7-?$2]2.#JFE'>>21GF2(0FMXE4O=SFWF5^+&*B>GJ[G37P%KMG& MRBUDGBW"62Y$+;'>XG8R^R4_/(V/1YK#5QV^.:'A:0!,J O/O#GBN+X[V;B3 MGU=R73[5&X]O3;;'CW4=G=L50>^E2M^N>)L>K;9FN_IG2ST=@V_[E)LF%+W3L\^Y4-^J]U2U M.!OW,/(&UQ!O.YZ>#>MN*.].#^6/P:&\/1Q*FV.G24;7XK;D;4=YHAL6IQ/7 M5?JH/^0'KW \=#O=M8\_S ZNBCQV8W]T\+=B53QMG]JD+9GD.$ER!-)S4^&SV[_[$MGO5R]55L%A'A61*+ M# @6,P ECP&F:0P0$HA'22XR:$4)--39W.9F)^M-\*REK5=(T2' M$= X48"2E %-M:ZYEQ)E[' (B Q)%&'))62+S7I#EA,#O>OR_R= FYV?N(+/ MLQ7=(W>_0^[C'KFO \C9Y_P;0.(J^W^HJVEY R4/F($,'EG)&];^4!6Q3]K M3^W]>E6MEP6O?ZBO;^MBI56WT7BWK8J5J*H/8L?SKH2Y96R]7>F#FWOU,BM$ MM=]0I4(P@I((*-=+4ZWG.< XRT&:2!E!A%)&B!7_FT]IY[9:_%6L1&EZSS/- M>)J9NMF,DF=;V=?S)CC0]*:)O=$;Y[ZVZI];?8.>PK61W:L<=#I[2AV;9'A< MD>QYE75:LKXI8#\B_9NDTQ&G\G\3G+!VSZFW!)*@$. PIP"R- 2(11(@758M MSW@.4_.(^5[#VJJGG*NV*ATD],2 M4/64..*6Z#!IEO*9!7(VLJQ(-H^68MNC"M7 =E5&XNL&1 MUK1+0+Z3VC9_6JY_KW;UTWD&DU"&(8BB7+DH<1@!DL@8I&F:"\;SF-K51QCJ M;&XV<;\=%;R7/:^#\W3E^EIV7:>^KEN_4CO3X*DN6-O6D_ZN/J*VH'18%Y2. M@U^V*[+EA6K/MES/T!@9&DY'R/NVC6=P]E&QW@025T9MJ*MI[9:!TD>FR>2= M*_-K/Q056ZYUCM9M50E]B; K#JVL7Y>^=;OI)7>MQ&/<_V<,J!&Y\Y>SW4KA-EKY#H;?)BKX?P;!JL M@Z9'%LG6W>T=%8EBEL01 XG:A@,8QD('?,0@(PS)/(Y"+HR.T4\W/S>3VTAG M67+Z$# S@S<>!L^VJQ',B^MV6F=7Y92"0HPR2B .8P %9""A*:9E#'.4VE^ M#6;1\=QF]EYTG66P$S[HI ]VXK<'-C:W2C8#8G#GY@EFSY9C-@A;W.MY0GJB M>S][Q%U=$H[ ;? 2T::]Z2X91VAY< DYYGUG._([:>@X-I.&PEP@M18 E&,7*D_#P9"YXEB>#0*/O0F41S6T!.;NKT@=>);=W@KL[&]KD;W]'[<'^C M]A:[< \#YF('/@YD?_MO2WG>>O<]#CZ#O??(AD=25NR9KTZ(LN AB\)<[;]A M%DH DYP ',9<;<]>[G6P9+ 8QCHB M*$F23 *9)1F 7.<3I3$%,22YQ*D06)>P-$]S<8CU!(DN/W0?WK U6XG<(>9Y MF>D)>A.<7',**"F2XLVEI0(P4/Z( ,7MKQ F,\N:?2;&CK_U1%L/X BEP!)&(.((B$8C\,L-*NG9]CAW"SVCD%YHX4=P]YM@K+! M<8IC[#S;DU;:/0%U+>\U;-XF,%J1=FE@B2ASN9FA6O1@E+\%*NM96FU04S-O#A72'FWN4>UEFZ"!CGW MA8Q-,'&7H'R^JZD3E"\J?2)!^?([X\S%5['105&JAY\%%_S=RZ^5X)]7GXH5 M63'-'M/$42O'<0'S+$-1'(%4!YW#&$8 <48 22*."8L%9HG-5M"\Z[EM"W6I M1J:C^YY;V0/Z$LA.[H#L!+N+]HR8-B]9=@ M)WQP>QEF:Y-DCY@C V71\:3FRAZ0U\9K1 LC]J%?M]H8:DK+NBB\KDE9?1.: M/E?PVY^D6-:\5^MWXG-5;05?))0R"$,),@&1/M=* :4XU8=;*,G2*&.949G9 M,9W/S3-JQ->GB:Q6(*AJ#92OU*@0D$X'34E'15#4:@2_%-VCA@'AHT;*8%_K M$7_?QJZ!_DY3YM;0-\('G?3!3GS-_?A.!(T&'N&VV/]ZA'VBO?#(+]_5WG@D M@(/[9-LVI]LSC]3V8/\\MHUKJ--KPN0>:\.774@W1TDBF8 @DDQMI_^_\KZV M-W(=._/[_@H!&P0SV.)$HBB)2H %W&]!8WNNO7U],\C.AP)?NVNG7.61RMW7 M\^N7I*1Z+Q7)HF0%&R0W;EL2SWDH/3PD#Y^#$0,J!D9 IJAD>,VF5U%O]=&<0/774KT(35$3]FKE83G0,W_W"UZ^BHT)BSZ2:J6FV76[7$VR',@%-NWCD=HP&IJ7.P*BS M<(#5_GX0 @4<%QH9-<[H=_0XO+AR]:T:,Q^?GI?K5R':C0,S8WJG0AFN9E!Z MV]$P_-URV99OOY>Z@N2WU>(?@C^(:K%6U]7[.B<XI5-CH#V-FIWAS7(/H-K-:-_/2#OCJUT3NL_M2&X2/3DP M3S;=97R)'LBK.5!RIQ,POXE&P+G=R^=F _4]>5YLR%+[-8ONGK3.XT@:. /U M0'"-G-!VOI&&SD!P7];8&:K!F].U]1;UB?[/'+-<4))#@)B>VS)" .<>B81GVUP:OO%)VG$AA[J/;O_^;]CF!3_9E3T747+KL)ON6@6$-2A M5\V.D/S8C]HMV<6]4(3/+S[?W%ME&/R.& MM0>SD#UW=1;.V?!7^WQPWF//[UFD/8^TZU'G>_2U[YUP#WK'ZJ=0P>_@]HX; M!(\%_TDP/%K#?N-5MYZCXNW.C@6;%^I_6$$A8#%. 4JHBH0+R@!E&#,8(T%+ MI^63LZU,;5PP1D7+=5U'SZ(Z2+4P.41\O5R2JOFC^:VCON1YJ.UH_F8 !Z;F M[8*L,K#AWZ;VR>5"!\X,V@M!(-8[W\:H3-7KYC&[]%_L60OJH *WD<&]E[_5 MC:S9/,D23E&< DI)JJ-/O2^#4A6,)C)# D,DW&HY];4V-88PYH&U!"^UB(B' M]%@_MG94$ RQ@2EA:V>7-;)%[[=:-)H. :L9V8 2JAI1;UOC5A.R=5O:E>=O).94)QCM1<-8$9!ZB0)2A%S ')DHS%:<)RZ:14BG(7,.2SN*N!&AH:=Q>\K\7]:K;^!15$_1$61U>!F7'E0",<.Y M%D;E@QX7CUF@[U)?C?LU^UN3T/KAI=*EPLP:OIG$;'<"]#6=HI8N9#D7*,YR M*A/ .1, E233Q2$ER'()42IY$4-'\7L/*Z;&']I^HGI\/^5;VQS]7&R^&RE\ MT;K2_OZY4Y#3E6Y=9>]]NLUR=6KHSAB:J@RXC0-1XT'4N#!K5I%F4>=&4V1D M)^7WT-<1'BKZ-P 93%[?QX:1=?=O@.E4D/^6AWF*.9_46=SJ%&-6\#0E%!0) M(0!13E4$5<: *YI$)8XQ=IMY76YJ:FQXMBCJ=;UC5X#M*"T,; /SEB=B[@K1 M5\$(I19]N:%QE:.O.GRB(GW]#C^JZ$H5W:UX4ZOH_F53;\B*JZ9T1#V/L9IY M215*Y8D*KY# '% <"Q#G<4(90[B ?/Y#5'1M2QG7FG3Y O8;'NY#V);W$K^+ MBBUJ'>;.] JN(G(WXK@*-\X)1[2(08:YXF>1EX!F, 9Y(=,2B8(CXG3**B38 M8["TSBEC.G%9-?84&%L[:@Z)V, $O7TO=5Y(6W=NS]I9]-@'HC-/VR(3B*VO M-C^S8:AS0!^:Q[F#HR6+_7L6DYDCZ UFH2?/6'[VRT7@4:9="GQR]!=:@ATJ] M#'F#\Z:W ';^*.I-3_0L_;TD=7TO6^)N:WAV9_%_%4S-XG7>WWNR7&J%E^-B MGW/.DUS@N 1YEB* ,*1 3;-5,,=X0KG67*%.:Y$WVC,UNPW M6C-N*?^_J]^O&^>ES_7,TERU"*)5?< MRG. 4A6XE@E. 80LY1#I50ENI1YPN8VID69C9M3:.8NTI?KST[9:'JSO ;2? M^@+!-#"=>2%D?^C^.@9G**<6[$_?UC_^1=W=L(WZ84VQ_4M M+KWU].Y746^JA5[\T1)Z:KZL_Y\^3O&#+'6LMSNC67 9$RPPD&JB"E#.!*!) MR4&6,\1*]?FCU*F*L(<-4R.(_70(;?.LD97<,WW6K!)M'307^)ZZM>\KRRW> M87M@8.[I;-;9U9$^SZRA;P[%'O;!2"=BG3$,?M;5WH(W.L7J#-'E\ZGNC_)0 M3WJO8JIU]6FQ^<KQVTAOJ O1(7!81KZ+G>"5)WFIW6UY5/ MW !S$&L*!-Q(XDTM@'('H*9WM@,PE+"3!2R]0D]]]X\G_&3AQ8$0E,WU'J39 M)<%BPL8%PP@J%?K*(T!@8P"%L,B02)! M,K':#W%O>FK$VEJITP ;,R.P.)-+:&R?12NQT;_=UE3Q4TIVZRL+9AZL!P;F MZFW6YIY.L.-S)X>7HP5O@]P6/T^*H/U][+CTW.CU -,%$_K!>KS?\1U?I^)03BQAC20H0IU("E!4<4%D*(!G-TICD:6)72-FYY:F-'?\4_RE.'/C("64+ MVA\*NZ&7$+15FO([PZ/&\LB8'FG;(V5\U%SG$;8[X>Q ^T/A/1+K-WB:\*7% M_7D?]W]HW-<*=W/2/A3=^V#6R_9.#QR/['W\/.!ZKP>X;S1]:-^U1]7+]4*_ M<%_%\[K:S&F)65*D6!&ZA "510HPI"F()>$QE#B!&;;=:;K4R-0(O+,SVAD: M-9;:;S1=!/3Z3E,(F ;F:@^$G#::KD'@M=-T\:&C;35=N?6OI@7DJ19&E!09H7.4 8$T!+6@)!\Y0E1*?NY"Y;2A=;FMKG MOE4J:N?O:KICBJ+RZ ]+4=?1YCM9.6;B7$;9;C,H"'9#S]([V%HC9]'.S'!; M.E>1"+1Q<[F=4;=GKKI[O ES_0:/>5^7\OOX?5%M7C\MJGKS^'/]^'W]4I,5 M?_RI:.GUDWJ1VEBY%"3%)31E9@O%'"0'A$@*&&&DR$2<%] N1G!O>VI3!$]'^&9&KY; M<6S6%^]>U*M0::GI. M?[^W7#[KR@J2K;DWY'3WX&T72P9"<>C]^;U]GEE7%G-G:<#TZNMPA$J=[FEI MW+3HZRZ?I#Q;W.(16)ID:2WAN?HAJLV"+L4OZXVH'\BK3@IK!]@DY06*DQ*D MA2X\7G(53@J9@Z2$92YRP4IDOPMMT^+4R*2U.=HS.C)61ZW9#L&-%>(6\6-H M' >FDZL0^@2*5E@ZA(>A,1TI*.RP97O8K@RVSXWEH>) %WQZHS^K!XT7\[GX M=1#I.=WHNS[X0^A,I->OY.>?B6*[!5G6Q6J[Q;B_*9ZQHBAXF8.4Q7JA3Q2@ M3/,$H$(@3$26$G)CBL>%EJ=&#?^4Q'^*XUMS#R[!;!&.#07>P-QQ,<=#F;Z? MYQ$VQ^,2SK?F> 3 ^ZUS/#3NS[L\C^%S/*Y@YI[C<>F!;YSC<<7/ZSD>UQ[@ M*99#5OS=RV*IA0:T(,_GI^=J_<.D"W8U;CGFJ0KK4E (D>BSQ0Q@R"&(.P\C.YUWE;KE+EJWTM3>49]M]K1R'CJ*!(;]AVP MX\PWZ]F!Z777J;.N5\FE7EWO]RJYH5>=&7D0] .1=UC;1N7Y06 ]'A*&:<3K MI+9L5FNQTZGE2ZA:K#<$P6KH+>06GCTCH];*(# Y'>T. -=H M![M/WJJ(-=:&.])]!8XK![HOW3WF<>XK'AP=YKYVM5],_5"MGT6U>=4%$C:* M?K7$QK.I=-EI[\=8Q$E)"Y S&.N]9(QDJ(X)<@I!>=JBU/CRL[@ MF2D_;ZHYTSR@LI8@J(H M.4!YG .JTQ"2A-(L3S'-B-]B\+G6IC8&;"V,&OGJOVHC?==ES\+KN,YZ*VA# M;TNYX>6_XMF'0^@5S+-MOV_RHXQV@5+3V.?5\\OF43W&O,ZI M9#F+,P8@*;$*-*D 98D$*&1!\JR4^N\N;'&IH:D1Q9Z=D3$TTI:Z$<5%4.TX M(@14 ]/#>92"L\0U) (1Q,5F1N6&:\X>T\+5ZSWV$/XBM/:^X'<_5(SR36S5 M^LUAEH=*?'K1AW0[J?YYFL99GG$.: D90!P1@"6! +(BS7 )*P&D,7E7K\1/X="Q4RSV)8:#>F#>V:+<6MY5'+F7W>$W97W4 MF+\M-S(VD/;JHW/CI^XY-0FR%^^/7ND#@^'VS#'%,;R\/5+'\'M&*+'UNQ4_&:4NBDU3)G)&"0> M:8G5- 0B4&09R;,T9V5F=LU1Y2 MJMVIIRW&IU'[;^ 1ZZ*DN\XY/C/3&5+JW:F?;I5_'ZJ_QI:$'[+? BC%^\#L MKA[OU,H;*\K[(')=9=[KJ1Y#Z<%9.'/\[8ZN?XA/"[EYO5\)8TS@!*4[5= P2!$JJQLX409S%.58#*9ZK221=6XV>[A:X?+[[=@SW M]?Y3EOPIB_^' V%ZX&XQD@V+YP^/M\,)+<\!C?A$5N%+/U_&[! M/Z_:?.PY1C&1-(= QI0!%"<<8$)R #G,2%ER)C/FEG-XMIVIS9MV9D;/RDZ@ MICSM41+7+,#SL-IM!@< :V"FW\-)FZAS)]]?PZX7A6 )<.=;&3F'K=?5 MTS2T_LL]HD@5JDJAE=RUB#[[+N[:D+4=/G,B9(JY!!#3!" 4"X!360 *8UI* M@@J.[3=]^]N:&B5LK8U:8RPE6:8=8O3 MH]K&X$AWY4Z 26<;F)6T=6._\X&T*[C;!65!T1R<@O>!;)8A6W.W>F(!A:*M MH0EW&NU*>V.?1K-S_\QI-,L;_2AG5W;^X]/S493P#)< %3@ M&."B("#'"4NH>C>IL%(6&-3*J5&;\0489[89!W>5$9%K-L#;JC1-K? VH->. MS:*[I_6+'NN-7X['%X9Y ^P(\\W[=6"2';Y+G8EX4,@#D? ;FQV-D!E U[(4@6&V2B1]%WL& MDM_7U>915$_ZB=N33:Q(A"1)";(4E6J^*J'ZWF/U^<,2(BDR1#.G^>K95J;V MO1LC@;;2O-0SJT-0#J!:QE:W0C5X;.2!DGNXTX="J'#E;!OCAAM];IZ$"[T7 M^W[^9R.-7:Q;OWO=7=/&PG<_2<7;">VG=27%8O.B7K'/JR86.3JL<+#Q.9>( M8I%D"8 <4X $EH 4,0%9 45<8I@4Q&V*.;(#4R.M]SH[:;D4'+2.Z$G(R;FJ MHYP!Y6:3CF8R/_EZN215K1.UFRQ0Q^ILH[]#MD0ZW3=CQ/GKOO/[D]A:*Z>< MG>AJ"&;=HN(LVH-!;P8W0%Q]QT(.!6_3C\%&F9'-'WD >YO..1T;W\@.WQTC MH9-0VF6DNQ6_WWP752,YVREMIAE+2Y(SD!9E#)#>+E(CIPK):2$PB1%"+'/; M,[K:YM0&M];D[IQ"(_:\UF9WXIP1,?:[[AM=1S_+\CPE209H+C. (,:@A"D' MG- <$2E9D?'Y9KTAR[=!?]OR<.@_ZC;T\9&WZ@/;W;N@R Z?0F'@;,TU:!J# M6SWSV56U7H\]/&N @NWB76]QY'T\:PA.=_+L;[VQVN!?UM7?]#F"-1-U/8^Q M%#(M;F1KE:^/ 8@6>&_,\*PX>(FG' M([?C,S!U[-4Q"%UV\+"1MZD[>-;1BX4'SU_M]_D?GLW] M*KAX,B%I$X1^6#^1Q6I.4U[D$%)% 2D#B" *:%FJZ(1B5$*!0 I&-59.C4H\+ M",=$Y'2O+RTU"9-?A>*\%S$7C+,\I3F DN=:JIH#PF$!$HXE(Y3FU$[HY<+S MIT7??OE7BFY8HV=K955;<\R'P3K!W M-P?:\AVC\R:PMVN[M;OG[^SX-1AQ _?67AEKI];;SFEMR=X*M_/>Z\T-WG+J MN1/HZ3*9,QRG#&& ,2D 2B &M,P)$!(A*6%>RM1*_:"OD:E1_>[8KH>&\B4@ M^QDY%#S#[\8=(7/3.>8CB'P.,/M#-?;)Y>LOD^<)Y?,0V!U-/KKW#;K^+O+PO5T*=UI1IE0G/LHT)2 M:-W/%5N0Y7\*4LT+03E!.048,46*(L9:_B$!1)"8,)K'92:M2?$F4Z9&G:TS M$=EZ$ST;=Z*J]2>2ZTHG230>11OMDI' -3Y%K\HI!RJYK1\M.'FTWAF8N;N. MV3D2-9Y$G2LZ<3':.A,9;Z*M.]%_CMDQ#B/!:!TTTG@1Y L*I8(1!-S>D>BV M%L8;KX(@<3"JA7FBX]@G%O./JK'-ZU?Q;:&K[JTVOZB7<2XD1X1Q"A#4!YA$ M7( R$SG(),M$6<"2)5;+0I<:F-HXU=@8[8R,M)66_'8)Q"O#20!H!AXD'%&Q MYY(KKI]9D*@%^].W]8]_4;W+ +3$?I@8+;Q MA-]GQ<&W'QSBT!'Z8Z0(=-LOSVV_D+9?#E+:EZ9?ECM_0L6<-P+9&VWZ/GN\ M./-&[P\BS%N?Y2/!7F\63WHGM(UN.UVG^Y56AC^4A5<1[L??-\H6H]#QX45\ M4#?>R\\KQ?VBWMROEJ_=S^TJ>#WGN60XA@S /)< 2:R&L81G@'*"LYSA5&9V M<>H(QDYMN-NZ&SVU<\SG3AQMO3(U44X+HNBIINC\UG_EZB*N=T'5SXO6877[ M\G7WK[:2D3NAE&#K*W[X'W5K#5B3O?A49;T\J=^BUH:W+^J_* MZ4A[K7_N?(VTX[M_/4SO/7#1OI_.^S"64/[(_!!,9'^*#>KU\K)DJB6$=@E*-P$S\##:86*L&T31ZX+OP=2\CI\_ MLI+7!?=.5;PN7>B^]OVA'4F;6E)DFF+-?_SX/Y/4%\)OA&?BC=D;&:0V\UWNO M1?#S3QQM%;S7H?UE\/X+/18:WB])7=_+-B/DOOJJM4>VDB.FE3DJ4O7UIA!D MD$J "GT$BQ$*$I[FD@J10"&L%PLL&IS:9]Z5FMC*QS\;,QWF8S8H6\RM V,W M],"NK=7SV@Z_^RHR%L_V-)N&0-)A=AH8T9%FF &0=9L:.L#4.[VS>5#R+^M-LZJ\)JMNS?D7L9DSF9 ,L;31QD<$IH#&) ,P+^)$S:!0 M5@@;::"^1IRH=P0M(&62 SE<0LZ"6@/@,3"=&@N;K3QMXW:W+PQ$#IP9 *J1 M>+*!S.RR&7Q;-^D^9Y MRCB5+ ,%Q8H=DY(!3&D!4I$F12%A29-ROC(GS[C=:E(HTZP^C++Y,/8-''1G MNO,LXGNN.5:D#-5U=FM8HW;':)D;VW[8]VD6;;TR[+7OURSJ/)M%QK>9N63K M7L!JF8$!#U5>,Y19X];C# SF20'/T,]_FP/7;12MQY9>*69()48I*4 )D3+#7!QYQ M0I[BWO-^2K+<8?ML(F>\;:W^+W7BV[$K0I__=FW>]XC(>]5N19:?5US\_K_$ MZYS+(LTAER!'L HI0B0/*8@+R$N2%H616J]37:VA:F-,NUQB-;*R)@9*3M= MCXD< WE]F^QF> :F8V=D/(Z*7/#^AK,BQT\<^;#(!8=.3XM;]OLN/-X1S!.YNFN]_N1U=YAA$]D41E9&_WLY;I^J<0=U8?H MV&;.>:$FT#P' B:*JBA3H4A"8I!FN9I&9S&)I94 @UNS4R.J@T-1G9&.4LZ6 M@-OQ4W@8!V:G/8-GD3:YT?**=D;; .O,3&XX!>(ERT9'924W((XYR?%N3T9: MU_7[M3F@+U;LU1RB(LN[S7M25:_JEXW>'BY$R@N(=?&)!* $Q8!"-4LB>2I3 M1,LX$_E<3=+HVIJ2;-IU^93V6Q_PBU)F1VQG=W-XD"P=6;/0\>G,O7,=+("7+CF[LD)AJLW>*[L+$W?"'Y^1;D]Z#VG:28H M3M1D"26EBDU(IF*3A(",9QB7DE(BW-9UK)J=&G,T.T/4[ RQ_1VD5M7 <6'' M#GK+99W@@(ZX&[?=9=OM7\PZ!8^ :SE.$(5:R;%K=-QU'"<@3E9QW.[VHZ5S M"7=SF)4PST0*I, 0()%F )," 8(RBG,D,L*<2.A<(U.C'%,0U(U7SF)GQR*W M(C(P9^QR6@_2@,-11)__@0CA;!.C?OY]3AY_[+W7>LY(2/U=_Y].N_I!EOIP M]5=1;ZH%4YRB_Z":._S%WI6?5VSYHN4,/RSJYW5-EO]>K5^>N\5C/95Z$?S^ M652&B^KMVB,NJ!!QF0(HL*[E1QG ,10 %RR6F$O(D]AM;>4MW)C>4DU3KUA[ M-S/_C?:<-!_J#@+S]W]UG&.]Q;MB.7V;>/\//3,\V^6SX_Z>G7L)#N_88A%U M8$0&C=V67HM'M -DD!7UM^S14+/;MW!AW(GS&W;2R9S\+6WQ&WP_/CTOUZ]" MM+6F]G8_N@+PE!49PWD,XC1!*LAF,: H+H!$K.!9F8BD=*IZ>[7%J47<^Y.9 MF9K9=^RT(;_;ZG;:HVTWU@3%<."!H;,55&U]NH/]T=;><*1M#4T@AKW>WJAT M:.W^,7?9W^A'-'KOPGQ"CX)]7RW^_B+:DLX9S'B>Q3$H$RYU\3@!2I'HX[Q0 M$I2D*"=.-6TO-30U6MG:&=T]/U=KPKZ; &=KM6<9[8LXVS%+"/0&)I3;@7,F ME6NH!.*2B\V,2B'7G#UFCJO7^Q'&F>R+^E'\OGFG;/W;/"5IFN>,@Y3K @,H M2T&)20DP)6F>,EIF.'=AC=[6ID8=>TE%?Q9$V^J@B6F'KQU;!$-M8,HXFX6E M)HW:UL@8&Y LK$ )Q!C];8U*&U9N'W.'W4W^ZXIJ^G0TS=JE>\82$4HI2&$N M ,JH %CP&!!=C[L@<883)P;I;VYJ%&*67?2P>;)(YYOT>05N^T6T,"".L-SE MC9_72M1U6 *N&?4T-OKJSG7'SZW#6-SE1ROWF^^BTFL"E?BN%6-_B,\KMGX2 M.GGK%[&YEX_D]P>=U[Y>W6TVU8*^;/0FR>/Z@9@9?H92R(M4@(*5!""!]K=GUOM)WML\:3NG/T[D#ZSO5>GWJ$WRIA'M(N72L^SPHA4D"AX$UI!(Q9 M O*,0\:)/D1>VM<9/'SXU'A[:Y[C^O]9X"Q(]P8X!B;7H$BX%-WS1V2L8GJ= MA<'*XYUWN;_LW=$](Y:S.V_M89FZ"]=X*KD9CM-E8_B'ETJ753;"QF;E\A?Q MT_REGL>Y0!"A##"$4JUU$0/%30DH). M/.+&\$C-&IRDXMV@MYNM!X=S8 9L8\D&Q\;B5LI\UNQFZ#GYS^:"@!H73C"% MT@2S:G-<12\7&$[TN)QN]LS=^OO+8O/JN,)^>-.$7O;&L$&6S\_['"H!Z/#A MXV;[G'7L)+7G_%5^+]WGU0\UJJZKU]V.W6[7F*9JF..4 I[H SE:3(6P0IK&D,_- "660+7@;1 )]_KU- MC4H&-DX?4X/5/9[[9$VJ\NJ;*0A])"KY5>BHO/OCHZB>DCG-,HHA9Z LA0"H M8!)03A& 94E35!9)7D*GC3%' Z9&*%L56=*JR%:=S6V==&7$D^.FF&N?6.Z" M#8CTT-M>G>F1,>^,=N_6_N:*Z+$/=??]+4_H0FUHN38_[@Z6)S@G6U:^S_%C MOJ]"D>J+^*3\T6HN.NCZRV+S_?U+O5D_B>IC=X+@KJZ%^E_^2'Z?T[)@(L44 M""(R@!(L =$R+*+,",MB6&#DE 7M8WXC0P(?E Y*%-=QF#8%)T9YH867GNLI.G M0G,]UX;,MOZR6(G/&_%4SS,)!2QR F*:) )B@$IB-9JX3 3, N3;KUM;VI4 MT),OK&V.C-%!,JYWD-L11$ @!^:*&S$,E'5]@LR@:=>[UB:0=WWBNEWB]>EM M[M5#[I[$BNO]W$]+\FV>Q2PM&"L!+_3I+\QB4$HB09HR4N0LSP2U2_ [?O+4 M:&-K7*2MLZ\1<@A7/Q'L[ ^4*GNNBZ(G)=/35%A[8GK'(J8\(+@!G, 2(I!&66 M%2 F1&0H8V5L=T;S=E.F]EGW+3(N9%-=[E60JK:L*!>@LZYPQ*A=,'0<<5'$ M=L^96;1S)]KSQ_E\7(@/R3YY;;0^&BG5[::^"I0=%P33WERZVUH8+_,N"!(' M>7IAGACT@/!108"8"0*%3 !+U0"&:*)BS3*#((%I(D0ITB2UBC6=6IW:@+6= M>C']@]C9'>2,L%<)AN XOM7L=1:13=19W>3U#7YR>-"R#'9M3F ^:UF6P>UF MCS#[EY$\T%UA:@JP5MFK.<"%ZF(U72W*'@)$"MB0%/U4Y&0C(@4 MXQ+:'VJS:7%J'-38W!Q3VQ5B?N[,CGZV=IOHN3G8YA(^6W6"190<&MJ!::E% M]5X>E+?>6MS%72Y' JV0=(AI0R,Z4NAJ^[Z&.L3A E-O-&KUH/&"3A>_#F)+ MIQL'2'+KZA=^U>?BE E&_4%%BV66)*#DN-!Y'C$@6@)"9BA.4)H7/+$ZRN9K MP-1(_23)K:N)&E7Z7">(UML$+9/TYAAP.O>/7>PY).H#\_WUA+?._D@[,(M: M%T9*>>L!;XR4MW/-3R?EK0<'0?= ,G %+-%0YNV MGT[VGCPO-F2Y^(=BF^ZB6;1CI#NV6?PPFK,ACP*2BY10"$J9JU FA:4NO).#-$YX+&#&A%UI]Y,G3^WK M-K9%SXUQ#O.@ [0L9HZ^& S\.3?N/]SFOL-TSQ>&D:9U!V]#J+G;.9][YV@' M-XPW%SMGY\&G5=Z1>U+^JV3/A]ZO_(-5"3^=T )/, MBZQ(4H$%(*4^=:B504I2E("+,I8Q+Z6@L4NP8=OPU'A*VQTMMH;/U,_M0*SG M4FXQB37X=L'*$) .3'L&S<][:!JKH\;L:+V*.L/-/"E9:3A$(!09RP M$B "*2"89H!)Q#&E"&$ A&138NCQT M2]X?%LN7KB)KO9=.,4^0H+)@!.2*=@"*LQ00JOZ9944L:,;3PBYSUK/]J85, M)\O/J^VF#6]<:'<2H_7."?<-1M_>(IR7,*8"<)80U5LR!V62)P"FC"0HR]0$ MG,\W^ISDV_?6UHK_;WO+;LP9L \&'G].=@IV.YR-V8:U'X<8B3^0"C4NN MK8\Z1GE"^3[&)[6\60O6&J*+35._QIQJQ+%((%,C$D*\ (CG!2CC' .4 ME)*5E&:XL%(!Z6MD:J-0:V;4V/G4'&ER.";:"ZC%PF, F :FGD.$1&"(7/*K M;X=JK,SI%C*V9VJHYX3?<+4!*? N;&^3;[(U:P/"I?U: MJWL]]8QU)/>.U(+O%S>^TREQWPS)O7O=7=+NYMS])!7O(L+=L8PF*+Q[V7Q? M5WIC?\X27@J(2X"Q+KZ1H!000E. 8X1R$><)3C,7VAK0UNFQ':N,QMAVQJIF MNF2Q-+L,+RO5O^;HQ>955T12;NH:/<_J"?Y3W"%?!#M.G4CW#DS%QC1@?(CV M_8SV'(WH:[1_7>ML9+R=[4VV]PZ[M?/NG<\!5:"'[YA0VM$#6CJNXO3PD)_H M5(_0Y(VIU>T(N"LE20J$4H8P@)BHP!B5.2!I48 TSAE*(6$HLTH\NMK2U,:' M7:9<5ZCI7SW3H4\PM2/K($@-3+4[D#HC!]$4OPI%Z'3EDW;>)B_YDKL7$Y O MWA!TPZLAGT9P7V_SLWF.*(,<)D"DF6()KA,5<5*"5&94XHS+$O( .UTG#4^- M-$XV3=K(LBW/$7IWY+0C;MH6N0G>-]\/:>QN4H?8X!LA%[$:=@?DM-DI;'U< M!,-RS^/R_9XI0DWL5#^N[YB:PU7B8F[ 7*(\3S-(0)ZB&*"8$4"3- ^R8,F/6B'O1=3XK59_6\S8!YWF; B,YT MQR0B^_ZP([# &(^44M0:K4OWMF9'1VE&L\,\HX"I1"4*1+G*-"S/"<7N)H_TC^U!_,>*K-AW\:X]D-^^WK @<4HE 07E#""8 M:A'!0M%(5A8,QRFGN;UT8'];4^./G?1&:V[TKA/A<$AUN()O/WT$1FWH&.8R M8-?9PQDYAUR1< B.E#*R0W+3(DD[E9(MDJ%22.S ZRT)G:IH:EQ:FMG9 R-.DN]2C%6QQW7;U^H+R/^M)VW_VSOK+^^/OSHC(WU9]734G;H_6S5FQ)S3P73,PS MDF+DE5ZP+SP%)?>G>4X5]F9)2E5 M\7<,4(9S-3 B ;"(8Y!A5A"6T1@C-U7IWN:F-HSM'W0QDLCKE4X5$"O6I_WD M@[/=0!(.O8%I?Q^XP:MHVZ$22C2ZO[%QU:*M'#^1B;:[RU^K_DB ^JNH-XJH M%'VU M6'O]B[\O.J56!3=CVO:[+\]VK]\JSN,$* ^M-[$;Q-V%'L."^X@*D^ M=,=$"0%*$P0P5N04YQPC6&0PY^G\V3#HKQM2;2PI:D077#[98T<&G%F+;XN5 MJ?*B][)-L^[Z^:.]!9S04DW;&."D3 $J*=4EB1DH:4;S)"6QC+DF^DH,'<&9]^"T!LC.U:BY1+\91[\\O&.+0=2!$!D4S)W[.$0[ M(,(6%AF[^P+6)QG-]-'+G(S=*>>JI8QN@V<64UV+33V/12F1(!2P(E&!3LYC M@*4N34XPP5(/=C1W&>R:QTYS&"+&-L=,I 8FRY0C9^>'SBWJ]]@]?>C P5!Y M0LU#QTT(.G#D)//G\*^>9[A4!%-]61"Z6!I9[RZ'(BE@QC(*J(!J?ID4#) R M1T"0E&&*(&:IE<9+?S-36_0R5D9[9CJ>W3J/I=U7>3M" W^E)^ ,D/C7#T*H M\UKG&QGWL%:OHR%:MUWE>E>$[3@A#&X#\X(O9,[D_9KJ7?4UU6[\^Z4EW8.P_[O_T9D!O[@?4&Q M_N![W._[PM5M>U^W^M?NRS[WQ%$^Y1Y7NF^W[Q+'M'VQF+]?_Q#55C,@+0M9 M)$4,2J@K(Y=I 2@E3(WFHH!<)&6:62G]G#QY:A^J,YAM4/^P^O],GC9/Y?%;&AA1>#@ #H?JQ"$>Z!&- M_*K&95%_0MM3;+]NUNQO[8HT*6"1"PZ!*+)2S> S""BA"*A909(@691<6!TR MN]K2U$:HQM;H$T ._-8+I<6P$@J@@8>-#AL4[0Z9&DM]CNCV8N; ^:&P&XG3 M+V(8BJ=M\.CEX=X'C,>S-GX<\*C5#7X;(5O%E?;UI#+!#,,,"*%F8*@L$T!E M@11/E@PB)#!)G8I5'CU_:IQX73?("C6['8T;L!B8_K:6#;"M><'K0-L5QT\? M=8_B@FO'&Q.7+O,NYLB$X/4G98[6?],'<;^YLS;2G64T),U9\=U$PS&KX0K8=M]]. @'IH%# M]#[OH?>7:^CY5&ZT "5OPV=RH_CO<&(&M7U:; MZG7^VZ]S'I^34OO#?_O3KY:GI M)5CZ/V0_9P?^8'_[Y?/CQP_1KX]WCQ]_O?W[//6Q9T^TO;CY#-M_[+[ O4>- M\J6=FMY]46?^$FH;=*\BY=?UE3_W/&RR3'6H4TT<5S4YW17Z 2X#1) M.4_*@@JK[\NUX:E]A9=W;/;LC_ZJ/8A:%YR**CITB>\VV>U O]FNV.@8W[KG M=3O6HVYQ7<%\R!VL?J3<-ZPN/.^-]Z?ZO;R^'77E?D\A,[-@>W=^ P#F6):( M 4DP4W%5G +,TN@Y(*/&IGI;&U8FZ[O*)I)/%+7[\\(DLJO\@RQ?1'&.[6_&# RY$ M2[/P^]57P=1L3C&3NN"7]:KJ_JD+?M3Z?C.$/0KV?;7X^\O^$8NB2&*2925( M8(( RDH)RBS'0$W=$L4^DL5"N)#,T 9/C:FTOY%Q.&J],[LCGU?/+ZTJPM:; M:.?.#<=E!G\C[)AR2OT\,-T.V<7.A#P6[H%8?7!S1QT:Q@+_>'P9K=TPIZ-5 MVZQ=S;;GE=:;KQ%%A MBC0%/'KM"%6H@]BVS8Y[+-L1C)-#VJ[W>^S"=#4R]S+-M?CI>K7-VRF2 BG> MD2!C*FI!(B\ *4@!&*10S8UQ@KG]*::KS4TMAMG5@=T_;,&,S=L\*??*NY;8 M6VRR!$5T8%9JP;R7!P>,&G.OITWY .BP@Q(4R)'V3:S>SE IY=8 ]6Z77'_* M>)LDUAX=;(W8W^4YESPNMS[G92'BDF2@2(L$H%QB4*:(@53-+2F*&<8(N82" M)RU,,N:+UMO@1;1V.LX93X"TG"K> L_0,\0M)A^O8>(^+;SD=ZC9X,GSQYT$ M7G+O9.YW\4)_P?>[U;$^YKD2!T69T4P2!!!")4 E2T%9\!*P-&60B8QQ[J2F M9]WRU,*N\]*ZYX1TW<63[;K"CBH& 7A@"C&HFE(=Q_ .7X;"%:Z ,L%V[8ZN M\>L$QSF!7K<'>.9HL.^"ORR%"GJJ:EV]7U>58$:V5[5NI)T:9:<[_G]?:E,W M8T^HZ%%'2',L>2$I)H!B40"D2:[$$@+(D+C71@1!J-J(%C M(F5%O+MQ"H5%W(W_KU-:Q+MC@A87\;?";]Q4U*LM>*C6/Q9<\'>OO]5"-?]I ML2(KIM.-U"C^PR0*;!5"U;P&D0QG((E1JB8\6:[&/DY!EN2($LX2Y*:-[F[" MU"8X[[<5KYI#\[(S/2);V__5;?SRZ!>[,6A8M(?>9U.!@@&[,U]7C_Z#]D#% M"G^,MDY$.R^""L+>#F(@%O)*_&-+F5==O7J\4(W]8/Y'% M:HXP9IG(.4@(AP!E,0149A3$,"<$Q7F20J=<^K.M3(W7&B.CK97N^DBG0-JQ MU,WP#$Q$Q\A$?VU,#"R9=!&"@,))IVV,+I]TTEVQ_4"_3=](J5=[+9JO<' ]201S3";RR2!"DL@0RUU74!=>9CI@#@0K$ M:1DG>9G,?XB*KJT7APN^ZY\;E MB&B?H^?6Z48IUM0F;3)(:G.D[@^DCHB6S];^6^8WC?#66"XX3^)-&'HAVG3M M.].U^VY&=X>OP/YUK:^1<786=>XVHL[Z'6C3LHS+9D&!!#V?H MN*O:@P-^LMH]?(L>&:]?=>O;[*VFC?J3^A8?UHO5YM/BA_@_HEJ;J]J#TY * MCM,8@U(RKM5]&" )$B M$X%*@B1,"^L,6.?FIQ;M_A/Z4Q8[)&FZX]W/[,.C M.#!;&ZOVDF!;SJTC;7]D'(BT!Y%V(6JN]E!6=L?=(5EV4/Q'2I[UZ(= F;3> MZ/5FUKH_=;Q,6V^/#S)O_9_B-^?Y(.CF\ZK>5.9U_+(K>YDG,$T+ ;79D8[.V\XP7\)6+N8/@!< U.\%U+.(?05 M' +%OY=:&35XO>+J<>1Y[7(_.C@JP=&= S Q;+VGC:0/F[,Y3D0NI$A!D;(4 MH (C0 LA@,1%$I=EALHT=2$)I]:G1AU_.:Y.L]J>7*':WO;T5+3>DUAS/E3E MUT^Q%#$O)0(%$5AK"W* !2-FQRZE%,N\+%QR5(;KIQ%23";<3W9CPV#H#SQB MG%39VAWM:FS?5\*;1<;\<".)%VJ!QA>WMD<==;Q@.1Z+_![B7M#UXVJC%_T; MD8*OXGE=Z2,LOZI9U$L]9TDIB2 %H 1+@)@D !.<@S1F&QLC]K-Z\[ZR)@?;>UWT?QUZ0J+U<^A M !Z87>RQ]5GO= +915EY(+#'DE;>@2X:T-<=Z+4!G70N!"L1Z@%8O\*RRP-' ME%CV\/-08]GG 1XCP6-%5NR[^+(FJT\O*Z[SPC;K76KM'3."_O,,<9C21"]H M)3NYML!F3O>ZD'C^EBW?L;]ZI?U1A@)5-58_4!>S0'<)$DA MD5+-Z6FNZ!LS DA.U'_4[[#,$XE9,5^);T19\VC)XOU-6GT/9?,]G#0\X.9+ M:[0#HUR!UH*: R UTM94:VATOXJ,J9&RU1!T';76A@/.@8+# 3@2]6Z!7*^B ME0%2G\I;&B"?&ZM#4:X=-KU4>^41XU&LG2\'U&IYRXUJ6Y]7;/VD^+O6^_MQ M4DA6*AR93DBF#%"4ZIBX(+",8XC+W$MO:]?&U#9^=KI22V6=I\[6'H1VNS4W M C,P5>XP:I^:,FMO1;>1G3KU,6+LEMG+O4(E^[J6@T# M7$VR?ZB@0PT%.I%4_[Q9*-8P3-(N!@F8((@Y!&E20("4FX PE &121YS)A*( MK-)YW)J=VMRW-3QB6\N;DP!;VYM1SB$XL.\!BP!K$%P')I .TIW1.MUPS^PV M O-8[;3'UB$&&P3CD<(QR]570PY9 <,/#X(%40R(M3Q7G@#!H,!)2A,A M,[OCME?;":!RV?#]:6>=>0(*6=3[?TAN4=>YU M^7Q9Y_Y;/)5HU_7F7JK9IUB]B#GD>Y$ E #&* "=2Q4TYYD24%Y*3; MO+;CA(/G>^Q4#\P#VCP]Y?ZV7O,ZJM?+RT78+."SXP!W2,;*"VVP:"T+J$!Z MSN%0 J$'SQY7O_.<6R?RFFS^\Z.3C9H7*E-J^L'C_JRZJ;:0DYXC#F,1< M@B(K.4 D9H"D<0'*%,9"_0HR[+28?I,U4R.,]P<[4ZN*5S;)EE),@' M)R$]3VBW+1I/6A7T662IW_7K:5(>^KK_HL\%[AR'DFXYBA4LUTD-&^E$0?T44@A5F&24Q*&!?S M9V/MQ]65J8]5BRZ?[&&[PWV[>^;-(K'B^O-LVO:LK'L5]A0) I$H 4\E @B6 M6IQ=(% 65,"DA))F]I)N(2$?18RC*UM\@/M.<. OMY4UO@J^Q>I^2$B'GKUJ M4W5>3VML=%]%QMQ]>$/"YW)V,2",8YU7-'"JM[ M7ZRX-JH,G'LECH,=5;3$ MI_]XXK6'C'@DT=*?PV.(MC=Y)EAOOHM*YS54XKM8U8L?8I??^8O8W,M'\OOY M?(99IQNTE3HW3CD9%_WKJD M2T4IGQP+:@3H+;MYQ[A],/ 8T,!_X,UASK@:7H59XU1>#5)J(QRY+6'>[*7#,A^:?I.T;B HI B!@7*"4"93 #%G /!!::T9!0F5K6) M+K8P-7YLQ7+;[2-RBY\(;2I"\NZXG_^Y83_[^N:FQROE"_T"6NPK9 MN[I@15+D@HH2D(SJHWY0 BJ@%GTG:9RJ/V'JMI8]I+53X]<3^<*O0M>([\.A.1G=CP[@X' &DP'Q@'4Z:B 1:ZP?1Q7D"*H; MQ$&Z)TU%(^3(,P>ID.,[?:I'+>J_J:?^IIRH-BK"U1O$S=&\YK_Z?)XYGC<7 M99EC#CE(D:X:E1123252#E@F8ES&C,+":C[AUNS4)@;:\.9;.+#=I8Z1->(6 MK#T(C@,SM[;9D/6!U5%[(-3E8.@MX+H4AQH"Y+&*0FFP]>OZLF]]*,IV1J:_ MX)/UTT8L].3JX6&!)^>[_5:2?JN%?%E^64CQZ_>U/N!^+_72Q+W\HI?=[ZN[ MNA:;WS;F%+;3,1OW!T^(:!KC(VW]+&KMUWM6QO9F[69=1<:%J/5A@(,Y_A & MFGI[&##J?-H?H.-)\@U/NO3=[;\'7]1/__._=;]1_]&%/O_G?_M_4$L#!!0 M ( *";5?,\#YT-J )8T!P 5 9&-T:"TR,#(S,#DS,%]P&UL M[+W9=IM)DB9XWT\1DW,[EN'[4J>J^BBT9.NT*J21E)4]I0DA0%-S?[W-S,W)9__N^_?[GXZ1LNEM/Y[%_^ MPO_*_O(3SM(\3V>?_N4O?__X"MQ?_ON__K?_]L__!\#_^N7]FY]>S-/E%YRM M?GJ^P+#"_--OT]7GGU:?\:=_S!?_,?T6?GIW$59EOO@"\*_K?_9\_O7[8OKI M\^HGP82\_K7KOUW\4V:>1XD6?/8"%/H /CB$%$I6P1GN7/R_/OV31.:D]0:T M*AD4,PY"X!FR*\ACL$$8MO[0B^GL/_ZI_A'#$G^B[__)M>_S;WW/Z__]N97E]/' M?I$^EO_\O_[MS8?T&;\$F,Z6JS!+=8'E])^6ZQ^^F:>P6G/]AW3]M/,WZG=P M_6M0?P1<@.1__7V9__*O_^VGGZ[8L9A?X'LL/]7__?O[UW>6S'A!A'S^:YI_ M^;G^_<_/YX2'=^%3I7;]KU??O^*__&4Y_?+UXN9GGQ=8_N4O.:T^0Q4K\Y+5 M-?_/VW_\\^WR7Q>X),RLM_N&?K#YC+K:4:3@[RN<9;S:X?4B%_-TYY1$B7JQ_.LDXG:P_^5E$\!!I+Z *\9 @:,!J;XN.%HFS M=W=>J5X2V6MQ+#']]=/\V\_TP3]7;M0OUFQ9L^3!L.8[NZ_/WD7YWXEW4 M5C@%D<=%NFS1?IIOLBX( 5RO5Q8I ?B MO0O=S6_\_#4LZ(,@?9Y>Y.M_71;S+RUDM9HWX-R56(CS_(*NXHF-/#@;. 1M+6%:: C> M?HFXF 3D MREG!P#M)-YY.GKXJ'H1%=$H7HW@\"0WW5SP(!;I?%)S$P2ZD_QX_32L39JM? MPQ><:'3.B"0@QZQ!&5T@"F($5]%:8;0EGZ4! NZN>A *3.\H.(&372#A-;GT M"U)A:\9_(/[C\_GE;+7X_GR><:*XXC+$ %:0T:.4MQ 2>=K>2RXUBTDYT0 8 M>XDX"">V=YRTXW,7L/D8?G^=B7W3,KV*56PTH<,2'3,6?/(5_PPA%'*AF"9* MI352H&L F!W+'P05USM46O"V"Y \RYE$L-S\SYOI#/F$,1>$DQ),# I4+&1( MHW1 [!(E!VL#V@8 >63I@\#A>P?'J3SM%!AB(A0K*;(()ID *IL$D6,$IG(H M9%5+T<0&>63IP\)7[(^'C*\+$VFAZNWBWF'^;SA).!%J99"I@-)+3 MY92%:+2#)*(0*NC,0FH'C'NK'X:.CF.=S5C;$T3>S9>KHKM1EIAXD$85>UK4<_?:A\&CX]AG([:.#(ZJ]9XM,%S1G;+% M6%&<,ND]YQ2X0G^D9,F[0D=6]&D&QO9JAP&@XTCGT:P;6>3U[?SBW>?Y["8V MIQ-MU7IP(44@>X@84)P (;UU"5FPT9\D]OLK'B;ZCL.;)[%P9/%_P'2Y(.AR M$3].5Q1>"&EXUJP^EYO09%50FY.0-">KB['0V:Y-#GXVZL> MAH&.(Y GL[(+=^#YY:*RZ^IMMD*:9'"YG'#IA'5&0RR)F(*2T8U&VBQY'G6, M@0N63X+$OM4/@T;W\<<&K.T"(J]G]&G$CNDW?!%68;.M2> J8Y$<+)DU9.DR M!M[D&ED5*>8L3!:GY+[A*=@G:Q! M=B1Z M\OZVF/^V^OQ\_N5KF'V?6!N#PDQVD4_50A*"U)K5X)*.*&-$%G4#/#RZ^&&X MZ#[,>#ICN\#'A\]X<7%-O4"E#3I.1K*GVXY+"\XJ#5F'6%BV(JL6L-A>\S T M=!QS/)&-78" "/]2$WSFZ3\^?":^+=]>KFJ%3_6L)\YZYH,VD%PM:#+*D97, M:A9Q2;8HKQ)O84/LH^$PD'048OK6$M,G+O+7L8-#J.7)[.S+'?JZY!9DE!D,E*)+&TR)Z%BQ\*'@:+C*&<+AG:%B:L2I:M- MQ&"UE;J T^CI]I.:-J$0.#-.9?*KF#KMQ6OGTH?AHN,09QNFCHR,9[2#O-[% M1?@T"3E%G96'E P1CJ9NH18F:9TD5V1=B]/2Y^XL=UC)7\<1S..9UTSJ__SS M ^:]H1\<7;)/=M!LB9F^6,XOIKFV9O@E7-2> ^1IX6KY]UFXS%/ZZ=V='%K4 M?_C'MRG[/W([)S8&N%S"IQ"^3M:9F%^5 MZ"+S.M;"C MF":G56H.Y'Y8X,%(Z2R9HW%?IE$)R[C&R&;1JX.'%ZOE]4]N3^!3Z#I6J5RO M\6RY)/[>[))E8;2/"EC@=,2")[LZ:$4&E!%T:T:&8I\S>\PN[U(P3MN!P9!P MK88:L'O$&^@N]1OK^V83TK+Z0*A)C48#R@5/_/"U+8E.*$,QRLM!,'./D'&A ML'02 .9#2Z,#B+U'XLPT MD5EPV/9TEF3C*P3PA3Y M':Q6=)5:#5KKA'TP(+-76@>30-4XWF.%0U%H2'8#K+O%9N:C) M@P4=T(%"S! U[< F+Z6MAT3OZ_%PLA,W3N.8 :^GH[E[/#3FJW#12._,O^)B M]?W=12!VS'*UV+[6L$C5H44P(Y!XD:0O!/,DH=8.@'$ADO/@0Q:M[9I]]/1@ M,C?Q^ILQO0/=\I9V$FHF^1L,2WQ?VP&_+7\GQ5G9-4F8F(DV0=+U10YUK5/7 M&HR(SLLB2E'[,B&.0=!>@GHPC9M J!W;.\#0%5\F5B85@A.00O)DL@4.CGD+ MQ9(-YWSB7@T37>S!$&X83GP2(SNX@]Y,0YQ>3%=37)(R7">%?9Y?$-.753&N MOM^P1I7,B],,C)*1;FE+OIZNT7E7-6-MNV7W%00> Y!#:1OW;AK\,6,0$76@ M>;;V==\D-"6BB8X,.1-EM?$U^"@22"M\44D&KO9EYYP(MJX>/(:1_FZ(G2** M#D!U':]Z%[[78-5- 54(MD0OP?/ *G,0:!,!\$ M7&2?"QJG<'@?;=SWC*%4T&G,[B"J] (7TV^A=K'8VLNO\UFZ4:C9RY(E2*&) M.QP]H=_6W2D=F8\J[NTFU2QH M04X#(Z?!* $ED^NI,U->MO;7=E/3C8D]'+(:B:(#4+V9SSY]Q,67;2MP(@L* MAQ$AB)Q!&8,0BT\0LRAT3T>>]Y84'V=M/Z2C&W-[P#CDJ>SO $);AM_U=K8- MP(GSPOK: 39$2LED+I &-;/)OP M: R+14&1V=0:_7I02H82T\*%[5:5YT/5NKT>4@9-[7@O;8.VV; MAK&3D0;!RDF,/AHH9+''>:O'_9S7&5GAXEV8YM>SY^'KE*RL22HU#R$P*"YI M4&@=>!LL)!-U\5DGVS[O\7%2QHT3#02<%FSO0-&\QU68SC"_#(L9&6W+9RE= M?KF\J TT7F"9INEJDI)#G;T#)Y4#I>L$4E_XNIM^1A^GR21E A1 [.U M[C(X7D=+&-"DB*4Q(G'=^II[(HGCAI2&4F8#BJF+2_(AWR:E>(:LUM@QN2[. M2N#J[,,ZUD)XK^I[YN#NW+A!IH'0="*S.X@N_*UYYNEB:P6RTUFSOUI+YC*MI(B/[SK::]VF[ MN]:9F[;MV>@Y.[AE'=./1K2<%Q(2UABJ0FZB3\[9U^Y=S='"[&RXA M7K]=K)?-:X?X'2[6O;0G >F&%RP#%X[N?%L4>,_IJ'&?')=1(6^=%74896/' ML!HC9W\TJXEX.G ,[N[JJEO[L\O5Y_EB^E^8)SZSR)A \+QZT9ZX%G2ICPBE M2+(>D/%]@Q).!]M]BL8.?IT59">)HU-PO5XN+VDGF)S2HKY$!4_'Q!R@9NS V B@.D(,G0)J>[8$4UEA"AH0,]F=F@7P6"QXX:,4 M9-GR< Y4/76BQX#QL1&@=:Q .L#7UBO$S@L^%0R.L03CLF8Y2)>Y: MA_KWD#-V<.Q\V#I)$#UB:G/-"QND]2A **9 ">;!1U (Z13@K/S.T=8=($3$^UL ;+ MP#H_HHX5Q1]I!,8-5Y?SLJFUIK\--:=QZT&L/H6UGX]QS-J#Q6%/9D2CN.S5 MV^,--3?(3AREDV3?)Q9K'U936Y$)#=$:GA3*6-R^>;O'];A]E)337R8W'_AQ MG:Z/W!CM:6-.^1IIH3^B\@%"TE8&P:.+K?LHW*5@W&AJ"WD_?(X\FL,C7HG+ MQ:IV=,R7:45N!RZ^31,^^WVZG.C"D/2V(UM0>C(-"T+,B""B]%H[I_5AB:.T MP!8ZZ+M;9.Q:NY-(^Q%RG#=D:A^@6+^ 7NU@^6+^)4QG$\.CX DU&%-?/[5W M$ H34$04A:MBW6&MH Y#QD,"QH%'&YD^!,B)#.[ FMYLY-_P2\3%)*3HO,A$ M/,= Q#M3>U99*)*SF$WRSK3.![U#P.CH.%6@#]OM'LG=?J!QRY%UVM=F+VBY M%^08UK0)7;D2P6=#WY;,I721>-8^FKV;GG&>W@8'SNF\[P!'-W-*:SWSD(I.GFN/MU0:,;@#B+S';SB[ MQ%?$I5H96,WY?TQ7GY]?+E=DZB]>_IXN+FM0H789IO^?:WYI#$8*E[$.ZJQ- M87*$0!VBS/904N$+."T8$N;16Y:5]1M45 )RJJ#7J.9^W3<>&O<#'#3S52U009 M?UO,ETNZE\MT-:%MLFQ9 ADT:6NG2%&CKB/M9$E*)EV:OUEL+=])2D@;5!S+ MU@XRP&\Z;6XF]MQVTN>>"^Y5Q;6J3RI!0=!*0D(7"H]1"]XZ]7LG,9UD>;1! M2QN6=W#/O"> M!%&4$GPS2B M4UM#R-L-D=Q-T+A63".A/QP;V4@"'<#I U[07WWZ&\Z(51>TI6?YRW0VK6RJ M+>^N=Y6+M9E)"RI@#7=5?T-:"2X9&4)&R7CSEX.#*!O7T!D&8 /(I .D/>#5 MQ$/,L>8BS1DIOH-6]=4?D(&9UD)#:VB8YD16FBW7"Y+/\ MOR^7JZN?H2""COVN,F;T$=9)S MV 8][5A_JI?^L>&H8[KO<+FZ.A ;]?GK?#:_/BEUVF$VT266)6B&=$2RR[7O M3P2TCFLNHE:^=:K8(71UDH38!ES-!=&# 51?8K;W<&=S$U]848Y+$)8;NO%Y M[0W$.)20DO?6T$];*ZO]%'62@]CHKFO'_ Z@1.C?NK.5%MJJFG\I:KV30 2' MY'=BD"X0OX1NGM9UAX!QFP,T!LKQK.W '#JDO\H[7$SGF7Z^J&-^7N#5_]XX M'AA*\BG4FSK3Q:UX!'(V"AT,TK5:I)ACZRJ-TZD^+,S$_B 0/+,4.]!G^W;\ M:K[ Z:?9U4B/]/TCV9=+VF*5[2ROO[NXDO2-&7K32<@H'RQ'"Q)KGYG@ WBA M-; 0(Y8@DFL_-VR0G8P<1CTS'I]P',X$C@Z.R",,N-D*"LV(O<13P22HHBIW MK8! %DUM_,^Q>1.]/>2,')(=%ZRMQ-2!,7'=*/"Z%O6&/SID'KP(X$K-EW?2 M@4_,@K8,G@J^[OXY>PG*:)BMJ)4C(X22=* M87*\R3+'2V7@?0 MFCDZ4:8V^C,.7'1&"ZLB#ZTG+NP@9=R;[2S(.8;I'6#G'V0%?B:ZGWW#1?B$ MOU[6?.>WY4%QZ=7!8-ZQ)&SM#5/'UF"]@Z,-($HT6)PUK-C&B'H2@>,^2@Z" ML^$$U"_Z-F?I884S"L&920GJ"$IB9)W*Q0L#*T*0N3!F?>L,Y">2.&[NUSD1 MV$1(?]0R](==3C>MP(>M0#]@V;,4GS]U^^W[@>[I95NB3C([NG(UJTV2E810 M; $6./FA(0=R45NG7!U"6..:=)U%R(JL4BF%IV,6J]M=>\ZC_".[K?50"+ M)?C,HTVR=:KTHX1T@IG3!7W?LSR9ZQU 9ZM1T::&EGLM"AF;D$M-D,.:=.)* M *^SB3D'9'; +G9C5KLW%.SN=E!'<+D#F-SM&+K9@PQ".*L0LA)8V] F<(PX M8I@K(DCFLFQ=Z_48'2,'K9J#Y61>=X"7'?.]-IMQ1H;Z-@F%3#M066D(4EE@ M:!U=VC(HT=HDWDO0R.&HY@AJQ_T.H'1_K-?U@> F*6L2H&.TBY0\^%00-*!OSN #4'S.2Z[CUC,3G2GX E8AU96"AQXU9C#*"8!I%*!W"[\3*>7X3E@?/FS]<)5Q;Y"6<&C&RU$GM&YO13ZZ M%:&<<;(V37-.@M*9KEG2H""%*&3)\U+NIX+LA\6CJXSK0 \ B]-YV\@9UXMNA*#6;.\#0P]3 M@(6T9+G3=#'W M"PU>SQX^];^?7UR\FB]^"XL\$UW-?4TP%5" KTL=(QJI2 M&NM\!F]:3U0_T];&M>W.B?D>L=+#G5XW=S6%[\7E@NZ4JQU=736_XF_KOUI. M G/DBKL"0; $RN:UDZ:!6V:\R47KYA5WAU$VKCM[=J7=5E*=N+V/[FO=$.QV M6X;\/32,+'+K.7&NUO$D]. LLI2",CRWS\\]@+!Q'XX[P-\)*=0/&[GP X .X1D^[W(U\?SQYLUW.40HP(F=>U:%@+$HC($VJ3EY%/ZV+J. M]22"QVU1V &*!Y#KV(^N=9-AEK#NY2:+^_7LW6+Z+:SPW07=(]5\OSJ_DRQ] MMD%ZX$JL;YL,WJ5(W*VU!%H:>;]UR([GMB/GEZ\7\.^+Z ME]Y=+M)GXC!M=;:<8!':%!$AY]JB(,@$41@/AK9!%D=,V>ES6H^[21VY+V(' M-VY38?:+V;5AL7.7DR*,#=9KP!1Y#2\8B(%.)_EV5NO(94RMF^C([;PZ MP&M#0?:+UJM#N1VA??D[+M)TB7D2G(]!60;%(SEPNA!W#;+:EM$:%1GRT/KQ M^^E4'H;3/\^KTW B[!>DZY/X^ 8E)AMK7K7&.G,U&0:QCIO3Y)]ECS%Z?TZ_ M^P2(_BD>B8858 <(/?X5[/&;9#'_M A??OPJ%HI5CJ<"P:$ 56P$[Z4 ='4P M3.#)V]8YD"-M];#3\J=XD?HC@*G+>,.S67ZWP%>7M0/4]9R;G=$5IYWP3GNR MS&1M8( %G LUT4<4'VICSG3OZ?4ID8BGD'(8M/_0CUTCR.P/C- )L=)YX1-P M:2(Y$3Q E-I!$BYDA2&Y/#@V#T/E'_I%ZZQRZL!*N3LYA9BELZUE\$8E4(SL M?[*J(@@3F"O2.(FM;>2G#Z7A?XK'IN,9WP%J#NK7/U^L!;=:+:;QTZ#*@@9"TZ2F"85(EI:8)N76QQ(LF'(?,/_1PUAG [P/+# M5&\C#9V]E E$M8$:Q_J26QO68K%S/%2F M?<3(O(@()9 F5^0I021&U/966GO-@T^M)VX>62DFI:)^!?*SZGD#[BL)IX)PV:UW, MZ%L'R@\@JY-^5H/AK;5D_JA3')Z'Y>=7%_/?EL-.;7ADF;-N_KN*<$-M5R)$WN>\@. 24KQI 7ET7KTW9$ M['@H& TM[;W1XZ>PO@/SB;65E01NM0"5K0%? M$YH32S%(LAFR:UVU.,0^QC7_SHSBT8$P]H/P5J+3=L[&U?9?_EY_0*Z7-#:B M9Y +>E#U@X.6&U<+3H^(.9#2J<#W?L":>4T76]D M$IW.W$<+LF "Y;F$X(D]2D=ER)DK$EN;A]OKCZOKNL':R:+I %:OPG2Q]N%O MN?JV7&=)3'B.6AG!P20=0$FFP../W MC7WVI;Y,_]=:F&_+^SH]]&TA]CU;+I$VD[TT3*,!*?-Z0C*#X&JC?YZMC5I+ M<[_[U8Z[=/\ZX[9*Z09@K272@:*[NYM7TUD@YLX^/9\O5\MGL_QBNDSSRWIL M9-(>'3EA61+35$U9=ZPPB+:DVJLC>-V\D=6!M(W;2*4;= XJT@Z@>I4<_C^G M,_J3/A67JXE..="1"D#:K,XYR1+(J$!P06:3BRFV>3SP(17CMD7I#GXGBJD# MH#U,\KCAU:8TX891PCAN@LX06"%CEN4,47A>)RYIP8Q6++3.B3FZ[3,+V)( U=!2I)7N^## R+"8ZG$'WK=.E#Z.JMB^^9@'BB@#J%W>O9-V+Z M?+'NQ^9U%AHE!.-R[75=P''A("9>DI7DJ>'PJG"+H-Y:YYX):,>*I%.$79^; M=^%[/32DN>DGBTM:;QKB]&+3"C K)VQD@)C9U4R :"R"" $Q295U.9^JVT=I M;]UPSZS\F@FQ2X-Q;5+\2J[AY:)*8WMOT10EO%; F;=T$%%#0!Y!81 J>24:WC>JP(F)16*8R&XUL5*3R2QMS:X9X)D.[%U@,K#@Q.39)A6IJ8@E4*G MS'!2_K1;4#((U-&A<*V-Q\.I&_?6/G^2V!!".QZ.C$ M,0DYUL-MLX*(=/1JU7660DD?TGE@N8?*;I+_SY(*VTI<'>A',H>OF_.D_[R< M+FJ''3IFJ^^U >"*K.1:0?%UW2#"AF(%0Z!]XRC;$Q M$ ^GKLLDVF8X>?#R,HC0NG"_#V?EA MBEJ2+)86::D0[A&CK Z>U*B=6O!>M M7>[#J>LR'W8H0 XDM'XO[)O']D<8*81R@4QR.FV6+)^LB)$Y4+,RU?$U-MV3P^Z.8GDT1E2^:+41M/*D$MH M-0.MO!4Z!I%,:]UX&&5=7M3-\/&@1KFYL+J%X%9][(3[+ 2K9U;4W#AT$5S( M$3CZDE&C8.$\Z-LBJLL+^;S .U9$70SA>H]?-V;OV_("XVKB0L"LM0%'CGYU M^!4$QCUHKHDUV:O2/._A/@U=)MX,A:F3!-"%;[%]*C9IXM==FI<3ZP1GEBLP MN8X3(0,8G'() @^DEDV,*JD!==9]>KH,^)U#79TDF,YNQ\?[@9>"UO!@@>M$ M!JZQ!9PN&2S]5)%3[JQNW:SRAT2-^_PV(MQ.%U$'F#NI28E#F3.'D1Z@;]\7MS"@<2&@=!$U>TO%)Y-N__#U]#K-/^)YN M\+>SNMGZ7PU.?@L7N,Y$(SY.$]WO]2^>S?+='VS]YNM9NKBL/19?3)=?Y\MP M\;?%_/+K=97#;#6=76+>/!#-ZZ E&4*LY3@Q%D\$LG<>=JG,+#S( -S[;E<"6;B4\IB:PS>"M(&4I2 M@<$K ]*X*-!S'V/K6^6\.QS7/AKL:'4,DP[NL7.JF%MQ%D7_QQ'0&3(IA"G@ M8PZ 4F#)5B;%6E<:C;'/<4V]/@_4.2#SQ[^=GGIW:^F$H'L;$G,UCS)[<+*. M:Y=C<%&)C6W $>140>QY[JE21VVF'FFHTY(J8VU'41A%=B8G"H&C9.MAP#4 M=<>Q?<:1]".J\DEL[P J=[DS49&7*(4 YT4 A8F^TKIN@2'G.AEW.]2ZV0/^ M-@7CW,Y=P.<$470 I+/:"2P;)43PD"+G5RG4'BV'8!C*D+7SS1,#NC-1F^>P M='$(NH51!['/#Y=?OUZL#:1P<6T@O9Z5^>++%39N3*7DDF%. ^1K.A4&(18 M9U8EHU'D0&)I'5TYD+2#@#W8X,/!(HQ#"*8#E7[=0ZQV%;O90T0K61*.]I#I MS"C:C0M60.+<*LF%8+%]S?I#.D8>]#"$P!]4 9_(_"6,WO#I5IGM \E0&=X"/VF6!CL]M4=(LW^3: MO"9=?:N>2_;<,IXA9\% R2@@A-J,2XG"@[%&8?/"LD.)&[G2]@RZ:!@Y=0# M>RV$W\95F,YJRM?U2_FK^>*FQOU-?4N_;;L0:4LZ<09)9$4.F@G@E:=S*U4L MGGZF>(B,\7J!!)M6G=@ )>E 5^"#,GXPNR]S(5=P>5#EQRYIF=0G W( M_*XA=3O7\VIC E/0V1O(S-/&6%D7*I&5D8)GG N+[+#.]T]9=>3"GI&!=8H( M.AUK^3>CGPCCM1?.>_CNI.=6,>KOX%&:;MO>W4SSIFU_"5QU_KM'VT>2P2\7M2Y2.*4-1P7!.EV?5#)$C=6S\=:6 M'+12K5^R!MW0R'.QVF#RONW5#P0Z57>/1+;#_5CV,;KPH,]M,J?WR1MHI$4W M8?_[SQ(W%Z[FV4HRLZ+$ *HD4_N-&0C26,%X$O&^-=+D,6@W12V>TAY^>GW# MN)@O+Q=X>RQ22=)PXX'QPLD*4)(L3,1LZLYB,*1D2U@=-5!F;J%ZI^Y=?N@/>2<'I1_\-&WD+4L*U>+0%P2 I2K"0>&(>0H63;20*=*8S->8S-6HUH)ZY[*SZ\:*F\FCQRA3P[ZW!:JYND; M:*2%[BY\=R#)]>K7"%36H. !0:P'145IP7.ZR*03.0H3O?;MNV,<3-Y)T:A[ M_'_V&/]O3XR.K"#/"*%H ^0)./ 9:SDH"T$;9"X>-M3X2VD7Y(5(.^,8\O\-B]S62(WLM"9XNSVH7=0@Q6 18A9$'AO&CM MBSV%OK'554O\/-(\9A@Y=:JF-F-2KO7R,T4$E[R6JEB*YFQ2ROA\6$ MBUNGG@6+6FL)Y'.39"/=0EXQ3W8Y)\EJ*WEL'0C:0\[)TX$/F([S&+Z%3TZZ MVO!&U#Y)8AWD" QG!". SR*U3O;1.J3A*'6W^ M90LM]!@1C93/U4??H,18)8P(%ER]3E2=$DD721UY85(2IJ#AK=M"W*7@5!7S M!LF$QZMW;+SZZ%L\RFBBXC) LBY65N2M76;IS&FID00'+-2:6) B%X"RPF(3GCDF/K8.)^BL9- M3FH.HB:,[_4NF8=9#;Q=9<6LIG25_CI?X?6U>M0E\X./;'+[/(7L1M=2[?S[ M2(0Z9&ZDU:7F@M?I$=P# 8W,&4?^E&5!%M7Z>GJJ6&XRZ=Y=+M)GTIO/ M/BT0CP_R[?RT1@\1!Q%[HB:YCO;N6.NVLC,X0I13$+VKLZE]'1Y7)PUFE)AT MTMG%'W'LP+5.>C^XA>XZ\6C'4EOWI8A>:$EW;^8)E%8$:QX]6,-YMEKEP,1! M^WKBPB,V2V@L[3OO!D.ROU.MLNY9_7E^01);7N7L'J--'OF4%EKD1\0ULD,> M+E--G]L7D:W<&*AIB]:#\YF#>A+W7F,L;1NJ74P<2-7TK;#S(.J[$'$TZG^^157;^;+ M)3F$ZP*!8Y3/_8]HH7GVDM5([;P,BQGYP+7W[7J1V_%YG"0I? ;/W7H0K:M3 M*BPD'[34+@036D?"=]%RY][BUV>G'9".DBR%% \)@@R"XB2?L@T;96W M;O.\DYAQ54D3'#QH=-Z$\9TJC=< M9:Z$1606K#1U5+7F$(N5H(7GUB"6$MJWM=A)SNDIG@\^>NNAB5N%/CFPC-"K M;*A3186MUC9#R5EBIGTVZVYZQD[Q;(.)ARF>C230J>JHA:[3U9=-$Y4TG#8>5#)TDXNG:JI5V&Z^/=P<8G_AJ%N;KW78Q34XQ_40C4=0&(CI72S MTJVPM_J?A:0L>;I@'(E894%WDBD&*@0L1A69:_U:M(^>4U7.8Y^]C6PG;-$6 M/&;:;!"2+N!8:\""%M&88)L/]-A+T+@*IQDN[NN7=D+H5+UL>@=X/O5GUM9Q;DDGA0'865ML5_' 1;G( 3D7!JT* YK MM'/PDMUV$7B*^.\\&PW#[;$[Z[R9_N?E-$]7WVEK?YL3P\BBHPW.'M^9-S): M7BTMK<@UC.N6+HQ!*C+9$(V-]K"7R"U!!8&H[K':3=;5IJW./;@UT) M5HQAY!58*UGM\Z? /.61T(4HV8WP&, M?L7?MGBTF,_HRW3EZCY^3'+!G*)7$!0F4#XG"-H(2$E+X26B+ZUUUU-I''?^ MZ$"0&U1070PZ?+>8SA=79)2=2X"=:J=#.@ >K[J>\.GG:F'MV'LQSNK?BUI'ABUX57;_(YJV/QQ0*>UK>*(/F(G*3+A&E=#SY@$\1;;-\LLFEKM6;O+:"-5I%V'? MJVGB@+KK*1WQN,U1>8^@1>1T%W(+P2<-N3;N-#;I]O4X9VB=>!LVO@+X\_F2 M/CM\G:["Q?2_,&](N+OV8XE?'I,V+ K(0I*_@@S!"UW(98I)!D6'S+:N*3B5 MYK';FPV#O84;+-;^Y(#=FJ\]5@>=OJ[[[-([^BT1#"BT/TK9: SQ)$<(^71 M,LDQMRXS.YRZ?OLQ/@4ON_W)IM+I5 5M.H$=K7GN_/MV[1@'U#/WNJHY84S1 MM;;.UT=@7@.>A!Y KY C]\B;6S2MFS+2IU4#_QXX%2M,6:XA1DT;B_7-*FH! MZ,AO$%R8TGP(R0Y2NFK%^!1Y/^RB=SJK.TBN>JP9X,U@VW\+J\M%'2%Y=XO6 MHPE*ZUK'40>%DS\:>:A3U;BLKB SX1RM&7] 9E?]&D]#VK BZO4VVM\-\81K MZJ //D-#QP$OMAUM_;142?F*"%6[KEO9P)(23/-B=0KC8&XY9#2.B!CJ(W4N?H6.M7\!]3U66SQZ>@8K>% MW$00'=R(MSO:Z%:R]=^6-_/9IX^X^%)W>4_79L,S0T'*O-0LUA D>)MHD\(P M3#E9,Z!?=AB-X]Z%@\)N "%U>B$^[$EV_!VX\[.&:1DXX$WW@R9P5EDK%4D[ MNUJ=Y80GP]P92%EF6]// V_^!#]LX\ ;Y*_7^>7[\YK=O%49+8PV3FFP,6M0 MV05P*2,PQZ7T*=)/6@\R^0%)73<)? H^=BNATT71U<6W[E;V"[D9F2S5=1S_ MM[#(ZTV^7:?++VME_I4(E\O++U<_NZ]Q ^98 B7![;D%W4<5S[]QN=OI^?G'Q:KZH#+BW06<$(Z?9@729>%V; M#0=O-!AE5J6?,$IK-/Z[_#19HN;R(.M]R* MR6IO2!0^K9M;UJF;6B=@N61NC-%:MP[DC;OC<2M]ASPG?QP@]7#L;FMQR%F: M?T?\@(MOTX0[V'BQ_DCZJF:SI_FGV3IO:EVNL\ZFVHK^6\V-KR-S6+2UL:L! M%]$#N9Z8A;"HL'7I\6";&;=&^2R7RICB[^H: M32W48!ER*L1^96FCM'60*6<6G9-*MT[".)K8<0N?TE_GB MRUIR[_$BK&^I]UD/Q6J#Q):.Y9_?L:)34 MGK:#P&K_0&#M08:=!G3O#3@X/IK[^ <-,(-AP#CNS@[\HC"M2JU"7!= .US? MJ0Q"-"QY--K$UL7K0TUBV$HGFZVF>7IQ6?OS?,"T><%X^7NZN"16OJ*#62V0 MR]7&[-@]2:".,I$2"V24 93@N0XYJ>9W$MEXSKD>[I6SU2XZG?WP%.3MR1P< M0]1=&9?_P&I^D'OY#1?A$_YZ^27B8A-\O!],="@%NI(@%W1UDQQ"20P2QUR4 MDM8V;PQV%*'C!H<'ANQ0 NOT'GZTB_;QM_&^CQNLZ?> -_/^%L\VF1Q2 ,NP M%H75R?.V>,"DA$LY22%"X_-ZEM;?6XG>&S;GMV2QDOI>T,%;]VO\^VP>E[CX M5CG_>D8:O 8'9HG^U5JFVU&!Y(+%#"%838W/]BNIKAE7>"%:^5! M>D%F3M0&8I#D<]I:6<&C%F; ,I>QMS^N73'8(>N(PT\"6 =GO^!\Q?9Y-__/R@1DGF,JA" L<19VEFPQX=)JL1^MC5C)$ MUOHI\"P;&_=E?/A+JQM0=&K;;SI0_EJCB]4#?X&K,+TXI3WF@X]JV"AS/YG# MM\Q,*12#/@"WM;\$JIH@2]^6)+ESA +E6F=+#C1]X^WB4YA-_VLM";H\EO39 M>?W-IM7ZNRU)_7*YG,YPN=SJ!WM52'J/L/7IF,CLD45!G+%U](Q6%GR.IK), M:.^X\]S]"$K#DMAM_\RGP.O.^T$?TAS[)6S3M.5J\MJ5V__L]^ER@MRQB(7V MH'T-^@0+09%I(Z**(CGC SL,D3L6& =//0E^WE@*'2+IQ?Q+F,XFR3!OA9; M1*RS :(#'[*KG7Z<#$4QGLNQ6+I:8D0T-1'=#[!P!!_'1L/FB%R7)=YK\U%M MR^V2T[6!60/"$R%(;T=IP 8C016TX'@D!HI@3(RY,,4/PLJ1!/2%I&,$/S^S M%,9&6BV(?4<.2)I^#1>;-,3K?7B.428>0C';1\^P*.PP0QVN/ MYI&!P;!P.@_'AL''S]-%?A<6J^\?<+6Z6/-ELPUNM&7.(.AJIRF^;JZC(\AD M18PFN.S\05#8O<8XJ>%#P:$1+\>&Q$WCA'7?A%VZSB81LZU]-;2M-V#4X)CF MX(VD+7GNV?T9X+MLUD.6&RBB@M.?PV)@9PF5\0[_UFCB^G.AL.19!G.6. M%&IA2-96Y8GA.MG,A9+R(*P-2N:(=DZ''GL_B.C@.>F1T24/)C3<_<'6;TZ, M+"&4J$ $U+3%L.ESA9ST ')68FC=(>TD@O]DH:LC43G]ND7[C74VH=^/P=3-8(R@$I(-7[.-G!52 M2>&\C:TSRO82-*(OW2\XVXEP;)/ZCM^Q]@LV@PDFSGN>F O@Z5(@9[*8VE') M0*%;0NC(HW7A,-=KUQ(C^N7]0:NA-/K#U*_$YE[18";V=D MJ;Z>I?D7K.64$YMS-*%PVIOR]?(G1,9 MI=EWFN1UFO;\P9#BL&M(\>D)E2 MT/.B&49>I$<2W6W.9I/0=?I,\Y/$N:(]_]RL9ILT;[.(LLBHY*^ /U'I L5P46R7P+* M;&TP3AQ6YD>?O85!^NX6?X\L.W)WU3-+?-Z&_?T@9_-^:V60PA8Z=4$(LEJ< M)ZN%UP9JO+A@2G+JH**WP[$S9C+FR>)[' 9'\')D('Q(. MT/LCD_3:=7RXO MOK_'K_/%"O/FX3T02\CM"6"CC:"<*;7C3@0,T=3,5*W]0049/\#%C^CH B;' MB'<^$*_[42"WFO4ZY0LS0RP)8I%UU PC;T21+ZVYX3P7*;(YZ!7K"=?0/1+& M>:IJBY96'!X[1O%L^9[@OKP!N1 ^^F(]:,/(5S5&0F2\EJA;49S,*>3#LFSO M?? X+T#M9'XRLSH(>1YJ@BVW6'8;.''":[=Z2298\1F<"37LYK64 MK5,[3B)XY/;LXQB^YQ=U![C^<+V#M^75=!9F:1HNWLV7T[6LK_W6K+Q(PEJZ MLVT]JZP G4X.@DQ)U%D55,U[61] U\BMSTU_38Z?Y M]6SS7#8).?C,N0=A-1F.6+>10H*DI MU[CQ#/-U%[=G*5U^N5PW0WV!99JFJTFPUFME! CM1!UHKB'6]@LH6(E9*A2^ M]6OECZD:>R#*P.AJ+):Q+?\M?FWRX:XN@/J2M<#/.%M.OZW?KVX'LF%.&!F2 M-Z,**.'(( DH0!87(R^%*7-8UL63EQZYF^+9;\DS"*@+/;=$(J"F$[_ ;W@Q M_UIWNZEHG>1H8V1U$'M,6)]G:3."V(B1?-H^X-3<@?YG.II5-M8_.]:Z\B9ZI$H'S8(E?TH)GY--[9U!I M;I4/S=\(#Z)LQ+3N\Z)N $%U +^;3//K.OV),TIZX1C4H3>@2J";0$0/@9=D M=6 NB];M"Q\0,6(Z]GE!=1K[C\?/G+R.MOC93B?BWA9=5:ZQI(&MX1 ,L89G M6W+RR:!LW=+]$3)&S+L>"4-'BJ #%-U-1],JI8@B@4L%:Q9XK#Z0A"Q%9MIZ M*6QK_#P]M7"8O.KS(N=XMG=P<]UAR=4V:#]OR\?P^\2C2CJ& ,QF4^%/2K2. M6K%D_;D2K95!-4;0'G)&S)L^+YY:B:0#C71_0$%-[4T3KK1DP4=((2I0KN9X ME%"3NTN6-JB"]Q\?FX]R61,R8O+S>1%UNA@ZT%3W-_&B#E/!/$%B0*ZM*#*/ M#A0K@G:0)3$F,6(:,\RX@=&T(>4@/+D_(9Z.$44'B-IBVL.)9[>Q9,-CJ;Z# MC8+5C#0& :T"KD-MX^]"M\*9V"L2R#\IS^L$R0&Z8"8,E,(,O)')8G.ZC/ M>XZGT8% >#RW.X#*%GMJMY!7%_/?;LTAD^I09FO HJ:]&#*'G"0'GG9B>,I6 MI.:M-/;1,^Z$^BXN]]-DU '>[AX6EK,I47KPPE6]*NG896G <%D\;4 ]Z%TY M@FHZQ_UXHESW:J2G,'G\Q(R;:WG[MK[:SQ:Z%!2 LA:A"!G!V9)!2,%#\#4CLG6&X'Z*6C2F?.33 M5\_#8O%].ONT'G;9]E[!Q;]F& M6'FL661;L8Q]_]:V^<\^+1"OJS)NS_-$6?3<8H"B50)5N %7M =I0Q%.Q,R* M.NC:W;/(N+?M %!IRM71T8&K^DEDB]#"T_L["4Y)LC@8Z,(<@9T1>[*H#=>R MBS)RR?# (17[EADWPCL80IIQ=FR,?*AS%*>K[Z_(65[OA91AOM=#=^(](YLU M1? RQ)J))"%*+2%E9G6RED5YH 5_P&KCA@V&0DQS/G<0'#BI^3)Y+Q>7F6[= M%]/EU_DR7/QM,;_\6A-YI\MT/2+W]AUP(E6).6 &SU*J_DVF0Y5)^QK.B327 MZ)(>P%HZU_[&R30ZD]'5)4B:I9:97CL#T ?E;?,!PN) MP -*>E:;PQ.@DG6(#CWY W\(KW33#_4!UQ\&15M!)9);[6*CIR MG+U&#<+I*'D6(HC6E_-#*D:=H3B(K/=V87\RX[N#SJ_A"V[ZG 2I4I(\0?+6 M@#*Y0/2&0T(6'?E2=*\/.P7@EI9QM=&I,MX+F2,9/K:/^A$77VI,YA5QZ]FZ MM_*_TV8N%_CV:^UZ=3E;C\5X=3G+;[YNVMV@=4*:4E_T%:/M60VQ]I!/R@D1 M/5F&5A]TB3U][9[PG6W">:5"A!(@!:^IZ*2YA M\JZT3O$Z(L9V9HO[2.$^K @_EM-'X^0;+N)\P'?QUS-2NP2P[R>X^P\^HX4K MOY^P1F[Z[2+39;J8+^GFN7'.R >3Q48%.D2ZU%CVX*0P8*W. DMV*%JG N\A MYU0M P7.;Z30$RX;:XS8A MX^J,5BBXKR].YWD'U\O-)OXQ7_S'Z]F[Q3SAL/.JMK#XC/EO\WFF$R X-U%F,$54.]X' M\+7$+GB=0^+&Y.8#)!^G9-P'Y,&Q\+.K[B:F% LF68,2C+5Z1.![#=# MN+=*<,<9H]T,A1A:?]QGX\%Q\E0.=_JZ]6ZQGAUYW>,DS/+;U6=<; :S/5LN M\:0Q/$_Y^!8&\-';:60;WUW_V6;YJW6OB;B&86$V1^097#"D6P0Z^DIX\-+G M6+*2,K6.8CR!O),"A)MUGM-?3E.X^%B-N&N97,_\TT+%Y%&#Y(*#TCE!3%R0 M:A7):LX=XX?-*3M@L7%-Y:% <2BCA%BP9,.13H.3O@,V1CMI&(*7>N7]=W4C&MCGTL;-9)&![@Z@&.3 MQ)U.BB<0RM92:A,@.+JIO2NT'V68;NZV'4#6N.F09[[WFLFG6Z=O_A47J^_O M+@)]V"S71Y]UH]Y:S3B?U<>?>=GY2R>Y@RT6;N,H-F=!,Q=R:]%G6XO>()Q) M'X)(#*2R 532#'R,I -3R89E5#JTKOK^(5'M9K7N7.KJ$9L5):VK[LM:XSN? M(!@?(3JTTJ*-Y;[;>'I/A0-I&]O+;(F;W>-7&\JGBQMYQVY^^?Z1/N)J?"1S M3D;:" IR>520BFX4FT$F$X/716!L;?(=0%8OPUE;XN'!==Q6.#WCK6[H.C/, MFYA3]*!S[1P@T->PL@#T):CLLC7-GWH.(*M3[78L% Z%VI%RZ0!J;\AB^>62 MN+H>.#/+K[]\7R\-$@9.MKCPJZ%NA<*HA(>S(H#.K6E^F/ MJ>H4:,<"83ZH5#K V?5NKJE/W":-#&PP= H5)F*.,(0$%V+RI01LW3SB+@5C MAVB'Q<\)W.X *]6[NJ2/N^'*9ALEAFH-()3:+E8Y4T=S< -%E<)3]D8>-M_^ M*1F]CY,R=KQV6/2TX'\','J#88FU$V'5H#??/*)*!1ZSUI]: \S$! M,\4J60R=C]8U@X?2-G;L=N!K;@@)=8"\^P>'QQB3Y0QX'0>CF [@$F;@+#G/ MDK+\?E.7TQN%'Z&P!HS,#HNC4_C= 5Q>72YFTUJ;0ZQY-?V]?G5CY7%M,@IB M@TL>E&:N-K/DP%&QQ(TPKK3V\G93,\XV3.W;3TVFP8V"-^51!=##S;.=>_K[$"VV8 *\4&=8E^R@Q6"7/]G#^5.([#:N<#;<# MB+C3+O<[L[Q:=/4[_,,'S6H[2_^^'V<@&8Q"6IT!C:MH2;YF:=*MJY)20A!\ MV-EM(/G?;1H1\I,4EWA0KGJ!E=GQ2"Y5R")&M]$?X7J-P]<5HO6JXN.WZB*8X M[9B'P%TBH]TYB+K$FMMCA(HFFN8MG_:04'%D[TEG(;LZ$ZU.,HJ\SB_BJ%FI@_=DZS/Q0Z)&#FHUAM4P MLN@ 7)NCLEVR]PJW"H6UTT:6#+P>$*62JP,3/&0AD4D>C,G-)[KNI6CD0-5 ML&HHA0XP]7I&GX7+U89;-R5ZQF9IO8$<8QW?4R?":\&@MMI(T1 AH76&Q..4 MC!R)&@A##;C> 7:NZNRNCL,CVM6CYTIG!!NJWX Z@L^^0"E"!>0UE#9(T>U. MBD:.#@V$I892Z !3NS=2&^":6KB996U"&;TEQ]%Y*,P4EAR71,XPU]N12!HN M\V;8F^U$WG=:/KM.9URVB [N^*06?OLA1#;RVZ^6NL&-SD5A,@A.53\+G8!@ M-0E<>1,9?17NM_INDW/;;%KD&S+&$->?N14%O\H0,IQI;I('ZU/M7\L-!&48 MI!Q0"+2H6&MK9@\YXSKQ)\C]8;IP&Y:/>.TL%ZO;<<-_P_FG1?CZN<8AUK5I M)7N5M9= _W%0S"$$S0S4EDPUD:&XPW!#JVQAAKZ[Q L9&2B/QSEOS>FS MX*?[6]CDNYJ0DS4'N> _ LPN L8!3$/!SEMS M>42HI/GE;+7X/OG[APG': T7$81FDJRRVCM=.09:6X_1!,N%V(.+)::_?II_ M^WGSB5?0V'QSBXS;]4:$01NAS4_B8 ,,] M8Y8\_;U]HY\F\]U !N.$CP1CD>6?NHZM%X/1($CP*LF40ZP-C=O6S> M8"<^*.EU+'3G&MI$CG6"C,TU8\UZGKS6S>N['R6D1S75!DFG\[W3]+RK*,.' MRR]?PN+[O*R_?3Y?GM26_(>?V2X"=RCAP\3BK&QT$4?C,R),VF3;UWI^$>)Q3U%[D^) MQ3V%Y6.'5G:&$;+29LT2B>0%*NWI;K7104@J::\E^84'-87X\\7BGB3>@V)Q M3^'UV(#9Z7QJIHW35@$SC.YEQ 0AV !%<)4=HR_M08E6?Z98W),$>U L[BE< M[B N\_*FY8+"'@OE24/T,L[A29/Y&#'3BT/W+: M+ N2V]IE7,K:;UQH<%XC>5S>N()1%SE,Q.0/&(L[QKX80@YCCRA9)UJMM_)Z M5N:++U?"N3;>R0OD);,,C*.L8WH*."<8E"B]%<0YE>[9ISLJ /8NTZ,5>J0T MYX.PM@/=H\RY\7W=.F]BD(@8LD*(C#E4P)2D?\?>V_: MY&:.XP]^(L3R/EZZJNS9VJ@J.VQW3\S_C0*\;.VD)8^D=)?GTR\H*4_G\4CB MHX?IWHH.=SHS+1+ CR! 7 Y4$<0R'3($#(P4M4PAM!ZN=>@>I[G8S@JWQH+J M'8AU.F>U#-^3F_DNKV+-$$W1)N)CG4M0.[T5TOI>B=KVQ6J?@PVI>7;NH7N< MIAQE2B">*JB^@PO[_G#+_L3-Y6J^^;XL=]FR?OUWO+BL#9@_?%ZN-O5$ M[KY_>C2BX28:AB_&8LTX\0[R2YW624/RC(,RLI!KZC1X1!:M"\';]HD1YXIW M!"LSXS$3<>1\JUI'CZ$6O7O,CD>MO#Z/I]E?O.,0N1\2[SB$Y5,_7S_Z5(M& MH([<@O&AME#S$CQ7DBX%SW/2QBL^Z$+]^>(=!XEW4+SC$%Y/#9A''_A9_QCE-D?B '._#7GT]2"\K4@:I1U\IRIR.$HAR( MY# I98V-Y\FZ>0'QCF/LBS'DT VL[GJ,5^7!WZ\>67<^)LGK;7DS7],)_*^, MJYEU"6-)$C)MC(Q[4I^H)=%L3!+$ Z]+Z^K_XW?;H[%[)&@&Y"J/(,&7@M7? M+O-?^>_-QW_EBV_YS^5B\WD]B\D:%YV%3"XHL;=D"%(KB*5H3#'&Q-J7/A^W MUQZ5YAEQ>JKT7A!*ZPG\^*_ES*,VR9E$MX^QH*+,@,9PD%+$'#%PDZ8"YWZ+ MTW9YZ@&3Q\CJI4&1L)5GV8EHD@E@2QTXQZ,"=!'!T96 GCGCQ21W^NU-3MLP MJALX'BRO%P1(#//[VW:'E,]P.\@ MZ70PI>%)NOZQ2/L8:NVF&^E77WVI?YM%([-GPD!@Y!JJ2$S$Y!R0_2&,Y1F% ME.>$X&,;G;93U61X;"*W+B;3/$+@+'FTB?PQR*:6'1:>:J,O5LN&HA4^*U3C M)EQ<;V40Q.Q+A%@+WO^[Y%#,[J4O391%,>-]YE'<9\]U)L7_=:P E[A8XR+] MNEQ\RZM-'?'QUW*3U_OF@#<5K$__WBD9,&UWT$1L(S*E4>[+;SEL:E[6Q7)= M9YM>Y4((G:SQVD$LP=08DP'/;.W;B%[S)'P)K=7YPSLY?;)&V/R^H,^ZO)G0 M69+F4I,.%LG6;@B.0"Z=*JV? A[;2T^8.5S&3T+F2(9W )SM M3;^_UO?3PZU//&J1R2-0EMA"9(3,/!GS7 @A'0K1_$G]AUWT!)9CI7O?(3^- MU1V Y1%S<$^,YL%DG3V@J+X>2[4$%AT$%D(1.42K6ZN:)SI?+=)M7;J;%:\3LD(, *8U42&X!N\9G2T1K<'(4."S'OO32_1T)1TIO65S M5DX-B*L2KK>+A^B99>_H$K6R=F1P]3E;@V,E@@].>2.#T58,0L73Z_2D*!I MHR%33XT1?!Q/;]2)Z8B.D.T5H7Q[988$#NL-*FU4/M-)B.IHK3'Y+/JSZ(Q# MV3AA2/,I&JY&N625-?.6_$%!5"A4D<#M-3"IE\0"B]@=2MA"OB!1(26>EHT=96I@?74S=.K,5<@R+^S9&_EHNXM50 M.AYDM$(!>7NN=O:G,Q&B &39*"E#YNZD2^AFJ6F3$\YU#QW)VAZRKQZ O"K) M)649&*\C**]JX8&3P+$0*8D1$JANO4%);A25&9<,7>_VO50X^5FL4$(\2\!(:.PMV\3YI;*S-E'HSP#YFN3 M,,\5.)U)>3HCG=6)K+-A3VM#5QSVTL9>#')&X?3TQLR-WEQ\VB9TW7XD0ANC M82% 3HE.@HT<,-"-RS$@)[-,%VS=>>VA?0R#THMXM6W&[JGOJ7VK+?R4:SWE M B_VV?&_+VJ*8$Z_+[9J=9^1K&U..J(%\@SKP'B&$!PQ3: 3J'6=!3+,%CYH MV6&X>3E/NN/Q?.IK[#8U,^9*JJ-9H4AR!)5(>CU\ORZ_++5UQ\7]-$,I(FUUPLJ0!\99&.$\2[05=.Z*??SNYH>58T@,!!<1\JC>X3M M$^+0:44FIH7$C0%5F(? &(?(19&AN(*I]1C%(?OJ$V7'8N$@J!TAF*F]@-]R MW"9!?OP\7VV^OYFOUIN/_UI^_+R\K,;,QW\1E=^W1?_[7$E#SC$J)&XI169O M2 :0NUQG)TMG+->%#WS3.FSAGE%UC-B79Y+!2\#7F^7E:D^:U,&GDH@6H0LH M7ULB2D%_Y%(L]UI*,

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end